PT J
AU Rendtorff, ND
   Lodahl, M
   Boulahbel, H
   Johansen, IR
   Pandya, A
   Welch, KO
   Norris, VW
   Arnos, KS
   Bitner-Glindzicz, M
   Emery, SB
   Mets, MB
   Fagerheim, T
   Eriksson, K
   Hansen, L
   Bruhn, H
   Möller, C
   Lindholm, S
   Ensgaard, S
   Lesperance, MM
   Tranebjaerg, L
AF Rendtorff, Nanna D.
   Lodahl, Marianne
   Boulahbel, Houda
   Johansen, Ida R.
   Pandya, Arti
   Welch, Katherine O.
   Norris, Virginia W.
   Arnos, Kathleen S.
   Bitner-Glindzicz, Maria
   Emery, Sarah B.
   Mets, Marilyn B.
   Fagerheim, Toril
   Eriksson, Kristina
   Hansen, Lars
   Bruhn, Helene
   Moller, Claes
   Lindholm, Sture
   Ensgaard, Stefan
   Lesperance, Marci M.
   Tranebjaerg, Lisbeth
TI Identification of p.A684V Missense Mutation in the <i>WFS1</i> Gene as a Frequent Cause of Autosomal Dominant Optic Atrophy and Hearing Impairment
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE autosomal dominant; hearing loss; optic atrophy; mutation; WFS1; Wolfram syndrome
ID wolfram-syndrome; opa1 mutations; r445h mutation; deafness; pedigrees; cataracts; japanese; disease; family; common
AB Optic atrophy (OA) and sensorineural hearing loss (SNHL) are key abnormalities in several syndromes, including the recessively inherited Wolfram syndrome, caused by mutations in WFS1. In contrast, the association of autosomal dominant OA and SNHL without other phenotypic abnormalities is rare, and almost exclusively attributed to mutations in the Optic Atrophy-1 gene (OPA1), most commonly the p.R445H mutation. We present eight probands and their families from the US, Sweden, and UK with OA and SNHL, whom we analyzed for mutations in OPA1 and WFS1. Among these families, we found three heterozygous missense mutations in WFS1 segregating with OA and SNHL: p.A684V (six families), and two novel mutations, p.G780S and p.D797Y, all involving evolutionarily conserved amino acids and absent from 298 control chromosomes. Importantly, none of these families harbored the OPA1 p.R445H mutation. No mitochondrial DNA deletions were detected in muscle from one p.A684V patient analyzed. Finally, wolframin p.A684V mutant ectopically expressed in HEK cells showed reduced protein levels compared to wild-type wolframin, strongly indicating that the mutation is disease-causing. Our data support OA and SNHL as a phenotype caused by dominant mutations in WFS1 in these additional eight families. Importantly, our data provide the first evidence that a single, recurrent mutation in WFS1, p.A684V, may be a common cause of ADOA and SNHL, similar to the role played by the p.R445H mutation in OPA1. Our findings suggest that patients who are heterozygous for WFS1 missense mutations should be carefully clinically examined for OA and other manifestations of Wolfram syndrome. (C) 2011 Wiley-Liss, Inc.
C1 [Tranebjaerg, Lisbeth] HS Bispebjerg Hosp, Dept Audiol, DK-2400 Copenhagen NV, Denmark.
   [Rendtorff, Nanna D.; Lodahl, Marianne; Johansen, Ida R.; Hansen, Lars; Tranebjaerg, Lisbeth] Univ Copenhagen, Panum Inst, Wilhelm Johannsen Ctr Funct Genome Res, Dept Cellular & Mol Med ICMM, DK-2200 Copenhagen, Denmark.
   [Boulahbel, Houda] Univ Copenhagen, BRIC, Copenhagen, Denmark.
   [Pandya, Arti] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA.
   [Welch, Katherine O.; Norris, Virginia W.; Arnos, Kathleen S.] Gallaudet Univ, Dept Biol, Washington, DC 20002 USA.
   [Bitner-Glindzicz, Maria] UCL Inst Child Hlth, London, England.
   [Emery, Sarah B.; Lesperance, Marci M.] Univ Michigan Hlth Syst, Div Pediat Otolaryngol, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI USA.
   [Mets, Marilyn B.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Evanston, IL USA.
   [Mets, Marilyn B.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Evanston, IL USA.
   [Fagerheim, Toril] Univ Hosp N Norway, Div Child & Adolescent Hlth, Dept Med Genet, Tromso, Norway.
   [Eriksson, Kristina] Lundby Hosp, Dept Ophthalmol, Gothenburg, Sweden.
   [Bruhn, Helene] Karolinska Inst, Karolinska Univ Hosp, Div Metab Dis, Dept Lab Med, Stockholm, Sweden.
   [Moller, Claes] Univ Orebro, Dept Audiol Disabil Res SIDR, Orebro, Sweden.
   [Lindholm, Sture] Cty Hosp, Dept Audiol, Kalmar, Sweden.
   [Ensgaard, Stefan] Karolinska Inst, Dept Psychiat, S-10401 Stockholm, Sweden.
C3 University of Copenhagen; University of Copenhagen; University of Copenhagen; Virginia Commonwealth University; University of London; University College London; University of Michigan System; University of Michigan; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; UiT The Arctic University of Tromso; University Hospital of North Norway; Karolinska Institutet; Karolinska University Hospital; Orebro University; Karolinska Institutet
RP Tranebjaerg, L (corresponding author), HS Bispebjerg Hosp, Dept Audiol, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.
EM tranebjaerg@sund.ku.dk
FU Lundbeck Foundation [32011]; Widex AS; US National Institutes of Health [0R01DC006707]
CR Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Amati-Bonneau P, 2009, INT J BIOCHEM CELL B, V41, P1855, DOI 10.1016/j.biocel.2009.04.012
   Arnos KS, 2008, AM J HUM GENET, V83, P200, DOI 10.1016/j.ajhg.2008.07.001
   BARRETT TG, 1995, LANCET, V346, P1458, DOI 10.1016/S0140-6736(95)92473-6
   Bespalova IN, 2001, HUM MOL GENET, V10, P2501, DOI 10.1093/hmg/10.22.2501
   Cryns K, 2003, HUM MUTAT, V22, P275, DOI 10.1002/humu.10258
   Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002
   Eiberg H, 2006, J MED GENET, V43, P435, DOI 10.1136/jmg.2005.034892
   Fujikawa T, 2010, LARYNGOSCOPE, V120, P166, DOI 10.1002/lary.20691
   Fukuoka H, 2007, J HUM GENET, V52, P510, DOI 10.1007/s10038-007-0144-3
   Gómez-Zaera M, 2001, MOL GENET METAB, V72, P72, DOI 10.1006/mgme.2000.3107
   Hansen L, 2005, EUR J HUM GENET, V13, P1275, DOI 10.1038/sj.ejhg.5201491
   Hofmann S, 2003, HUM MOL GENET, V12, P2003, DOI 10.1093/hmg/ddg214
   Hogewind BFT, 2010, MOL VIS, V16, P26
   Ke Tie, 2006, ZHONGHUA YIXUE YICHUANXUE ZAZHI, V23, P481
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Li CM, 2005, AM J MED GENET A, V138A, P208, DOI 10.1002/ajmg.a.30794
   Mellersh CS, 2006, VET OPHTHALMOL, V9, P369, DOI 10.1111/j.1463-5224.2006.00496.x
   Mets RB, 2010, OPHTHALMIC GENET, V31, P227, DOI 10.3109/13816810.2010.516056
   Pandya A, 2003, GENET MED, V5, P295, DOI 10.1097/01.GIM.0000078026.01140.68
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Puomila A, 2005, ACTA OPHTHALMOL SCAN, V83, P337, DOI 10.1111/j.1600-0420.2005.00448.x
   SAMUELSON A, 1940, NORDISK MED HYGIEA, V6, P769
   Shimizu S, 2003, AM J OPHTHALMOL, V135, P256, DOI 10.1016/S0002-9394(02)01929-3
   Tessa A, 2001, HUM MUTAT, V17, P348, DOI 10.1002/humu.32
   Tranebjaerg L, 2009, WFSI RELATED DISORDE, V0, P0
   Valero R, 2008, DIABETIC MED, V25, P657, DOI 10.1111/j.1464-5491.2008.02448.x
   Young TL, 2001, HUM MOL GENET, V10, P2509, DOI 10.1093/hmg/10.22.2509
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 32
TC 88
Z9 93
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4825
EI 
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JUN 15
PY 2011
VL 155A
IS 6
BP 1298
EP 1313
DI 10.1002/ajmg.a.33970
PG 16
WC Genetics & Heredity
SC Genetics & Heredity
GA 781OV
UT WOS:000291944200013
PM 21538838
DA 2024-11-01
ER

PT J
AU Bruno, C
   Cassandrini, D
   Fattori, F
   Pedemonte, M
   Fiorillo, C
   Brigati, G
   Brisca, G
   Minetti, C
   Santorelli, FM
AF Bruno, Claudio
   Cassandrini, Denise
   Fattori, Fabiana
   Pedemonte, Marina
   Fiorillo, Chiara
   Brigati, Giorgia
   Brisca, Giacomo
   Minetti, Carlo
   Santorelli, Filippo M.
TI Mitochondrial myopathy in a child with a muscle-restricted mutation in the mitochondrial transfer RNA<SUP>Asn</SUP> gene
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondrial myopathy; mt-tRNA gene; Exercise intolerance
ID transfer-rna mutations; trna(asn) gene; dna mutations; disease; ophthalmoplegia; disorders; sequence
AB We report an 11-year-old boy with exercise-related myopathy, and a novel mutation m.5669G>A in the mitochondrial tRNA Asparagine gene (mt-tRNA(Asn), MTTN). Muscle biopsy studies showed COX-negative, SDH-positive fibers at histochemistry and biochemical defects of oxidative metabolism. The m.5669G>A mutation was present only in patient's muscle resulting in the first muscle-specific MTTN mutation. Mt-tRNA(Asn) steady-state levels and in silico predictions supported the pathogenicity of this mutation. A mitochondrial myopathy should be considered in the differential diagnosis of exercise intolerance in children. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Bruno, Claudio; Pedemonte, Marina; Brigati, Giorgia; Brisca, Giacomo; Minetti, Carlo] IRCCS Giannina Gaslini Inst, Lab Muscle Pathol, Unit Muscular & Neurodegenerat Dis, I-16147 Genoa, Italy.
   [Cassandrini, Denise; Fiorillo, Chiara; Santorelli, Filippo M.] IRCCS Stella Maris, Mol Med Unit, Pisa, Italy.
   [Fattori, Fabiana] IRCCS Bambino Gesu Hosp, Unit Mol Med Neuromuscular & Neurodegenerat Disor, Rome, Italy.
C3 University of Genoa; IRCCS Istituto Giannina Gaslini; IRCCS Fondazione Stella Maris; IRCCS Bambino Gesu
RP Bruno, C (corresponding author), IRCCS Giannina Gaslini Inst, Lab Muscle Pathol, Unit Muscular & Neurodegenerat Dis, Largo G Gaslini 5, I-16147 Genoa, Italy.
EM claudiobruno@ospedale-gaslini.ge.it
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   Dubowitz V, 2007, MUSCLE BIOPSY: A PRACTICAL APPROACH, V0, P0
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, PW70, DOI 10.1093/nar/gkn188
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Tuppen HAL, 2008, J MED GENET, V45, P55, DOI 10.1136/jmg.2007.051185
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 20
TC 6
Z9 6
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 9
PY 2011
VL 412
IS 4
BP 518
EP 521
DI 10.1016/j.bbrc.2011.06.155
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 823TD
UT WOS:000295148500002
PM 21741368
DA 2024-11-01
ER

PT J
AU Park, KP
   Kim, HS
   Kim, ES
   Park, YE
   Lee, CH
   Kim, DS
AF Park, Kyung-Pil
   Kim, Hyang-Sook
   Kim, Eun-Sook
   Park, Young-Eun
   Lee, Chang-Hoon
   Kim, Dae-Seong
TI <i>SLC25A4</i> and <i>C10ORF2</i> Mutations in Autosomal Dominant Progressive External Ophthalmoplegia
SO JOURNAL OF CLINICAL NEUROLOGY
LA English
DT Article
DE autosomal dominant trait; progressive external ophthalmoplegia; mutation; SLC25A4; C10ORF2
ID mitochondrial-dna deletions; multiple deletions; polymerase-gamma; twinkle; gene; protein
AB Background and Purpose Progressive external ophthalmoplegia (PEO) with Mendelian inheritance is a heterogeneous group of diseases associated with multiple deletions of mitochondrial DNA (mtDNA), which results from the disturbed replication and maintenance of mtDNA secondary to the mutations of nuclear genes including POLG, SLC25A4, C10ORF2, POLG2, OPA1, and RRM2B. The aim of this study was to identify the genetic defects underlying the pathology and clinical features in two Korean kindreds with autosomal dominant PEO. Methods Two pathologically proven PEO patients with a clear autosomal dominant pattern of inheritance were selected. To exclude a large-scale rearrangement, a long-range polymerase chain reaction (PCR) was performed using DNA extracted from biopsied muscle tissue taken from each patient. All coding regions and exon-intron boundaries of POLG, SLC25A4, C10ORF2, and POLG2 were amplified by PCR and directly sequenced. Results One patient showed multiple deletions of mtDNA on long-range PCR analysis, and two known heterozygous missense mutations in SLC25A4 (p.Asp104Gly) and C10ORF2 (p.Glu479Lys) were identified in each patient. The p.Asp104Gly mutation in SLC25A4 was identified in the patient with an early onset, slowly progressive, pure PEO phenotype, while the p.Glu479Lys mutation in C10ORF2 was identified in the other patient, with a late-onset disease and PEO plus phenotype. Conclusions Two mutations affecting nuclear genes were identified in Korean patients with autosomal dominant PEO. Further studies are necessary to identify the clear pathogenetic mechanisms and establish genotype-phenotype correlations in autosomal dominant PEO. J Clin Neurol 2011;7:25-30
C1 [Park, Kyung-Pil; Kim, Dae-Seong] Pusan Natl Univ, Yangsan Hosp, Dept Neurol, Yangsan 626770, South Korea.
   [Park, Kyung-Pil; Kim, Hyang-Sook; Kim, Eun-Sook; Park, Young-Eun; Lee, Chang-Hoon; Kim, Dae-Seong] Pusan Natl Univ, Sch Med, Med Res Inst, Yangsan 626770, South Korea.
   [Park, Young-Eun] Pusan Natl Univerd Hosp, Dept Neurol, Pusan, South Korea.
   [Lee, Chang-Hoon] Pusan Natl Univerd Hosp, Dept Pathol, Pusan, South Korea.
C3 Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital
RP Kim, DS (corresponding author), Pusan Natl Univ, Yangsan Hosp, Dept Neurol, Yangsan 626770, South Korea.
EM dskim@pusan.ac.kr
FU Pusan National University [2007-7]
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KIM SH, 2006, J KOREAN NEUROL ASS, V24, P260
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   KOH KN, 2004, J KOREAN CHILD NEURO, V12, P43
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   LI K, 1989, J BIOL CHEM, V264, P13998
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   SEONG MW, 2005, J KOREAN OPHTHALMOL, V46, P323
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stenson PD, 2009, GENOME MED, V1, P0, DOI 10.1186/gm13
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 23
TC 9
Z9 11
U1 0
U2 1
PU KOREAN NEUROLOGICAL ASSOC
PI SEOUL
PA 1111 DAEIL BLD, 43 INSA-DONG, JONGNO-GU, SEOUL, 110-741, SOUTH KOREA
SN 1738-6586
EI 
J9 J CLIN NEUROL
JI J. Clin. Neurol.
PD MAR 15
PY 2011
VL 7
IS 1
BP 25
EP 30
DI 10.3988/jcn.2011.7.1.25
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 751IQ
UT WOS:000289611100004
PM 21519523
DA 2024-11-01
ER

PT J
AU Pronicka, E
   Weglewska-Jurkiewicz, A
   Pronicki, M
   Sykut-Cegielska, J
   Kowalski, P
   Pajdowska, M
   Jankowska, I
   Kotulska, K
   Kalicinski, P
   Jakóbkiewicz-Banecka, J
   Wegrzyn, G
AF Pronicka, Ewa
   Weglewska-Jurkiewicz, Anna
   Pronicki, Maciej
   Sykut-Cegielska, Jolanta
   Kowalski, Pawel
   Pajdowska, Magdalena
   Jankowska, Irena
   Kotulska, Katarzyna
   Kalicinski, Piotr
   Jakobkiewicz-Banecka, Joanna
   Wegrzyn, Grzegorz
TI Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed <i>post mortem</i> by identification of p.W748S mutation in <i>POLG</i> gene
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE drug-resistant epilepsy; valproate liver toxicity; Alpers-Huttenlocher syndrome; POLG gene mutation
ID mitochondrial-dna polymerase; ataxic neuropathy; gamma; disease; degeneration; depletion; childhood; w748s; a467t
AB Background: POLG (polymerase gamma) gene mutations lead to a variety of neurological disorders, including Alpers-Huttenlocher syndrome (AHS). The diagnostic triad of AHS is: resistant epilepsy, liver impairment triggered by sodium valproate (VA), and mitochondrial DNA depletion. Material/Methods: A cohort of 28 children with mitochondrial encephalopathy and liver failure was qualified for retrospective study of mitochondrial DNA depletion and POLG mutations. Results: The p. W748S POLG gene mutation was revealed in 2 children, the only ones in the cohort who fulfilled the AHS criteria. Depletion of mtDNA (16% of control value) was confirmed post mortem in available liver tissue and was not detected in the muscle. The disease started with drug-resistant seizures, failure to thrive and developmental regression at the ages of 7 and 18 months, respectively. Irreversible liver failure developed after VA administration. Co-existence of epilepsy, VA liver toxicity, lactic acidemia and muscle respiratory chain dysfunction led finally to the diagnosis of mitochondrial disorder (and AHS suspicion). Conclusions: Our results confirm, for the first time, the occurrence of a pathology caused by POLG gene mutation(s) in the Polish population. POLG mutation screening and mtDNA depletion assessment should be included in differential diagnosis of drug-resistant epilepsy associated with a hepatopathy.
C1 [Weglewska-Jurkiewicz, Anna; Jakobkiewicz-Banecka, Joanna; Wegrzyn, Grzegorz] Univ Gdansk, Dept Mol Biol, PL-80952 Gdansk, Poland.
   [Pronicki, Maciej] CMHI, Dept Pathol, PL-04730 Warsaw, Poland.
   [Kowalski, Pawel] CMHI, Dept Med Genet, PL-04730 Warsaw, Poland.
   [Pajdowska, Magdalena] CMHI, Dept Biochem & Expt Med, PL-04730 Warsaw, Poland.
   [Jankowska, Irena] CMHI, Dept Gastroenterol, PL-04730 Warsaw, Poland.
   [Pronicka, Ewa; Weglewska-Jurkiewicz, Anna; Sykut-Cegielska, Jolanta] CMHI, Dept Metab Dis Endocrinol & Diabetol, PL-04730 Warsaw, Poland.
   [Kotulska, Katarzyna] CMHI, Dept Neurol & Epileptol, PL-04730 Warsaw, Poland.
   [Kalicinski, Piotr] CMHI, Dept Surg & Transplantol, PL-04730 Warsaw, Poland.
C3 Fahrenheit Universities; University of Gdansk; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute
RP Pronicka, E (corresponding author), CMHI, Dept Metab Dis Endocrinol & Diabetol, Aleja Dzieci Polskich 20 Str, PL-04730 Warsaw, Poland.
EM e.pronicka@czd.pl
FU CMHI [119/09]; Polish Mitochondrial Network;  [PB 0890/P05/2005/29]
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Boes M, 2009, SEIZURE-EUR J EPILEP, V18, P232, DOI 10.1016/j.seizure.2008.08.003
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, MITOCHONDRION, V9, P340, DOI 10.1016/j.mito.2009.05.002
   Constantin T, 2009, MED SCI MONITOR, V15, P0
   Craig K, 2007, BRAIN, V130, P0, DOI 10.1093/brain/awm009
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Delarue A, 2000, PEDIATR TRANSPLANT, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   DEVRIES MC, 2008, J INHERIT METAB DIS, V0, P0
   Di Donato S, 2009, J NEUROL, V256, P693, DOI 10.1007/s00415-009-5028-3
   DREIFUSS FE, 1989, NEUROLOGY, V39, P201, DOI 10.1212/WNL.39.2.201
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Hassanein T, 2004, MITOCHONDRION, V4, P609, DOI 10.1016/j.mito.2004.07.015
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Joshi CN, 2009, PEDIATR NEUROL, V40, P314, DOI 10.1016/j.pediatrneurol.2008.10.023
   Jurkiewicz E, 2010, POL J RADIOL, V75, P51
   Kurt B, 2010, ARCH NEUROL-CHICAGO, V67, P239, DOI 10.1001/archneurol.2009.332
   Lee WS, 2007, HEPATOLOGY, V45, P1555, DOI 10.1002/hep.21710
   LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   McHugh JC, 2010, MUSCLE NERVE, V41, P265, DOI 10.1002/mus.21494
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Paprocka J, 2010, MED SCI MONITOR, V16, P0
   Pronicka E, 2007, PEDIATR RES, V62, P101, DOI 10.1203/PDR.0b013e318068641a
   Pronicka E, 2011, J APPL GENET, V52, P61, DOI 10.1007/s13353-010-0008-y
   Rantamäki M, 2007, CLIN GENET, V72, P532, DOI 10.1111/j.1399-0004.2007.00908.x
   RETTIE AE, 1987, SCIENCE, V235, P890, DOI 10.1126/science.3101178
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 48
TC 32
Z9 33
U1 0
U2 12
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
EI 
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD APR 15
PY 2011
VL 17
IS 4
BP CR203
EP CR209
DI 10.12659/MSM.881716
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 748FC
UT WOS:000289374400020
PM 21455106
DA 2024-11-01
ER

PT J
AU Souilem, S
   Chebel, S
   Mancuso, M
   Petrozzi, L
   Siciliano, G
   FrihAyed, M
   Hentati, F
   Amouri, R
AF Souilem, Sihem
   Chebel, Saber
   Mancuso, Michelangelo
   Petrozzi, Lucia
   Siciliano, Gabriele
   FrihAyed, Mahbouba
   Hentati, Faycal
   Amouri, Rim
TI A novel mitochondrial tRNA<SUP>Ile</SUP> point mutation associated with chronic progressive external ophthalmoplegia and hyperCKemia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial diseases; PEO; mtDNA; tRNA mutation; HyperCKemia
ID trna(leu(uur)) gene; a3243g mutation; dna; deficiency; myopathy; disease
AB We have sequenced the entire mitochondrial DNA (mtDNA) from a 54-year-old man with chronic progressive external ophthalmoplegia (PEO) and hyperCKemia. Muscle biopsy showed ragged red and SDH positive/COX negative fibres, and the biochemistry was suggestive mitochondrial respiratory chain dysfunction. Analysis of mtDNA revealed a heteroplasmic m. 4308G>A mutation in the transfer RNA isoleucine gene (MT-TI gene). Our report expands the genetic heterogeneity of PRO. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Souilem, Sihem] Inst Natl Neurol, Lab Neurobiol Mol & Neuropathol, Dept Mol Neurobiol & Neuropathol, Tunis 1007, Tunisia.
   [Chebel, Saber; FrihAyed, Mahbouba] Univ Hosp Monastir, Dept Neurol, Monastir 5000, Tunisia.
   [Mancuso, Michelangelo; Petrozzi, Lucia; Siciliano, Gabriele] Univ Pisa, Neurol Clin, Dept Neurosci, I-56100 Pisa, Italy.
C3 Universite de Tunis-El-Manar; Institut National de Neurologie; Universite de Monastir; Hopital Fattouma Bourguiba; University of Pisa
RP Souilem, S (corresponding author), Inst Natl Neurol, Lab Neurobiol Mol & Neuropathol, Dept Mol Neurobiol & Neuropathol, Tunis 1007, Tunisia.
EM sihemsouilem@yahoo.fr
CR Berardo A, 2010, NEUROMUSCULAR DISORD, V20, P204, DOI 10.1016/j.nmd.2010.01.006
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   FANCESCHINA L, 1998, J NEUROL, V245, P755
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Laforêt P, 2000, REV NEUROL-FRANCE, V156, P1136
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
NR 18
TC 7
Z9 9
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2011
VL 300
IS 1-2
BP 187
EP 190
DI 10.1016/j.jns.2010.08.065
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 714ZT
UT WOS:000286850900040
PM 20884012
DA 2024-11-01
ER

PT J
AU Spiegler, J
   Stefanova, I
   Hellenbroich, Y
   Sperner, J
AF Spiegler, J.
   Stefanova, I.
   Hellenbroich, Y.
   Sperner, J.
TI Bowel Obstruction in Patients with Alpers-Huttenlocher Syndrome
SO NEUROPEDIATRICS
LA English
DT Article
DE Alpers-Huttenlocher syndrome (AHS); constipation; gastrointestinal dysmotility; urinary retention; ketogenic diet; lacosamide; refractory convulsive status; EEG; MRI
ID mitochondrial neurogastrointestinal encephalomyopathy; progressive external ophthalmoplegia; polymerase-gamma; gene mutation; polg; disease; cajal
AB Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder. AHS is caused by homozygous or compound heterozygous mutations in the nuclear gene encoding mitochondrial DNA polymerase gamma (POLG, chromosome 15q25). Most patients become symptomatic before the age of 2 years. We report 3 patients who were treated in our clinic between 2007 and 2010. All patients suffered from myoclonic seizures and had at least one refractory convulsive status which led to the diagnosis. All of them had varying degrees of developmental delay, 2 of them additionally ataxia. Gastrointestinal motility problems were severe in all patients despite only mildly deranged liver function. While in most aspects our patients present with typical AHS features, they also share intestinal problems, a feature that has not been recognized as typical for AHS before. AHS is a multisystem disorder that does affect all cell systems. Liver and brain are organs with the highest energy demand and are therefore usually affected early in the disease course of AHS. However, constipation and bowel obstruction should be regarded as typical complications in AHS and patients should be monitored and treated to improve quality of life. Regarding treatment options for epilepsy in AHS ketogenic diet as well as lacosamide might be considered.
C1 [Spiegler, J.] Univ Lubeck, Klin Kinder & Jugendmed, D-23538 Lubeck, Germany.
   [Stefanova, I.; Hellenbroich, Y.] Univ Lubeck, Inst Humangenet, D-23538 Lubeck, Germany.
C3 University of Lubeck; University of Lubeck
RP Spiegler, J (corresponding author), Univ Lubeck, Klin Kinder & Jugendmed, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM uni@dr-spiegler.de
CR Amiot A, 2009, GASTROENTEROLOGY, V137, P101, DOI 10.1053/j.gastro.2009.03.054
   Cardenas JF, 2010, SEMIN PEDIATR NEUROL, V17, P62, DOI 10.1016/j.spen.2010.02.012
   Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   COHEN BH, 2010, SOURCE GENEREVIEWS, V0, P0
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   Horvath R, 2009, J NEUROL, V256, P810, DOI 10.1007/s00415-009-5023-8
   Joshi CN, 2009, PEDIATR NEUROL, V40, P314, DOI 10.1016/j.pediatrneurol.2008.10.023
   Kapur RP, 2011, AM J SURG PATHOL, V35, P714, DOI 10.1097/PAS.0b013e31821433af
   Kurt B, 2010, ARCH NEUROL-CHICAGO, V67, P239, DOI 10.1001/archneurol.2009.332
   Sergeant GP, 2008, J PHYSIOL-LONDON, V586, P4631, DOI 10.1113/jphysiol.2008.159194
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Zimmer V, 2009, NEUROGASTROENT MOTIL, V21, P627, DOI 10.1111/j.1365-2982.2009.01264.x
NR 14
TC 12
Z9 13
U1 0
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD OCT 15
PY 2011
VL 42
IS 5
BP 194
EP 196
DI 10.1055/s-0031-1287812
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 859AN
UT WOS:000297846200006
PM 22006280
DA 2024-11-01
ER

PT J
AU Mima, A
   Shiota, F
   Matsubara, T
   Iehara, N
   Akagi, T
   Abe, H
   Nagai, K
   Matsuura, M
   Murakami, T
   Kishi, S
   Araoka, T
   Kishi, F
   Kondo, N
   Shigeta, R
   Yoshikawa, K
   Kita, T
   Doi, T
   Fukatsu, A
AF Mima, Akira
   Shiota, Fumihiko
   Matsubara, Takeshi
   Iehara, Noriyuki
   Akagi, Taro
   Abe, Hideharu
   Nagai, Kojiro
   Matsuura, Motokazu
   Murakami, Taichi
   Kishi, Seiji
   Araoka, Toshikazu
   Kishi, Fumi
   Kondo, Naoki
   Shigeta, Reiko
   Yoshikawa, Kazuhiro
   Kita, Toru
   Doi, Toshio
   Fukatsu, Atsushi
TI An Autopsy Case of Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) with Intestinal Bleeding in Chronic Renal Failure
SO RENAL FAILURE
LA English
DT Article
DE MELAS syndrome; end-stage renal disease; gastrointestinal bleeding
ID encephalomyopathy melas; trna(leu(uur)) gene; mutation
AB A 50-year-old man who underwent hemodialysis (HD) at local outpatient HD center due to end-stage renal disease (ESRD) was transferred to our hospital because of pneumonia. He had severe emaciation and past history of congestive heart failure. Presenting symptoms almost consistently involved difficulty in hearing and recurrent attacks of migraine-like headaches. He was diagnosed with dilated cardiomyopathy, showing diastolic mechanical dyssynchrony by tissue Doppler echocardiography. On the day of death, he had hematemesis and hemorrhagic shock. Autopsy revealed perforation of duodenum, and genetic analysis using mitochondrial DNA from cardiac muscle and iliopsoas muscle revealed a 3243A > G mutation in the mitochondrial tRNA<SULeu(UUR)</SU gene, which is related to mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Multiple organ failure due to the mutation of mitochondrial DNA with gastrointestinal bleeding is not a common.
C1 [Mima, Akira; Abe, Hideharu; Nagai, Kojiro; Matsuura, Motokazu; Murakami, Taichi; Kishi, Seiji; Araoka, Toshikazu; Kishi, Fumi; Kondo, Naoki; Shigeta, Reiko; Yoshikawa, Kazuhiro; Doi, Toshio] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Nephrol, Tokushima 7708503, Japan.
   [Mima, Akira; Shiota, Fumihiko; Matsubara, Takeshi; Iehara, Noriyuki; Fukatsu, Atsushi] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan.
   [Akagi, Taro] Touseikai Nijo Akagi Clin, Kyoto, Japan.
   [Kita, Toru] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan.
C3 Tokushima University; Kyoto University; Kyoto University
RP Mima, A (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Nephrol, Tokushima 7708503, Japan.
EM akiramima@clin.med.tokushima-u.ac.jp
FU Grants-in-Aid for Scientific Research [22390169] Funding Source: KAKEN
CR BAN S, 1992, ACTA PATHOL JAPON, V42, P818
   BARAK Y, 1995, ISRAEL J MED SCI, V31, P224
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Kato H, 2006, J NEUROL, V253, P529, DOI 10.1007/s00415-005-0010-1
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   MATSUSHITA T, 1993, PEDIATR NEUROL, V9, P391, DOI 10.1016/0887-8994(93)90109-P
   Mochizuki H, 1996, CLIN NEPHROL, V46, P347
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   RUBANYI GM, 1986, AM J PHYSIOL, V250, PH822, DOI 10.1152/ajpheart.1986.250.5.H822
   SUZUKI S, 1994, DIABETOLOGIA, V37, P818, DOI 10.1007/s001250050183
   Tsujita Y, 2008, INT J CARDIOL, V128, PE43, DOI 10.1016/j.ijcard.2007.05.072
   Yanagihara C, 2001, INTERNAL MED, V40, P662, DOI 10.2169/internalmedicine.40.662
   YONEDA M, 1989, J NEUROL SCI, V92, P143, DOI 10.1016/0022-510X(89)90132-9
NR 14
TC 20
Z9 22
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0886-022X
EI 1525-6049
J9 RENAL FAILURE
JI Ren. Fail.
PD JUN 15
PY 2011
VL 33
IS 6
BP 622
EP 625
DI 10.3109/0886022X.2011.585730
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 776LF
UT WOS:000291535600012
PM 21631236
DA 2024-11-01
ER

PT J
AU Blum, S
   Robertson, T
   Klingberg, S
   Henderson, RD
   McCombe, P
AF Blum, S.
   Robertson, T.
   Klingberg, S.
   Henderson, R. D.
   McCombe, P.
TI Atypical clinical presentations of the A3243G mutation, usually associated with MELAS
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE MELAS syndrome; mitochondrial diseases; mitochondrial DNA; rhabdomyolysis; retinitis pigmentosa
ID mitochondrial-dna mutations; severe lactic-acidosis; in-vivo; rhabdomyolysis; population; encephalopathy; myopathy; episodes; blood; load
AB Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is a clinical syndrome associated with mitochondrial abnormalities. In approximately 80% of patients, the syndrome is associated with the A3243G mutation. However, it has been realized that the A3243G mutation is not uncommon in the general population and is found in many patients with clinical presentations other than MELAS. We present four patients who presented with rhabdomyolysis, muscle fatigue, external ophthalmoplegia and myoclonic jerks respectively. These patients were all found to have the A3243G mutation on muscle biopsy. These patients illustrate the variety of presentations associated with A3243G mutation.
C1 [McCombe, P.] Univ Queensland Ctr Clin Res, Brisbane, Qld, Australia.
C3 University of Queensland
RP Blum, S (corresponding author), Royal Brisbane & Womens Hosp, Dept Neurol, Dr Stefan Blum, Cnr Butterfield St & Bowen Bridge Rd, Herston, Qld 7675, Australia.
EM stefan_blum@health.qld.gov.au
FU RBWH
CR Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2000, MOL MED TODAY, V6, P425, DOI 10.1016/S1357-4310(00)01805-0
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   HIROSE Y, 1993, INTERNAL MED, V32, P798, DOI 10.2169/internalmedicine.32.798
   Inoue Shigeaki, 2007, J INTENSIVE CARE MED, V22, P240, DOI 10.1177/0885066607301343
   Jacobs L, 2007, MOL HUM REPROD, V13, P149, DOI 10.1093/molehr/gal112
   Kaufmann P, 2009, ARCH NEUROL-CHICAGO, V66, P85, DOI 10.1001/archneurol.2008.526
   Kwon JH, 2003, EUR NEUROL, V50, P123, DOI 10.1159/000072517
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Mehrazin M, 2009, AM J MED GENET A, V149A, P584, DOI 10.1002/ajmg.a.32703
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rajasimha HK, 2008, AM J HUM GENET, V82, P333, DOI 10.1016/j.ajhg.2007.10.007
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
NR 20
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1444-0903
EI 
J9 INTERN MED J
JI Intern. Med. J.
PD FEB 15
PY 2011
VL 41
IS 2
BP 200
EP 202
DI 10.1111/j.1445-5994.2010.02379.x
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 726UM
UT WOS:000287751900012
PM 22747555
DA 2024-11-01
ER

PT J
AU Yarham, JW
   Al-Dosary, M
   Blakely, EL
   Alston, CL
   Taylor, RW
   Elson, JL
   McFarland, R
AF Yarham, John W.
   Al-Dosary, Mazhor
   Blakely, Emma L.
   Alston, Charlotte L.
   Taylor, Robert W.
   Elson, Joanna L.
   McFarland, Robert
TI A Comparative Analysis Approach to Determining the Pathogenicity of Mitochondrial tRNA Mutations
SO HUMAN MUTATION
LA English
DT Article
DE mitochondrial tRNA; pathogenicity; trans-mitochondrial cybrid study; MTTF; MTTL2
ID dna mutations; human-disease; dilated cardiomyopathy; myopathy; database; defects; genome
AB Distinguishing pathogenic from polymorphic changes poses significant problems for geneticists and despite 30 years of postgenomic experience this remains the case in mitochondrial genetics. Base substitutions in mitochondrial tRNA (mt-tRNA) genes are particularly difficult, but important, because they are common causes of pathology and associated with high rates of transmission. Providing accurate genetic advice to patients and their families is of paramount importance in disease prevention, and brings into sharp focus the factors used to distinguish pathogenic from polymorphic variants. We have reevaluated our pathogenicity scoring system for mt-tRNA mutations following a considerable increase in the number reported since the system was devised in 2004. This allowed us to address notable issues including the underestimation of "definitely pathogenic" mutations resulting from insufficient data collection. We illustrate the robustness of our revised scoring system using novel pathogenic and previously reported polymorphic changes and conclude that while clear evidence from single-fiber and/or trans-mitochondrial cybrid studies remains the gold standard for assigning pathogenicity, our scoring system is valuable for deciding which mt-tRNA mutations to investigate further using these labor-intensive techniques. Hum Mutat 32: 1319-1325, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Yarham, John W.; Al-Dosary, Mazhor; Blakely, Emma L.; Alston, Charlotte L.; Taylor, Robert W.; Elson, Joanna L.; McFarland, Robert] Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP McFarland, R (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
FU Medical Research Council (UK); Research Council UK; Wellcome Trust [074454/Z/04/Z]; MRC Centre for Translational Research in Neuromuscular Disease, Mitochondrial Disease Patient Cohort (UK) [G0800674]; HEFCE/DoH; NHS; MRC [G90/63, G0800674, G108/539] Funding Source: UKRI
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Bandelt HJ, 2009, HUM MUTAT, V30, P191, DOI 10.1002/humu.20846
   Bortot B, 2009, MITOCHONDRION, V9, P123, DOI 10.1016/j.mito.2009.01.006
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Davidson MM, 2009, J MOL CELL CARDIOL, V46, P936, DOI 10.1016/j.yjmcc.2009.02.011
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Gambello MJ, 2006, MUSCLE NERVE, V34, P437, DOI 10.1002/mus.20605
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Kornblum C, 2008, BIOSCIENCE REP, V28, P89, DOI 10.1042/BSR20080004
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meulemans A, 2007, ARCH NEUROL-CHICAGO, V64, P1339, DOI 10.1001/archneur.64.9.1339
   Mimaki M, 2009, MITOCHONDRION, V9, P115, DOI 10.1016/j.mito.2009.01.005
   Pereira C, 2007, BIOCHEM BIOPH RES CO, V354, P937, DOI 10.1016/j.bbrc.2007.01.068
   Pütz J, 2007, RNA, V13, P1184, DOI 10.1261/rna.588407
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Sanaker PS, 2010, ACTA NEUROL SCAND, V121, P109, DOI 10.1111/j.1600-0404.2009.01243.x
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Servidei Serenella, 2003, NEUROMUSCUL DISORD, V13, P848
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Tuppen HAL, 2010, BRAIN, V133, P2952, DOI 10.1093/brain/awq232
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   van Oven M, 2009, HUM MUTAT, V30, PE386, DOI 10.1002/humu.20921
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
NR 36
TC 157
Z9 163
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1059-7794
EI 
J9 HUM MUTAT
JI Hum. Mutat.
PD NOV 15
PY 2011
VL 32
IS 11
BP 1319
EP 1325
DI 10.1002/humu.21575
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 840HJ
UT WOS:000296429800016
PM 21882289
DA 2024-11-01
ER

PT J
AU Zaragoza, MV
   Brandon, MC
   Diegoli, M
   Arbustini, E
   Wallace, DC
AF Zaragoza, Michael V.
   Brandon, Martin C.
   Diegoli, Marta
   Arbustini, Eloisa
   Wallace, Douglas C.
TI Mitochondrial cardiomyopathies: how to identify candidate pathogenic mutations by mitochondrial DNA sequencing, MITOMASTER and phylogeny
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondria; cardiomyopathies; genetic variation; phylogeny; genetic databases
ID hereditary optic neuropathy; dilated cardiomyopathy; hypertrophic cardiomyopathy; point mutations; transfer rnaleu(uur); diseases; genome; mtdna; abnormality; selection
AB Pathogenic mitochondrial DNA (mtDNA) mutations leading to mitochondrial dysfunction can cause cardiomyopathy and heart failure. Owing to a high mutation rate, mtDNA defects may occur at any nucleotide in its 16 569 bp sequence. Complete mtDNA sequencing may detect pathogenic mutations, which can be difficult to interpret because of normal ethnic/geographic-associated haplogroup variation. Our goal is to show how to identify candidate mtDNA mutations by sorting out polymorphisms using readily available online tools. The purpose of this approach is to help investigators in prioritizing mtDNA variants for functional analysis to establish pathogenicity. We analyzed complete mtDNA sequences from 29 Italian patients with mitochondrial cardiomyopathy or suspected disease. Using MITOMASTER and PhyloTree, we characterized 593 substitution variants by haplogroup and allele frequencies to identify all novel, non-haplogroup-associated variants. MITOMASTER permitted determination of each variant's location, amino acid change and evolutionary conservation. We found that 98% of variants were common or rare, haplogroup-associated variants, and thus unlikely to be primary cause in 80% of cases. Six variants were novel, non-haplogroup variants and thus possible contributors to disease etiology. Two with the greatest pathogenic potential were heteroplasmic, nonsynonymous variants: m.15132T>C in MT-CYB for a patient with hypertrophic dilated cardiomyopathy and m.6570G>T in MT-CO1 for a patient with myopathy. In summary, we have used our automated information system, MITOMASTER, to make a preliminary distinction between normal mtDNA variation and pathogenic mutations in patient samples; this fast and easy approach allowed us to select the variants for traditional analysis to establish pathogenicity. European Journal of Human Genetics (2011) 19, 200-207; doi:10.1038/ejhg.2010.169; published online 27 October 2010
C1 [Zaragoza, Michael V.; Brandon, Martin C.; Wallace, Douglas C.] Univ Calif Irvine, Ctr Mitochondrial & Mol Med & Genet, Irvine, CA 92697 USA.
   [Zaragoza, Michael V.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
   [Diegoli, Marta; Arbustini, Eloisa] Univ Calif Irvine, Dept Pediat, Div Genet & Metab, Irvine, CA 92697 USA.
   [Wallace, Douglas C.] IRCCS Fdn Policlin San Matteo, Ctr Inherited Cardiovasc Dis, Pavia, Italy.
C3 University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; IRCCS Fondazione San Matteo
RP Zaragoza, MV (corresponding author), Univ Calif Irvine, Ctr Mitochondrial & Mol Med & Genet, 2011 Hewitt Hall, Irvine, CA 92697 USA.
EM mzaragoz@uci.edu; dwallace@uci.edu
FU NIH NHLBI [HL081222]; Ministry of Health for Inherited Cardiomyopathies; EC [241924, Health-2009-2.4.2-3]; NIH [NS21328, AG13154, AG24373, AG16573, DK73691]; CIRM
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0
   Arbustini E, 1998, HEART, V80, P548, DOI 10.1136/hrt.80.6.548
   Brandon MC, 2009, HUM MUTAT, V30, P1, DOI 10.1002/humu.20801
   Brega A, 2001, J NUCL CARDIOL, V8, P89, DOI 10.1067/mnc.2001.112755
   Costa-Guda Jessica, 2007, BMC ENDOCR DISORD, V7, P8, DOI 10.1186/1472-6823-7-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Ionita-Laza I, 2009, P NATL ACAD SCI USA, V106, P5008, DOI 10.1073/pnas.0807815106
   JOHNSON MJ, 1983, J MOL EVOL, V19, P255, DOI 10.1007/BF02099973
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Li YY, 1997, J MOL CELL CARDIOL, V29, P2699, DOI 10.1006/jmcc.1997.0501
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   Marin-Garcia J, 2000, J CARD FAIL, V6, P321, DOI 10.1054/jcaf.2000.19232
   MARINGARCIA J, 1994, CARDIOVASC RES, V28, P456, DOI 10.1093/cvr/28.4.456
   MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Nan DN, 2002, POSTGRAD MED J, V78, P298, DOI 10.1136/pmj.78.919.298
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   Parr RL, 2006, J MOL DIAGN, V8, P312, DOI 10.2353/jmoldx.2006.050112
   Pereira L, 2009, AM J HUM GENET, V84, P628, DOI 10.1016/j.ajhg.2009.04.013
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Ruppert V, 2004, BIOCHEM BIOPH RES CO, V318, P535, DOI 10.1016/j.bbrc.2004.04.061
   Schrijver I, 2009, GENET MED, V11, P118, DOI 10.1097/GIM.0b013e318190356b
   TORRONI A, 1994, J BIOENERG BIOMEMBR, V26, P261, DOI 10.1007/BF00763098
   van Oven M, 2009, HUM MUTAT, V30, PE386, DOI 10.1002/humu.20921
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 35
TC 47
Z9 49
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD FEB 15
PY 2011
VL 19
IS 2
BP 200
EP 207
DI 10.1038/ejhg.2010.169
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 705YK
UT WOS:000286176500015
PM 20978534
DA 2024-11-01
ER

PT J
AU Du, AL
   Naviaux, RK
   Thuy, L
   Xu, CF
   Sommer, SS
   Haas, RH
AF Du, Ailian
   Naviaux, Robert K.
   Thuy Le
   Xu, Congfeng
   Sommer, Steven S.
   Haas, Richard H.
TI Fibroblast immuno-diagnosis of cytochrome oxidase (COX) deficiency in mitochondrial disease
SO MITOCHONDRION
LA English
DT Article
DE Fibroblast; Immunocytochemistry; Cytochrome oxidase (COX); Quantitative confocal microscopy; mtDNA heteroplasmy; SURF1
ID embryonic stem-cells; c-oxidase; skeletal-muscle; gene-mutations; somatic-cells; leigh-disease; dna; deletions; fibers; surf1
AB We studied cytochrome c oxidase (COX) expression patterns in nuclear and mtDNA gene defects. Using quantitative immunocytochemical assay for COX. heteroplasmic staining was seen in MELAS patients with mtDNA mutations but similar staining variability was seen in control cell lines and nuclear gene defects. All fibroblast lines showed a wide variability in cell-to-cell COX I staining intensity. All 8 patient fibroblast lines had reduced COX staining on immunocytochemistry. In 6 lines reduced protein amount was seen on Western blotting and 7 had low COX activity. This study demonstrates that nuclear gene defects can produce a heteroplasmic appearance on immunocytochemistry. (C) 2010 Published by Elsevier B.V. and Mitochondria Research Society.
C1 [Du, Ailian] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Du, Ailian; Naviaux, Robert K.; Thuy Le; Haas, Richard H.] Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
   [Xu, Congfeng] Sanford Burnham Inst Med Res, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA.
   [Sommer, Steven S.] MEDomics, Azusa, CA 91702 USA.
   [Haas, Richard H.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
   [Haas, Richard H.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA.
C3 Zhejiang University; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego
RP Haas, RH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
EM rhaas@ucsd.edu
FU Autism Speaks [5668]
CR Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Capaldi RA, 2004, MITOCHONDRION, V4, P417, DOI 10.1016/j.mito.2004.07.006
   Cervantes RB, 2002, P NATL ACAD SCI USA, V99, P3586, DOI 10.1073/pnas.062527199
   Crugnola V, 2010, ARCH NEUROL-CHICAGO, V67, P849, DOI 10.1001/archneurol.2010.128
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Gourley PL, 2007, J BIOMED OPT, V12, P0, DOI 10.1117/1.2799198
   Hanson BJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1281, DOI 10.1177/002215540205001001
   HATEFI Y, 1961, ARCH BIOCHEM BIOPHYS, V94, P148, DOI 10.1016/0003-9861(61)90022-4
   Hong Y, 2007, MUTAT RES-FUND MOL M, V614, P48, DOI 10.1016/j.mrfmmm.2006.06.006
   Mancuso M, 2010, ADV EXP MED BIOL, V685, P34
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Parfait B, 1997, HUM GENET, V101, P247, DOI 10.1007/s004390050625
   Pronicki M, 2008, J CLIN PATHOL, V61, P460, DOI 10.1136/jcp.2007.051060
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Sacconi S, 2009, J HUM GENET, V54, P419, DOI 10.1038/jhg.2009.36
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Taanman JW, 2001, BIOCHEM SOC T, V29, P446, DOI 10.1042/BST0290446
   Tam EWY, 2008, NEUROPEDIATRICS, V39, P328, DOI 10.1055/s-0029-1202287
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Tubbs RR, 2004, AM J SURG PATHOL, V28, P417, DOI 10.1097/00000478-200403000-00022
   Vielhaber S, 2002, J NEUROPATH EXP NEUR, V61, P885, DOI 10.1093/jnen/61.10.885
   Virgilio R, 2009, J NEUROL SCI, V281, P85, DOI 10.1016/j.jns.2009.01.025
   von Kleist-Retzow JC, 1999, BBA-MOL BASIS DIS, V1455, P35, DOI 10.1016/S0925-4439(99)00050-2
   Willis JH, 2009, BBA-BIOENERGETICS, V1787, P533, DOI 10.1016/j.bbabio.2008.10.009
   YAMAMOTO M, 1989, J NEUROL SCI, V91, P207, DOI 10.1016/0022-510X(89)90088-9
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 30
TC 0
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD MAY 15
PY 2011
VL 11
IS 3
BP 430
EP 436
DI 10.1016/j.mito.2010.12.014
PG 7
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 753HS
UT WOS:000289763500008
PM 21187165
DA 2024-11-01
ER

PT J
AU Mezghani, N
   Mnif, M
   Mkaouar-Rebai, E
   Kallel, N
   Salem, IH
   Charfi, N
   Abid, M
   Fakhfakh, F
AF Mezghani, Najla
   Mnif, Mouna
   Mkaouar-Rebai, Emna
   Kallel, Nozha
   Salem, Ikhlass Haj
   Charfi, Nadia
   Abid, Mohamed
   Fakhfakh, Faiza
TI The mitochondrial ND1 m.3337G&gt;A mutation associated to multiple mitochondrial DNA deletions in a patient with Wolfram syndrome and cardiomyopathy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Wolfram syndrome; Mitochondrial deletion; m.3337G > A; Mitochondrial mutations; Skeletal muscle
ID diabetes-mellitus; optic atrophy; gene; insipidus; deafness
AB Wolfram syndrome (WFS) is a rare hereditary disorder also known as DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). It is a heterogeneous disease and full characterization of all clinical and biological features of this disorder is difficult. The wide spectrum of clinical expression, affecting several organs and tissues, and the similarity in phenotype between patients with Wolfram syndrome and those with certain types of respiratory chain diseases suggests mitochondrial DNA (mtDNA) involvement in Wolfram syndrome patients. We report a Tunisian patient with clinical features of moderate Wolfram syndrome including diabetes, dilated cardiomyopathy and neurological complications. The results showed the presence of the mitochondrial ND1 m.3337G>A mutation in almost homoplasmic form in 3 tested tissues of the proband (blood leukocytes, buccal mucosa and skeletal muscle). In addition, the long-range PCR amplifications revealed the presence of multiple deletions of the mitochondrial DNA extracted from the patient's skeletal muscle removing several tRNA and protein-coding genes. Our study reported a Tunisian patient with clinical features of moderate Wolfram syndrome associated with cardiomyopathy, in whom we detected the ND1 m.3337G>A mutation with mitochondrial multiple deletions. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Mezghani, Najla; Mkaouar-Rebai, Emna; Salem, Ikhlass Haj; Fakhfakh, Faiza] Univ Sfax, Lab Genet Mol Humaine, Fac Med Sfax, Sfax 3029, Tunisia.
   [Mnif, Mouna; Kallel, Nozha; Charfi, Nadia; Abid, Mohamed] CHU, Serv Endocrinol, Habib Bourguiba De Sfax, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Habib Bourguiba
RP Mkaouar-Rebai, E (corresponding author), Univ Sfax, Lab Genet Mol Humaine, Fac Med Sfax, Ave Magida Boulila, Sfax 3029, Tunisia.
EM emna_mkaouar@mail2world.com
FU The Ministry of Higher Education and Scientific Research in Tunisia
CR Barrientos A, 1996, AM J HUM GENET, V58, P963
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965
   CREMERS CWR, 1977, ACTA PAEDIATR SCAND, V51, P0
   El-Shanti H, 2000, AM J HUM GENET, V66, P1229, DOI 10.1086/302858
   GUNN T, 1976, J PEDIATR-US, V89, P565, DOI 10.1016/S0022-3476(76)80387-3
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Mkaouar-Rebai E, 2007, BIOCHEM BIOPH RES CO, V355, P1031, DOI 10.1016/j.bbrc.2007.02.083
   PAGE MM, 1976, Q J MED, V45, P505
   POLYMEROPOULOS MH, 1994, NAT GENET, V8, P95, DOI 10.1038/ng0994-95
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267
   Strom TM, 1998, HUM MOL GENET, V7, P2021, DOI 10.1093/hmg/7.13.2021
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Van Hove JLK, 2008, EUR J PEDIATR, V167, P771, DOI 10.1007/s00431-007-0587-8
   Wolfram DJ, 1938, MAYO CLIN PROC, V1, P715, DOI 10.1186/1757-1626-2-9355
   Zifa E, 2008, MITOCHONDRION, V8, P229, DOI 10.1016/j.mito.2008.04.001
NR 20
TC 18
Z9 20
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 29
PY 2011
VL 411
IS 2
BP 247
EP 252
DI 10.1016/j.bbrc.2011.06.106
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 806LS
UT WOS:000293809900004
PM 21723259
DA 2024-11-01
ER

PT J
AU Yu-Wai-Man, P
   Griffiths, PG
   Chinnery, PF
AF Yu-Wai-Man, Patrick
   Griffiths, Philip G.
   Chinnery, Patrick F.
TI Mitochondrial optic neuropathies - Disease mechanisms and therapeutic strategies
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Dominant optic atrophy; Glaucoma; Hereditary spastic paraplegia; Leber hereditary optic neuropathy; Mitochondrial DNA; Mitofusin; Multiple sclerosis; Neuroprotection; Optic neuritis; Optic neuropathy; Retinal ganglion cell
ID retinal ganglion-cells; normal-tension glaucoma; nerve-fiber layer; progressive external ophthalmoplegia; open-angle glaucoma; sensorineural hearing-loss; mohr-tranebjaerg-syndrome; large brazilian pedigree; x-inactivation patterns; triggers opa1 release
AB Leber hereditary optic neuropathy (LHON) and autosomal-dominant optic atrophy (DOA) are the two most common inherited optic neuropathies in the general population. Both disorders share striking pathological similarities, marked by the selective loss of retinal ganglion cells (RGCs) and the early involvement of the papillomacular bundle. Three mitochondrial DNA (mtDNA) point mutations; m.3460G>A, m.11778G>A, and m.14484T>C account for over 90% of LHON cases, and in DOA, the majority of affected families harbour mutations in the OPA1 gene, which codes for a mitochondrial inner membrane protein. Optic nerve degeneration in LHON and DOA is therefore due to disturbed mitochondrial function and a predominantly complex 1 respiratory chain defect has been identified using both in vitro and in vivo biochemical assays. However, the trigger for RGC loss is much more complex than a simple bioenergetic crisis and other important disease mechanisms have emerged relating to mitochondrial network dynamics, mtDNA maintenance, axonal transport, and the involvement of the cyto-skeleton in maintaining a differential mitochondrial gradient at sites such as the lamina cribosa. The downstream consequences of these mitochondrial disturbances are likely to be influenced by the local cellular milieu. The vulnerability of RGCs in LHON and DOA could derive not only from tissue-specific, genetically-determined biological factors, but also from an increased susceptibility to exogenous influences such as light exposure, smoking, and pharmacological agents with putative mitochondrial toxic effects. Our concept of inherited mitochondrial optic neuropathies has evolved over the past decade, with the observation that patients with LHON and DOA can manifest a much broader phenotypic spectrum than pure optic nerve involvement. Interestingly, these phenotypes are sometimes clinically indistinguishable from other neurodegenerative disorders such as Charcot-Marie-Tooth disease, hereditary spastic paraplegia, and multiple sclerosis, where mitochondrial dysfunction is also thought to be an important pathophysiological player. A number of vertebrate and invertebrate disease models has recently been established to circumvent the lack of human tissues, and these have already provided considerable insight by allowing direct RGC experimentation. The ultimate goal is to translate these research advances into clinical practice and new treatment strategies are currently being investigated to improve the visual prognosis for patients with mitochondrial optic neuropathies. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Yu-Wai-Man, Patrick; Chinnery, Patrick F.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Yu-Wai-Man, Patrick; Griffiths, Philip G.; Chinnery, Patrick F.] Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Sch Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Yu-Wai-Man, Patrick; Griffiths, Philip G.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle University - UK
RP Yu-Wai-Man, P (corresponding author), Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM Patrick.Yu-Wai-Man@ncl.ac.uk
FU Medical Research Council (MRC, UK) [G0701386]; Parkinson's UK; Association Francaise contre les Myopathies; Medical Research Council Translational Muscle Centre; UK NIHR Biomedical Research Centre in Ageing and Age-related Disease; MRC [G0701386] Funding Source: UKRI
CR Ahn J, 2008, BRIT J OPHTHALMOL, V92, P1685, DOI 10.1136/bjo.2008.144816
   Ahrlich KG, 2010, INVEST OPHTH VIS SCI, V51, P1458, DOI 10.1167/iovs.09-3806
   Aijaz S, 2004, INVEST OPHTH VIS SCI, V45, P1667, DOI 10.1167/iovs.03-1093
   Akepati VR, 2008, J NEUROCHEM, V106, P372, DOI 10.1111/j.1471-4159.2008.05401.x
   Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Alward WL, 1998, AM J OPHTHALMOL, V126, P498
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Andrews RM, 1999, BRIT J OPHTHALMOL, V83, P231, DOI 10.1136/bjo.83.2.231
   Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651
   Araie M, 1997, BRIT J OPHTHALMOL, V81, P852, DOI 10.1136/bjo.81.10.852
   Arnold AC, 2005, AM J OPHTHALMOL, V139, P1101, DOI 10.1016/j.ajo.2005.01.031
   Artal-Sanz M, 2009, TRENDS ENDOCRIN MET, V20, P394, DOI 10.1016/j.tem.2009.04.004
   Assink JJM, 1997, AM J HUM GENET, V61, P934, DOI 10.1086/514884
   Aung T, 2002, HUM GENET, V110, P52, DOI 10.1007/s00439-001-0645-7
   Balcer LJ, 2006, NEW ENGL J MED, V354, P1273, DOI 10.1056/NEJMcp053247
   Ban T, 2010, HUM MOL GENET, V19, P2113, DOI 10.1093/hmg/ddq088
   Baracca A, 2005, ARCH NEUROL-CHICAGO, V62, P730, DOI 10.1001/archneur.62.5.730
   Barbet F, 2003, EUR J HUM GENET, V11, P966, DOI 10.1038/sj.ejhg.5201070
   BARBET F, 2005, J MED GENET, V0, P42
   BARBIROLI B, 1995, NEUROLOGY, V45, P1364, DOI 10.1212/WNL.45.7.1364
   Barboni P, 2005, OPHTHALMOLOGY, V112, P120, DOI 10.1016/j.ophtha.2004.06.034
   BARBONI P, 2009, OPHTHALMOLOGY, V0, P0
   Barboni P, 2006, INVEST OPHTH VIS SCI, V47, P5303, DOI 10.1167/iovs.06-0520
   Barboni P, 2010, OPHTHALMOLOGY, V117, P1547, DOI 10.1016/j.ophtha.2009.12.042
   Barnils N, 2007, ARCH SOC ESP OFTALMOL, V82, P377
   Barron MJ, 2004, BRIT J OPHTHALMOL, V88, P286, DOI 10.1136/bjo.2003.027664
   BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   BERN C, 1995, NEW ENGL J MED, V333, P1176
   BERNINGER TA, 1991, BRIT J OPHTHALMOL, V75, P49, DOI 10.1136/bjo.75.1.49
   Besch D, 1999, GRAEF ARCH CLIN EXP, V237, P745, DOI 10.1007/s004170050307
   Bette S, 2005, ACTA NEUROPATHOL, V109, P393, DOI 10.1007/s00401-004-0970-8
   BHAT NK, 1981, BIOCHEM BIOPH RES CO, V103, P621, DOI 10.1016/0006-291X(81)90496-4
   Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903
   Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174
   Biousse V, 1997, NEUROLOGY, V49, P1136, DOI 10.1212/WNL.49.4.1136
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   Blesa JR, 2007, NEUROMOL MED, V9, P285, DOI 10.1007/s12017-007-8000-3
   Boldogh IR, 2007, TRENDS CELL BIOL, V17, P502, DOI 10.1016/j.tcb.2007.07.008
   Borchert M, 2008, CURR NEUROL NEUROSCI, V8, P395, DOI 10.1007/s11910-008-0061-7
   BOWER SPC, 1992, LANCET, V339, P1427, DOI 10.1016/0140-6736(92)91257-9
   Bremner FD, 2001, INVEST OPHTH VIS SCI, V42, P675
   Bristow EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P791
   Brown DT, 2006, LANCET, V368, P87, DOI 10.1016/S0140-6736(06)68972-1
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Brown MD, 2001, HUM GENET, V109, P33, DOI 10.1007/s004390100538
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   Brown MD, 2000, J BIOL CHEM, V275, P39831, DOI 10.1074/jbc.M006476200
   BU XD, 1992, CLIN GENET, V42, P143
   BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, P0, DOI 10.1186/1471-2458-6-58
   Buono Lawrence M, 2002, CURR OPIN OPHTHALMOL, V13, P362, DOI 10.1097/00055735-200212000-00004
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   Cann RL, 2001, SCIENCE, V291, P1742, DOI 10.1126/science.1058948
   Carelli V, 2006, AM J HUM GENET, V78, P564, DOI 10.1086/501236
   Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009
   Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 2008, NEUROLOGY, V70, P1075, DOI 10.1212/01.wnl.0000307668.75233.35
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Carelli V, 2007, NEUROLOGY, V68, P0
   Carelli V, 2007, ENVIRON HEALTH PERSP, V115, P113, DOI 10.1289/ehp.9245
   Carelli V, 2009, BBA-BIOENERGETICS, V1787, P518, DOI 10.1016/j.bbabio.2009.02.024
   Cartoni R, 2009, EXP NEUROL, V218, P268, DOI 10.1016/j.expneurol.2009.05.003
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chalasani ML, 2008, EXP EYE RES, V87, P1, DOI 10.1016/j.exer.2007.10.021
   Chalasani ML, 2007, INVEST OPHTH VIS SCI, V48, P1607, DOI 10.1167/iovs.06-0834
   Chalmers RM, 1996, BRAIN, V119, P1481, DOI 10.1093/brain/119.5.1481
   CHALMERS RM, 1995, J NEUROL, V242, P332, DOI 10.1007/BF00878877
   Chen HC, 2009, HUM MOL GENET, V18, PR169, DOI 10.1093/hmg/ddp326
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Cheng JW, 2009, OPHTHALMOLOGY, V116, P1243, DOI 10.1016/j.ophtha.2009.01.036
   Chevrollier A, 2008, ANN NEUROL, V63, P794, DOI 10.1002/ana.21385
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Chinnery Patrick F, 2008, NEUROMUSCUL DISORD, V18, P259, DOI 10.1016/j.nmd.2007.11.005
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chinnery PF, 2001, AM J MED GENET, V98, P235, DOI 10.1002/1096-8628(20010122)98:3<235::AID-AJMG1086>3.0.CO;2-O
   Chinnery PF, 2002, TRENDS GENET, V18, P173, DOI 10.1016/S0168-9525(01)02636-1
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Chung H, 2009, TOXICOL APPL PHARM, V235, P163, DOI 10.1016/j.taap.2008.11.006
   Ciccosanti F, 2010, ANTIVIR THER, V15, P377, DOI 10.3851/IMP1530
   Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021
   Cock HR, 1999, J NEUROL SCI, V165, P10, DOI 10.1016/S0022-510X(99)00088-X
   COCK HR, 1995, AM J HUM GENET, V57, P1501
   Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208
   COGAN DG, 1973, INVEST OPHTH VISUAL, V12, P534
   COHN AC, 2008, BR J OPHTHALMOL, V24, P24
   Cohn AC, 2007, AM J OPHTHALMOL, V143, P656, DOI 10.1016/j.ajo.2006.12.038
   Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101
   Cornille K, 2008, ANN NEUROL, V63, P667, DOI 10.1002/ana.21376
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cortelli P, 1997, J NEUROL SCI, V148, P25, DOI 10.1016/S0022-510X(96)00311-5
   COSTEFF H, 1989, NEUROLOGY, V39, P595, DOI 10.1212/WNL.39.4.595
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Craig JE, 2006, BRIT J OPHTHALMOL, V90, P1420, DOI 10.1136/bjo.2006.099333
   Craven L, 2010, NATURE, V465, P82, DOI 10.1038/nature08958
   Cree LM, 2009, BBA-MOL BASIS DIS, V1792, P1097, DOI 10.1016/j.bbadis.2009.03.002
   CULLOM ME, 1993, ARCH OPHTHALMOL-CHIC, V111, P1482, DOI 10.1001/archopht.1993.01090110048021
   Das M, 2010, METHOD CELL BIOL, V97, P203, DOI 10.1016/S0091-679X(10)97012-X
   Daut PM, 2000, AM J OPHTHALMOL, V130, P519, DOI 10.1016/S0002-9394(00)00558-4
   Davey KM, 2006, J MED GENET, V43, P385, DOI 10.1136/jmg.2005.036657
   Davies V, 2006, EXP EYE RES, V83, P1003, DOI 10.1016/j.exer.2005.11.021
   Davies VJ, 2008, BRAIN, V131, P368, DOI 10.1093/brain/awm333
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   De Marco N, 2006, J BIOL CHEM, V281, P16147, DOI 10.1074/jbc.M601467200
   De Marinis M, 2001, J NEUROL, V248, P818, DOI 10.1007/s004150170103
   De Vriese AS, 2006, CLIN INFECT DIS, V42, P1111, DOI 10.1086/501356
   Decanini-Mancera A, 2009, J NEURO-OPHTHALMOL, V29, P159, DOI 10.1097/WNO.0b013e3181a591b5
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   del Toro D, 2009, MOL BIOL CELL, V20, P1478, DOI 10.1091/mbc.E08-07-0726
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   Di Prospero NA, 2007, LANCET NEUROL, V6, P878, DOI 10.1016/S1474-4422(07)70220-X
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   DiMauro S, 2009, BBA-MOL BASIS DIS, V1792, P1159, DOI 10.1016/j.bbadis.2008.10.015
   Dotti MT, 1998, J NEUROL, V245, P302, DOI 10.1007/s004150050223
   Dudkina NV, 2010, BBA-BIOENERGETICS, V1797, P664, DOI 10.1016/j.bbabio.2009.12.013
   Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   ELIOTT D, 1993, AM J OPHTHALMOL, V115, P360, DOI 10.1016/S0002-9394(14)73589-5
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6
   Fauser S, 2002, BIOCHEM BIOPH RES CO, V295, P342, DOI 10.1016/S0006-291X(02)00672-1
   Fauser Sascha, 2002, OPHTHALMIC GENET, V23, P191, DOI 10.1076/opge.23.3.191.7881
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Ferré M, 2009, HUM MUTAT, V30, PE692, DOI 10.1002/humu.21025
   FIGUEROAMARTINEF, 2010, MITOCHONDRION, V0, P0
   FLCREANI M, 2005, FEBS J, V272, P1124
   Folliot S, 2003, J GENE MED, V5, P493, DOI 10.1002/jgm.367
   Fortuna F, 2009, BRAIN, V132, P116, DOI 10.1093/brain/awn269
   Fournier AV, 2001, OPHTHALMOLOGY, V108, P1595, DOI 10.1016/S0161-6420(01)00696-0
   Fox CM, 2004, J NEUROL NEUROSUR PS, V75, P56
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   Frerichs FCP, 2002, NEW ENGL J MED, V347, P1895, DOI 10.1056/NEJM200212053472320
   Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Friedmann T, 2000, SCIENCE, V287, P2163, DOI 10.1126/science.287.5461.2163
   Frohman EM, 2008, NAT CLIN PRACT NEURO, V4, P664, DOI 10.1038/ncpneuro0950
   Frohman EM, 2005, LANCET NEUROL, V4, P111, DOI 10.1016/S1474-4422(05)00992-0
   Fuhrmann N, 2009, J MED GENET, V46, P136, DOI 10.1136/jmg.2008.062570
   Gabaldón T, 2004, BBA-BIOENERGETICS, V1659, P212, DOI 10.1016/j.bbabio.2004.07.011
   GARCIN R, 1961, REV NEUROL PARIS, V104, P373
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   GHELLI A, 2009, PLOS ONE, V0, P4
   Ghelli A, 2008, INVEST OPHTH VIS SCI, V49, P671, DOI 10.1167/iovs.07-0880
   GIORDANO C, 2010, BRAIN, V0, P0
   GIRAUDET S, 2010, BRIT J OPHTHALMOL, V0, P31
   GODEL V, 1980, ARCH OPHTHALMOL-CHIC, V98, P1417
   Gray DC, 2008, INVEST OPHTH VIS SCI, V49, P467, DOI 10.1167/iovs.07-0605
   Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476
   Grönlund MA, 2010, BRIT J OPHTHALMOL, V94, P121, DOI 10.1136/bjo.2008.154187
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   Grzybowski A, 2007, EYE, V21, P1448, DOI 10.1038/sj.eye.6702950
   Grzybowski A, 2011, ACTA OPHTHALMOL, V89, P495, DOI 10.1111/j.1755-3768.2009.01853.x
   Guillet V, 2010, MITOCHONDRION, V10, P115, DOI 10.1016/j.mito.2009.11.004
   Guo L, 2008, PROG BRAIN RES, V173, P437, DOI 10.1016/S0079-6123(08)01130-8
   Gvozdjak J, 1987, CZECH MED, V10, P47
   Hanein S, 2009, AM J HUM GENET, V84, P493, DOI 10.1016/j.ajhg.2009.03.003
   HARDING AE, 1983, LANCET, V1, P1151
   HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979
   HARDING AE, 1995, AM J HUM GENET, V57, P77
   HARDING AE, 1995, MUSCLE NERVE, V0, PS82
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Hauser MA, 2006, J GLAUCOMA, V15, P358, DOI 10.1097/01.ijg.0000212255.17950.42
   Hayreh SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1082, DOI 10.1001/archophthalmol.2009.199
   Hayreh SS, 2009, PROG RETIN EYE RES, V28, P34, DOI 10.1016/j.preteyeres.2008.11.002
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Heiduschka P, 2010, INVEST OPHTH VIS SCI, V51, P1424, DOI 10.1167/iovs.09-3606
   Heng JE, 1999, INVEST OPHTH VIS SCI, V40, P190
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HO G, 2008, J INHERITED METABOLI, V7, P7
   Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155
   Horvath J, 2002, J INHERIT METAB DIS, V25, P323, DOI 10.1023/A:1016518811940
   Horvath R, 2008, NEUROTHERAPEUTICS, V5, P558, DOI 10.1016/j.nurt.2008.07.002
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Howell N, 1996, AM J HUM GENET, V59, P501
   Howell N, 2003, AM J HUM GENET, V72, P1460, DOI 10.1086/375537
   HOWELL N, 1991, AM J HUM GENET, V48, P935
   Howell N, 1998, AM J HUM GENET, V63, P1220, DOI 10.1086/302049
   HOWELL N, 1991, AM J HUM GENET, V49, P939
   HOWELL N, 1993, AM J HUM GENET, V53, P959
   HOYT CS, 1980, OPHTHALMOLOGY, V87, P245
   Huang TS, 2009, BRAIN RES, V1300, P97, DOI 10.1016/j.brainres.2009.08.083
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Hudson G, 2007, MOL VIS, V13, P2339
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Huizing M, 2010, MOL GENET METAB, V100, P149, DOI 10.1016/j.ymgme.2010.03.005
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   HUOPONEN K, 1993, HUM GENET, V92, P379, DOI 10.1007/BF01247339
   Hwang JM, 2003, J NEUROL, V250, P87, DOI 10.1007/s00415-003-0960-0
   Ikeda A, 2006, JPN J OPHTHALMOL, V50, P280, DOI 10.1007/s10384-005-0308-7
   Inglese M, 2001, J NEUROL NEUROSUR PS, V70, P444, DOI 10.1136/jnnp.70.4.444
   Ito Y, 2007, INVEST OPHTH VIS SCI, V48, P4079, DOI 10.1167/iovs.07-0024
   Jansen PHP, 1996, J NEUROL SCI, V135, P176, DOI 10.1016/0022-510X(95)00287-C
   Jaros E, 2007, NEUROLOGY, V69, P214, DOI 10.1212/01.wnl.0000265598.76172.59
   Javaheri M, 2007, BRIT J OPHTHALMOL, V91, P111, DOI 10.1136/bjo.2006.102541
   Jazin E, 1998, NAT GENET, V18, P109, DOI 10.1038/ng0298-109
   Ji YL, 2010, MOL VIS, V16, P416
   Ji YL, 2008, AM J HUM GENET, V83, P760, DOI 10.1016/j.ajhg.2008.11.002
   JOHNS DR, 1993, BIOCHEM BIOPH RES CO, V196, P810, DOI 10.1006/bbrc.1993.2321
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P1491, DOI 10.1001/archopht.1993.01090110057023
   JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P495, DOI 10.1001/archopht.1993.01090040087038
   Ju WK, 2008, INVEST OPHTH VIS SCI, V49, P4903, DOI 10.1167/iovs.07-1661
   Ju WK, 2010, MOL VIS, V16, P1331
   Ju WK, 2008, MOL VIS, V14, P2629
   Ju WK, 2009, INVEST OPHTH VIS SCI, V50, P707, DOI 10.1167/iovs.08-2499
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Kamei S, 2005, INVEST OPHTH VIS SCI, V46, P4288, DOI 10.1167/iovs.03-1407
   Katz BJ, 2006, AM J MED GENET A, V140A, P2207, DOI 10.1002/ajmg.a.31455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kawasaki A, 2010, CLIN EXP OPHTHALMOL, V38, P322, DOI 10.1111/j.1442-9071.2010.02212.x
   KELLARWOOD H, 1994, ANN NEUROL, V36, P109, DOI 10.1002/ana.410360121
   Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805
   Kerrison JB, 2000, AM J OPHTHALMOL, V130, P803, DOI 10.1016/S0002-9394(00)00603-6
   Khrapko K, 2008, NAT GENET, V40, P134, DOI 10.1038/ng0208-134
   Kim JY, 2002, ANN NEUROL, V51, P630, DOI 10.1002/ana.10177
   Kim TW, 2007, J GLAUCOMA, V16, P655, DOI 10.1097/IJG.0b013e31804d23aa
   Kim U, 2009, EUR J OPHTHALMOL, V19, P466, DOI 10.1177/112067210901900323
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Kirkman MA, 2009, INVEST OPHTH VIS SCI, V50, P3112, DOI 10.1167/iovs.08-3166
   Kjer B, 1996, ACTA OPHTHALMOL SCAN, V74, P3
   KJER B, 1956, DANISH MED B, V3, P135
   KJER P, 1959, ACTA OPHTHALMOL SUPPL, V164, P1
   KLINE LB, 1979, ARCH OPHTHALMOL-CHIC, V97, P1680, DOI 10.1001/archopht.1979.01020020248013
   Klivenyi P, 2001, J NEUROL NEUROSUR PS, V70, P359, DOI 10.1136/jnnp.70.3.359
   Köbbert C, 2000, PROG NEUROBIOL, V62, P327, DOI 10.1016/S0301-0082(00)00019-8
   Koch-Henriksen N, 2010, LANCET NEUROL, V9, P520, DOI 10.1016/S1474-4422(10)70064-8
   Kovács GG, 2005, BRAIN, V128, P35, DOI 10.1093/brain/awh310
   Kumaramanickavel G, 2005, INVESTIG OPHTHALMOL, V46, P3811
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   La Morgia C, 2008, NEUROLOGY, V70, P762, DOI 10.1212/01.wnl.0000295505.74234.d0
   La Morgia C, 2010, BRAIN, V133, P2426, DOI 10.1093/brain/awq155
   LAMMINEN T, 1995, AM J HUM GENET, V56, P1238
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511
   Lascaratos G, 2007, VISION RES, V47, P1191, DOI 10.1016/j.visres.2006.12.014
   Lee EJ, 2008, J NEURO-OPHTHALMOL, V28, P269, DOI 10.1097/WNO.0b013e31818e3c6b
   Lenaers G, 2009, INT J BIOCHEM CELL B, V41, P1866, DOI 10.1016/j.biocel.2009.04.013
   Leo-Kottler B, 2002, GRAEF ARCH CLIN EXP, V240, P758, DOI 10.1007/s00417-002-0494-7
   Lessell S, 1998, J NEURO-OPHTHALMOL, V18, P106
   Leung CKS, 2009, EXP EYE RES, V88, P831, DOI 10.1016/j.exer.2008.09.006
   Li CH, 2010, TOXICOL SCI, V116, P140, DOI 10.1093/toxsci/kfq085
   Libby RT, 2005, ANNU REV GENOM HUM G, V6, P15, DOI 10.1146/annurev.genom.6.080604.162209
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Liguori M, 2008, J NEUROL, V255, P127, DOI 10.1007/s00415-008-0571-x
   Lodi R, 2000, BRAIN, V123, P1896, DOI 10.1093/brain/123.9.1896
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Lodi R, 1997, ANN NEUROL, V42, P573, DOI 10.1002/ana.410420407
   Lodi R, 2002, J NEUROL NEUROSUR PS, V72, P805, DOI 10.1136/jnnp.72.6.805
   Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F
   Luca CC, 2004, MITOCHONDRION, V4, P31, DOI 10.1016/j.mito.2004.05.002
   Maagaard A, 2006, HIV MED, V7, P53, DOI 10.1111/j.1468-1293.2005.00336.x
   Mabuchi F, 2007, AM J OPHTHALMOL, V143, P125, DOI 10.1016/j.ajo.2006.09.028
   MacKenzie JA, 2007, BBA-MOL BASIS DIS, V1772, P509, DOI 10.1016/j.bbadis.2006.12.002
   MACKEY D, 1992, AM J HUM GENET, V51, P1218
   Mackey DA, 2003, EYE, V17, P312, DOI 10.1038/sj.eye.6700362
   Mackey DA, 1996, AM J HUM GENET, V59, P481
   MACKEY DA, 1992, AUST NZ J OPHTHALMOL, V20, P177, DOI 10.1111/j.1442-9071.1992.tb00937.x
   Mackey DA, 2010, NAT REV NEUROL, V6, P357, DOI 10.1038/nrneurol.2010.77
   Mahad DJ, 2007, J NEUROL NEUROSUR PS, V78, P1032
   Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046
   Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x
   MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Mao PZ, 2010, BBA-MOL BASIS DIS, V1802, P66, DOI 10.1016/j.bbadis.2009.07.002
   Marchbank NJ, 2002, J MED GENET, V39, P0, DOI 10.1136/jmg.39.8.e47
   Marella M, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011472
   MARGULIS L, 1971, SCI AM, V225, P49
   Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096
   Martinelli P, 2010, BBA-BIOENERGETICS, V1797, P1, DOI 10.1016/j.bbabio.2009.07.013
   Maruyama H, 2010, NATURE, V465, P223, DOI 10.1038/nature08971
   Mashima Y, 1998, CURR EYE RES, V17, P403, DOI 10.1080/02713689808951221
   Mashima Y, 2000, J NEURO-OPHTHALMOL, V20, P166, DOI 10.1097/00041327-200020030-00006
   Mashima Y, 1996, CLIN GENET, V50, P535
   Mayorov V, 2005, ANN NEUROL, V58, P807, DOI 10.1002/ana.20669
   McFarland R, 2007, NEUROLOGY, V69, P911, DOI 10.1212/01.wnl.0000267843.10977.4a
   McKinley SH, 2005, J NEURO-OPHTHALMOL, V25, P18, DOI 10.1097/00041327-200503000-00005
   MEIRE F, 1985, OPHTHALMIC PAED GEN, V5, P91, DOI 10.3109/13816818509007861
   MEIRE FM, 1995, OPHTHALMIC GENET, V16, P119, DOI 10.3109/13816819509059971
   Melamud A, 2003, MAYO CLIN PROC, V78, P1409, DOI 10.4065/78.11.1409
   Meyer E, 2010, MOL VIS, V16, P650
   Milea D, 2010, ACTA OPHTHALMOL, V88, P342, DOI 10.1111/j.1755-3768.2008.01469.x
   Miller JW, 2008, NEW ENGL J MED, V358, P2282, DOI 10.1056/NEJMe0803081
   Mokranjac D, 2006, EMBO J, V25, P4675, DOI 10.1038/sj.emboj.7601334
   MONTAGNA P, 1995, J NEUROL NEUROSUR PS, V58, P640, DOI 10.1136/jnnp.58.5.640
   Moore BA, 2010, MAMM GENOME, V21, P350, DOI 10.1007/s00335-010-9272-8
   Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009
   Morgan JE, 2004, EYE, V18, P1089, DOI 10.1038/sj.eye.6701574
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Newman NJ, 2009, BRAIN, V132, P2306, DOI 10.1093/brain/awp195
   Newman NJ, 2005, AM J OPHTHALMOL, V140, P407, DOI 10.1016/j.ajo.2005.03.058
   Newman NJ, 2004, EYE, V18, P1144, DOI 10.1038/sj.eye.6701591
   NEWMAN NJ, 1994, AM J OPHTHALMOL, V118, P158, DOI 10.1016/S0002-9394(14)72895-8
   Nijtmans LGJ, 2004, TOP CURR GENET, V8, P149
   NIKOSKELAINEN E, 1977, ARCH OPHTHALMOL-CHIC, V95, P969
   Nikoskelainen EK, 1996, OPHTHALMOLOGY, V103, P504
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   NIKOSKELAINEN EK, 1994, CLIN NEUROSCI, V2, P115
   NIKOSKELAINEN EK, 1994, LANCET, V344, P857, DOI 10.1016/S0140-6736(94)92830-4
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nochez Y, 2009, MOL VIS, V15, P598
   Nolan D, 2004, ANTIVIR THER, V9, P849
   Olichon A, 2006, BBA-MOL CELL RES, V1763, P500, DOI 10.1016/j.bbamcr.2006.04.003
   Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950
   Oostra RJ, 1996, HUM GENET, V97, P500
   OOSTRA RJ, 1995, BIOCHEM BIOPH RES CO, V215, P1001, DOI 10.1006/bbrc.1995.2563
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Ostojic J, 2009, ACTA NEUROL BELG, V109, P305
   Palace J, 2009, J NEUROL SCI, V286, P24, DOI 10.1016/j.jns.2009.09.009
   Pareyson D, 2009, LANCET NEUROL, V8, P654, DOI 10.1016/S1474-4422(09)70110-3
   PARKER WD, 1989, NEW ENGL J MED, V320, P1331, DOI 10.1056/NEJM198905183202007
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pegoraro E, 1996, AM J MED GENET, V61, P356
   Pei WH, 2010, DEVELOPMENT, V137, P2587, DOI 10.1242/dev.043745
   Pellegrini L, 2007, CELL DEATH DIFFER, V14, P1275, DOI 10.1038/sj.cdd.4402145
   Pello R, 2008, HUM MOL GENET, V17, P4001, DOI 10.1093/hmg/ddn303
   PERALESCLEMENTE E, 2010, NUCL ACIDS RES, V0, P0
   Perkins G, 1997, J STRUCT BIOL, V119, P260, DOI 10.1006/jsbi.1997.3885
   Pesch UEA, 2004, INVEST OPHTH VIS SCI, V45, P4217, DOI 10.1167/iovs.03-1261
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Pfeffer G, 2009, NEUROLOGY, V73, P71, DOI 10.1212/WNL.0b013e3181aae814
   Phasukkijwatana N, 2010, HUM GENET, V128, P39, DOI 10.1007/s00439-010-0821-8
   Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149
   Pommer R, 2008, CLIN NEUROPATHOL, V27, P414
   Ponjavic V, 1996, ACTA OPHTHALMOL SCAN, V74, P632
   Powell B, 2003, MOL VIS, V9, P460
   Pradhan M, 2010, SURV OPHTHALMOL, V55, P378, DOI 10.1016/j.survophthal.2009.10.005
   Puomila A, 2005, ACTA OPHTHALMOL SCAN, V83, P337, DOI 10.1111/j.1600-0420.2005.00448.x
   Puomila A, 2007, EUR J HUM GENET, V15, P1079, DOI 10.1038/sj.ejhg.5201828
   Purohit SS, 1997, NEURO-OPHTHALMOLOGY, V18, P111, DOI 10.3109/01658109709044128
   Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P1, DOI 10.1167/iovs.06-0789
   Qi XP, 2007, ARCH OPHTHALMOL-CHIC, V125, P268, DOI 10.1001/archopht.125.2.268
   Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175
   Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quiros PA, 2006, BRIT J OPHTHALMOL, V90, P150, DOI 10.1136/bjo.2005.074526
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1
   Ramos CDF, 2009, INVEST OPHTH VIS SCI, V50, P1666, DOI 10.1167/iovs.08-2695
   Ray K, 2009, J GENET, V88, P451, DOI 10.1007/s12041-009-0065-3
   Reid E, 2003, J MED GENET, V40, P81, DOI 10.1136/jmg.40.2.81
   REYNIER P, 2004, J MED GENET, V0, P41
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   RIZZO JF, 1993, AM J OPHTHALMOL, V116, P84, DOI 10.1016/S0002-9394(14)71749-0
   Rodriguez MC, 2007, MUSCLE NERVE, V35, P235, DOI 10.1002/mus.20688
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   Rötig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4
   Rötig A, 1998, EUR J HUM GENET, V6, P36
   Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620
   Rucker JC, 2006, NEUROLOGY, V66, P595, DOI 10.1212/01.wnl.0000201313.24970.b8
   Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0
   Rustin P, 2004, NEUROLOGY, V62, P524, DOI 10.1212/WNL.62.3.524
   Ryu SW, 2010, CELL MOL LIFE SCI, V67, P2839, DOI 10.1007/s00018-010-0365-z
   Sacai PY, 2010, DOC OPHTHALMOL, V121, P147, DOI 10.1007/s10633-010-9241-2
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Sadun A A, 2000, TRANS AM OPHTHALMOL SOC, V98, P223
   SADUN AA, 1994, ARCH OPHTHALMOL-CHIC, V112, P691, DOI 10.1001/archopht.1994.01090170139037
   Sadun AA, 2003, AM J OPHTHALMOL, V136, P231, DOI 10.1016/S0002-9394(03)00099-0
   Sadun Alfredo A, 2006, TRANS AM OPHTHALMOL SOC, V104, P51
   Saijo T, 2005, AM J OPHTHALMOL, V139, P1114, DOI 10.1016/j.ajo.2004.11.047
   Sala G, 2008, J NEUROSCI RES, V86, P3331, DOI 10.1002/jnr.21773
   Salinas S, 2008, LANCET NEUROL, V7, P1127, DOI 10.1016/S1474-4422(08)70258-8
   Salomao SR, 2004, DOC OPHTHALMOL, V108, P147, DOI 10.1023/B:DOOP.0000036829.37053.31
   Samuels DC, 2006, IUBMB LIFE, V58, P403, DOI 10.1080/15216540600791571
   Sanchez RN, 2006, J NEURO-OPHTHALMOL, V26, P268, DOI 10.1097/01.wno.0000249320.27110.ab
   Sapey E, 2001, NEURO-OPHTHALMOLOGY, V26, P119, DOI 10.1076/noph.26.2.119.10307
   Sato M, 2003, INVEST OPHTH VIS SCI, V44, P1124
   Savini G, 2005, OPHTHALMOLOGY, V112, P127, DOI 10.1016/j.ophtha.2004.09.033
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schimpf S, 2006, HUM GENET, V118, P767, DOI 10.1007/s00439-005-0096-7
   Schmucker S, 2010, HUM MOL GENET, V19, PR103, DOI 10.1093/hmg/ddq165
   Schon EA, 2010, TRENDS MOL MED, V16, P268, DOI 10.1016/j.molmed.2010.04.007
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   Scruggs ER, 2008, PHARMACOLOGY, V82, P83, DOI 10.1159/000134943
   Seo JH, 2010, CLIN EXP OPHTHALMOL, V38, P363, DOI 10.1111/j.1442-9071.2010.02240.x
   SEO JH, 2009, EYE LONDON, V0, P0
   Shah VA, 2008, SURV OPHTHALMOL, V53, P403, DOI 10.1016/j.survophthal.2008.04.003
   Shahrestani P, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0006867
   Shaikh S, 2001, AM J OPHTHALMOL, V131, P143, DOI 10.1016/S0002-9394(00)00716-9
   Shankar SP, 2008, OPHTHALMIC GENET, V29, P17, DOI 10.1080/13816810701867607
   Shi P, 2010, BBA-MOL BASIS DIS, V1802, P45, DOI 10.1016/j.bbadis.2009.08.012
   Shimizu S, 2003, AM J OPHTHALMOL, V135, P256, DOI 10.1016/S0002-9394(02)01929-3
   Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131
   Shorr N, 1987, OPHTHALMIC PLAST RECONSTR SURG, V3, P141, DOI 10.1097/00002341-198703030-00005
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Shy ME, 2002, LANCET NEUROL, V1, P110, DOI 10.1016/S1474-4422(02)00042-X
   Sigal IA, 2010, EXP EYE RES, V90, P70, DOI 10.1016/j.exer.2009.09.013
   Sigal IA, 2009, EXP EYE RES, V88, P799, DOI 10.1016/j.exer.2009.02.003
   Siguroardóttir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902
   SKINNIDER LF, 1976, ARCH PATHOL LAB MED, V100, P601
   SMITH KH, 1993, ARCH OPHTHALMOL-CHIC, V111, P1486, DOI 10.1001/archopht.1993.01090110052022
   SMITH PR, 1994, J NEUROL SCI, V122, P80, DOI 10.1016/0022-510X(94)90055-8
   SMITH U, 1970, J CELL SCI, V7, P501
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzi M, 2008, HUM MOL GENET, V17, P3291, DOI 10.1093/hmg/ddn225
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6
   Spruijt L, 2006, AM J OPHTHALMOL, V141, P676, DOI 10.1016/j.ajo.2005.11.007
   Spruijt L, 2007, ARCH NEUROL-CHICAGO, V64, P890, DOI 10.1001/archneur.64.6.890
   Sripriya S, 2006, MOL VIS, V12, P816
   Stemmler TL, 2010, J BIOL CHEM, V285, P26737, DOI 10.1074/jbc.R110.118679
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   STONE EM, 1992, J CLIN NEURO-OPHTHAL, V12, P10
   Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508
   Sugisaka E, 2007, CLIN EXP OPHTHALMOL, V35, P868, DOI 10.1111/j.1442-9071.2007.01628.x
   Tachibana M, 2009, NATURE, V461, P367, DOI 10.1038/nature08368
   Talman LS, 2010, ANN NEUROL, V67, P749, DOI 10.1002/ana.22005
   Tang S, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0004492
   Tarnopolsky MA, 2008, ADV DRUG DELIVER REV, V60, P1561, DOI 10.1016/j.addr.2008.05.001
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   TAYLOR RW, 2003, J MED GENET, V0, P40
   Tharaphan P, 2006, J NEURO-OPHTHALMOL, V26, P264, DOI 10.1097/01.wno.0000249318.88991.c4
   THOMAS DY, 1968, GENET RES, V11, P33, DOI 10.1017/S0016672300011174
   Tok JBH, 2003, CURR TOP MED CHEM, V3, P1001, DOI 10.2174/1568026033452131
   Tonon C, 2008, EXPERT OPIN PHARMACO, V9, P2327, DOI 10.1517/14656566.9.13.2327
   Tonska K, 2010, BBA-BIOENERGETICS, V1797, P1119, DOI 10.1016/j.bbabio.2010.02.032
   Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369
   TORRONI A, 1994, J BIOENERG BIOMEMBR, V26, P261, DOI 10.1007/BF00763098
   TOUITOU V, 2010, NEUROOPHTHALMOLOGY, V34, P271
   Tranebjaerg L, 2001, OPHTHALMIC GENET, V22, P207
   TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257
   Tranebjaerg L, 1997, AM J HUM GENET, V61, P0
   Tranebjaerg L, 1993, GENEREVIEWS, V0, P0
   TROBE JD, 1980, ARCH OPHTHALMOL-CHIC, V98, P1046
   Tsao K, 1999, BRIT J OPHTHALMOL, V83, P577, DOI 10.1136/bjo.83.5.577
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Ujike H, 2001, ARCH NEUROL-CHICAGO, V58, P1004, DOI 10.1001/archneur.58.6.1004
   Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VANJAARSVELD H, 1992, BASIC RES CARDIOL, V87, P393
   Vanopdenbosch L, 2000, J NEUROL, V247, P535, DOI 10.1007/s004150070153
   Venegas-Francke P, 2000, REV NEUROLOGIA, V31, P699, DOI 10.33588/rn.3107.2000406
   VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740
   Verny C, 2008, NEUROLOGY, V70, P1152, DOI 10.1212/01.wnl.0000289194.89359.a1
   Votruba M, 1998, J MED GENET, V35, P793, DOI 10.1136/jmg.35.10.793
   Votruba M, 2003, BRIT J OPHTHALMOL, V87, P48, DOI 10.1136/bjo.87.1.48
   Votruba M, 1998, ARCH OPHTHALMOL-CHIC, V116, P351, DOI 10.1001/archopht.116.3.351
   WAKAKURA M, 1995, BRIT J OPHTHALMOL, V79, P442, DOI 10.1136/bjo.79.5.442
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Walsh MK, 2008, J NEUROSCI METH, V169, P214, DOI 10.1016/j.jneumeth.2007.11.029
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Weisschuh N, 2005, MOL VIS, V11, P284
   Wheeler L, 2003, SURV OPHTHALMOL, V48, PS47, DOI 10.1016/S0039-6257(03)00004-3
   White KE, 2009, INVEST OPHTH VIS SCI, V50, P2567, DOI 10.1167/iovs.08-2913
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P30, DOI 10.1001/archopht.125.1.30
   Wilkinson PA, 2004, BRAIN, V127, P973, DOI 10.1093/brain/awh125
   Williams PA, 2010, BRAIN, V133, P2942, DOI 10.1093/brain/awq218
   Wissinger B, 1997, BIOCHEM BIOPH RES CO, V234, P511, DOI 10.1006/bbrc.1997.6660
   WOLF C, 2009, BMC MED GENET, V0, P10
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Woo SJ, 2004, J GLAUCOMA, V13, P492, DOI 10.1097/01.ijg.0000137870.25779.40
   Yaffe MP, 2003, P NATL ACAD SCI USA, V100, P11424, DOI 10.1073/pnas.1534703100
   Yang Z, 2007, MUTAT RES-FUND MOL M, V621, P61, DOI 10.1016/j.mrfmmm.2007.02.010
   Yao WL, 2006, MOL VIS, V12, P649
   Yarosh W, 2008, PLOS GENET, V4, P0, DOI 10.1371/journal.pgen.0040006
   Yen MY, 2004, INVEST OPHTH VIS SCI, V45, P1688, DOI 10.1167/iovs.03-0568
   Yen MY, 2002, JPN J OPHTHALMOL, V46, P45, DOI 10.1016/S0021-5155(01)00460-9
   Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2010, J MED GENET, V47, P120, DOI 10.1136/jmg.2009.067512
   Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270
   Yu-Wai-Man P, 2010, BRAIN, V0, P0
   Yu-Wai-Man P, 2008, J NEURO-OPHTHALMOL, V28, P155, DOI 10.1097/WNO.0b013e3181772db4
   Yu-Wai-Man P, 2010, OPHTHALMOLOGY, V117, P1538, DOI 10.1016/j.ophtha.2009.12.038
   Yu-Wai-Man P, 2010, HUM MOL GENET, V19, P3043, DOI 10.1093/hmg/ddq209
   Yu-Wai-Man P, 2009, INVEST OPHTH VIS SCI, V50, P4561, DOI 10.1167/iovs.09-3634
   YUNIS AA, 1989, AM J MED, V87, P0
   YUNIS AA, 1970, ARCH INTERN MED, V126, P272, DOI 10.1001/archinte.126.2.272
   YUWAIMAN P, 2010, OPHTHALMOLOGY, V0, P0
   Zanna C, 2003, ANN NY ACAD SCI, V1010, P213, DOI 10.1196/annals.1299.037
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   Zaveri MS, 2008, ARCH NEUROL-CHICAGO, V65, P924, DOI 10.1001/archneur.65.7.924
   Zeviani M, 2008, BRAIN, V131, P314, DOI 10.1093/brain/awm339
   Zhadanov SI, 2005, BIOCHEM BIOPH RES CO, V332, P1115, DOI 10.1016/j.bbrc.2005.05.059
   Zhang AM, 2010, HUM GENET, V128, P465, DOI 10.1007/s00439-010-0875-7
   Zhang X, 2002, NEUROSCI LETT, V326, P97, DOI 10.1016/S0304-3940(02)00327-0
   Zhu G, 2007, CURR BIOL, V17, P1438, DOI 10.1016/j.cub.2007.07.041
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
   Züchner S, 2006, NAT CLIN PRACT NEURO, V2, P45, DOI 10.1038/ncpneuro0071
NR 506
TC 435
Z9 466
U1 2
U2 72
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR 15
PY 2011
VL 30
IS 2
BP 81
EP 114
DI 10.1016/j.preteyeres.2010.11.002
PG 34
WC Ophthalmology
SC Ophthalmology
GA 735MX
UT WOS:000288420200001
PM 21112411
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Malfatti, E
   Da Pozzo, P
   Gallus, GN
   Carluccio, MA
   Rufa, A
   Volpi, N
   Dotti, MT
   Federico, A
AF Cardaioli, Elena
   Malfatti, Edoardo
   Da Pozzo, Paola
   Gallus, Gian Nicola
   Carluccio, Maria Alessandra
   Rufa, Alessandra
   Volpi, Nila
   Dotti, Maria Teresa
   Federico, Antonio
TI Progressive mitochondrial myopathy, deafness, and sporadic seizures associated with a novel mutation in the mitochondrial tRNASer<SUP>(AGY)</SUP> gene
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Encephalomyopathies; Mitochondrial DNA; tRNASer((AGY)); Heteroplasmy; Single fibres studies; Pathogenicity; Muscle biochemical analysis
ID transfer-rna mutations; point mutation; dna mutations
AB We sequenced the mitochondrial genome from a patient with progressive mitochondrial myopathy associated with deafness, sporadic seizures, and histological and biochemical features of mitochondrial respiratory chain dysfunction. Direct sequencing showed a heteroplasmic mutation at nucleotide 12262 in the tRNASer((AGY)) gene. RFLP analysis confirmed that 63% of muscle mtDNA harboured the mutation, while it was absent in all the other tissues. The mutation is predicted to influence the functional behaviour of the aminoacyl acceptor stem of the tRNA. Several point mutations on mitochondrial tRNA genes have been reported in patients affected by encephalomyopathies, but between them only four were reported for tRNASer((AGY)). (C) 2011 Elsevier B.V. All rights reserved.
C1 [Cardaioli, Elena; Malfatti, Edoardo; Da Pozzo, Paola; Gallus, Gian Nicola; Carluccio, Maria Alessandra; Rufa, Alessandra; Dotti, Maria Teresa; Federico, Antonio] Univ Siena, Dept Neurol Neurosurg & Behav Sci, I-53100 Siena, Italy.
   [Volpi, Nila] Univ Siena, Dept Biomed Sci, Sect Anat & Histol, I-53100 Siena, Italy.
C3 University of Siena; University of Siena
RP Federico, A (corresponding author), Univ Siena, Dept Neurol Neurosurg & Behav Sci, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
FU University of Siena [PAR 2008]
CR Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   HOLME E, 1995, BBA-MOL BASIS DIS, V1271, P249, DOI 10.1016/0925-4439(95)00035-3
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Wong LJC, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.040626
   Zeviani M, 1996, J INHERIT METAB DIS, V19, P504, DOI 10.1007/BF01799111
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 17
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2011
VL 303
IS 1-2
BP 142
EP 145
DI 10.1016/j.jns.2010.12.020
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 747SO
UT WOS:000289339900025
PM 21257182
DA 2024-11-01
ER

PT J
AU McKiernan, SH
   Colman, RJ
   Lopez, M
   Beasley, TM
   Aiken, JM
   Anderson, RM
   Weindruch, R
AF McKiernan, Susan H.
   Colman, Ricki J.
   Lopez, Marisol
   Beasley, T. Mark
   Aiken, Judd M.
   Anderson, Rozalyn M.
   Weindruch, Richard
TI Caloric restriction delays aging-induced cellular phenotypes in rhesus monkey skeletal muscle
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Sarcopenia; Calorie restriction; Rhesus monkey
ID dna deletion mutations; dietary restriction; causal role; sarcopenia; mass; abnormality; apoptosis; disease; atrophy; fibers
AB Sarcopenia is the age-related loss of skeletal muscle mass and function and is characterized by a reduction in muscle mass and fiber cross-sectional area, alterations in muscle fiber type and mitochondrial functional changes. In rhesus monkeys, calorie restriction (CR) without malnutrition improves survival and delays the onset of age-associated diseases and disorders including sarcopenia. We present a longitudinal study on the impact of CR on early stage sarcopenia in the upper leg of monkeys from similar to 16 years to similar to 22 years of age. Using dual-energy X-ray absorptiometry we show that CR delayed the development of maximum muscle mass and, unlike Control animals, muscle mass of the upper leg was preserved in CR animals during early phase sarcopenia. Histochemical analyses of vastus lateralis muscle biopsies revealed that CR opposed age-related changes in the proportion of Type II muscle fibers and fiber cross-sectional area. In contrast the number of muscle fibers with mitochondrial electron transport system enzyme abnormalities (ETSab) was not significantly affected by CR. Laser capture microdissection of ETSab fibers and subsequent PCR analysis of the mitochondria! DNA revealed large deletion mutations in fibers with abnormal mitochondrial enzyme activities. CR did not prevent stochastic mitochondrial deletion mutations in muscle fibers but CR may have contributed to the maintenance of affected fibers. (c) 2010 Elsevier Inc. All rights reserved.
C1 [McKiernan, Susan H.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA.
   [McKiernan, Susan H.; Colman, Ricki J.; Lopez, Marisol] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
   [Lopez, Marisol; Aiken, Judd M.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA.
   [Beasley, T. Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
   [Aiken, Judd M.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2M8, Canada.
   [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.
   [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, William S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; University of Alberta; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center
RP McKiernan, SH (corresponding author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA.
EM shmckier@wisc.edu
FU NIH [P01 AG-11915, P51 RR000167]; Ellison Medical Foundation; Research Facilities Improvement Program [RR15459-01, RR020141-01]
CR Anderson RM, 2010, TRENDS ENDOCRIN MET, V21, P134, DOI 10.1016/j.tem.2009.11.005
   Bua EA, 2004, FASEB J, V18, P582, DOI 10.1096/fj.03-0668fje
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Colman RJ, 2008, J GERONTOL A-BIOL, V63, P556, DOI 10.1093/gerona/63.6.556
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Colman RJ, 2005, EXP GERONTOL, V40, P573, DOI 10.1016/j.exger.2005.05.001
   Degens H, 2007, JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, V7, P246
   Degens H, 2006, INT J SPORTS MED, V27, P94, DOI 10.1055/s-2005-837571
   Dirks AJ, 2006, AGEING RES REV, V5, P179, DOI 10.1016/j.arr.2006.03.002
   Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, V2nd, P0
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   Gresl TA, 2001, AM J PHYSIOL-ENDOC M, V281, PE757, DOI 10.1152/ajpendo.2001.281.4.E757
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Hollmann W, 2007, EUR J CARDIOV PREV R, V14, P730, DOI 10.1097/HJR.0b013e32828622f9
   Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009
   Hughes VA, 2001, J GERONTOL A-BIOL, V56, PB209, DOI 10.1093/gerona/56.5.B209
   Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x
   KEMNITZ JW, 1993, J GERONTOL, V48, PB17, DOI 10.1093/geronj/48.1.B17
   LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91
   LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3
   Lushaj EB, 2008, J GERONTOL A-BIOL, V63, P921, DOI 10.1093/gerona/63.9.921
   Marzetti E, 2010, BBA-GEN SUBJECTS, V1800, P235, DOI 10.1016/j.bbagen.2009.05.007
   McKenzie D, 2002, EUR J BIOCHEM, V269, P2010, DOI 10.1046/j.1432-1033.2002.02867.x
   McKiernan SH, 2009, EXP GERONTOL, V44, P170, DOI 10.1016/j.exger.2008.09.014
   Nair K S, 2000, MAYO CLIN PROC, V75 Suppl, P0
   Pette D, 2002, CAN J APPL PHYSIOL, V27, P423, DOI 10.1139/h02-023
   Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2
   Redman LM, 2008, PHYSIOL BEHAV, V94, P643, DOI 10.1016/j.physbeh.2008.04.017
   Rossi Paola, 2008, CURR AGING SCI, V1, P182
   Roth SM, 2006, CURR OPIN RHEUMATOL, V18, P625, DOI 10.1097/01.bor.0000245722.10136.6d
   Roy A, 2006, BIOMETRICAL J, V48, P286, DOI 10.1002/bimj.200510192
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   Sheehan DC, 1980, THEORY AND PRACTICE OF HISTOTECHNOLOGY, Vsecond, P0
   Tews DS, 2005, MUSCLE NERVE, V32, P443, DOI 10.1002/mus.20348
   Thomas DR, 2007, CLIN NUTR, V26, P389, DOI 10.1016/j.clnu.2007.03.008
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Zierath JR, 2004, PLOS BIOL, V2, P1523, DOI 10.1371/journal.pbio.0020348
NR 37
TC 74
Z9 79
U1 0
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD JAN 15
PY 2011
VL 46
IS 1
BP 23
EP 29
DI 10.1016/j.exger.2010.09.011
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 710UP
UT WOS:000286542800004
PM 20883771
DA 2024-11-01
ER

PT J
AU Zhang, LS
   Chan, SSL
   Wolff, DJ
AF Zhang, Linsheng
   Chan, Sherine S. L.
   Wolff, Daynna J.
TI Mitochondrial Disorders of DNA Polymerase γ Dysfunction From Anatomic to Molecular Pathology Diagnosis
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Review
ID progressive external ophthalmoplegia; proton mr spectroscopy; p55 accessory subunit; base excision-repair; marie-tooth disease; alpers-syndrome; binding-protein; polg mutations; in-vitro; neuronal degeneration
AB Context.-Primary mitochondrial dysfunction is one of the most common causes of inherited disorders predominantly involving the neuromuscular system. Advances in the molecular study of mitochondrial DNA have changed our vision and our approach to primary mitochondrial disorders. Many of the mitochondrial disorders are caused by mutations in nuclear genes and are inherited in an autosomal recessive pattern. Among the autosomal inherited mitochondrial disorders, those related to DNA polymerase g dysfunction are the most common and the best studied. Understanding the molecular mechanisms and being familiar with the recent advances in laboratory diagnosis of this group of mitochondrial disorders are essential for pathologists to interpret abnormal histopathology and laboratory results and to suggest further studies for a definitive diagnosis. Objectives.-To help pathologists better understand the common clinical syndromes originating from mutations in DNA polymerase g and its associated proteins and use the stepwise approach of clinical, laboratory, and pathologic diagnosis of these syndromes. Data Sources-Review of pertinent published literature and relevant Internet databases. Conclusions-Mitochondrial disorders are now better recognized with the development of molecular tests for clinical diagnosis. A cooperative effort among primary physicians, diagnostic pathologists, geneticists, and molecular biologists with expertise in mitochondrial disorders is required to reach a definitive diagnosis. (Arch Pathol Lab Med. 2011;135:925-934)
C1 [Zhang, Linsheng; Wolff, Daynna J.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
   [Chan, Sherine S. L.] Med Univ S Carolina, S Carolina Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South Carolina
RP Zhang, LS (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,Suite 309,MSC 908, Charleston, SC 29425 USA.
EM zha@musc.edu
FU National Institutes of Health [5 R00 ES015555-03]
CR ALBERTS B, 2002, MOL BIOL CELL, V34, P808
   ALPERS BJ, 1960, J NERV MENT DIS, V130, P442, DOI 10.1097/00005053-196006000-00002
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bailey CM, 2009, ANTIMICROB AGENTS CH, V53, P2610, DOI 10.1128/AAC.01659-08
   Banchs I, 2009, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2009/985415
   Barshop BA, 2004, MITOCHONDRION, V4, P521, DOI 10.1016/j.mito.2004.07.010
   Bau V, 2005, STRABISMUS, V13, P133, DOI 10.1080/09273970500216432
   Bianchi MC, 2003, AM J NEURORADIOL, V24, P1958
   BOLDEN A, 1977, J BIOL CHEM, V252, P3351
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Castro-Gago M, 2006, PEDIATR NEUROL, V34, P204, DOI 10.1016/j.pediatrneurol.2005.07.011
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Coon KD, 2006, MITOCHONDRION, V6, P194, DOI 10.1016/j.mito.2006.07.002
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Daut PM, 2000, AM J OPHTHALMOL, V130, P519, DOI 10.1016/S0002-9394(00)00558-4
   Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753
   Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166
   Delarue A, 2000, PEDIATR TRANSPLANT, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Dinopoulos A, 2005, NEUROPEDIATRICS, V36, P290, DOI 10.1055/s-2005-872807
   Edmond Jane C, 2009, INT OPHTHALMOL CLIN, V49, P27, DOI 10.1097/IIO.0b013e3181a8de58
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Farr CL, 2004, J BIOL CHEM, V279, P17047, DOI 10.1074/jbc.M400283200
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   Frederiksen AL, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.039339
   Gauthier-Villars M, 2001, NEUROPEDIATRICS, V32, P150, DOI 10.1055/s-2001-16614
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Gordon N, 2006, DEV MED CHILD NEUROL, V48, P1001, DOI 10.1017/S0012162206002209
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Hong DJ, 2010, MUSCLE NERVE, V41, P92, DOI 10.1002/mus.21439
   HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kayihan N, 2000, PEDIATR TRANSPLANT, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LANGDON HM, 1928, T AM OPHTHAL SOC, V26, P247
   Lee HR, 2007, J BIOL CHEM, V282, P31982, DOI 10.1074/jbc.M705392200
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378
   LESTIENNE P, 1987, BIOCHEM BIOPH RES CO, V146, P1146, DOI 10.1016/0006-291X(87)90767-4
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Lin DDM, 2003, AM J NEURORADIOL, V24, P33
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   LOU HC, 1976, ARCH NEUROL-CHICAGO, V33, P455, DOI 10.1001/archneur.1976.00500060061014
   Maier D, 2001, MOL BIOL CELL, V12, P821, DOI 10.1091/mbc.12.4.821
   Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200
   Naess K, 2009, BBA-BIOENERGETICS, V1787, P484, DOI 10.1016/j.bbabio.2008.11.014
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   Pinz KG, 2006, DNA REPAIR, V5, P121, DOI 10.1016/j.dnarep.2005.08.014
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schwabe MJ, 1997, PEDIATR NEUROL, V16, P337, DOI 10.1016/S0887-8994(97)00030-1
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Szigeti K, 2009, EUR J HUM GENET, V17, P703, DOI 10.1038/ejhg.2009.31
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   WILSON DC, 1993, EUR J PEDIATR, V152, P260, DOI 10.1007/BF01956158
   Wong LJC, 2010, DEV DISABIL RES REV, V16, P154, DOI 10.1002/ddrr.104
   Yakubovskaya E, 2007, EMBO J, V26, P4283, DOI 10.1038/sj.emboj.7601843
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Ziebarth TD, 2010, J BIOL CHEM, V285, P14639, DOI 10.1074/jbc.M109.099663
   ZINTZ R, 1967, OPHTHALMOLOGICA, V153, P439, DOI 10.1159/000305086
NR 96
TC 9
Z9 12
U1 0
U2 7
PU COLLEGE AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD JUL 15
PY 2011
VL 135
IS 7
BP 925
EP 934
DI 
PG 10
WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology
GA 790PW
UT WOS:000292602700019
PM 21732785
DA 2024-11-01
ER

PT J
AU Giulivi, C
   Ross-Inta, C
   Omanska-Klusek, A
   Napoli, E
   Sakaguchi, D
   Barrientos, G
   Allen, PD
   Pessah, IN
AF Giulivi, Cecilia
   Ross-Inta, Catherine
   Omanska-Klusek, Alicja
   Napoli, Eleonora
   Sakaguchi, Danielle
   Barrientos, Genaro
   Allen, Paul D.
   Pessah, Isaac N.
TI Basal Bioenergetic Abnormalities in Skeletal Muscle from Ryanodine Receptor Malignant Hyperthermia-susceptible R163C Knock-in Mice
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID central-core disease; activated protein-kinase; saturated fatty-acids; rat skeletal; oxidative-phosphorylation; gene-expression; fiber-type; subcellular-fractions; calcium-homeostasis; diabetes-mellitus
AB Malignant hyperthermia (MH) and central core disease in humans have been associated with mutations in the skeletal ryanodine receptor (RyR1). Heterozygous mice expressing the human MH/central core disease RyR1 R163C mutation exhibit MH when exposed to halothane or heat stress. Considering that many MH symptoms resemble those that could ensue from a mitochondrial dysfunction (e.g. metabolic acidosis and hyperthermia) and that MH-susceptible mice or humans have a higher than normal cytoplasmic Ca2+ concentration at rest, we evaluated the role of mitochondria in skeletal muscle from R163C compared with wild type mice under basal (untriggered) conditions. R163C skeletal muscle exhibited a significant increase in matrix Ca2+, increased reactive oxygen species production, lower expression of mitochondrial proteins, and higher mtDNA copy number. These changes, in conjunction with lower myoglobin and glycogen contents, Myh4 and GAPDH transcript levels, GAPDH activity, and lower glucose utilization suggested a switch to a compromised bioenergetic state characterized by both low oxidative phosphorylation and glycolysis. The shift in bioenergetic state was accompanied by a dysregulation of Ca2+-esponsive signaling pathways regulated by calcineurin and ERK1/2. Chronically elevated resting Ca2+ in R163C skeletal muscle elicited the maintenance of a fast-twitch fiber program and the development of insulin resistance-like phenotype as part of a metabolic adaptation to the R163C RyR1 mutation.
C1 [Giulivi, Cecilia; Ross-Inta, Catherine; Omanska-Klusek, Alicja; Napoli, Eleonora; Sakaguchi, Danielle; Barrientos, Genaro; Pessah, Isaac N.] Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA.
   [Allen, Paul D.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
C3 University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital
RP Giulivi, C (corresponding author), Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, 1120 Haring Hall,1 Shields Ave, Davis, CA 95616 USA.
EM cgiulivi@ucdavis.edu
FU National Institutes of Health [012691, RC1DK087307]; NIEHS;  [2R0 AR043140];  [1P01 AR052354]
CR Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25
   Aleman M, 2004, MUSCLE NERVE, V30, P356, DOI 10.1002/mus.20084
   ALMARAZ L, 1989, FEBS LETT, V244, P417, DOI 10.1016/0014-5793(89)80575-7
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Andrienko T, 2003, J EXP BIOL, V206, P2059, DOI 10.1242/jeb.00242
   Argaud L, 2008, AM J PHYSIOL-HEART C, V294, PH386, DOI 10.1152/ajpheart.01035.2007
   Ashcroft SJH, 2002, BIOCHEMICAL SOCIETY TRANSACTIONS, V30, P0
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Benton CR, 2008, J BIOL CHEM, V283, P4228, DOI 10.1074/jbc.M704332200
   Bina S, 2006, ANESTHESIOLOGY, V104, P90, DOI 10.1097/00000542-200601000-00015
   Bizeau ME, 1998, J APPL PHYSIOL, V85, P1279, DOI 10.1152/jappl.1998.85.4.1279
   BOCEK RM, 1966, AM J PHYSIOL, V210, P1108, DOI 10.1152/ajplegacy.1966.210.5.1108
   BOCEK RM, 1966, AM J PHYSIOL, V210, P1101, DOI 10.1152/ajplegacy.1966.210.5.1101
   BOCEK RM, 1966, J HISTOCHEM CYTOCHEM, V14, P549, DOI 10.1177/14.7.549
   BOLENDER RP, 1978, J CELL BIOL, V77, P565, DOI 10.1083/jcb.77.2.565
   Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496
   BOOKELMAN H, 1978, BIOCHEM MED METAB B, V20, P404, DOI 10.1016/0006-2944(78)90090-X
   Boushel R, 2007, DIABETOLOGIA, V50, P790, DOI 10.1007/s00125-007-0594-3
   Britt BA, 1973, INT S MALIGNANT HYPE, V0, P387
   BRITT BA, 1973, CAN ANAESTH SOC J, V20, P431, DOI 10.1007/BF03026208
   Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281
   Buck ED, 1997, J BIOL CHEM, V272, P7360, DOI 10.1074/jbc.272.11.7360
   BULLOCK GR, 1973, BIOCHIM BIOPHYS ACTA, V292, P350, DOI 10.1016/0005-2728(73)90041-8
   BYRNE E, 1985, J NEUROL SCI, V69, P319, DOI 10.1016/0022-510X(85)90143-1
   Calabria E, 2009, P NATL ACAD SCI USA, V106, P13335, DOI 10.1073/pnas.0812911106
   CAMPBELL IT, 1981, ANESTHESIOLOGY, V55, P46, DOI 10.1097/00000542-198107000-00010
   Mulero M, 2007, BBA-MOL CELL RES, V1773, P330, DOI 10.1016/j.bbamcr.2006.12.007
   Carpenter D, 2009, BMC MED GENET, V10, P0, DOI 10.1186/1471-2350-10-104
   CHANCE B, 1955, NATURE, V175, P1120, DOI 10.1038/1751120a0
   CHANCE B, 1959, CIBA F S REGULATION, V0, P91
   Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020
   Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200
   Cherednichenko G, 2004, P NATL ACAD SCI USA, V101, P15793, DOI 10.1073/pnas.0403485101
   Cherednichenko G, 2008, MOL PHARMACOL, V73, P1203, DOI 10.1124/mol.107.043299
   Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499
   Cross HR, 2002, J MOL CELL CARDIOL, V34, P361, DOI 10.1006/jmcc.2001.1518
   Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x
   Davis MR, 2003, NEUROMUSCULAR DISORD, V13, P151, DOI 10.1016/S0960-8966(02)00218-3
   Delp MD, 1996, J APPL PHYSIOL, V80, P261, DOI 10.1152/jappl.1996.80.1.261
   DENBOROUGH MA, 1962, BRIT J ANAESTH, V34, P395, DOI 10.1093/bja/34.6.395
   DENBOROUGH MA, 1970, LANCET, V1, P1137
   Dennis G, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-9-r60
   DUBOWITZ V, 1960, LANCET, V2, P23
   Durham WJ, 2008, CELL, V133, P53, DOI 10.1016/j.cell.2008.02.042
   Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200
   Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, PH22, DOI 10.1152/ajpheart.00766.2003
   ELLIS FR, 1973, P ROY SOC MED, V66, P66, DOI 10.1177/00359157730661P132
   Engstrom I, 1996, SCAND J CLIN LAB INV, V56, P345, DOI 10.3109/00365519609090586
   Espinosa A, 2004, J ENDOCRINOL, V182, P339, DOI 10.1677/joe.0.1820339
   Estabrook RW, 1974, METHODS ENZYMOLOGY, V10, P41
   EVERTS ME, 1993, ACTA PHYSIOL SCAND, V147, P357, DOI 10.1111/j.1748-1716.1993.tb09512.x
   FENG L, 1992, CELL CALCIUM, V13, P79, DOI 10.1016/0143-4160(92)90001-9
   FENOGLIO JJ, 1977, AM J PATHOL, V89, P51
   FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6
   FOSTER PS, 1989, MUSCLE NERVE, V12, P390, DOI 10.1002/mus.880120509
   Fujisawa Y, 2009, BIOCHEM J, V423, P219, DOI 10.1042/BJ20090594
   GAZZOTTI P, 1985, BIOCHEM BIOPH RES CO, V127, P358, DOI 10.1016/S0006-291X(85)80167-4
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R
   GIULIVI C, 2003, SIGNAL TRANSDUCTION, V0, PP311, DOI 10.1007/0-306-48412-917
   Gubern C, 2009, BMC MOL BIOL, V10, P0, DOI 10.1186/1471-2199-10-57
   Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604
   Hancock CR, 2005, AM J PHYSIOL-CELL PH, V288, PC1287, DOI 10.1152/ajpcell.00567.2004
   Hannken T, 2000, J AM SOC NEPHROL, V11, P1387, DOI 10.1681/ASN.V1181387
   HARIGAYA S, 1968, J BIOCHEM, V63, P324
   Hatefi Y, 1978, METHODS ENZYMOL, V53, P21
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   HEDMAN R, 1962, BIOCHEM BIOPH RES CO, V8, P314, DOI 10.1016/0006-291X(62)90285-1
   Hollander AS, 2003, PEDIATRICS, V111, P1447, DOI 10.1542/peds.111.6.1447
   Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hwang H, 2010, DIABETES, V59, P33, DOI 10.2337/db09-0214
   Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4
   Imai K, 2006, BIOCHEM BIOPH RES CO, V351, P595, DOI 10.1016/j.bbrc.2006.10.056
   Jungbluth H, 2005, NEUROLOGY, V65, P1930, DOI 10.1212/01.wnl.0000188870.37076.f2
   Jungbluth Heinz, 2004, NEUROMUSCUL DISORD, V14, P754, DOI 10.1016/j.nmd.2004.07.007
   Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D
   Kilbane BJ, 2006, PEDIATR CRIT CARE ME, V7, P169, DOI 10.1097/01.PCC.0000192340.09136.82
   Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284
   Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61
   LEBARON FN, 1959, J NEUROCHEM, V4, P1, DOI 10.1111/j.1471-4159.1959.tb13168.x
   Leblondel G, 2001, BIOL TRACE ELEM RES, V83, P191, DOI 10.1385/BTER:83:3:191
   LEBLONDEL G, 1988, BIOL TRACE ELEM RES, V16, P115, DOI 10.1007/BF02797096
   Lin HY, 2003, FREE RADICAL BIO MED, V35, P528, DOI 10.1016/S0891-5849(03)00358-7
   LO S, 1970, J APPL PHYSIOL, V28, P234, DOI 10.1152/jappl.1970.28.2.234
   Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9
   Long YC, 2007, J BIOL CHEM, V282, P1607, DOI 10.1074/jbc.M609208200
   López JR, 2005, AM J PHYSIOL-CELL PH, V288, PC606, DOI 10.1152/ajpcell.00297.2004
   MANNESCHI L, 1995, J NEUROL SCI, V128, P151, DOI 10.1016/0022-510X(94)00227-F
   MARBAN E, 1980, NATURE, V286, P845, DOI 10.1038/286845a0
   MAX SR, 1972, ANAL BIOCHEM, V46, P576, DOI 10.1016/0003-2697(72)90328-4
   McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D
   Mezin P, 1997, BRIT J ANAESTH, V79, P327, DOI 10.1093/bja/79.3.327
   MEZON BJ, 1974, CAN J BIOCHEM CELL B, V52, P1024, DOI 10.1139/o74-143
   MICKELSON JR, 1980, ANAL BIOCHEM, V109, P255, DOI 10.1016/0003-2697(80)90645-4
   Missihoun C, 2009, MOL CELL BIOCHEM, V321, P45, DOI 10.1007/s11010-008-9908-0
   Monnier N, 2001, HUM MOL GENET, V10, P2581, DOI 10.1093/hmg/10.22.2581
   Monnier N, 2003, HUM MOL GENET, V12, P1171, DOI 10.1093/hmg/ddg121
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mu XD, 2007, PHYSIOL GENOMICS, V30, P300, DOI 10.1152/physiolgenomics.00286.2006
   Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545
   NISHIYAMA A, 1966, ACTA MED OKAYAMA, V20, P137
   OBRIEN PJ, 1990, RES VET SCI, V48, P124, DOI 10.1016/S0034-5288(18)31522-4
   OBRIEN PJ, 1990, CAN J VET RES, V54, P83
   PALMER JW, 1977, J BIOL CHEM, V252, P8731
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011
   PAYEN JF, 1993, ANESTHESIOLOGY, V78, P848, DOI 10.1097/00000542-199305000-00007
   PAYEN JF, 1991, LANCET, V337, P1550, DOI 10.1016/0140-6736(91)93247-7
   PETER JB, 1967, BIOCHEM BIOPH RES CO, V29, P430, DOI 10.1016/0006-291X(67)90475-5
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Porta S, 2007, EUR J NEUROSCI, V26, P1213, DOI 10.1111/j.1460-9568.2007.05749.x
   QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51
   Rasmussen HN, 1997, ANAL BIOCHEM, V252, P153, DOI 10.1006/abio.1997.2304
   Rasmussen HN, 1997, MOL CELL BIOCHEM, V174, P55, DOI 10.1023/A:1006851705996
   Ritov VB, 2010, AM J PHYSIOL-ENDOC M, V298, PE49, DOI 10.1152/ajpendo.00317.2009
   Riva A, 2005, AM J PHYSIOL-HEART C, V289, PH868, DOI 10.1152/ajpheart.00866.2004
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595
   Robinson R, 2006, HUM MUTAT, V27, P977, DOI 10.1002/humu.20356
   Robinson RL, 2002, HUM MUTAT, V20, P88, DOI 10.1002/humu.10098
   Ross-Inta C, 2008, BIOSCIENCE REP, V28, P239, DOI 10.1042/BSR20080090
   Rueffert H, 2004, AM J MED GENET A, V124A, P248, DOI 10.1002/ajmg.a.20404
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sahlin K, 2002, J PHYSIOL-LONDON, V541, P569, DOI 10.1113/jphysiol.2002.016683
   Sambuughin N, 2001, AM J HUM GENET, V69, P204, DOI 10.1086/321270
   Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200
   SCHILLER HH, 1974, J NEUROL SCI, V21, P93, DOI 10.1016/0022-510X(74)90109-9
   SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97
   Shi H, 2007, AM J PHYSIOL-CELL PH, V292, PC1681, DOI 10.1152/ajpcell.00466.2006
   Shi H, 2008, FASEB J, V22, P2990, DOI 10.1096/fj.07-097600
   SHUAIB A, 1987, MEDICINE, V66, P389, DOI 10.1097/00005792-198709000-00004
   SHY GM, 1956, BRAIN, V79, P610, DOI 10.1093/brain/79.4.610
   SMITH MJH, 1956, BIOCHEM J, V63, P524, DOI 10.1042/bj0630524
   Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305
   TAYLOR WM, 1980, BIOCHEM J, V188, P443, DOI 10.1042/bj1880443
   Tilgen N, 2001, HUM MOL GENET, V10, P2879, DOI 10.1093/hmg/10.25.2879
   Treves S, 2005, NEUROMUSCULAR DISORD, V15, P577, DOI 10.1016/j.nmd.2005.06.008
   Treves S, 2008, CURR OPIN PHARMACOL, V8, P319, DOI 10.1016/j.coph.2008.01.005
   VALLIERES J, 1975, ARCH BIOCHEM BIOPHYS, V170, P659, DOI 10.1016/0003-9861(75)90162-9
   Venkatraman R, 2006, INDIAN JOURNAL OF PEDIATRICS, V73, P55, DOI 10.1007/BF02758261
   WANG JK, 1969, ANESTHESIOLOGY, V30, P439, DOI 10.1097/00000542-196904000-00015
   Wappler F, 2001, EUR J ANAESTH, V18, P632, DOI 10.1046/j.1365-2346.2001.00888.x
   WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390
   WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764
   WILSON RD, 1971, SOUTHERN MED J, V64, P411, DOI 10.1097/00007611-197104000-00006
   Wright DC, 2004, LIFE SCI, V74, P815, DOI 10.1016/j.lfs.2003.06.041
   WROGEMANN K, 1973, ARCH BIOCHEM BIOPHYS, V159, P267, DOI 10.1016/0003-9861(73)90453-0
   Wu SW, 2006, BRAIN, V129, P1470, DOI 10.1093/brain/awl077
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yang TZ, 2006, ANESTHESIOLOGY, V105, P1164, DOI 10.1097/00000542-200612000-00016
   Yang TZ, 2007, AM J PHYSIOL-CELL PH, V292, PC1591, DOI 10.1152/ajpcell.00133.2006
   Yang TZ, 2003, J BIOL CHEM, V278, P25722, DOI 10.1074/jbc.M302165200
   Yoshida M, 2006, AM J PHYSIOL-REG I, V290, PR449, DOI 10.1152/ajpregu.00684.2004
   Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200
   ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46
   Zhao P, 2008, EXP BIOL MED, V233, P1289, DOI 10.3181/0803-RM-84
   ZHENG XX, 1990, BIOCHIM BIOPHYS ACTA, V1019, P1, DOI 10.1016/0005-2728(90)90118-N
   Zimmermann P, 2000, LIFE SCI, V67, P949, DOI 10.1016/S0024-3205(00)00688-3
NR 160
TC 41
Z9 45
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 7
PY 2011
VL 286
IS 1
BP 99
EP 113
DI 10.1074/jbc.M110.153247
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 700YZ
UT WOS:000285782800011
PM 20978128
DA 2024-11-01
ER

PT J
AU Schaller, A
   Desetty, R
   Hahn, D
   Jackson, CB
   Nuoffer, JM
   Gallati, S
   Levinger, L
AF Schaller, A.
   Desetty, R.
   Hahn, D.
   Jackson, C. B.
   Nuoffer, J. -M.
   Gallati, S.
   Levinger, L.
TI Impairment of mitochondrial tRNA<SUP>Ile</SUP> processing by a novel mutation associated with chronic progressive external ophthalmoplegia
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial disease; CPEO; Mitochondrial tRNA; 3 ' end processing; MT-TI
ID dna point mutation; transfer-rna; hypertrophic cardiomyopathy; parkinsons-disease; human-cells; in-vitro; gene; myopathy; genome; encephalomyopathy
AB We report a sporadic case of chronic progressive external ophthalmoplegia associated with ragged red fibers. The patient presented with enlarged mitochondria with deranged internal architecture and crystalline inclusions. Biochemical studies showed reduced activities of complex I, III and IV in skeletal muscle. Molecular genetic analysis of all mitochondrial tRNAs revealed a G to A transition at nt 4308; the G is a highly conserved nucleotide that participates in a GC base-pair in the T-stem of mammalian mitochondrial tRNA(Ile). The mutation was detected at a high level (approx. 50%) in muscle but not in blood. The mutation co-segregated with the phenotype, as the mutation was absent from blood and muscle in the patient's healthy mother. Functional characterization of the mutation revealed a six-fold reduced rate of tRNA(Ile) precursor 3' end maturation in vitro by tRNAse Z. Furthermore, the mutated tRNA(Ile) displays local structural differences from wild-type. These results suggest that structural perturbations reduce efficiency of tRNA(Ile) precursor 3' end processing and contribute to the molecular pathomechanism of this mutation. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Schaller, A.; Jackson, C. B.; Gallati, S.] Univ Hosp Bern, Div Human Genet, Bern, Switzerland.
   [Desetty, R.; Levinger, L.] CUNY York Coll, Dept Biol, Jamaica, NY 11451 USA.
   [Hahn, D.; Nuoffer, J. -M.] Univ Hosp Bern, Inst Clin Chem, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; City University of New York (CUNY) System; York College NY (CUNY); University of Bern; University Hospital of Bern
RP Schaller, A (corresponding author), Inselspital Bern, Dept Paediat, Div Human Genet, CH-3010 Bern, Switzerland.
EM andre.schaller@insel.ch
FU Novartis; NIH [R15CA12072, SC3GM08153]
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Berardo A, 2010, NEUROMUSCULAR DISORD, V20, P204, DOI 10.1016/j.nmd.2010.01.006
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   Campos Y, 2002, MUSCLE NERVE, V25, P185, DOI 10.1002/mus.10012.abs
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Degoul F, 1998, HUM MOL GENET, V7, P347, DOI 10.1093/hmg/7.3.347
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Elson JL, 2009, HUM MUTAT, V30, PE984, DOI 10.1002/humu.21113
   Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1
   HAYASHI JI, 1994, J BIOL CHEM, V269, P19060
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   KAIDO M, 1995, J NEUROL SCI, V131, P170, DOI 10.1016/0022-510X(95)00111-E
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334
   Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Maizels N, 1999, BIOL BULL, V196, P331, DOI 10.2307/1542963
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   MCKECHNIE NM, 1985, BRIT J OPHTHALMOL, V69, P63, DOI 10.1136/bjo.69.1.63
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Mierau GW, 2004, PEDIATR DEVEL PATHOL, V7, P637, DOI 10.1007/s10024-004-5048-z
   MITSUMOTO H, 1983, NEUROLOGY, V33, P452, DOI 10.1212/WNL.33.4.452
   MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V176, P938, DOI 10.1016/S0006-291X(05)80276-1
   Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487
   ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SANTORELLI FM, 1995, BIOCHEM BIOPH RES CO, V216, P835, DOI 10.1006/bbrc.1995.2697
   SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597
   SIHEM S, 2010, J NEUROL SCI, V300, P187
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
   Suomalainen A, 1997, ANN MED, V29, P235, DOI 10.3109/07853899708999341
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Yan H, 2006, J BIOL CHEM, V281, P3926, DOI 10.1074/jbc.M509822200
   Zanssen S, 1997, MOL CELL BIOCHEM, V174, P231, DOI 10.1023/A:1006864709515
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 58
TC 15
Z9 16
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD MAY 15
PY 2011
VL 11
IS 3
BP 488
EP 496
DI 10.1016/j.mito.2011.01.005
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 753HS
UT WOS:000289763500015
PM 21292040
DA 2024-11-01
ER

PT J
AU Nalini, A
   Gayathri, N
AF Nalini, Atchayaram
   Gayathri, Narayanappa
TI Mitochondrial neurogastrointestinal encephalopathy in an Indian family with possible manifesting carriers of heterozygous <i>TYMP</i> mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial neurogastrointestinal encephalomyopathy; MNGIE; Thymidine phosphorylase
ID thymidine phosphorylase-deficiency; encephalomyopathy mngie; multiple deletions; dna depletion; disorder; leukoencephalopathy; ophthalmoplegia; dysfunction; features
AB Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a distinctive autosomal recessive disorder with mitochondrial alterations due to mutations TYMP gene encoding thymidine phosphorylase. Materials and methods: Study of clinical and biochemical characteristics of a family with MNGIE. Results: Index case was a 32 year old man presenting with recurrent vomiting, early satiety and progressive weight loss. He had ptosis, restricted eye movements, generalized muscle wasting, and absent tendon reflexes. Lactate levels were elevated in venous blood and CSF lactate. MRI brain showed diffuse leucoencephalopathy. Barium swallow showed near total obstruction at mid portion of vertical limb of duodenum with ileus. Esophageal manometry suggested myopathy. Muscle biopsy revealed moderate numbers of ragged blue and ragged red fibers as well as cytochrome c oxidase deficient fibers. An elder brother had similar symptoms and expired after a surgical procedure and a 28 year old brother has similar illness. The father had asymptomatic bilateral ptosis with mild ophthalmoparesis. The paternal grandfather and paternal aunt also had bilateral ptosis. Clinical diagnosis of MNGIE was confirmed in the two living brothers by demonstrating severe defects of thymidine phosphorylase activity in buffy coat, elevated thymidine and deoxyuridine in plasma, and a homozygous 7YMP c.893 G>A mutation. Conclusions: This family with biochemically and genetically confirmed mitochondrial neurogastrointestinal encephalopathy syndrome uncharacteristically included heterozygous IYMP mutation carriers manifesting extra-ocular weakness. It is important to identify MNGIE patients early because therapeutic options are emerging. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Nalini, Atchayaram] Natl Inst Mental Hlth & Neurosci, Dept Neurol, Bangalore 560029, Karnataka, India.
   [Gayathri, Narayanappa] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India.
C3 National Institute of Mental Health & Neurosciences - India; National Institute of Mental Health & Neurosciences - India
RP Nalini, A (corresponding author), Neurosci Fac Block,Behind Neuroctr,Hosur Rd, Bangalore 560029, Karnataka, India.
EM atchayaramnalini@yahoo.co.in
FU Columbia University Medical Center, New York
CR Carod-Artal FJ, 2007, EUR J NEUROL, V14, P581, DOI 10.1111/j.1468-1331.2007.01720.x
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   Halter J, 2011, BONE MARROW TRANSPL, V46, P330, DOI 10.1038/bmt.2010.100
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2004, NUCLEOS NUCLEOT NUCL, V23, P1217, DOI 10.1081/NCN-200027485
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Lara MC, 2007, BIOSCIENCE REP, V27, P151, DOI 10.1007/s10540-007-9043-2
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Millar WS, 2004, AM J ROENTGENOL, V182, P1537, DOI 10.2214/ajr.182.6.1821537
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Szigeti K, 2004, ANN NEUROL, V56, P881, DOI 10.1002/ana.20302
   UNCINI A, 1994, MUSCLE NERVE, V17, P667, DOI 10.1002/mus.880170616
   Yavuz H, 2007, ARCH NEUROL-CHICAGO, V64, P435, DOI 10.1001/archneur.64.3.435
NR 20
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD OCT 15
PY 2011
VL 309
IS 1-2
BP 131
EP 135
DI 10.1016/j.jns.2011.06.052
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 825SV
UT WOS:000295303300027
PM 21794876
DA 2024-11-01
ER

PT J
AU Karri, B
   Sebastian, RT
   Kyle, G
   Hart, IK
   Mountford, RC
AF Karri, B.
   Sebastian, R. T.
   Kyle, G.
   Hart, I. K.
   Mountford, R. C.
TI Ptosis as the Only Presenting Feature of a Mitochondrial Cytopathy
SO NEURO-OPHTHALMOLOGY
LA English
DT Article
DE age-related CPEO; chronic progressive external ophthalmoplegia; isolated ptosis; mitochondrial cytopathies; myasthenia gravis
ID external ophthalmoplegia; extraocular-muscle; dna deletions; disease; mtdna; accumulation; management; mutations; defects; twinkle
AB Mitochondrial cytopathies (MCs) result from a genetic defect in cells that leads to reduction in energy production. This can affect any organ, especially those with high-energy consumption. The authors highlight two cases of MCs who presented with isolated ptosis. The characteristics initially suggested myasthenia gravis. Subsequently the ptosis became progressive and the diagnosis was revised to MC because mitochondrial rearrangements were found in skeletal muscle DNA. Limb muscle biopsy was conclusive in one patient, but the other patient required periocular muscle to confirm the diagnosis. MC can present in this manner because heteroplasmy of mitochondrial DNA means that not all organs will exhibit clinical manifestations.
C1 [Karri, B.] Aintree Univ Hosp NHS Fdn Trust, Elect Care Ctr, Dept Ophthalmol, Liverpool L9 7AL, Merseyside, England.
   [Hart, I. K.] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England.
   [Mountford, R. C.] Liverpool Womens NHS Fdn Trust, Cheshire & Merseyside Reg Mol Genet Lab, Liverpool, Merseyside, England.
C3 Aintree University Hospitals NHS Foundation Trust; Walton Centre
RP Karri, B (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Elect Care Ctr, Dept Ophthalmol, Liverpool L9 7AL, Merseyside, England.
EM BHAVANI.KARRI@aintree.nhs.uk
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Carta A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1441
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Finsterer J, 2009, EUR J NEUROL, V16, P1255, DOI 10.1111/j.1468-1331.2009.02811.x
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Ghezzi D, 2010, AM J HUM GENET, V86, P639, DOI 10.1016/j.ajhg.2010.03.002
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   LEFORESTIER N, 1995, MUSCLE NERVE, V18, P1338, DOI 10.1002/mus.880181120
   LI YY, 1995, BIOCHEM BIOPH RES CO, V210, P211, DOI 10.1006/bbrc.1995.1648
   Marchington D, 2010, J MED GENET, V47, P257, DOI 10.1136/jmg.2009.072900
   MILLAY DJ, 1989, ARCH OTOLARYNGOL, V115, P198
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SRIDHARAN GV, 1995, AGE AGEING, V24, P21, DOI 10.1093/ageing/24.1.21
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   WALLACE DC, 1994, EPILEPSIA, V35, PS43, DOI 10.1111/j.1528-1157.1994.tb05928.x
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wong VA, 2002, OPHTHALMOLOGY, V109, P1023, DOI 10.1016/S0161-6420(02)01009-6
   Yu-Wai-Man P, 2010, INVEST OPHTH VIS SCI, V51, P3347, DOI 10.1167/iovs.09-4660
NR 33
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0165-8107
EI 1744-506X
J9 NEURO-OPHTHALMOLOGY
JI Neuro-Ophthalmol.
PD OCT-DEC 15
PY 2011
VL 35
IS 5-6
BP 284
EP 288
DI 10.3109/01658107.2011.615453
PG 5
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 855VP
UT WOS:000297594300012
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Cosi, A
   Tonduti, D
   Orcesi, S
   Bordoni, A
   Fortunato, F
   Rizzuti, M
   Sciacco, M
   Collotta, M
   Cagdas, S
   Capovilla, G
   Moggio, M
   Berardinelli, A
   Veggiotti, P
   Comi, GP
AF Ronchi, Dario
   Cosi, Alessandra
   Tonduti, Davide
   Orcesi, Simona
   Bordoni, Andreina
   Fortunato, Francesco
   Rizzuti, Mafalda
   Sciacco, Monica
   Collotta, Martina
   Cagdas, Sophie
   Capovilla, Giuseppe
   Moggio, Maurizio
   Berardinelli, Angela
   Veggiotti, Pierangelo
   Comi, Giacomo P.
TI Clinical and molecular features of an infant patient affected by Leigh Disease associated to m.14459G &gt; A mitochondrial DNA mutation: a case report
SO BMC NEUROLOGY
LA English
DT Article
DE Leigh Syndrome; mitochondrial DNA; LHON; MT-ND6; MT-CYB; mitochondrial Complex I
ID hereditary optic neuropathy; g14459a mutation; dystonia; expression
AB Background: Leigh Syndrome (LS) is a severe neurodegenerative disorder characterized by bilateral symmetrical necrotic lesions in the basal ganglia and brainstem. Onset is in early infancy and prognosis is poor. Causative mutations have been disclosed in mitochondrial DNA and nuclear genes affecting respiratory chain subunits and assembly factors. Case presentation: Here we report the clinical and molecular features of a 15-month-old female LS patient. Direct sequencing of her muscle-derived mtDNA revealed the presence of two apparently homoplasmic variants: the novel m.14792C > G and the already known m.14459G > A resulting in p.His16Asp change in cytochrome b (MT-CYB) and p.Ala72Val substitution in ND6 subunit, respectively. The m.14459G > A was heteroplasmic in the mother's blood-derived DNA. Conclusions: The m.14459G > A might lead to LS, complicated LS or Leber Optic Hereditary Neuropathy. A comprehensive re-evaluation of previously described 14459G > A-mutated patients does not explain this large clinical heterogeneity.
C1 [Tonduti, Davide; Orcesi, Simona; Berardinelli, Angela; Veggiotti, Pierangelo] Fdn IRCCS Ist Neurol C Mondino, I-27100 Pavia, Italy.
   [Cagdas, Sophie; Capovilla, Giuseppe] C Poma Hosp, Dept Child Neuropsychiat, Epilepsy Ctr, I-46100 Mantua, Italy.
   [Ronchi, Dario; Cosi, Alessandra; Bordoni, Andreina; Fortunato, Francesco; Rizzuti, Mafalda; Sciacco, Monica; Collotta, Martina; Moggio, Maurizio; Comi, Giacomo P.] Univ Milan, Dept Neurol Sci, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Ctr Dino Ferrari, I-20122 Milan, Italy.
C3 IRCCS Fondazione Casimiro Mondino; Hospital Carlo Poma; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Comi, GP (corresponding author), Univ Milan, Dept Neurol Sci, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Ctr Dino Ferrari, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
FU Associazione Amici del Centro Dino Ferrari; Italian Telethon [GUP09004]
CR DAurelio M, 2010, HUM MOL GENET, V19, P374, DOI 10.1093/hmg/ddp503
   Funalot B, 2002, ANN NEUROL, V52, P374, DOI 10.1002/ana.10299
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   JOHNS DR, 1993, OPHTHALMOLOGY, V100, P981
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Lodi R, 2000, BRAIN, V123, P1896, DOI 10.1093/brain/123.9.1896
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Tucker EJ, 2010, CURR NEUROL NEUROSCI, V10, P277, DOI 10.1007/s11910-010-0112-8
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270
NR 16
TC 20
Z9 21
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2377
EI 
J9 BMC NEUROL
JI BMC Neurol.
PD JUL 12
PY 2011
VL 11
IS 
BP 
EP 
DI 10.1186/1471-2377-11-85
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 801YJ
UT WOS:000293476200001
PM 21749722
DA 2024-11-01
ER

PT J
AU Tang, S
   Wang, J
   Lee, NC
   Milone, M
   Halberg, MC
   Schmitt, ES
   Craigen, WJ
   Zhang, W
   Wong, LJC
AF Tang, Sha
   Wang, Jing
   Lee, Ni-Chung
   Milone, Margherita
   Halberg, Michelle C.
   Schmitt, Eric S.
   Craigen, William J.
   Zhang, Wei
   Wong, Lee-Jun C.
TI Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; comparative genomic hybridization; polg mutations; exonuclease domain; depletion syndrome; ataxic neuropathy; parkinson-disease; alpers-syndrome; gene; encephalomyopathy
AB Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial diseases in children and adults. This study sequenced the exons and flanking intronic regions of the POLG gene from 2697 unrelated patients with clinical presentations suggestive of POLG deficiency. Informative mutations have been identified in 136 unrelated individuals (5%), including 92 patients with two recessive pathogenic alleles and three patients harbouring a dominant mutation. Twenty-four novel recessive mutations and a novel possible dominant mutation, p.Y951N, were identified. All missense mutations occurred at evolutionarily conserved amino acids within functionally important regions identified by molecular modelling analyses. Oligonucleotide array comparative genomic hybridisation analyses performed on DNA samples from 81 patients with one mutant POLG allele identified a large intragenic deletion in only one patient, suggesting that large deletions in POLG are rare. The 92 patients with two mutant alleles exhibited a broad spectrum of disease. Almost all patients in all age groups had some degree of neuropathy. Seizures, hepatopathy, and lactic acidaemia were predominant in younger patients. By comparison, patients who developed symptoms in adulthood had a higher percentage of myopathy, sensory ataxia, and chronic progressive external ophthalmoplegia (CPEO)/ptosis. In conclusion, POLG mutations account for a broad clinical spectrum of mitochondrial disorders. Sequence analysis of the POLG gene should be considered as a part of routine screening for mitochondrial disorders, even in the absence of apparent mitochondrial DNA abnormalities.
C1 [Tang, Sha; Wang, Jing; Halberg, Michelle C.; Schmitt, Eric S.; Craigen, William J.; Zhang, Wei; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Lee, Ni-Chung] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan.
   [Milone, Margherita] Mayo Clin, Dept Neurol, Rochester, MN USA.
C3 Baylor College of Medicine; National Taiwan University; National Taiwan University Hospital; Mayo Clinic
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Bolszak M, 2009, EPILEPSY RES, V85, P300, DOI 10.1016/j.eplepsyres.2009.03.004
   Brahimi N, 2009, MOL GENET METAB, V97, P221, DOI 10.1016/j.ymgme.2009.03.007
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Compton AG, 2011, MITOCHONDRION, V11, P104, DOI 10.1016/j.mito.2010.07.012
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Giordano C, 2010, ARCH NEUROL-CHICAGO, V67, P1144, DOI 10.1001/archneurol.2010.200
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Richards CS, 2008, GENET MED, V10, P294, DOI 10.1097/GIM.0b013e31816b5cae
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Stopinska K, 2006, ACTA BIOCHIM POL, V53, P591
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Tarutani Y, 2010, NATURE, V466, P983, DOI 10.1038/nature09308
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vockley J, 2000, MOL GENET METAB, V71, P10, DOI 10.1006/mgme.2000.3066
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 44
TC 124
Z9 129
U1 0
U2 12
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD OCT 15
PY 2011
VL 48
IS 10
BP 669
EP 681
DI 10.1136/jmedgenet-2011-100222
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 822FZ
UT WOS:000295030700004
PM 21880868
DA 2024-11-01
ER

PT J
AU Nakhro, K
   Chung, KW
   Kim, SM
   Sunwoo, IN
   Cho, EM
   Park, SW
   Hwang, JH
   Choi, BO
AF Nakhro, Khriezhanuo
   Chung, Ki Wha
   Kim, Seung-Min
   Sunwoo, Il-Nam
   Cho, Eun Min
   Park, Sun Wha
   Hwang, Jung Hee
   Choi, Byung-Ok
TI Compound mutations of PEO1 and TYMP in a progressive external ophthalmoplegia patient with incomplete mitochondrial neurogastrointestinal encephalomyopathy phenotype
SO GENES & GENOMICS
LA English
DT Article
DE Mitochondrial disease; Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); PEO; PEO1; TYMP
ID autosomal-dominant; mtdna maintenance; helicase twinkle; dna; mngie; gene; deletions; depletion; spectrum; disease
AB The Mendelian inherited progressive external ophthalmoplegia (PEO) and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) are genetically heterogeneous mitochondrial diseases caused by nuclear-mitochondrial intergenomic defects. The PEO1 and TYMP nuclear genes are closely related in the machinery of the mitochondrial DNA (mtDNA) replication. Mutations in PEO1 and TYMP genes usually cause autosomal dominant PEO, and autosomal recessive MNGIE. We identified a PEO family of Korean origin with additional phenotype of incomplete MNGIE symptom (Family ID: MT16). The entire mitochondrial genome and all coding exons of PEO1, TYMP, ANT1, POLG1, POLG2, DGUOK, and TK2 nuclear genes were sequenced. Clinical information was obtained through history taking, physical examinations, clinical observations, and electrophysiological investigations. Muscle biopsy of left biceps brachii and shoulder magnetic resonance imaging (MRI) were undertaken. We found two heterozygous mutations, Arg374Gln in PEO1 and Glu106Gln in TYMP from the proband who showed complex phenotypes of a typical PEO and late-onset incomplete MNGIE. The PEO1 Arg374Gln has been reported in several PEO patients, but TYMP Glu106Gln has not been reported. Neither large deletion nor causative point mutations were observed in the mtDNA. We suggest that the heterozygous TYMP mutation might affect complex phenotypes as a secondary genetic cause in the co-presence of PEO1 mutation.
C1 [Choi, Byung-Ok] Ewha Womans Univ, Dept Neurol, Sch Med, Seoul, South Korea.
   [Nakhro, Khriezhanuo; Chung, Ki Wha; Cho, Eun Min; Park, Sun Wha] Kongju Natl Univ, Dept Biol Sci, Gongju, Chungnam, South Korea.
   [Nakhro, Khriezhanuo; Chung, Ki Wha; Cho, Eun Min; Park, Sun Wha] Kongju Natl Univ, Biotechnol Res Ctr, Gongju, Chungnam, South Korea.
   [Kim, Seung-Min; Sunwoo, Il-Nam] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea.
   [Hwang, Jung Hee] Natl Forens Serv, DNA Anal Div, Seoul, South Korea.
C3 Ewha Womans University; Kongju National University; Kongju National University; Yonsei University; Yonsei University Health System; National Forensic Service
RP Choi, BO (corresponding author), Ewha Womans Univ, Dept Neurol, Sch Med, Seoul, South Korea.
EM bochoi@ewha.ac.kr
FU MEST [KRF-2008-313-C00750]; MEST, Republic of Korea [R01-2008-000-20604-0]
CR BAKKER JA, 2010, J INHERIT M IN PRESS, V0, P0
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Massa R, 2009, NEUROMUSCULAR DISORD, V19, P837, DOI 10.1016/j.nmd.2009.08.013
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Szigeti K, 2004, J MED GENET, V41, P125, DOI 10.1136/jmg.2003.013789
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
NR 26
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1976-9571
EI 
J9 GENES GENOM
JI Genes Genom.
PD AUG 15
PY 2011
VL 33
IS 4
BP 431
EP 437
DI 10.1007/s13258-011-0089-y
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA 813EF
UT WOS:000294348900015
DA 2024-11-01
ER

PT J
AU Ma, YY
   Zhang, XL
   Wu, TF
   Liu, YP
   Wang, Q
   Zhang, Y
   Song, JQ
   Wang, YJ
   Yang, YL
AF Ma, Yan-Yan
   Zhang, Xue-Lin
   Wu, Tong-Fei
   Liu, Yu-Peng
   Wang, Qiao
   Zhang, Yao
   Song, Jin-Qing
   Wang, Yu-Jie
   Yang, Yan-Ling
TI Analysis of the Mitochondrial Complex I-V Enzyme Activities of Peripheral Leukocytes in Oxidative Phosphorylation Disorders
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE oxidative phosphorylation; mitochondrial disease; Leigh syndrome; respiratory chain complex deficiency; leukocytes
ID chinese patients; leigh-syndrome; deficiency; fibroblasts; children; tissue; disease
AB Mitochondrial oxidative phosphorylation defects are a common cause of mitochondrial diseases, which are characterized by multiorgan involvement and clinically heterogeneous manifestations. Diagnosis is difficult because of the lack of clinically feasible methods. In this study, mitochondrial complex I-V enzyme activity was measured in 64 patients with suspected mitochondrial disease and 200 healthy controls. Spectrophotometric assay was used for the analysis of mitochondrial complex I-V enzyme activity in peripheral leukocytes. Diagnosis was based on clinical presentation, magnetic resonance imaging (MRI), muscle pathology, and point mutation screening in mitochondrial DNA. The differential diagnosis of aminoacidopathies, organic acidurias, and fatty acid beta-oxidation defects was made. Thirty-five patients (54.7%) were diagnosed with Leigh syndrome based on characteristic brain MRI. Complex enzyme activity in controls was found to be stable. A deficiency in the oxidative phosphorylation was found in 29 patients (45.3%). Twenty (31.2%) patients had isolated complex defects, complex I deficiency (n = 2, 3.1%), complex II deficiency (n = 3, 4.7%), complex III deficiency (n = 5, 7.8%), complex IV deficiency (n = 5, 7.8%), and complex V deficiency (n 5, 7.8%). Nine patients were found to have combined deficiencies, 3 (4.7%) had combined deficiencies of complex I and IV, 2 (3.1%) had combined deficiencies of complex III and V, and 2 (3.1%) had a combined deficiency of complex I and V. In conclusion, the peripheral leukocyte oxidative phosphorylation enzyme activity assay was found to be a reliable method for the diagnosis of mitochondrial diseases.
C1 [Ma, Yan-Yan; Wu, Tong-Fei; Liu, Yu-Peng; Wang, Qiao; Zhang, Yao; Song, Jin-Qing; Wang, Yu-Jie; Yang, Yan-Ling] Peking Univ, Dept Pediat, Hosp 1, Beijing 100034, Peoples R China.
   [Zhang, Xue-Lin] Capital Inst Phys Educ, Beijing, Peoples R China.
C3 Peking University
RP Yang, YL (corresponding author), Peking Univ, Dept Pediat, Hosp 1, 1 Xi An Men Rd, Beijing 100034, Peoples R China.
EM amino_acid3003@126.com
FU National Nature Science Foundation of China [30872794]; National Key Technology R and D Programme [2006BAI05A07]
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Bugiani M, 2006, BRAIN DEV-JPN, V28, P576, DOI 10.1016/j.braindev.2006.04.001
   Cameron JM, 2004, MITOCHONDRION, V4, P387, DOI 10.1016/j.mito.2004.07.039
   CHRETIEN D, 1994, CLIN CHIM ACTA, V228, P53, DOI 10.1016/0009-8981(94)90056-6
   GERARD B, 1993, EUR J PEDIATR, V152, P270
   Gu Xue-fan, 2004, ZHONGHUA ER KE ZA ZHI, V42, P401
   Kimura H, 1999, TOHOKU J EXP MED, V188, P317, DOI 10.1620/tjem.188.317
   Luo C, 2008, CLIN CHIM ACTA, V395, P38, DOI 10.1016/j.cca.2008.04.025
   Munnich A, 1996, EUR J PEDIATR, V155, P262
   Munnich A, 1996, J INHERIT METAB DIS, V19, P521, DOI 10.1007/BF01799112
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rubio-Gozalbo ME, 2000, HUM MUTAT, V15, P522, DOI 10.1002/1098-1004(200006)15:6<522::AID-HUMU4>3.0.CO;2-Y
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Skladal D, 2003, CLIN PEDIATR, V42, P703, DOI 10.1177/000992280304200806
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   SKLADAL D, 1995, PADIATR PRAX, V50, P79
   Song J, 2006, ZHONGGUO YIKAN, V41, P38, DOI 10.3969/j.issn.10081070.2006.02.015
   SUN F, 2005, CHIN J NEUROL, V38, P560
   SUN F, 2005, CHIN J CONT PEDIAT, V7, P25
   Thorburn DR, 2004, MITOCHONDRION, V4, P363, DOI 10.1016/j.mito.2004.07.003
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6
   Wei Xiao-Qiong, 2009, ZHONGGUO DANG DAI ER KE ZA ZHI, V11, P333
   Yang YL, 2006, CHINESE MED J-PEKING, V119, P373, DOI 10.1097/00029330-200603010-00004
   Yu Q, 2007, MITOCHONDRION, V7, P147, DOI 10.1016/j.mito.2006.11.019
   Zhang Y, 2007, J INHERIT METAB DIS, V30, P265, DOI 10.1007/s10545-006-0481-y
   Zhang Yao, 2007, ZHONGGUO DANG DAI ER KE ZA ZHI, V9, P216
NR 29
TC 27
Z9 36
U1 0
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD AUG 15
PY 2011
VL 26
IS 8
BP 974
EP 979
DI 10.1177/0883073811399905
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 796WY
UT WOS:000293085400007
PM 21540367
DA 2024-11-01
ER

PT J
AU Garone, C
   Tadesse, S
   Hirano, M
AF Garone, Caterina
   Tadesse, Saba
   Hirano, Michio
TI Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy
SO BRAIN
LA English
DT Article
DE mitochondrial disease; MNGIE; encephalomyopathy; TYMP; BMT
ID cell growth-factor; thymidine phosphorylase; tissue distribution; mngie; dna; mutations; muscle; deoxyuridine; expression; depletion
AB Mitochondrial neurogastrointestinal encephalomyopathy is a rare multisystemic autosomic recessive disorder characterized by: onset typically before the age of 30 years; ptosis; progressive external ophthalmoplegia; gastrointestinal dysmotility; cachexia; peripheral neuropathy; and leucoencephalopathy. The disease is caused by mutations in the TYMP gene encoding thymidine phosphorylasethymine phosphorylase. Anecdotal reports suggest that allogeneic haematopoetic stem cell transplantation may be beneficial for mitochondrial neurogastrointestinal encephalomyopathy, but is associated with a high mortality. After selecting patients who fulfilled the clinical criteria for mitochondrial neurogastrointestinal encephalomyopathy and had severe thymidine phosphorylase deficiency in the buffy coat (< 10% of normal activity), we reviewed their medical records and laboratory studies. We identified 102 patients (50 females) with mitochondrial neurogastrointestinal encephalomyopathy and an average age of 32.4 years (range 11-59 years). We found 20 novel TYMP mutations. The average age-at-onset was 17.9 years (range 5 months to 35 years); however, the majority of patients reported the first symptoms before the age of 12 years. The patient distribution suggests a relatively high prevalence in Europeans, while the mutation distribution suggests founder effects for a few mutations, such as c.866A > G in Europe and c.518T > G in the Dominican Republic, that could guide genetic screening in each location. Although the sequence of clinical manifestations in the disease varied, half of the patients initially had gastrointestinal symptoms. We confirmed anecdotal reports of intra- and inter-familial clinical variability and absence of genotype-phenotype correlation in the disease, suggesting genetic modifiers, environmental factors or both contribute to disease manifestations. Acute medical events such as infections often provoked worsening of symptoms, suggesting that careful monitoring and early treatment of intercurrent illnesses may be beneficial. We observed endocrine/exocrine pancreatic insufficiency, which had not previously been reported. Kaplan-Meier analysis revealed significant mortality between the ages of 20 and 40 years due to infectious or metabolic complications. Despite increasing awareness of this illness, a high proportion of patients had been misdiagnosed. Early and accurate diagnosis of mitochondrial neurogastrointestinal encephalomyopathy, together with timely treatment of acute intercurrent illnesses, may retard disease progression and increase the number of patients eligible for allogeneic haematopoetic stem cell transplantation.
C1 [Garone, Caterina; Tadesse, Saba; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Garone, Caterina] Univ Turin, Human Genet Joint PhD Programme, I-10125 Turin, Italy.
   [Garone, Caterina] Univ Bologna, I-40125 Bologna, Italy.
C3 Columbia University; University of Turin; University of Bologna
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
FU National Institutes of Health [R01HD056103, R01HD057543, RC1NS070232, P01HD032062]; Associazione Malattie Metaboliche Congenite ereditarie (AMMeC); Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF); Muscular Dystrophy Association
CR [Anonymous], 2000, DIAGN STAT MAN MENT, V0, P0
   Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   Davidson MM, 2009, J MOL CELL CARDIOL, V46, P936, DOI 10.1016/j.yjmcc.2009.02.011
   ECCLESTON PA, 1995, NEUROSCI LETT, V192, P137, DOI 10.1016/0304-3940(95)11622-4
   FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212
   Halter J, 2011, BONE MARROW TRANSPL, V46, P330, DOI 10.1038/bmt.2010.100
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   Kintarak J, 2007, CLIN NEUROL NEUROSUR, V109, P613, DOI 10.1016/j.clineuro.2007.04.008
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Matsukawa K, 1996, BBA-MOL CELL RES, V1314, P71, DOI 10.1016/S0167-4889(96)00078-X
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   OKAMURA K, 1976, J NEUROL SCI, V27, P79, DOI 10.1016/0022-510X(76)90236-7
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Petcharunpaisan S, 2010, J COMPUT ASSIST TOMO, V34, P247, DOI 10.1097/RCT.0b013e3181c71d48
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Said G, 2005, J NEUROL, V252, P655, DOI 10.1007/s00415-005-0712-4
   Schuepbach WMM, 2007, J NEUROL, V254, P146, DOI 10.1007/s00415-006-0255-3
   Schupbach M, 2009, NEUROLOGY, V73, P332
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Szigeti K, 2004, J MED GENET, V41, P125, DOI 10.1136/jmg.2003.013789
   Valentino ML, 2007, FEBS LETT, V581, P3410, DOI 10.1016/j.febslet.2007.06.042
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   WALTENBERGER J, 1992, FEBS LETT, V313, P129, DOI 10.1016/0014-5793(92)81428-O
   YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X
   Zimmer V, 2009, NEUROGASTROENT MOTIL, V21, P627, DOI 10.1111/j.1365-2982.2009.01264.x
NR 38
TC 147
Z9 160
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD NOV 15
PY 2011
VL 134
IS 
BP 3326
EP 3332
DI 10.1093/brain/awr245
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 847MH
UT WOS:000296976500025
PM 21933806
DA 2024-11-01
ER

PT J
AU Glatz, C
   D'Aco, K
   Smith, S
   Sondheimer, N
AF Glatz, Catherine
   D'Aco, Kristin
   Smith, Sabrina
   Sondheimer, Neal
TI Mutation in the mitochondrial tRNA<SUP>va1</SUP> causes mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA; Mitochondrial disease; Heteroplasmy; MELAS; Mitochondrial tRNA; Penetrance
ID transfer-rna; melas; myopathy
AB An m.1630A>G mutation in the mitochondrial tRNA(va1) (MTTV) was identified in a patient with hearing impairment, short stature and new onset of stroke. This mutation has previously been identified in a patient with the mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). The mother of the proband also had high levels of the m.1630A>G allele present in blood and other tissues, without symptoms. To confirm the pathogenicity of this mutation, we created cybrid cell lines with various mutation loads. The m.1630A>G mutation impairs oxygen consumption, affects the stability of the MTTV and reduces the levels of subunits of the electron transport chain. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Glatz, Catherine; D'Aco, Kristin; Sondheimer, Neal] Childrens Hosp Philadelphia, Sect Biochem Genet, Philadelphia, PA 19104 USA.
   [Smith, Sabrina] Childrens Hosp Philadelphia, Neurol Sect, Philadelphia, PA 19104 USA.
   [Smith, Sabrina; Sondheimer, Neal] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania
RP Sondheimer, N (corresponding author), Childrens Hosp Philadelphia, Sect Biochem Genet, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM glatzc@email.chop.edu; dacok@email.chop.edu; smithsa@email.chop.edu; sondheimer@email.chop.edu
FU NIH [HD58022]
CR Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Coulter-Mackie MB, 1998, CLIN BIOCHEM, V31, P627, DOI 10.1016/S0009-9120(98)00074-5
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Ghelli A, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0007922
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, PW70, DOI 10.1093/nar/gkn188
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Horvath R, 2009, J NEUROL, V256, P810, DOI 10.1007/s00415-009-5023-8
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Phasukkijwatana N, 2010, HUM GENET, V128, P39, DOI 10.1007/s00439-010-0821-8
   Pütz J, 2007, RNA, V13, P1184, DOI 10.1261/rna.588407
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
NR 17
TC 27
Z9 31
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JUL 15
PY 2011
VL 11
IS 4
BP 615
EP 619
DI 10.1016/j.mito.2011.04.003
PG 5
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 779GD
UT WOS:000291765200010
PM 21540128
DA 2024-11-01
ER

PT J
AU Villarroya, J
   Lara, MC
   Dorado, B
   Garrido, M
   García-Arumí, E
   Meseguer, A
   Hirano, M
   Vilà, MR
AF Villarroya, Joan
   Lara, Mari-Carmen
   Dorado, Beatriz
   Garrido, Marta
   Garcia-Arumi, Elena
   Meseguer, Anna
   Hirano, Michio
   Vila, Maya R.
TI Targeted impairment of thymidine kinase 2 expression in cells induces mitochondrial DNA depletion and reveals molecular mechanisms of compensation of mitochondrial respiratory activity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondrial DNA; siRNA; Thymidine kinase 2; Mitochondrial depletion syndrome; Respiratory chaia
ID human-equilibrative-nucleoside-transporter-1 hent1; triphosphate pools; mtdna depletion; deficiency; mutations; encephalomyopathy; fibroblasts; membrane; toxicity; myopathy
AB The mitochondrial DNA (mtDNA) depletion syndrome comprises a clinically heterogeneous group of diseases characterized by reductions of the mtDNA abundance, without associated point mutations or rearrangements. We have developed the first in vitro model to study of mtDNA depletion due to reduced mitochondrial thymidine kinase 2 gene (77(2) expression in order to understand the molecular mechanisms involved in mtDNA depletion syndrome due to TK2 mutations. Small interfering RNA targeting TK2 mRNA was used to decrease TK2 expression in Ost TK1(-) cells, a cell line devoid of endogenous thymidine kinase 1 (TK1). Stable TK2-deficient cell lines showed a reduction of TK2 levels close to 80%. In quiescent conditions, TK2-deficient cells showed severe mtDNA depletion, also close to 80% the control levels. However, 11(2-deficient clones showed increased cytochrome c oxidase activity, higher cytochrome c oxidase subunit I transcript levels and higher subunit II protein expression respect to control cells. No alterations of the deoxynucleotide pools were found, whereas a reduction in the expression of genes involved in nucleoside/nucleotide homeostasis (human equilibrative nucleoside transporter 1, thymidine phosphorylase) and mtDNA maintenance (DNA-polymerase 7, mitochondrial transcription factor A) was observed. Our findings highlight the importance of cellular compensatory mechanisms that enhance the expression of respiratory components to ensure respiratory activity despite profound depletion in mtDNA levels. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Villarroya, Joan; Lara, Mari-Carmen; Garcia-Arumi, Elena; Meseguer, Anna; Vila, Maya R.] Hosp Univ Vall dHebron, Inst Recerca, Barcelona, Spain.
   [Villarroya, Joan] Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona, Spain.
   [Lara, Mari-Carmen; Dorado, Beatriz; Hirano, Michio] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA.
   [Lara, Mari-Carmen; Garcia-Arumi, Elena] ISCIII, CIBERER, Madrid, Spain.
   [Garrido, Marta] Hosp del Mar, IMIM, Unitat Biol Cellular & Mol, Barcelona, Spain.
C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Columbia University; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital del Mar Research Institute; Hospital del Mar
RP Villarroya, J (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.
EM joanvillarroya@gmail.com
FU Fondo de Investigacion Sanitaria [FIS 04/0415]; CIBER Obesidad y Nutricion, Spain; Fundismun Foundation; Muscular Dystrophy Association, USA
CR AKMAN HO, 2008, HUM MOL GENET, V0, P0
   Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lee EW, 2006, J BIOL CHEM, V281, P16700, DOI 10.1074/jbc.M513825200
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MARIOTTI C, 1995, J NEUROL, V242, P547, DOI 10.1007/BF00868806
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   PRESSACCO J, 1995, BRIT J CANCER, V72, P939, DOI 10.1038/bjc.1995.437
   Rampazzo C, 2007, J BIOL CHEM, V282, P34758, DOI 10.1074/jbc.M705923200
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Villarroya J, 2009, EXP CELL RES, V315, P1429, DOI 10.1016/j.yexcr.2009.02.018
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 28
TC 5
Z9 6
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 8
PY 2011
VL 407
IS 2
BP 333
EP 338
DI 10.1016/j.bbrc.2011.03.018
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 753DU
UT WOS:000289746700012
PM 21382338
DA 2024-11-01
ER

PT J
AU Smits, P
   Antonicka, H
   van Hasselt, PM
   Weraarpachai, W
   Haller, W
   Schreurs, M
   Venselaar, H
   Rodenburg, RJ
   Smeitink, JA
   van den Heuvel, LP
AF Smits, Paulien
   Antonicka, Hana
   van Hasselt, Peter M.
   Weraarpachai, Woranontee
   Haller, Wolfram
   Schreurs, Marieke
   Venselaar, Hanka
   Rodenburg, Richard J.
   Smeitink, Jan A.
   van den Heuvel, Lambert P.
TI Mutation in subdomain G' of mitochondrial elongation factor G1 is associated with combined OXPHOS deficiency in fibroblasts but not in muscle
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE combined OXPHOS deficiency; mitochondrial translation; EFG1/GFM1
ID blue-native-electrophoresis; factor ef-g; translation; complexes; ribosome; proteins; capacity; l7/12; dna
AB The mitochondrial translation system is responsible for the synthesis of 13 proteins required for oxidative phosphorylation (OXPHOS), the major energy-generating process of our cells. Mitochondrial translation is controlled by various nuclear encoded proteins. In 27 patients with combined OXPHOS deficiencies, in whom complex II (the only complex that is entirely encoded by the nuclear DNA) showed normal activities, and mutations in the mitochondrial genome as well as polymerase gamma were excluded, we screened all mitochondrial translation factors for mutations. Here, we report a mutation in mitochondrial elongation factor G1 (GFM1) in a patient affected by severe, rapidly progressive mitochondrial encephalopathy. This mutation is predicted to result in an Arg250Trp substitution in subdomain G' of the elongation factor G1 protein and is presumed to hamper ribosome-dependent GTP hydrolysis. Strikingly, the decrease in enzyme activities of complex I, III and IV detected in patient fibroblasts was not found in muscle tissue. The OXPHOS system defects and the impairment in mitochondrial translation in fibroblasts were rescued by overexpressing wild-type GFM1, establishing the GFM1 defect as the cause of the fatal mitochondrial disease. Furthermore, this study evinces the importance of a thorough diagnostic biochemical analysis of both muscle tissue and fibroblasts in patients suspected to suffer from a mitochondrial disorder, as enzyme deficiencies can be selectively expressed. European Journal of Human Genetics (2011) 19, 275-279; doi:10.1038/ejhg.2010.208; published online 1 December 2010
C1 [Smits, Paulien; Schreurs, Marieke; Rodenburg, Richard J.; Smeitink, Jan A.; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   [Antonicka, Hana; Weraarpachai, Woranontee] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
   [Antonicka, Hana; Weraarpachai, Woranontee] McGill Univ, Dept Human Genet, Montreal, PQ, Canada.
   [van Hasselt, Peter M.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat, Utrecht, Netherlands.
   [Haller, Wolfram] Evangel Krankenhaus Bielefeld, Ctr Child & Adolescent Med, Bielefeld, Germany.
   [Venselaar, Hanka] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Ctr Mol & Biomol Informat, NL-6500 HB Nijmegen, Netherlands.
   [van den Heuvel, Lambert P.] Acad Hosp Leuven, Dept Pediat, Louvain, Belgium.
C3 Radboud University Nijmegen; McGill University; McGill University; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Evangelical Hospital Bethel (EvKB) - House Gilead I; Radboud University Nijmegen
RP van den Heuvel, LP (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, Geert Grootepl 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM B.vandenHeuvel@cukz.umcn.nl
FU European Union [LSHMCT-2004-005260]
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Diaconu M, 2005, CELL, V121, P991, DOI 10.1016/j.cell.2005.04.015
   Gao YG, 2009, SCIENCE, V326, P694, DOI 10.1126/science.1179709
   Hansson S, 2005, J MOL BIOL, V348, P939, DOI 10.1016/j.jmb.2005.02.066
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Janssen AJM, 2008, ANN NEUROL, V63, P473, DOI 10.1002/ana.21328
   KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523
   Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104
   Leary SC, 2009, METHODS MOL BIOL, V554, P143, DOI 10.1007/978-1-59745-521-3_10
   Lochmüller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Nechifor R, 2007, J BIOL CHEM, V282, P36998, DOI 10.1074/jbc.M707179200
   Nechifor R, 2007, J MOL BIOL, V368, P1412, DOI 10.1016/j.jmb.2007.03.009
   Savelsbergh A, 2005, EMBO J, V24, P4316, DOI 10.1038/sj.emboj.7600884
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Wintermeyer W, 2004, BIOCHEM SOC T, V32, P733, DOI 10.1042/BST0320733
NR 23
TC 39
Z9 49
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD MAR 15
PY 2011
VL 19
IS 3
BP 275
EP 279
DI 10.1038/ejhg.2010.208
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 722PA
UT WOS:000287445600011
PM 21119709
DA 2024-11-01
ER

PT J
AU Domenis, DR
   Okubo, PMCI
   Sobreira, C
   Dantas, RO
AF Domenis, Danielle Ramos
   Carvalho Issa Okubo, Paula Macedo
   Sobreira, Claudia
   Dantas, Roberto Oliveira
TI Esophageal Contractions in Patients with Chronic Progressive External Ophthalmoplegia
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Chronic progressive external ophthalmoplegia; Dysphagia; Mitochondrial myopathy; Esophageal manometry; Esophageal motility
ID kearns-sayre-syndrome; mitochondrial-dna; dysphagia; deletions; manifestations; myopathy
AB Background Chronic progressive external ophthalmoplegia is a mitochondrial myopathy that causes muscular or multisystem symptoms and has dysphagia as one manifestation. Aim To evaluate esophageal contractions in patients with chronic progressive external ophthalmoplegia. Methods We studied 14 patients with chronic progressive external ophthalmoplegia and 16 asymptomatic volunteers. The diagnosis of the disease was established by the clinical picture and by mitochondrial DNA analysis in skeletal muscle. We used the manometric method with a perfusion catheter that recorded the esophageal contractions at 2, 7, 12, 17, and 22 cm from the lower esophageal sphincter (LES). All subjects performed in the supine position 20 swallows of a 5-ml bolus of water at room temperature, ten every 30 s and ten every 10 s. Results The amplitude, duration, and area under the curve of contractions at 17 and 22 cm from the LES were lower in patients than in volunteers for swallows performed at 10-s and 30-s intervals (P < 0.01). There was no difference in contractions at 7 and 2 cm, except for the contractions at 2 cm after swallows performed at 30-s intervals. The interval between the onset of contractions between 7 and 2 cm and between 22 and 2 cm was lower in patients than in volunteers, with swallows performed every 10 s and every 30 s. Conclusions There is impairment of esophageal contractions in patients with chronic progressive external ophthalmoplegia, mainly in the proximal esophageal body.
C1 [Dantas, Roberto Oliveira] Ribeirao Preto USP, Dept Clin Med, Fac Med, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Domenis, Danielle Ramos; Carvalho Issa Okubo, Paula Macedo; Sobreira, Claudia; Dantas, Roberto Oliveira] Univ Sao Paulo, Med Sch Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [Domenis, Danielle Ramos; Carvalho Issa Okubo, Paula Macedo] Univ Hosp Ribeirao Preto USP, Dept Ophthalmol Otolaryngol & Head & Neck Surg, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Sobreira, Claudia] Med Sch Ribeirao Preto USP, Dept Neurosci, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Dantas, Roberto Oliveira] Med Sch Ribeirao Preto USP, Dept Med, BR-14049900 Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Dantas, RO (corresponding author), Ribeirao Preto USP, Dept Clin Med, Fac Med, BR-14049900 Ribeirao Preto, SP, Brazil.
EM danefono@ig.com.br; paula_issa@hotmail.com; csobreira@rnp.fmrp.usp.br; rodantas@fmrp.usp.br
CR Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Carod-Artal FJ, 2003, REV NEUROLOGIA, V37, P1029, DOI 10.33588/rn.3711.2003547
   Chen CL, 2008, NEUROGASTROENT MOTIL, V20, P611, DOI 10.1111/j.1365-2982.2008.01086.x
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   Garciduenas ALC, 2000, GAC MED MEX, V163, P267
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Jiménez-Caballero PE, 2006, REV NEUROLOGIA, V43, P724, DOI 10.33588/rn.4312.2006440
   Kallmuenzer B, 2008, NEUROGASTROENT MOTIL, V20, P597, DOI 10.1111/j.1365-2982.2007.01075.x
   Katsanos KH, 2001, DIS ESOPHAGUS, V14, P63, DOI 10.1111/j.1442-2050.2001.00152.x
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Littell RC, 1996, SAS SYSTEMS MIXED MO, V0, P0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   SCHALL R, 1991, BIOMETRIKA, V78, P719
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SHAKER R, 1992, GASTROENTEROLOGY, V103, P1328, DOI 10.1016/0016-5085(92)91524-8
   Sonies Barbara C, 1997, CURRENT OPINION IN RHEUMATOLOGY, V9, P486, DOI 10.1097/00002281-199711000-00003
   TRIADAFILOPOULOS G, 1992, DIGEST DIS SCI, V37, P551, DOI 10.1007/BF01307579
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wise James L, 2002, CURR GASTROENTEROL REP, V4, P205, DOI 10.1007/s11894-002-0064-5
NR 20
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG 15
PY 2011
VL 56
IS 8
BP 2343
EP 2348
DI 10.1007/s10620-011-1631-0
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 799ON
UT WOS:000293296100019
PM 21399928
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Bordoni, A
   Cosi, A
   Rizzuti, M
   Fassone, E
   Di Fonzo, A
   Servida, M
   Sciacco, M
   Collotta, M
   Ronzoni, M
   Lucchini, V
   Mattioli, M
   Moggio, M
   Bresolin, N
   Corti, S
   Comi, GP
AF Ronchi, Dario
   Bordoni, Andreina
   Cosi, Alessandra
   Rizzuti, Mafalda
   Fassone, Elisa
   Di Fonzo, Alessio
   Servida, Maura
   Sciacco, Monica
   Collotta, Martina
   Ronzoni, Marco
   Lucchini, Valeria
   Mattioli, Marco
   Moggio, Maurizio
   Bresolin, Nereo
   Corti, Stefania
   Comi, Giacomo P.
TI Unusual adult-onset Leigh syndrome presentation due to the mitochondrial m.9176T&gt;C mutation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Leigh's disease; Leigh disease maternally inherited; Mitochondrial disease; MT-ATP6 protein
ID t9176c mutation
AB Leigh syndrome (LS) is an incurable, nearly always fatal, neurodegenerative, pediatric disorder that results from respiratory chain failure. The most common mitochondrial DNA (mtDNA) mutations that result in LS are m.8993T -> C/G and m.9176T -> C/G, which were previously found in several patients with early-onset Leigh syndrome. Here, we describe clinical and molecular features of a novel pedigree, where LS developed in two siblings. The proband was a young woman with an unusual adult-onset LS. She harbored a homoplasmic m.9176T -> C mutation, based on analysis of a muscle biopsy. In contrast, the brother died at a young age. This novel case report and literature review highlights the variability of phenotypic expression of the m.9176T -> C mutation. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ronchi, Dario; Cosi, Alessandra; Rizzuti, Mafalda; Fassone, Elisa; Di Fonzo, Alessio; Servida, Maura; Sciacco, Monica; Collotta, Martina; Lucchini, Valeria; Moggio, Maurizio; Bresolin, Nereo; Corti, Stefania; Comi, Giacomo P.] Univ Milan, Dept Neurol Sci, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Bordoni, Andreina; Bresolin, Nereo; Corti, Stefania; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
   [Ronzoni, Marco; Mattioli, Marco] Azienda Osped, Guido Salvini, Garbagnate, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, Dept Neurol Sci, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
FU Associazione Amici del Centro Dino Ferrari; Telethon [GUP09004, GTB07001]; University of Milan; Eurobiobank [QLTR-2001-02769, R.F. 02.187]
CR Akagi M, 2002, NEUROMUSCULAR DISORD, V12, P53, DOI 10.1016/S0960-8966(01)00242-5
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   Dionisi-Vici C, 1998, J INHERIT METAB DIS, V21, P2, DOI 10.1023/A:1005397227996
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Hung PC, 2007, DEV MED CHILD NEUROL, V49, P65, DOI 10.1017/S0012162207000163
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   Tucker EJ, 2010, CURR NEUROL NEUROSCI, V10, P277, DOI 10.1007/s11910-010-0112-8
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
NR 13
TC 13
Z9 15
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 26
PY 2011
VL 412
IS 2
BP 245
EP 248
DI 10.1016/j.bbrc.2011.07.076
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 816JM
UT WOS:000294594500009
PM 21819970
DA 2024-11-01
ER

PT J
AU Biffi, S
   Bortot, B
   Carrozzi, M
   Severini, GM
AF Biffi, Stefania
   Bortot, Barbara
   Carrozzi, Marco
   Severini, Giovanni Maria
TI Quantification of Heteroplasmic Mitochondrial DNA Mutations for DNA Samples in the Low Picogram Range by Nested Real-time ARMS-qPCR
SO DIAGNOSTIC MOLECULAR PATHOLOGY
LA English
DT Article
DE nested real-time PCR; ARMS-PCR; SYBR Green; mitochondrial DNA; heteroplasmy; single-fiber PCR
ID rapid identification; pcr analysis; copy number; melas; encephalomyopathy; expression; nuclease; disease; tissue; fibers
AB In many mitochondrial diseases, different clinical manifestations are related to tissue-specific distribution of mutated mitochondrial DNA (mtDNA). In this study, we describe an assay for the determination of mutated mtDNA copy number in small clinical samples, using standard polymerase chain reaction (PCR) followed by SYBR Green real-time allelic-specific PCR [amplification refractory mutation system-quantitative PCR (ARMS-qPCR)]. To assess the degree of heteroplasmy in a patient harboring 2 cosegregating mtDNA mutations (4415A > G and 9922A > C) starting from picogram amounts of DNA, we first amplified the mutated target sequence by standard PCR, and then analyzed it by real-time ARMS-qPCR. To validate this method, we analyzed by real-time ARMS-qPCR the PCR amplification products derived from different mixtures containing known proportions of mutant and wild-type cloned mtDNA fragments. The correlation coefficient of 0.994 between expected and observed values for the percentage of mutant A4415G confirms that the relative proportion of mutated and wild-type mtDNA was maintained after the first PCR amplification. This method allows the precise quantification of heteroplasmic mutations in DNA samples extracted from hairs, urine, small stomach biopsies, and, more importantly, single-muscle fiber, with a limit of detection close to 0.5%. This nested real-time ARMS-PCR represents a rapid, efficient, and less expensive method for the detection and quantification of heteroplasmic mutant mtDNA, even in very small clinical samples.
C1 [Biffi, Stefania; Bortot, Barbara; Severini, Giovanni Maria] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Dept Mol Med & Lab, I-34137 Trieste, Italy.
   [Carrozzi, Marco] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Child Neurol & Psychiat Unit, I-34137 Trieste, Italy.
   [Biffi, Stefania] CBM Scrl, Opt Imaging Lab, Trieste, Italy.
C3 IRCCS Burlo Garofolo; IRCCS Burlo Garofolo
RP Severini, GM (corresponding author), IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Dept Mol Med & Lab, Via Istria 65-1, I-34137 Trieste, Italy.
EM severini@burlo.trieste.it
FU Italian Ministry of Health
CR Alvarez-Iglesias V, 2008, BMC MED GENET, V9, P0, DOI 10.1186/1471-2350-9-26
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Bannwarth S, 2006, NAT PROTOC, V1, P2037, DOI 10.1038/nprot.2006.318
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Bonin S, 2003, J CLIN PATHOL-MOL PA, V56, P184, DOI 10.1136/mp.56.3.184
   Bortot B, 2009, MITOCHONDRION, V9, P123, DOI 10.1016/j.mito.2009.01.006
   Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Nomiyama T, 2002, DIABETOLOGIA, V45, P1577, DOI 10.1007/s00125-002-0893-7
   Sambrook J, 1999, MOL CLONING LAB MANU, V0, P0
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.3.e13
   vandeCorput MPC, 1997, J HISTOCHEM CYTOCHEM, V45, P55
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
NR 20
TC 4
Z9 6
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1052-9551
EI 
J9 DIAGN MOL PATHOL
JI Diagn. Mol. Pathol.
PD JUN 15
PY 2011
VL 20
IS 2
BP 117
EP 122
DI 10.1097/PDM.0b013e3181efe2c6
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pathology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pathology
GA 764VI
UT WOS:000290662100009
PM 21532488
DA 2024-11-01
ER

PT J
AU Slee, M
   Finkemeyer, J
   Krupa, M
   Raghupathi, R
   Gardner, J
   Blumbergs, P
   Agzarian, M
   Thyagarajan, D
AF Slee, M.
   Finkemeyer, J.
   Krupa, M.
   Raghupathi, R.
   Gardner, J.
   Blumbergs, P.
   Agzarian, M.
   Thyagarajan, D.
TI A novel mitochondrial DNA deletion producing progressive external ophthalmoplegia associated with multiple sclerosis
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Mitochondrial disease; Multiple sclerosis; Progressive external ophthalmoplegia
ID hereditary optic neuropathy; kearns-sayre-syndrome; white-matter disease; parkinsons-disease; complex-i; mutations; combination; disorder; risk; gene
AB We report a previously undescribed 7676 base pair mitochondria! (mt)DNA deletion involving genes of complex I, complex IV subunits 2 and 3 (cytochrome oxidase [Cox] II, III), adenosine triphosphatase 8 and 6, cytochrome b and 8 transfer (t)RNA genes producing myopathy and progressive external ophthalmoplegia (PEO) in a 44-year-old right-handed Caucasian man with features of multiple sclerosis (MS). We performed complete mtDNA sequencing and deletion analysis, spectrophotometric analysis of muscle and platelet respiratory chain activity, measurement of platelet mitochondrial membrane potential with the potentiometric dye JC-1 and magnetic resonance spectroscopy (MRS) and MRI studies of normal-appearing and lesional cerebral tissue. The deletion resulted in significant respiratory chain deficiency in muscle and blood and abnormalities of the platelet mitochondrial membrane potential. However, cerebrospinal fluid analysis, magnetic resonance spectroscopy and MRI features suggested inflammatory central nervous system demyelination rather than a primary respiratory chain disorder. We conclude that this novel mtDNA deletion causing myopathy and PEO is associated with severe muscle and platelet cellular energetic abnormalities. Furthermore, clinical and paraclinical features of multiple sclerosis were found. The potential pathomechanistic interaction between mtDNA variation and multiple sclerosis is reviewed. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Slee, M.; Raghupathi, R.; Thyagarajan, D.] Flinders Univ S Australia, Dept Human Physiol, Adelaide, SA, Australia.
   [Slee, M.; Krupa, M.; Thyagarajan, D.] Flinders Med Ctr, Dept Neurol, Bedford Pk, SA 5042, Australia.
   [Finkemeyer, J.] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia.
   [Blumbergs, P.] Univ Adelaide, Hanson Inst Neurol Dis, Adelaide, SA 5005, Australia.
   [Agzarian, M.] Flinders Med Ctr, Div Med Imaging, Bedford Pk, SA, Australia.
C3 Flinders University South Australia; Flinders Medical Centre; Flinders University South Australia; Hanson Institute; University of Adelaide; Flinders Medical Centre
RP Slee, M (corresponding author), Flinders Univ S Australia, Dept Human Physiol, Adelaide, SA, Australia.
EM mark.slee@flinders.edu.au
FU Multiple Sclerosis Research Australia; Flinders University of South Australia; Government of Australia
CR Ban M, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0002891
   BET L, 1994, J NEUROL, V241, P511, DOI 10.1007/BF00919714
   Bhatti MT, 1999, J NEURO-OPHTHALMOL, V19, P28
   Buhmann C, 2002, ACTA NEUROL SCAND, V106, P236, DOI 10.1034/j.1600-0404.2002.01323.x
   DAguanno S, 2008, J NEUROIMMUNOL, V193, P156, DOI 10.1016/j.jneuroim.2007.10.004
   Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6
   Hoppenbrouwers IA, 2008, ARCH NEUROL-CHICAGO, V65, P345, DOI 10.1001/archneurol.2007.63
   Horváth R, 2000, J NEUROL, V247, P65, DOI 10.1007/s004150050015
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Huoponen K, 2001, NEUROGENETICS, V3, P119, DOI 10.1007/s100480100115
   Hwang JM, 2001, OPHTHALMOLOGICA, V215, P398, DOI 10.1159/000050896
   Jamrozik Zygmunt, 2003, NEUROL NEUROCHIR POL, V37, P713
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Kovács GG, 2005, BRAIN, V128, P35, DOI 10.1093/brain/awh310
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Küker W, 2007, EUR J NEUROL, V14, P591, DOI 10.1111/j.1468-1331.2007.01757.x
   Miller DH, 2007, LANCET NEUROL, V6, P903, DOI 10.1016/S1474-4422(07)70243-0
   Mojon DS, 1999, GRAEF ARCH CLIN EXP, V237, P348, DOI 10.1007/s004170050243
   Mojon DS, 1999, OPHTHALMOLOGICA, V213, P171, DOI 10.1159/000027414
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9
   OLSEN NK, 1995, ACTA NEUROL SCAND, V91, P326, DOI 10.1111/j.1600-0404.1995.tb07016.x
   Parry-Jones A R, 2008, PRACT NEUROL, V8, P118, DOI 10.1136/jnnp.2007.139360
   Perez F, 2009, CLIN NEUROL NEUROSUR, V111, P83, DOI 10.1016/j.clineuro.2008.06.021
   Porcelli AM, 2009, J BIOL CHEM, V284, P2045, DOI 10.1074/jbc.M807321200
   Saneto RP, 2008, MITOCHONDRION, V8, P396, DOI 10.1016/j.mito.2008.05.003
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Sheremata WA, 2008, J NEUROINFLAMM, V5, P0, DOI 10.1186/1742-2094-5-27
   Tanji K, 2000, J NEUROL SCI, V178, P29, DOI 10.1016/S0022-510X(00)00354-3
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Thyagarajan D, 2002, INT REV NEUROBIOL, V53, P93
   Tran M, 2001, AM J OPHTHALMOL, V132, P591, DOI 10.1016/S0002-9394(01)01045-5
   TROUNCE I, 1996, MITOCHONDRIAL BIOGEN, V0, P484
   Vanopdenbosch L, 2000, J NEUROL, V247, P535, DOI 10.1007/s004150070153
   Verhoeven AJ, 2005, TRANSFUSION, V45, P82, DOI 10.1111/j.1537-2995.2005.04023.x
   Verny C, 2008, NEUROLOGY, V70, P1152, DOI 10.1212/01.wnl.0000289194.89359.a1
   Vyshkina T, 2005, J NEUROL SCI, V228, P55, DOI 10.1016/j.jns.2004.09.027
   Wallace DC, 2001, MENT RETARD DEV D R, V7, P158, DOI 10.1002/mrdd.1023
   Yu XH, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0001530
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 40
TC 15
Z9 17
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD OCT 15
PY 2011
VL 18
IS 10
BP 1318
EP 1324
DI 10.1016/j.jocn.2011.02.019
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 824FX
UT WOS:000295188900007
PM 21795050
DA 2024-11-01
ER

PT J
AU Belostotsky, R
   Ben-Shalom, E
   Rinat, C
   Becker-Cohen, R
   Feinstein, S
   Zeligson, S
   Segel, R
   Elpeleg, O
   Nassar, S
   Frishberg, Y
AF Belostotsky, Ruth
   Ben-Shalom, Efrat
   Rinat, Choni
   Becker-Cohen, Rachel
   Feinstein, Sofia
   Zeligson, Sharon
   Segel, Reeval
   Elpeleg, Orly
   Nassar, Suheir
   Frishberg, Yaacov
TI Mutations in the Mitochondrial Seryl-tRNA Synthetase Cause Hyperuricemia, Pulmonary Hypertension, Renal Failure in Infancy and Alkalosis, HUPRA Syndrome
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID dual-mode recognition; aminoacylation; deficiency; trnas(ser); disorders; myopathy; gene
AB An uncharacterized multisystemic mitochondrial cytopathy was diagnosed in two infants from consanguineous Palestinian kindred living in a single village. The most significant clinical findings were tubulopathy (hyperuricemia, metabolic alkalosis), pulmonary hypertension, and progressive renal failure in infancy (HUPRA syndrome). Analysis of the consanguineous pedigree suggested that the. causative mutation is in the nuclear DNA. By using genome-wide SNP homozygosity analysis, we identified a homozygous identity-by-descent region on chromosome 19 and detected the pathogenic mutation c.1169A>G (p.Asp390Gly) in SARS2, encoding the mitochondrial seryl-tRNA synthetase. The same homozygous mutation was later identified in a third infant with HUPRA syndrome. The carrier rate of this mutation among inhabitants of this Palestinian isolate was found to be 1:15. The mature enzyme catalyzes the ligation of serine to two mitochondrial tRNA isoacceptors: tRNA(AGY)(Ser) and tRNA(UCN)(Ser). Analysis of amino acylation of the two target tRNAs, extracted from immortalized peripheral lymphocytes derived from two patients, revealed that the p.Asp390Gly mutation significantly impacts on the acylation of tRNA(AGY)(Ser) but probably not that of tRNA(UCN)(Ser). Marked decrease in the expression of the nonacylated transcript and the complete absence of the acylated tRNA(AGY)(Ser) suggest that this mutation leads to significant loss of function and that the uncharged transcripts undergo degradation.
C1 [Belostotsky, Ruth; Ben-Shalom, Efrat; Rinat, Choni; Becker-Cohen, Rachel; Feinstein, Sofia; Frishberg, Yaacov] Shaare Zedek Med Ctr, Div Pediat Nephrol, IL-91031 Jerusalem, Israel.
   [Zeligson, Sharon; Segel, Reeval; Frishberg, Yaacov] Shaare Zedek Med Ctr, Inst Med Genet, IL-91031 Jerusalem, Israel.
   [Ben-Shalom, Efrat; Rinat, Choni; Becker-Cohen, Rachel; Feinstein, Sofia] Hadassah Hebrew Univ, Sch Med, IL-91120 Jerusalem, Israel.
   [Elpeleg, Orly] Hadassah Hebrew Univ, Monique & Jacques Roboh Dept Genet Res, Dept Genet & Metab Dis, Med Ctr, IL-91120 Jerusalem, Israel.
   [Nassar, Suheir] Makassed Hosp, Mol Genet Lab, IL-91194 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center
RP Frishberg, Y (corresponding author), Shaare Zedek Med Ctr, Div Pediat Nephrol, IL-91031 Jerusalem, Israel.
EM yaacovf@ekmd.huji.ac.il
CR Bacman SR, 2003, BIOCHEM J, V374, P131, DOI 10.1042/BJ20030222
   Bendayan D, 2003, RESP MED, V97, P130, DOI 10.1053/rmed.2003.1440
   Chernyakov I, 2008, METHOD ENZYMOL, V449, P221, DOI 10.1016/S0076-6879(08)02411-7
   Chimnaronk S, 2005, EMBO J, V24, P3369, DOI 10.1038/sj.emboj.7600811
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Finsterer J, 2009, EUR J NEUROL, V16, P1255, DOI 10.1111/j.1468-1331.2009.02811.x
   Gibbons WJ, 2004, BIOCHEM BIOPH RES CO, V317, P774, DOI 10.1016/j.bbrc.2004.03.113
   Hall AM, 2008, QJM-INT J MED, V101, P755, DOI 10.1093/qjmed/hcn060
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Hutchin TP, 2001, EUR J HUM GENET, V9, P385, DOI 10.1038/sj.ejhg.5200640
   Papp LV, 2008, NUCLEIC ACIDS RES, V36, P7192, DOI 10.1093/nar/gkn829
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Robinson BH, 2006, MOL GENET METAB, V89, P3, DOI 10.1016/j.ymgme.2006.05.015
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Shimada N, 2001, J BIOL CHEM, V276, P46770, DOI 10.1074/jbc.M105150200
   STEINBERG S, 1994, J MOL BIOL, V236, P982, DOI 10.1016/0022-2836(94)90004-3
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   VARSHNEY U, 1991, J BIOL CHEM, V266, P24712
   Wong LJC, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.040626
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Yokogawa T, 2000, J BIOL CHEM, V275, P19913, DOI 10.1074/jbc.M908473199
   Zhu XY, 2009, ACTA BIOCH BIOPH SIN, V41, P179, DOI 10.1093/abbs/gmn021
NR 23
TC 137
Z9 162
U1 0
U2 21
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD FEB 11
PY 2011
VL 88
IS 2
BP 193
EP 200
DI 10.1016/j.ajhg.2010.12.010
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 725YZ
UT WOS:000287684100007
PM 21255763
DA 2024-11-01
ER

PT J
AU Patel, G
   Johnson, DS
   Sun, B
   Pandey, M
   Yu, X
   Egelman, EH
   Wang, MD
   Patel, SS
AF Patel, Gayatri
   Johnson, Daniel S.
   Sun, Bo
   Pandey, Manjula
   Yu, Xiong
   Egelman, Edward H.
   Wang, Michelle D.
   Patel, Smita S.
TI A257T Linker Region Mutant of T7 Helicase-Primase Protein Is Defective in DNA Loading and Rescued by T7 DNA Polymerase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID progressive external ophthalmoplegia; bacteriophage t7; crystal-structure; gene-4 protein; nucleotide hydrolysis; hexameric helicases; central channel; ring helicase; replication; mechanism
AB The helicase and primase activities of the hexameric ring-shaped T7 gp4 protein reside in two separate domains connected by a linker region. This linker region is part of the subunit interface between monomers, and point mutations in this region have deleterious effects on the helicase functions. One such linker region mutant, A257T, is analogous to the A359T mutant of the homologous human mitochondrial DNA helicase Twinkle, which is linked to diseases such as progressive external opthalmoplegia. Electron microscopy studies show that A257T gp4 is normal in forming rings with dTTP, but the rings do not assemble efficiently on the DNA. Therefore, A257T, unlike the WT gp4, does not preassemble on the unwinding DNA substrate with dTTP without Mg(II), and its DNA unwinding activity in ensemble assays is slow and limited by the DNA loading rate. Single molecule assays measured a 45 times slower rate of A257T loading on DNA compared with WT gp4. Interestingly, once loaded, A257T has almost WT-like translocation and DNA unwinding activities. Strikingly, A257T preassembles stably on the DNA in the presence of T7 DNA polymerase, which restores the ensemble unwinding activity of A257T to similar to 75% of WT, and the rescue does not require DNA synthesis. The DNA loading rate of A257T, however, remains slow even in the presence of the polymerase, which explains why A257T does not support T7 phage growth. Similar types of defects in the related human mitochondrial DNA helicase may be responsible for inefficient DNA replication leading to the disease states.
C1 [Patel, Gayatri; Pandey, Manjula; Patel, Smita S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.
   [Johnson, Daniel S.; Sun, Bo; Wang, Michelle D.] Cornell Univ, Dept Phys, Lab Atom & Solid State Phys, Ithaca, NY 14853 USA.
   [Wang, Michelle D.] Cornell Univ, Howard Hughes Med Inst, Ithaca, NY 14853 USA.
   [Yu, Xiong; Egelman, Edward H.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; Cornell University; Cornell University; Howard Hughes Medical Institute; University of Virginia
RP Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.
EM patelss@umdnj.edu
FU National Institutes of Health [GM55310, GM035269, GM059849]; National Science Foundation [MCB-0820293]; Div Of Molecular and Cellular Bioscience; Direct For Biological Sciences [0820293] Funding Source: National Science Foundation
CR Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418
   BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066
   Cavaluzzi MJ, 2004, NUCLEIC ACIDS RES, V32, P0, DOI 10.1093/nar/gnh015
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Donmez I, 2007, J BIOL CHEM, V282, P21116, DOI 10.1074/jbc.M702136200
   Donmez I, 2006, NUCLEIC ACIDS RES, V34, P4216, DOI 10.1093/nar/gkl508
   EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869
   Ghosh S, 2008, J BIOL CHEM, V283, P32077, DOI 10.1074/jbc.M805062200
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Hamdan SM, 2009, ANNU REV BIOCHEM, V78, P205, DOI 10.1146/annurev.biochem.78.072407.103248
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101
   Johnson DS, 2007, CELL, V129, P1299, DOI 10.1016/j.cell.2007.04.038
   Koch SJ, 2002, BIOPHYS J, V83, P1098, DOI 10.1016/S0006-3495(02)75233-8
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325
   Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8
   Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200
   Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125
   Mao Chih-Chieh, 2009, CHANG GUNG MED J, V32, P354
   MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445
   Matsushima Y, 2009, BBA-BIOENERGETICS, V1787, P290, DOI 10.1016/j.bbabio.2008.11.005
   MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208
   Pandey M, 2010, METHODS MOL BIOL, V587, P57, DOI 10.1007/978-1-60327-355-8_5
   Pandey M, 2009, NATURE, V462, P940, DOI 10.1038/nature08611
   PATEL SS, 1992, J BIOL CHEM, V267, P15013
   PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Picha KM, 2000, BIOCHEMISTRY-US, V39, P6401, DOI 10.1021/bi992857i
   Pyle AM, 2008, ANNU REV BIOPHYS, V37, P317, DOI 10.1146/annurev.biophys.37.032807.125908
   Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Shundrovsky A, 2006, NAT STRUCT MOL BIOL, V13, P549, DOI 10.1038/nsmb1102
   Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615
   STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367
   Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740
NR 41
TC 14
Z9 17
U1 1
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 10
PY 2011
VL 286
IS 23
BP 20490
EP 20499
DI 10.1074/jbc.M110.201657
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 772WC
UT WOS:000291267600036
PM 21515672
DA 2024-11-01
ER

PT J
AU Ameur, A
   Stewart, JB
   Freyer, C
   Hagström, E
   Ingman, M
   Larsson, NG
   Gyllensten, U
AF Ameur, Adam
   Stewart, James B.
   Freyer, Christoph
   Hagstrom, Erik
   Ingman, Max
   Larsson, Nils-Goran
   Gyllensten, Ulf
TI Ultra-Deep Sequencing of Mouse Mitochondrial DNA: Mutational Patterns and Their Origins
SO PLOS GENETICS
LA English
DT Article
ID somatic mtdna mutations; skeletal-muscle; point mutations; deletions; mice; transcription; replication; polymerase; increase; disease
AB Somatic mutations of mtDNA are implicated in the aging process, but there is no universally accepted method for their accurate quantification. We have used ultra-deep sequencing to study genome-wide mtDNA mutation load in the liver of normally-and prematurely-aging mice. Mice that are homozygous for an allele expressing a proof-reading-deficient mtDNA polymerase (mtDNA mutator mice) have 10-times-higher point mutation loads than their wildtype siblings. In addition, the mtDNA mutator mice have increased levels of a truncated linear mtDNA molecule, resulting in decreased sequence coverage in the deleted region. In contrast, circular mtDNA molecules with large deletions occur at extremely low frequencies in mtDNA mutator mice and can therefore not drive the premature aging phenotype. Sequence analysis shows that the main proportion of the mutation load in heterozygous mtDNA mutator mice and their wildtype siblings is inherited from their heterozygous mothers consistent with germline transmission. We found no increase in levels of point mutations or deletions in wildtype C57Bl/6N mice with increasing age, thus questioning the causative role of these changes in aging. In addition, there was no increased frequency of transversion mutations with time in any of the studied genotypes, arguing against oxidative damage as a major cause of mtDNA mutations. Our results from studies of mice thus indicate that most somatic mtDNA mutations occur as replication errors during development and do not result from damage accumulation in adult life.
C1 [Ameur, Adam; Ingman, Max; Gyllensten, Ulf] Uppsala Univ, Rudbeck Lab, SciLifeLab Uppsala, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Stewart, James B.; Freyer, Christoph; Larsson, Nils-Goran] Max Planck Inst Biol Ageing, Cologne, Germany.
   [Hagstrom, Erik; Larsson, Nils-Goran] Karolinska Inst, Dept Lab Med, Div Metab Dis, Stockholm, Sweden.
C3 SciLifeLab; Uppsala University; Max Planck Society; Karolinska Institutet
RP Ameur, A (corresponding author), Uppsala Univ, Rudbeck Lab, SciLifeLab Uppsala, Dept Immunol Genet & Pathol, Uppsala, Sweden.
EM ulf.gyllensten@igp.uu.se
FU Swedish Research Council (VR); Knut and Alice Wallenberg Foundation, through the Center for Metagenomic Sequence Analysis (CMS); ERC
CR Ameur A, 2010, GENOME BIOL, V11, P0, DOI 10.1186/gb-2010-11-3-r34
   Bailey LJ, 2009, NUCLEIC ACIDS RES, V37, P2327, DOI 10.1093/nar/gkp091
   Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Edgar D, 2010, CELL METAB, V11, P1, DOI 10.1016/j.cmet.2009.12.001
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jensen-Seaman MI, 2009, J MOL EVOL, V68, P688, DOI 10.1007/s00239-009-9243-4
   KATAYAMA M, 1991, BIOCHEM INT, V25, P47
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Kraytsberg Y, 2009, AGING CELL, V8, P502, DOI 10.1111/j.1474-9726.2009.00484.x
   Krishnan KJ, 2007, NUCLEIC ACIDS RES, V35, P7399, DOI 10.1093/nar/gkm635
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kukat A, 2009, EXP GERONTOL, V44, P101, DOI 10.1016/j.exger.2008.05.006
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   PIKO L, 1992, ANN NY ACAD SCI, V663, P450, DOI 10.1111/j.1749-6632.1992.tb38698.x
   ROVIO AT, 2006, DNA POLYMERASE GAMMA, V0, P0
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vermulst M, 2009, CELL METAB, V10, P437, DOI 10.1016/j.cmet.2009.11.001
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 39
TC 136
Z9 163
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
EI 
J9 PLOS GENET
JI PLoS Genet.
PD MAR 15
PY 2011
VL 7
IS 3
BP 
EP 
DI 10.1371/journal.pgen.1002028
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 743DD
UT WOS:000288996600057
PM 21455489
DA 2024-11-01
ER

PT J
AU Wenz, TN
   Wang, X
   Marini, M
   Moraes, CT
AF Wenz, Tina
   Wang, Xiao
   Marini, Matteo
   Moraes, Carlos T.
TI A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE mitochondria; bezafibrate; mitochondrial disease; PPAR; PGC-1a
ID respiratory-chain; protein-synthesis; point mutation; pgc-1-alpha; disorders; myopathy; disease; muscle; cells; overexpression
AB Mutations in mitochondrial DNA-encoded tRNA genes are associated with many human diseases. Activation of peroxisome proliferator-activated receptors (PPARs) by synthetic agonists stimulates oxidative metabolism, induces an increase in mitochondrial mass and partially compensates for oxidative phosphorylation system (OXPHOS) defects caused by single OXPHOS enzyme deficiencies in vitro and in vivo. Here, we analysed whether treatment with the PPAR panagonist bezafibrate in cybrids homoplasmic for different mitochondrial tRNA mutations could ameliorate the OXPHOS defect. We found that bezafibrate treatment increased mitochondrial mass, mitochondrial tRNA steady state levels and enhanced mitochondrial protein synthesis. This improvement resulted in increased OXPHOS activity and finally in enhanced mitochondrial ATP generating capacity. PPAR panagonists are known to increase the expression of PPAR gamma coactivator-1a (PGC-1a), a master regulator of mitochondrial biogenesis. Accordingly, we found that clones of a line harbouring a mutated mitochondrial tRNA gene mutation selected for the ability to grow in a medium selective for OXPHOS function had a 3-fold increase in PGC-1a expression, an increase that was similar to the one observed after bezafibrate treatment. These findings show that increasing mitochondrial mass and thereby boosting residual OXPHOS capacity can be beneficial to an important class of mitochondrial defects reinforcing the potential therapeutic use of approaches stimulating mitochondrial proliferation for mitochondrial disorders.
C1 [Wenz, Tina; Marini, Matteo; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Wang, Xiao] Univ Miami, Sch Med, Canc Biol Grad Program, Miami, FL 33136 USA.
   [Marini, Matteo; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
C3 University of Miami; University of Miami; University of Miami
RP Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU Public Health Service [AG036871, CA85700, EY10804]; Florida James and Esther King Biomedical Research Program; Muscular Dystrophy Association; United Mitochondrial Disease Foundation
CR Anderson Rozalyn M, 2007, V35, V0, P18
   Barrientos A, 1998, J NEUROSCI RES, V53, P475, DOI 10.1002/(SICI)1097-4547(19980815)53:4<475::AID-JNR9>3.0.CO;2-3
   Bastin J, 2008, J CLIN ENDOCR METAB, V93, P1433, DOI 10.1210/jc.2007-1701
   Benton CR, 2008, APPL PHYSIOL NUTR ME, V33, P843, DOI 10.1139/H08-074
   Cantó C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Dong WP, 2007, MED HYPOTHESES, V69, P700, DOI 10.1016/j.mehy.2007.01.017
   Goldenberg I, 2008, VASC HEALTH RISK MAN, V4, P131, DOI 10.2147/vhrm.2008.04.01.131
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   Hao HL, 1999, HUM MOL GENET, V8, P1117, DOI 10.1093/hmg/8.6.1117
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   Hondares E, 2007, BIOCHEM BIOPH RES CO, V354, P1021, DOI 10.1016/j.bbrc.2007.01.092
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657
   Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Nadanaciva S, 2007, TOXICOL APPL PHARM, V223, P277, DOI 10.1016/j.taap.2007.06.003
   Pérez-Martínez X, 2008, CURR TOP MED CHEM, V8, P1335, DOI 10.2174/156802608786141124
   Robinson BH, 2006, MOL GENET METAB, V89, P3, DOI 10.1016/j.ymgme.2006.05.015
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P3065, DOI 10.1093/nar/gkn147
   Sasarman F, 2008, HUM MOL GENET, V17, P3697, DOI 10.1093/hmg/ddn265
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Srivastava S, 2009, HUM MOL GENET, V18, P1805, DOI 10.1093/hmg/ddp093
   Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460
   Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wenz T, 2009, J APPL PHYSIOL, V106, P1712, DOI 10.1152/japplphysiol.91571.2008
NR 29
TC 18
Z9 18
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV 15
PY 2011
VL 15
IS 11
BP 2317
EP 2325
DI 10.1111/j.1582-4934.2010.01223.x
PG 9
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 859DQ
UT WOS:000297855400005
PM 21129152
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Fassone, E
   Bordoni, A
   Sciacco, M
   Lucchini, V
   Di Fonzo, A
   Rizzuti, M
   Colombo, I
   Napoli, L
   Ciscato, P
   Moggio, M
   Cosi, A
   Collotta, M
   Corti, S
   Bresolin, N
   Comi, GP
AF Ronchi, Dario
   Fassone, Elisa
   Bordoni, Andreina
   Sciacco, Monica
   Lucchini, Valeria
   Di Fonzo, Alessio
   Rizzuti, Mafalda
   Colombo, Irene
   Napoli, Laura
   Ciscato, Patrizia
   Moggio, Maurizio
   Cosi, Alessandra
   Collotta, Martina
   Corti, Stefania
   Bresolin, Nereo
   Comi, Giacomo P.
TI Two novel mutations in <i>PEO1</i> (Twinkle) gene associated with chronic external ophthalmoplegia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Progressive external ophthalmoplegia; PEO1 (C100RF2); Mitochondrial myopathy; mtDNA multiple deletions; COX deficiency
ID mitochondrial-dna depletion; mtdna maintenance; optic atrophy; deletions; spectrum; disorder; helicase; ataxia; adpeo
AB Maintenance and replication of mitochondrial DNA require the concerted action of several factors encoded by nuclear genome. The mitochondrial helicase Twinkle is a key player of replisome machinery. Heterozygous mutations in its coding gene, PEO1, are associated with progressive external ophthalmoplegia (PEO) characterised by ptosis and ophthalmoparesis, with cytochrome c oxidase (COX)-deficient fibres, ragged-red fibres (RRF) and multiple mtDNA deletions in muscle. Here we describe clinical, histological and molecular features of two patients presenting with mitochondrial myopathy associated with PEO. PEO1 sequencing disclosed two novel mutations in exons 1 and 4 of the gene, respectively. Although mutations in PEO1 exon 1 have already been described, this is the first report of mutation occurring in exon 4. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ronchi, Dario; Fassone, Elisa; Bordoni, Andreina; Sciacco, Monica; Lucchini, Valeria; Di Fonzo, Alessio; Rizzuti, Mafalda; Colombo, Irene; Napoli, Laura; Ciscato, Patrizia; Moggio, Maurizio; Cosi, Alessandra; Collotta, Martina; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Dept Neurol Sci, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, Dept Neurol Sci, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
FU 'Associazione Amici del Centro Dino Ferrari'; Telethon [GTB07001ER]; Eurobiobank [QLTR-2001-02769, GUP09004C]
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Matsushima Y, 2008, J BIOL CHEM, V283, P23964, DOI 10.1074/jbc.M803674200
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
NR 20
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2011
VL 308
IS 1-2
BP 173
EP 176
DI 10.1016/j.jns.2011.05.042
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 816IO
UT WOS:000294592100037
PM 21689831
DA 2024-11-01
ER

PT J
AU Atanassova, N
   Fusté, JM
   Wanrooij, S
   Macao, B
   Goffart, S
   Bäckström, S
   Farge, G
   Khvorostov, I
   Larsson, NG
   Spelbrink, JN
   Falkenberg, M
AF Atanassova, Neli
   Fuste, Javier Miralles
   Wanrooij, Sjoerd
   Macao, Bertil
   Goffart, Steffi
   Backstrom, Stefan
   Farge, Geraldine
   Khvorostov, Ivan
   Larsson, Nils-Goran
   Spelbrink, Johannes N.
   Falkenberg, Maria
TI Sequence-specific stalling of DNA polymerase γ and the effects of mutations causing progressive ophthalmoplegia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID human mitochondrial-dna; synthesis in-vitro; external ophthalmoplegia; autosomal-dominant; accessory subunit; ribonucleotide reductase; mtdna maintenance; rna-polymerase; replication; twinkle
AB A large number of mutations in the gene encoding the catalytic subunit of mitochondrial DNA polymerase gamma (POL gamma A) cause human disease. The Y955C mutation is common and leads to a dominant disease with progressive external ophthalmoplegia and other symptoms. The biochemical effect of the Y955C mutation has been extensively studied and it has been reported to lower enzyme processivity due to decreased capacity to utilize dNTPs. However, it is unclear why this biochemical defect leads to a dominant disease. Consistent with previous reports, we show here that the POL gamma A:Y955C enzyme only synthesizes short DNA products at dNTP concentrations that are sufficient for proper function of wild-type POL gamma A. In addition, we find that this phenotype is overcome by increasing the dNTP concentration, e.g. dATP. At low dATP concentrations, the POL gamma A:Y955C enzyme stalls at dATP insertion sites and instead enters a polymerase/exonuclease idling mode. The POL gamma A:Y955C enzyme will compete with wild-type POL gamma A for primer utilization, and this will result in a heterogeneous population of short and long DNA replication products. In addition, there is a possibility that POL gamma A:Y955C is recruited to nicks of mtDNA and there enters an idling mode preventing ligation. Our results provide a novel explanation for the dominant mtDNA replication phenotypes seen in patients harboring the Y955C mutation, including the existence of site-specific stalling. Our data may also explain why mutations that disturb dATP pools can be especially deleterious for mtDNA synthesis.
C1 [Fuste, Javier Miralles; Wanrooij, Sjoerd; Macao, Bertil; Backstrom, Stefan; Falkenberg, Maria] Univ Gothenburg, Dept Med Biochem & Cell Biol, SE-40530 Gothenburg, Sweden.
   [Atanassova, Neli; Fuste, Javier Miralles; Farge, Geraldine; Khvorostov, Ivan; Larsson, Nils-Goran] Karolinska Inst, Div Metab Dis, SE-17177 Stockholm, Sweden.
   [Farge, Geraldine] Vrije Univ Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands.
   [Farge, Geraldine] Vrije Univ Amsterdam, Ctr Laser, Amsterdam, Netherlands.
   [Goffart, Steffi; Spelbrink, Johannes N.] Univ Tampere, Pirkanmaa Hosp Dist, Tampere Univ Hosp, Inst Med Technol, FI-33014 Tampere, Finland.
   [Goffart, Steffi; Spelbrink, Johannes N.] Univ Tampere, Pirkanmaa Hosp Dist, Tampere Univ Hosp, Ctr Lab Med, FI-33014 Tampere, Finland.
   [Spelbrink, Johannes N.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Inst Genet & Metab Dis, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   [Larsson, Nils-Goran; Falkenberg, Maria] Max Planck Inst Biol Alterns, D-50931 Cologne, Germany.
C3 University of Gothenburg; Karolinska Institutet; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Tampere University; Tampere University Hospital; Pirkanmaa Hospital District; Tampere University; Tampere University Hospital; Pirkanmaa Hospital District; Radboud University Nijmegen; Max Planck Society
RP Falkenberg, M (corresponding author), Univ Gothenburg, Dept Med Biochem & Cell Biol, POB 440, SE-40530 Gothenburg, Sweden.
EM maria.falkenberg@medkem.gu.se
FU Swedish Research Council; Swedish Cancer Society; Swedish Strategic Foundation; Academy of Finland (CoE); Sigrid Juselius Foundation; Tampere University Hospital [9J119, 9K126, 9L097]; Netherlands Organization for Scientific Research (NWO)
CR Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Di Re M, 2009, NUCLEIC ACIDS RES, V37, P5701, DOI 10.1093/nar/gkp614
   Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Fusté JM, 2010, MOL CELL, V37, P67, DOI 10.1016/j.molcel.2009.12.021
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Li Y, 2004, NAT STRUCT MOL BIOL, V11, P784, DOI 10.1038/nsmb792
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wanrooij S, 2008, P NATL ACAD SCI USA, V105, P11122, DOI 10.1073/pnas.0805399105
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 39
TC 23
Z9 26
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 15
PY 2011
VL 20
IS 6
BP 1212
EP 1223
DI 10.1093/hmg/ddq565
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 726WW
UT WOS:000287758600015
PM 21228000
DA 2024-11-01
ER

PT J
AU Tiliscan, C
   Arama, V
   Mihailescu, R
   Streinu-Cercel, A
   Coman, OA
   Ion, D
   Ghita, I
   Arama, SS
AF Tiliscan, Catalin
   Arama, Victoria
   Mihailescu, Raluca
   Streinu-Cercel, Adrian
   Coman, Oana Andreia
   Ion, Daniela
   Ghita, Isabel
   Arama, Stefan Sorin
TI DIAGNOSIS AND MONITORING OF MITOCHONDRIAL TOXICITY INDUCED BY NUCLEOSIDE-ANALOGUE REVERSE-TRANSCRIPTASE INHIBITORS IN HIV-INFECTED PATIENTS UNDERGOING ANTIRETROVIRAL THERAPY
SO FARMACIA
LA English
DT Article
DE Mitochondrial DNA; HIV; Nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors (NRTIs); Highly Active Antiretroviral Therapy (HAART)
ID mechanisms; didanosine
AB Highly Active Antiretroviral Therapy (HAART) containing nucleoside reverse transcriptase inhibitors (NRTIs) has been associated with various side effects following mitochondrial toxicity. The most important clincal consequences of mitochondrial DNA (mtDNA) depletion are: lipodystrophy, hepatic toxicity, lactic acidosis, myopathy and polyneuropathy. In order to prevent the onset of clinical and biological side effects during NRTIs treatment, different methods have been proposed to assess metabolic toxicity non-invasively and to adequately predict the metabolic risk. These methods have to be harmonized and validated, and there is a need for available commercial tests. Further studies are needed, in order to clarify whether clinicians can prevent mitochondrial toxicity based on the results of mtDNA measurements.
C1 [Tiliscan, Catalin; Arama, Victoria; Streinu-Cercel, Adrian; Coman, Oana Andreia; Ion, Daniela; Ghita, Isabel; Arama, Stefan Sorin] Univ Med & Pharm Carol Davila, Bucharest 020021, Romania.
   [Arama, Victoria; Mihailescu, Raluca; Streinu-Cercel, Adrian] Prof Dr Matei Bals Natl Inst Infect Dis, Bucharest 21106, Romania.
C3 Carol Davila University of Medicine & Pharmacy; National Institute for Infectious Diseases "Matei Bals"
RP Arama, SS (corresponding author), Univ Med & Pharm Carol Davila, 37 Dionisie Lupu Str, Bucharest 020021, Romania.
EM sorinarama@gmail.com
FU SLD-ART [62077/2008]; National Authority for Scientific Research (ANCS) [PNCDI-II]
CR Bauer AM, 2004, HIV MED, V5, P371, DOI 10.1111/j.1468-1293.2004.00237.x
   BISSUEL F, 1994, J INTERN MED, V235, P367, DOI 10.1111/j.1365-2796.1994.tb01088.x
   Casademont J, 2004, MED SCI MONITOR, V10, P0
   de Mendoza C, 2004, AIDS REV, V6, P169
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Loffler M, 1997, MOL CELL BIOCHEM, V174, P125, DOI 10.1023/A:1006859115450
   LOGAN J, 2009, FOX REAL TIME NASBA, V0, P0
   Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005
   McComsey GA, 2004, ANTIVIR THER, V9, P205
   Negredo E, 2004, AIDS, V18, P459, DOI 10.1097/00002030-200402200-00012
   Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929
   SCHEFFER IE, 2008, BASIC MOL BIOL MITOC, V0, P37
   Scruggs ER, 2008, PHARMACOLOGY, V82, P83, DOI 10.1159/000134943
   Setzer B, 2005, ANTIVIR THER, V10, P327
   Timmermans EC, 2006, CLIN CHEM, V52, P979, DOI 10.1373/clinchem.2005.062901
   WALKER UA, 2008, LIPOATROPHY OTHER MA, V0, P273
   Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468-1293.2009.00716.x
NR 18
TC 2
Z9 2
U1 0
U2 4
PU SOC STIINTE FARMACEUTICE ROMANIA
PI BUCURESTI
PA BUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIA
SN 0014-8237
EI 2065-0019
J9 FARMACIA
JI Farmacia
PD JUL-AUG 15
PY 2011
VL 59
IS 4
BP 453
EP 461
DI 
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 799UP
UT WOS:000293311900001
DA 2024-11-01
ER

PT J
AU Kwon, MJ
   Ki, CS
   Kim, JY
   Lee, ST
   Kim, JW
   Kang, SY
AF Kwon, Min-Jung
   Ki, Chang-Seok
   Kim, Ji-Youn
   Lee, Seung-Tae
   Kim, Jong-Won
   Kang, Sa-Yoon
TI Multiplex Ligation-Dependent Probe Amplification (MLPA) Assay for the Detection of Mitochondrial DNA Deletion in Chronic Progressive External Ophthalmoplegia (CPEO)
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE Chronic Progressive External Ophthalmoplegia; CPEO; Mitochondrial DNA; deletion; Multiplex ligation-dependent probe amplification; MLPA
AB Chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial myopathy commonly caused by deleterious changes in the mitochondrial DNA (mtDNA). We describe a 45-year-old man who was referred to us for investigation of progressive ptosis. We performed a multiplex ligation-dependent probe amplification (MLPA) assay of mtDNA from muscle tissue and peripheral blood leukocytes, and followed up with gap-polymerase chain reaction (PCR) and direct sequence analysis. Results showed a deletion of a 4,407 bp segment in the mtDNA region, ranging from nucleotide position 8,577 in the MT-ATP6 gene to nucleotide position 12,983 in the MT-ND5 gene. To the best of our knowledge, this is the first report of a CPEO patient with a large novel deletion of mtDNA genetically confirmed by MLPA assay. MLPA can be a feasible platform for clinical laboratories to detect large deletion mutations in the mtDNA for suspected cases.
C1 [Ki, Chang-Seok; Lee, Seung-Tae; Kim, Jong-Won] Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea.
   [Kwon, Min-Jung] Sungkyunkwan Univ, Dept Lab Med, Kangbuk Samsung Hosp, Sch Med, Seoul 135710, South Korea.
   [Kim, Ji-Youn] Samsung Biomed Res Inst, Clin Res Ctr, Seoul, South Korea.
   [Kang, Sa-Yoon] Jeju Natl Univ, Dept Neurol, Coll Med, Cheju 690756, Jeju Do, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Samsung; Jeju National University
RP Ki, CS (corresponding author), Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, 50 Irwon Dong, Seoul 135710, South Korea.
EM changski@skku.edu; neurokang@jejunu.ac.k
FU National Research Foundation of Korea (NRF); Korea government (MEST) [2010-0004450]
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1993, GENEREVIEWS, V0, P0
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   ROTIG A, 1989, LANCET, V1, P902
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 14
TC 6
Z9 6
U1 0
U2 9
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD FAL 15
PY 2011
VL 41
IS 4
BP 385
EP 389
DI 
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 872PP
UT WOS:000298822100013
PM 22166510
DA 2024-11-01
ER

PT J
AU Mezghani, N
   Mnif, M
   Kacem, M
   Mkaouar-Rebai, E
   Salem, IH
   Kallel, N
   Charfi, N
   Abid, M
   Fakhfakh, F
AF Mezghani, Najla
   Mnif, Mouna
   Kacem, Maha
   Mkaouar-Rebai, Emna
   Salem, Ikhlass Hadj
   Kallel, Nozha
   Charfi, Nadia
   Abid, Mohamed
   Fakhfakh, Faiza
TI A whole mitochondrial genome screening in a MELAS patient: A novel mitochondrial tRNA<SUP>Val</SUP> mutation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MELAS syndrome; Mitochondrial mutations; m.3243A > G; tRNA(Val) gene
ID lactic-acidosis; mtdna mutation; nd5 gene; dna; identification; prevalence; myopathy; disease; rna
AB Mitochondrial encephalopathy, lactic acidosis and strokelike episodes (MELAS) syndrome is a mitochondrial disorder characterized by a wide variety of clinical presentations and a multisystemic organ involvement. In this study, we report a Tunisian girl with clinical features of MELAS syndrome who was negative for the common m.3243A>G mutation, but also for the reported mitochondrial DNA (mtDNA) mutations and deletions. Screening of the entire mtDNA genome showed several known mitochondrial variants besides to a novel transition m.1640A>G affecting a wobble adenine in the anticodon stem region of the tRNA(Val). This nucleotide was conserved and it was absent in 150 controls suggesting its pathogenicity. In addition, no mutations were found in the nuclear polymerase gamma-1 gene (POLG1). These results suggest further investigation nuclear genes encoding proteins responsible for stability and structural components of the mtDNA or to the oxidative phosphorylation machinery to explain the phenotypic variability in the studied family. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Mezghani, Najla; Mkaouar-Rebai, Emna; Salem, Ikhlass Hadj; Fakhfakh, Faiza] Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Sfax 3029, Tunisia.
   [Mnif, Mouna; Kallel, Nozha; Charfi, Nadia; Abid, Mohamed] CHU Habib Bourguiba Sfax, Serv Endocrinol, Sfax, Tunisia.
   [Kacem, Maha] CHU Fattouma Bourguiba Monastir, Serv Med Interne, Monastir, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Habib Bourguiba; Hopital Hedi Chaker; Universite de Monastir; Hopital Fattouma Bourguiba
RP Mkaouar-Rebai, E (corresponding author), Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Ave Magida Boulila, Sfax 3029, Tunisia.
EM emna_mkaouar@mail2world.com
FU Ministry of Higher Education and Scientific Research in Tunisia
CR Abu-Amero EK, 2006, J CHILD NEUROL, V21, P971, DOI 10.2310/7010.2006.00208
   Aharoni S, 2010, J NEUROL SCI, V296, P101, DOI 10.1016/j.jns.2010.06.029
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   Finsterer J, 2009, INT J CARDIOL, V137, P60, DOI 10.1016/j.ijcard.2008.04.089
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kivisild T, 2004, AM J HUM GENET, V75, P752, DOI 10.1086/425161
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Matsumoto Joyce, 2005, REV NEUROL DIS, V2, P30
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Menotti Francesca, 2004, ITAL HEART J, V5, P460
   Mkaouar-Rebai E, 2007, BIOCHEM BIOPH RES CO, V355, P1031, DOI 10.1016/j.bbrc.2007.02.083
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
NR 33
TC 5
Z9 6
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 22
PY 2011
VL 407
IS 4
BP 747
EP 752
DI 10.1016/j.bbrc.2011.03.094
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 759KI
UT WOS:000290240500022
PM 21447323
DA 2024-11-01
ER

PT J
AU Trevisson, E
   DiMauro, S
   Navas, P
   Salviati, L
AF Trevisson, Eva
   DiMauro, Salvatore
   Navas, Placido
   Salviati, Leonardo
TI Coenzyme Q deficiency in muscle
SO CURRENT OPINION IN NEUROLOGY
LA English
DT Article
DE CoQ10; CoQ10 deficiency; myopathy; oral supplementation
ID diphosphate synthase subunit-2; respiratory-chain dysfunction; coq(10) deficiency; q(10) deficiency; mitochondrial encephalomyopathy; dehydrogenase-deficiency; ubiquinone deficiency; cerebellar-ataxia; oxidative stress; mutations
AB Purpose of review Coenzyme Q (CoQ) is a vital component of the mitochondrial respiratory chain. A number of patients with CoQ deficiency presented with different clinical phenotypes, often affecting skeletal muscle, and responded well to CoQ supplementation. We discuss recent advances in this field with special attention to muscle involvement. Recent findings The identification of genetic defects causing CoQ deficiency has allowed to distinguish primary forms, due to mutations in biosynthetic genes, from secondary defects caused either by mutations in genes unrelated to CoQ biosynthesis or by nongenetic factors. To date, none of the patients with genetically proven primary deficiency presented with an exclusively (or prominently) myopathic phenotype. Most patients with myopathy were found to harbor other genetic defects (mutations in electron-transferring-flavoprotein dehydrogenase or mitochondrial DNA). The majority of patients with CoQ deficiency still lack a genetic diagnosis. The pathogenesis of CoQ deficiency cannot be attributed solely to the bioenergetic defect, suggesting that other roles of CoQ, including its antioxidant properties or its role in pyrimidine metabolism, may also play crucial roles. Summary Early recognition of CoQ deficiency is essential to institute appropriate and timely treatment, thus avoiding irreversible tissue damage.
C1 [Salviati, Leonardo] Univ Padua, Dipartimento Pediat, Serv Genet Clin, Clin Genet Unit, I-35128 Padua, Italy.
   [DiMauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA.
   [Navas, Placido] Univ Pablo de Olavide, CSIC, Ctr Andaluz Biol Desarrollo, Seville, Spain.
   [Navas, Placido] Inst Salud Carlos III, CIBERER, Seville, Spain.
C3 University of Padua; Columbia University; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III
RP Salviati, L (corresponding author), Univ Padua, Dipartimento Pediat, Serv Genet Clin, Clin Genet Unit, Via Giustiniani 3, I-35128 Padua, Italy.
EM leonardo.salviati@unipd.it
FU CARIPARO Foundation; Telethon Italy [GGP09207]; Spanish FIS [PI080500]; Junta de Andalucia [P08-CTS-03988]
CR Aeby A, 2007, J INHERIT METAB DIS, V30, P827, DOI 10.1007/s10545-007-0612-0
   Artuch R, 2009, ADV EXP MED BIOL, V652, P117, DOI 10.1007/978-90-481-2813-6_8
   Avis HJ, 2011, J PEDIATR-US, V158, P458, DOI 10.1016/j.jpeds.2010.08.015
   Barshop BA, 2007, MITOCHONDRION, V7, PS89, DOI 10.1016/j.mito.2007.04.002
   Bentinger M, 2003, FREE RADICAL BIO MED, V34, P563, DOI 10.1016/S0891-5849(02)01357-6
   Casarin A, 2008, BIOCHEM BIOPH RES CO, V372, P35, DOI 10.1016/j.bbrc.2008.04.172
   Caso G, 2007, AM J CARDIOL, V99, P1409, DOI 10.1016/j.amjcard.2006.12.063
   Castellotti B, 2011, NEUROGENETICS, V0, P0
   Cordero MD, 2009, CLIN BIOCHEM, V42, P732, DOI 10.1016/j.clinbiochem.2008.12.010
   Cordero MD, 2010, CLIN BIOCHEM, V43, P1174, DOI 10.1016/j.clinbiochem.2010.06.013
   COTAN D, 2011, FASEB J, V0, P0
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Emma F, 2012, PEDIATR NEPHROL, V27, P539, DOI 10.1007/s00467-011-1926-6
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Haas D, 2009, J INHERIT METAB DIS, V32, P570, DOI 10.1007/s10545-009-1150-8
   Harper CR, 2010, CURR ATHEROSCLER REP, V12, P322, DOI 10.1007/s11883-010-0120-9
   Heeringa SF, 2011, J CLIN INVEST, V121, P2013, DOI 10.1172/JCI45693
   Kaminsky P, 2011, MUSCLE NERVE, V43, P444, DOI 10.1002/mus.21881
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Liang WC, 2009, NEUROMUSCULAR DISORD, V19, P212, DOI 10.1016/j.nmd.2009.01.008
   López LC, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011897
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   López-Martín JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058
   Marbois B, 2009, BBA-MOL CELL BIOL L, V1791, P69, DOI 10.1016/j.bbalip.2008.10.006
   Mas E, 2010, CURR ATHEROSCLER REP, V12, P407, DOI 10.1007/s11883-010-0134-3
   Miles MV, 2008, MITOCHONDRION, V8, P170, DOI 10.1016/j.mito.2008.01.003
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Montero R, 2005, BIOFACTORS, V25, P109, DOI 10.1002/biof.5520250112
   Montero R, 2008, CLIN BIOCHEM, V41, P697, DOI 10.1016/j.clinbiochem.2008.03.007
   Montero R, 2009, CLIN BIOCHEM, V42, P742, DOI 10.1016/j.clinbiochem.2008.10.027
   Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Peng M, 2008, PLOS GENET, V4, P0, DOI 10.1371/journal.pgen.1000061
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113
   Quinzii CM, 2008, FASEB J, V22, P1874, DOI 10.1096/fj.07-100149
   Quinzii CM, 2007, MITOCHONDRION, V7, PS122, DOI 10.1016/j.mito.2007.03.004
   Quinzii CM, 2010, FASEB J, V24, P3733, DOI 10.1096/fj.09-152728
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Rodríguez-Hernández A, 2009, AUTOPHAGY, V5, P19, DOI 10.4161/auto.5.1.7174
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Saiki R, 2008, AM J PHYSIOL-RENAL, V295, PF1535, DOI 10.1152/ajprenal.90445.2008
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Tran UC, 2007, MITOCHONDRION, V7, PS62, DOI 10.1016/j.mito.2007.03.007
   Xie LTX, 2011, BBA-MOL CELL BIOL L, V1811, P348, DOI 10.1016/j.bbalip.2011.01.009
   Young JA, 2007, AM J CARDIOL, V100, P1400, DOI 10.1016/j.amjcard.2007.06.030
NR 51
TC 60
Z9 65
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1350-7540
EI 
J9 CURR OPIN NEUROL
JI Curr. Opin. Neurol.
PD OCT 15
PY 2011
VL 24
IS 5
BP 449
EP 456
DI 10.1097/WCO.0b013e32834ab528
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 817NB
UT WOS:000294679400006
PM 21844807
DA 2024-11-01
ER

PT J
AU Payne, BAI
   Wilson, IJ
   Hateley, CA
   Horvath, R
   Santibanez-Koref, M
   Samuels, DC
   Price, DA
   Chinnery, PF
AF Payne, Brendan A. I.
   Wilson, Ian J.
   Hateley, Charlotte A.
   Horvath, Rita
   Santibanez-Koref, Mauro
   Samuels, David C.
   Price, D. Ashley
   Chinnery, Patrick F.
TI Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations
SO NATURE GENETICS
LA English
DT Article
ID hiv-infected patients; dna mutations; polymerase-gamma; point mutations; deletions; cells; age; disease; muscle; accumulation
AB There is emerging evidence that people with successfully treated HIV infection age prematurely, leading to progressive multi-organ disease(1), but the reasons for this are not known. Here we show that patients treated with commonly used nucleoside analog anti-retroviral drugs progressively accumulate somatic mitochondrial DNA (mtDNA) mutations, mirroring those seen much later in life caused by normal aging(2,3). Ultra-deep re-sequencing by synthesis, combined with single-cell analyses, suggests that the increase in somatic mutation is not caused by increased mutagenesis but might instead be caused by accelerated mtDNA turnover. This leads to the clonal expansion of preexisting age-related somatic mtDNA mutations and a biochemical defect that can affect up to 10% of cells. These observations add weight to the role of somatic mtDNA mutations in the aging process and raise the specter of progressive iatrogenic mitochondrial genetic disease emerging over the next decade.
C1 [Payne, Brendan A. I.; Wilson, Ian J.; Hateley, Charlotte A.; Horvath, Rita; Santibanez-Koref, Mauro; Chinnery, Patrick F.] Newcastle Univ, Mitochondrial Res Grp, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Payne, Brendan A. I.; Price, D. Ashley] Royal Victoria Infirm, Dept Infect & Trop Med, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Samuels, David C.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
C3 Newcastle University - UK; Newcastle University - UK; Vanderbilt University
RP Chinnery, PF (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Medical Research Council; British Infection Society; Newcastle Healthcare Charity; UK National Institute for Health Research (NIHR) Biomedical Research Centre for Aging and Age-related disease; Wellcome Trust; MRC [G0800470, G1000848] Funding Source: UKRI
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   [Anonymous], 2006, ANT THER HIV INF AD, V0, P0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Cherry CL, 2006, JAIDS-J ACQ IMM DEF, V42, P435, DOI 10.1097/01.qai.0000224974.67962.ce
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Desquilbet L, 2007, J GERONTOL A-BIOL, V62, P1279, DOI 10.1093/gerona/62.11.1279
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Durham SE, 2006, NEUROMUSCULAR DISORD, V16, P381, DOI 10.1016/j.nmd.2006.03.012
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Greaves LC, 2009, AGING CELL, V8, P566, DOI 10.1111/j.1474-9726.2009.00505.x
   Guaraldi G, 2009, CLIN INFECT DIS, V49, P1756, DOI 10.1086/648080
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Maagaard A, 2006, ANTIVIR THER, V11, P601
   McComsey GA, 2005, AIDS, V19, P15, DOI 10.1097/00002030-200501030-00002
   Oursler KK, 2006, AIDS RES HUM RETROV, V22, P1113, DOI 10.1089/aid.2006.22.1113
   Pereira L, 2009, AM J HUM GENET, V84, P628, DOI 10.1016/j.ajhg.2009.04.013
   Quinlan AR, 2008, NAT METHODS, V5, P179, DOI 10.1038/nmeth.1172
   Shieh DB, 2007, CHEM-BIOL INTERACT, V165, P211, DOI 10.1016/j.cbi.2006.12.008
   Smyth K, 2007, HIV MED, V8, P367, DOI 10.1111/j.1468-1293.2007.00478.x
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Valcour V, 2004, NEUROLOGY, V63, P822, DOI 10.1212/01.WNL.0000134665.58343.8D
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
NR 35
TC 178
Z9 189
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 
J9 NAT GENET
JI Nature Genet.
PD AUG 15
PY 2011
VL 43
IS 8
BP 806
EP U121
DI 10.1038/ng.863
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 798CD
UT WOS:000293178300019
PM 21706004
DA 2024-11-01
ER

PT J
AU Nalbandian, A
   Donkervoort, S
   Dec, E
   Badadani, M
   Katheria, V
   Rana, P
   Nguyen, C
   Mukherjee, J
   Caiozzo, V
   Martin, B
   Watts, GD
   Vesa, J
   Smith, C
   Kimonis, VE
AF Nalbandian, Angele
   Donkervoort, Sandra
   Dec, Eric
   Badadani, Mallikarjun
   Katheria, Veeral
   Rana, Prachi
   Christopher Nguyen
   Mukherjee, Jogeshwar
   Caiozzo, Vincent
   Martin, Barbara
   Watts, Giles D.
   Vesa, Jouni
   Smith, Charles
   Kimonis, Virginia E.
TI The Multiple Faces of Valosin-Containing Protein-Associated Diseases: Inclusion Body Myopathy with Paget's Disease of Bone, Frontotemporal Dementia, and Amyotrophic Lateral Sclerosis
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Valosin containing protein; Amyotrophic lateral sclerosis; Inclusion body myopathy; Paget's disease of bone; Frontotemporal dementia; Autophagy; NFKB; Ubiquitin; TAR DNA Binding Protein-43; Endoplasmic reticulum associated degradation
ID motor-neuron disease; kappa-b; endoplasmic-reticulum; vcp mutations; aaa-atpase; lobar degeneration; autophagic removal; ubiquitin; tdp-43; family
AB Inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD) is a progressive, fatal genetic disorder with variable penetrance, predominantly affecting three main tissue types: muscle (IBM), bone (PDB), and brain (FTD). IBMPFD is caused by mutations in the ubiquitously expressed valosin-containing protein (VCP) gene, a member of the AAA-ATPase superfamily. The majority of individuals who develop IBM have progressive proximal muscle weakness. Muscle biopsies reveal rimmed vacuoles and inclusions that are ubiquitin- and TAR DNA binding protein-43 (TDP-43)-positive using immunohistochemistry. PDB, seen in half the individuals, is caused by overactive osteoclasts and is associated clinically with pain, elevated serum alkaline phosphatase, and X-ray findings of coarse trabeculation and sclerotic lesions. FTD diagnosed at a mean age of 55 years in a third of individuals is characterized clinically by comprehension deficits, dysnomia, dyscalculia, and social unawareness. Ubiquitin- and TDP-43-positive neuronal inclusions are also found in the brain. Genotype-phenotype correlations are difficult with marked intra-familial and inter-familial variations being seen. Varied phenotypes within families include frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism, myotonia, cataracts, and anal incompetence, among others. Cellular and animal models indicate pathogenetic disturbances in IBMPFD tissues including altered protein degradation, autophagy pathway alterations, apoptosis, and mitochondrial dysfunction. Currently, mouse and drosophila models carrying VCP mutations provide insights into the human IBMPFD pathology and are useful as tools for preclinical studies and testing of therapeutic strategies. In this review, we will explore the pathogenesis and clinical phenotype of IBMPFD caused by VCP mutations.
C1 [Nalbandian, Angele; Donkervoort, Sandra; Dec, Eric; Badadani, Mallikarjun; Katheria, Veeral; Rana, Prachi; Christopher Nguyen; Vesa, Jouni; Kimonis, Virginia E.] Univ Calif Irvine, Dept Pediat, Div Genet & Metab, Irvine, CA 92696 USA.
   [Mukherjee, Jogeshwar] Univ Calif Irvine, Dept Psychiat & Human Behav, Preclin Imaging Ctr, Irvine, CA 92697 USA.
   [Caiozzo, Vincent] Univ Calif Irvine, Coll Hlth Sci, Dept Physiol & Biophys, Irvine, CA 92697 USA.
   [Caiozzo, Vincent] Univ Calif Irvine, Coll Hlth Sci, Dept Orthoped, Irvine, CA 92697 USA.
   [Martin, Barbara; Smith, Charles] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
   [Watts, Giles D.] Univ E Anglia, Sch Med Hlth Policy & Practice, Biomed Res Ctr, Norwich NR4 7TJ, Norfolk, England.
C3 University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Kentucky; University of East Anglia
RP Kimonis, VE (corresponding author), Univ Calif Irvine, Dept Pediat, Div Genet & Metab, 2501 Hewitt Hall, Irvine, CA 92696 USA.
EM vkimonis@uci.edu
FU NIH [AR050236, AG025159]; Muscular Dystrophy Association; UC Irvine Institute of Translational Science (ICTS)
CR Acharyya S, 2007, J CLIN INVEST, V117, P889, DOI 10.1172/JCI30556
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Alexandru G, 2008, CELL, V134, P804, DOI 10.1016/j.cell.2008.06.048
   Alonso A, 2009, EUR J NEUROL, V16, P745, DOI 10.1111/j.1468-1331.2009.02586.x
   Arnold SE, 2000, NEUROBIOL AGING, V21, P913, DOI 10.1016/S0197-4580(00)00173-1
   Badadani M, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0013183
   Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448
   Bersano A, 2009, NEUROBIOL AGING, V30, P752, DOI 10.1016/j.neurobiolaging.2007.08.009
   Bhatnagar S, 2010, J MOL MED, V88, P155, DOI 10.1007/s00109-009-0550-4
   Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182
   Chang YC, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1001288
   CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710
   Crippa V, 2010, AUTOPHAGY, V6, P958, DOI 10.4161/auto.6.7.13042
   Crippa V, 2010, HUM MOL GENET, V19, P3440, DOI 10.1093/hmg/ddq257
   Custer SK, 2010, HUM MOL GENET, V19, P1741, DOI 10.1093/hmg/ddq050
   Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056
   Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562
   DeLaBarre B, 2006, MOL CELL, V22, P451, DOI 10.1016/j.molcel.2006.03.036
   Djamshidian A, 2009, MUSCLE NERVE, V39, P389, DOI 10.1002/mus.21225
   Fanganiello RD, 2011, BRAZ J MED BIOL RES, V44, P374, DOI 10.1590/S0100-879X2011007500028
   Farpour F, 2011, RADIOLOGICAL FEATURE, V0, P0
   Fernández-Sáiz V, 2010, EMBO REP, V11, P479, DOI 10.1038/embor.2010.49
   Gidaro T, 2008, MUSCLE NERVE, V37, P111, DOI 10.1002/mus.20890
   Graham KM, 2010, J NEUROL SCI, V294, P43, DOI 10.1016/j.jns.2010.04.007
   Guyant-Maréchal L, 2006, NEUROLOGY, V67, P644, DOI 10.1212/01.wnl.0000225184.14578.d3
   Haslbeck KM, 2005, ACTA NEUROPATHOL, V110, P247, DOI 10.1007/s00401-005-1043-3
   Haubenberger D, 2005, NEUROLOGY, V65, P1304, DOI 10.1212/01.wnl.0000180407.15369.92
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hübbers CU, 2007, BRAIN, V130, P381, DOI 10.1093/brain/awl238
   Janiesch PC, 2007, NAT CELL BIOL, V9, P379, DOI 10.1038/ncb1554
   Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x
   Johnson JO, 2010, NEURON, V68, P857, DOI 10.1016/j.neuron.2010.11.036
   Ju JS, 2010, HUM MOL GENET, V19, PR38, DOI 10.1093/hmg/ddq157
   Kakizuka A, 2008, BIOCHEM SOC T, V36, P105, DOI 10.1042/BST0360105
   Kaleem M, 2007, NEURODEGENER DIS, V4, P376, DOI 10.1159/000105158
   Kim EJ, 2011, ARCH NEUROL-CHICAGO, V68, P787, DOI 10.1001/archneurol.2010.376
   Kimonis VE, 2000, GENET MED, V2, P232, DOI 10.1097/00125817-200007000-00006
   Kimonis VE, 2008, AM J MED GENET A, V146A, P745, DOI 10.1002/ajmg.a.31862
   Kimonis VE, 2008, BBA-MOL BASIS DIS, V1782, P744, DOI 10.1016/j.bbadis.2008.09.003
   Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Kovach MJ, 2001, MOL GENET METAB, V74, P458, DOI 10.1006/mgme.2001.3256
   Krause S, 2007, CLIN NEUROPATHOL, V26, P232
   Kumar KR, 2010, NEUROMUSCULAR DISORD, V20, P330, DOI 10.1016/j.nmd.2010.03.002
   Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066
   Lagier-Tourenne C, 2010, HUM MOL GENET, V19, PR46, DOI 10.1093/hmg/ddq137
   Leigh PN, 2010, NAT REV NEUROL, V6, P191, DOI 10.1038/nrneurol.2010.33
   Leyton CE, 2010, ANN INDIAN ACAD NEUR, V13, P74, DOI 10.4103/0972-2327.74249
   Ling SC, 2010, P NATL ACAD SCI USA, V107, P13318, DOI 10.1073/pnas.1008227107
   Logroscino G, 2008, J NEUROL NEUROSUR PS, V79, P6, DOI 10.1136/jnnp.2006.104828
   Lomen-Hoerth C, 2003, NEUROLOGY, V60, P1094, DOI 10.1212/01.WNL.0000055861.95202.8D
   McGuire V, 1996, NEUROLOGY, V47, P571, DOI 10.1212/WNL.47.2.571
   Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181
   Miller TD, 2009, J NEUROL NEUROSUR PS, V80, P583, DOI 10.1136/jnnp.2008.148676
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Müller JMM, 2007, BIOCHEM BIOPH RES CO, V354, P459, DOI 10.1016/j.bbrc.2006.12.206
   Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546
   Pasquali L, 2010, CNS NEUROL DISORD-DR, V9, P268, DOI 10.2174/187152710791292594
   Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002
   Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9
   Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Roberson ED, 2011, METHODS MOL BIOL, V670, P1, DOI 10.1007/978-1-60761-744-0_1
   Rohrer JD, 2011, J NEUROL, V258, P1494, DOI 10.1007/s00415-011-5966-4
   Rusten TE, 2008, AUTOPHAGY, V4, P233, DOI 10.4161/auto.5396
   Schröder R, 2005, ANN NEUROL, V57, P457, DOI 10.1002/ana.20407
   Shaw CE, 2010, NEURON, V68, P812, DOI 10.1016/j.neuron.2010.11.040
   Siciliano G, 2010, CNS NEUROL DISORD-DR, V9, P305, DOI 10.2174/187152710791292648
   Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961
   Spina, 2008, FASEB J, V22, P584
   Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584
   Stojkovic T, 2009, NEUROMUSCULAR DISORD, V19, P316, DOI 10.1016/j.nmd.2009.02.012
   Strong MJ, 2003, ANN NEUROL, V54, PS20, DOI 10.1002/ana.10574
   Traynor BJ, 1999, NEUROLOGY, V52, P504, DOI 10.1212/WNL.52.3.504
   Turner RS, 1996, ANN NEUROL, V39, P166, DOI 10.1002/ana.410390205
   van der Zee J, 2009, NEUROLOGY, V73, P626, DOI 10.1212/WNL.0b013e3181b389d9
   Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942
   Vesa J, 2009, NEUROMUSCULAR DISORD, V19, P766, DOI 10.1016/j.nmd.2009.08.003
   Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014
   Watts GDJ, 2007, CLIN GENET, V72, P420, DOI 10.1111/j.1399-0004.2007.00887.x
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Watts GDJ, 2003, NEUROMUSCULAR DISORD, V13, P559, DOI 10.1016/S0960-8966(03)00070-1
   Weihl CC, 2006, HUM MOL GENET, V15, P189, DOI 10.1093/hmg/ddi426
   Weihl CC, 2007, HUM MOL GENET, V16, P919, DOI 10.1093/hmg/ddm037
   Weihl CC, 2009, NEUROMUSCULAR DISORD, V19, P308, DOI 10.1016/j.nmd.2009.01.009
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a
   Zhukareva V, 2001, ANN NEUROL, V49, P165, DOI 10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3
NR 88
TC 103
Z9 115
U1 0
U2 16
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD NOV 15
PY 2011
VL 45
IS 3
BP 522
EP 531
DI 10.1007/s12031-011-9627-y
PG 10
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 841NL
UT WOS:000296518900029
PM 21892620
DA 2024-11-01
ER

PT J
AU Schaaf, CP
   Blazo, M
   Lewis, RA
   Tonini, RE
   Takei, H
   Wang, J
   Wong, LJ
   Scaglia, F
AF Schaaf, Christian P.
   Blazo, Maria
   Lewis, Richard Alan
   Tonini, Ross E.
   Takei, Hidehiro
   Wang, Jing
   Wong, Lee-Jun
   Scaglia, Fernando
TI Early-onset severe neuromuscular phenotype associated with compound heterozygosity for <i>OPA1</i> mutations
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Optic atrophy; Semi-dominant inheritance; Mitochondrial dysfunction; Neurological disease; Compound heterozygosity
ID mitochondrial-dna depletion; dominant optic atrophy; mouse model; gene; dysfunction; deficiency; morphology; features; defects
AB Introduction: Pathogenic mutations in the OPA1 gene are the most common identifiable cause of autosomal dominant optic atrophy (DOA), which is characterized by selective retinal ganglion cell loss, a distinctive pattern of temporal pallor of the optic nerve and a typical color vision deficit, with variable effects on visual acuity. Haploinsufficiency has been suggested as the major pathogenic mechanism for DOA. Here we present two siblings with severe ataxia, hypotonia, gastrointestinal dysmotility, dysphagia, and severe, early-onset optic atrophy who were found to be compound heterozygotes for two pathogenic OPA1 mutations. This example expands the clinical phenotype of OPA1-associated disorders and provides additional evidence for semi-dominant inheritance. Methods and results: Molecular analysis of the OPA1 gene in this family by Sanger sequencing revealed compound heterozygosity for two mutations in trans configuration, a p.I382M missense mutation and a p.V903GfsX3 frameshift deletion in both affected siblings. Electron microscopy of a skeletal muscle biopsy of the older sibling revealed dense osmiophilic bodies within the mitochondria. Mitochondrial DNA (mtDNA) content was within normal limits, and electron transport chain analysis showed no deficiencies of the mitochondrial respiratory chain enzymes. Multiple mtDNA deletions were not found. Conclusion: Compound heterozygosity of pathogenic OPA1 mutations may cause severe neuromuscular phenotypes in addition to early-onset optic atrophy. While a role for OPA1 in mtDNA maintenance has been discussed, compound biallelic pathogenic OPA1 mutations in our patients did not result in altered mtDNA copy number, mtDNA deletions, or deficiencies of the electron transport chain, despite the severe clinical phenotype. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Schaaf, Christian P.; Lewis, Richard Alan; Wang, Jing; Wong, Lee-Jun; Scaglia, Fernando] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Blazo, Maria] Scott & White Hosp, Div Med Genet, Temple, TX USA.
   [Lewis, Richard Alan] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
   [Tonini, Ross E.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA.
   [Takei, Hidehiro] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Houston Methodist Hospital
RP Scaglia, F (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
EM fscaglia@bcm.edu
FU Research to Prevent Blindness, New York, N.Y
CR Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Enns GM, 2005, CLIN GENET, V68, P337, DOI 10.1111/j.1399-0004.2005.00499.x
   Mayorov Vladimir I, 2008, BMC BIOCHEMISTRY, V9, P9, DOI 10.1186/1471-2091-9-22
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Schimpf S, 2008, HUM MUTAT, V29, P106, DOI 10.1002/humu.20607
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spinazzi M, 2008, HUM MOL GENET, V17, P3291, DOI 10.1093/hmg/ddn225
   Thiselton DL, 2002, INVEST OPHTH VIS SCI, V43, P1715
   Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369
   Votruba M, 1998, ARCH OPHTHALMOL-CHIC, V116, P351, DOI 10.1001/archopht.116.3.351
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2010, OPHTHALMOLOGY, V117, P1538, DOI 10.1016/j.ophtha.2009.12.038
   Yu-Wai-Man P, 2010, HUM MOL GENET, V19, P3043, DOI 10.1093/hmg/ddq209
   Yu-Wai-Man P, 2009, INVEST OPHTH VIS SCI, V50, P4561, DOI 10.1167/iovs.09-3634
NR 22
TC 63
Z9 65
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD AUG 15
PY 2011
VL 103
IS 4
BP 383
EP 387
DI 10.1016/j.ymgme.2011.04.018
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 809ZY
UT WOS:000294096400012
PM 21636302
DA 2024-11-01
ER

PT J
AU Tucker, EJ
   Compton, AG
   Calvo, SE
   Thorburn, DR
AF Tucker, Elena J.
   Compton, Alison G.
   Calvo, Sarah E.
   Thorburn, David R.
TI The Molecular Basis of Human Complex I Deficiency
SO IUBMB LIFE
LA English
DT Review
DE mitochondrial disorders; molecular genetics; mitochondria; human molecular disease
ID respiratory-chain disorders; mitochondrial-dna mutations; assembly factor; chaperone; subunit; involvement; prevalence; disease; foxred1; patient
AB Disorders of oxidative phosphorylation (OXPHOS) have a birth prevalence of similar to 1/5,000 and are the most common inborn errors of metabolism. The most common OXPHOS disorder is complex I deficiency. Patients with complex I deficiency present with variable symptoms, such as muscle weakness, cardiomyopathy, developmental delay or regression, blindness, seizures, failure to thrive, liver dysfunction or ataxia. Molecular diagnosis of patients with complex I deficiency is a challenging task clue to the clinical heterogeneity of patients and the large number of candidate disease genes, both nuclear-encoded and mitochondria! DNA (mtDNA)-encoded. In this review, we have thoroughly surveyed the literature to identify 149 patients described with both isolated complex 1 deficiency and pathogenic mutations within nuclear genes. In total, 115 different pathogenic mutations have been reported in 22 different nuclear genes encoding complex I subunits or assembly factors, highlighting the allelic and locus heterogeneity of this disorder. Missense mutations predominate in genes encoding core subunits and some assembly factors while null-type mutations are common in the genes encoding supernumerary subunits and other assembly factors. Despite developments in molecular technology, many patients do not receive molecular diagnosis and no gene has yet been identified that accounts for more than 5% of cases, suggesting that there are likely many disease genes that await discovery. (C) 2011 IUBMB IUBMB Life, 63(9): 669-677, 2011
C1 [Tucker, Elena J.; Compton, Alison G.; Thorburn, David R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Tucker, Elena J.; Thorburn, David R.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Calvo, Sarah E.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Calvo, Sarah E.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
   [Calvo, Sarah E.] Broad Inst, Cambridge, MA USA.
   [Thorburn, David R.] Royal Childrens Hosp, Genet Hlth Serv Victoria, Melbourne, Vic, Australia.
C3 Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Royal Children's Hospital Melbourne
RP Tucker, EJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM ejtucker@student.unimelb.edu.au
FU Australian National Health and Medical Research Council (NHMRC); NHMRC; Australian Postgraduate Award
CR Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fassone E, 2010, HUM MOL GENET, V19, P4837, DOI 10.1093/hmg/ddq414
   Gabaldón T, 2005, J MOL BIOL, V348, P857, DOI 10.1016/j.jmb.2005.02.067
   Gerards M, 2010, J MED GENET, V47, P507, DOI 10.1136/jmg.2009.067553
   Gerards M, 2011, BRAIN, V134, P210, DOI 10.1093/brain/awq273
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Haack TB, 2010, NAT GENET, V42, P1131, DOI 10.1038/ng.706
   Herzer M, 2010, NEUROPEDIATRICS, V41, P30, DOI 10.1055/s-0030-1255062
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hunte C, 2010, SCIENCE, V329, P448, DOI 10.1126/science.1191046
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Küffner R, 1998, J MOL BIOL, V283, P409, DOI 10.1006/jmbi.1998.2114
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Lebon S, 2007, MOL GENET METAB, V92, P104, DOI 10.1016/j.ymgme.2007.05.010
   Lebon S, 2007, MOL GENET METAB, V90, P379, DOI 10.1016/j.ymgme.2006.12.007
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Mckenzie M, 2010, IUBMB LIFE, V62, P497, DOI 10.1002/iub.335
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   MITONIAP, 2010, MITOMAP HUM MIT GEN, V0, P0
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pagniez-Mammeri H, 2009, MOL GENET METAB, V96, P196, DOI 10.1016/j.ymgme.2008.12.003
   Potluri P, 2009, MOL GENET METAB, V96, P189, DOI 10.1016/j.ymgme.2008.12.004
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Sheftel AD, 2009, MOL CELL BIOL, V29, P6059, DOI 10.1128/MCB.00817-09
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Sugiana C, 2008, AM J HUM GENET, V83, P468, DOI 10.1016/j.ajhg.2008.09.009
   Swalwell H, 2011, EUR J HUM GENET, V19, P769, DOI 10.1038/ejhg.2011.18
   Thorburn DR, 2004, MITOCHONDRION, V4, P363, DOI 10.1016/j.mito.2004.07.003
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Vogel RO, 2007, GENE DEV, V21, P615, DOI 10.1101/gad.408407
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 50
TC 38
Z9 41
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD SEP 15
PY 2011
VL 63
IS 9
BP 669
EP 677
DI 10.1002/iub.495
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 817FZ
UT WOS:000294658000001
PM 21766414
DA 2024-11-01
ER

PT J
AU Pronicka, E
   Weglewska-Jurkiewicz, A
   Taybert, J
   Pronicki, M
   Szymanska-Debinska, T
   Karkucinska-Wieckowska, A
   Jakobkiewicz-Banecka, J
   Kowalski, P
   Piekutowska-Abramczuk, D
   Pajdowska, M
   Socha, P
   Sykut-Cegielska, J
   Wegrzyn, G
AF Pronicka, Ewa
   Weglewska-Jurkiewicz, Anna
   Taybert, Joanna
   Pronicki, Maciej
   Szymanska-Debinska, Tamara
   Karkucinska-Wieckowska, Agnieszka
   Jakobkiewicz-Banecka, Joanna
   Kowalski, Pawel
   Piekutowska-Abramczuk, Dorota
   Pajdowska, Magdalena
   Socha, Piotr
   Sykut-Cegielska, Jolanta
   Wegrzyn, Grzegorz
TI Post mortem identification of deoxyguanosine kinase (<i>DGUOK</i>) gene mutations combined with impaired glucose homeostasis and iron overload features in four infants with severe progressive liver failure
SO JOURNAL OF APPLIED GENETICS
LA English
DT Article
DE DGUOK gene mutation; mtDNA depletion; Neonatal liver failure; Hypoglycemia; Iron overload; Natural history of the disease
ID mitochondrial-dna depletion; respiratory-chain; deficiency; metabolism
AB Deoxyguanosine kinase deficiency (dGK) is a frequent cause of the hepatocerebral form of mitochondrial depletion syndrome (MDS). A group of 28 infants with severe progressive liver failure of unknown cause was recruited for post mortem search for deoxyguanosine kinase (DGUOK) gene mutations. Four affected patients (14% of the studied group), two homozygotes, one compound heterozygote, and one heterozygote, with DGUOK mutation found on only one allele, were identified. Three known pathogenic mutations in the DGUOK gene were detected, c.3G > A (p.Met1Ile), c. 494A > T (p.Glu165Val), and c.766_767insGATT (p.Phe256X), and one novel molecular variant of unknown pathogeneity, c.813_814insTTT (p.Asn271_Thr272insPhe). Profound mitochondrial DNA depletion was confirmed in available specimens of the liver (4%, 15%, and 10% of the normal value) and in the muscle (4%, 23%, 45%, and 6%, respectively). The patients were born with low weights for gestational age and they presented adaptation trouble during the first days of life. Subsequently, liver failure developed, leading to death at the ages of 18, 6, 5.5, and 2.25 months, respectively. Mild neurological involvement was observed in all children (hypotonia, psychomotor retardation, and ptosis). Hypoglycemia (hypoketotic) and lactic acidosis were the constant laboratory findings. Elevated transferrin saturation, high ferritin, and alpha-fetoprotein levels resembled, in two cases, a neonatal hemochromatosis. Liver histopathology showed severe hepatic damage ranging from micronodular formation and cirrhosis to the total loss of liver architecture with diffuse fibrosis and neocholangiolar proliferation. Pancreatic islet cell hyperplasia with numerous confluent giant islets was found in both autopsied infants. Analysis of the natural history of the disease in our patients and the literature data led us to the following observations: (i) islet cell hyperplasia (and hyperinsulinism) may contribute to MDS-associated hypoglycemia; (ii) iron overload may additionally damage mtDNA-depleted tissues; (iii) low birth weight, adaptation trouble, and abnormal amino acids in newborn screening are frequent in dGK-deficient neonates.
C1 [Pronicka, Ewa; Weglewska-Jurkiewicz, Anna; Taybert, Joanna; Sykut-Cegielska, Jolanta] CMHI, Dept Metab Dis Endocrinol & Diabetol, PL-04730 Warsaw, Poland.
   [Weglewska-Jurkiewicz, Anna; Jakobkiewicz-Banecka, Joanna; Wegrzyn, Grzegorz] Univ Gdansk, Dept Mol Biol, PL-80952 Gdansk, Poland.
   [Pronicki, Maciej; Szymanska-Debinska, Tamara; Karkucinska-Wieckowska, Agnieszka] CMHI, Dept Pathol, PL-04730 Warsaw, Poland.
   [Kowalski, Pawel; Piekutowska-Abramczuk, Dorota] CMHI, Dept Med Genet, PL-04730 Warsaw, Poland.
   [Pajdowska, Magdalena] CMHI, Dept Biochem & Expt Med, PL-04730 Warsaw, Poland.
   [Socha, Piotr] CMHI, Dept Gastroenterol Hepatol & Immunol, PL-04730 Warsaw, Poland.
C3 Children's Memorial Health Institute; Fahrenheit Universities; University of Gdansk; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute
RP Pronicka, E (corresponding author), CMHI, Dept Metab Dis Endocrinol & Diabetol, Aleja Dzieci Polskich 20, PL-04730 Warsaw, Poland.
EM e.pronicka@czd.pl
FU Polish Mitochondrial Network;  [PB 0890/P05/2005/29]
CR BACON BR, 1993, GASTROENTEROLOGY, V105, P1134, DOI 10.1016/0016-5085(93)90959-G
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Brahimi N, 2009, MOL GENET METAB, V97, P221, DOI 10.1016/j.ymgme.2009.03.007
   Dimmock DP, 2008, LIVER TRANSPLANT, V14, P1480, DOI 10.1002/lt.21556
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Hargreaves IP, 2002, J INHERIT METAB DIS, V25, P7, DOI 10.1023/A:1015104910239
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1445, DOI 10.1001/archneur.60.10.1445
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Müller-Höcker J, 2002, HUM PATHOL, V33, P247, DOI 10.1053/hupa.2002.31477
   Parini R, 2009, J HEPATOL, V50, P215, DOI 10.1016/j.jhep.2008.08.019
   Ponka P, 2002, SEMIN HEMATOL, V39, P249, DOI 10.1053/shem.2002.35638
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Rabinowitz SS, 2004, J PEDIATR GASTR NUTR, V38, P216, DOI 10.1097/00005176-200402000-00022
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Scheers I, 2005, J PEDIATR-US, V146, P414, DOI 10.1016/j.jpeds.2004.10.023
   Siafakas CG, 1997, J PEDIATR GASTR NUTR, V25, P321, DOI 10.1097/00005176-199709000-00015
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Weglewska Anna, 2005, JOURNAL OF APPLIED GENETICS, V46, P423
   Weglewska-Jurkiewicz A, 2009, THESIS GDANSK, V0, P0
NR 26
TC 40
Z9 44
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1234-1983
EI 2190-3883
J9 J APPL GENET
JI J. Appl. Genetics
PD FEB 15
PY 2011
VL 52
IS 1
BP 61
EP 66
DI 10.1007/s13353-010-0008-y
PG 6
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 760SY
UT WOS:000290345300008
PM 21107780
DA 2024-11-01
ER

PT J
AU Smits, BW
   Fermont, J
   Delnooz, CCS
   Kalkman, JS
   Bleijenberg, G
   van Engelen, BGM
AF Smits, Bart W.
   Fermont, Jiske
   Delnooz, Catherine C. S.
   Kalkman, Joke S.
   Bleijenberg, Gijs
   van Engelen, Baziel G. M.
TI Disease impact in chronic progressive external ophthalmoplegia: More than meets the eye
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Chronic progressive external ophthalmoplegia; Kearns-Sayre syndrome; Quality of life; Depression; Myotonic dystrophy
ID sensory ataxic neuropathy; muscle mitochondrial-dna; kearns-sayre-syndrome; major depression; myotonic-dystrophy; chronic fatigue; ant1 gene; features; mutations; deletions
AB We determined the extent of disease impact in 28 patients with genetically confirmed chronic progressive external ophthalmoplegia (CPEO) and compared the outcomes to those of matched myotonic dystrophy type I patients. CPEO patients reported a high frequency of severe fatigue (67.9%), pain (96.2%), depression (32.1%) and dependency in daily life (46.4%). The frequency and extent of depression were significantly higher than in DM1 patients (32.1% vs. 7.1%, p = 0.040; mean Beck's depression inventory for primary care score 3.8 +/- 3.5 vs. 1.3 +/- 1.4, p = 0.001), as were fatigue severity, pain intensity and extent of functional impairments. CPEO patients with polymerase gamma-1 mutations reported more functional impairments than those with mitochondrial DNA mutations. Disease impact was however not influenced by most clinical features. The present results help physicians to identify and to treat the factors that influence quality of life in CPEO patients and to provide symptomatic treatment where needed. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Smits, Bart W.; Fermont, Jiske; Delnooz, Catherine C. S.; van Engelen, Baziel G. M.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Neuromuscular Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands.
   [Kalkman, Joke S.; Bleijenberg, Gijs] Radboud Univ Nijmegen, Med Ctr, Expert Ctr Chron Fatigue, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Smits, BW (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Neuromuscular Ctr Nijmegen, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM b.smits@neuro.umcn.nl
FU Global FSH; Netherlands Organization for Scientific Research; Prinses Beatrix Fonds; Dutch FSHD Foundation
CR Amemiya S, 2000, NEUROLOGY, V55, P600, DOI 10.1212/WNL.55.4.600
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Arpa J, 2003, MUSCLE NERVE, V28, P690, DOI 10.1002/mus.10507
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bau V, 2009, KLIN MONATSBL AUGENH, V226, P822, DOI 10.1055/s-0028-1109800
   Beck Aaron T, 1997, BEHAVIOUR RESEARCH AND THERAPY, V35, P785, DOI 10.1016/S0005-7967(97)00025-9
   Bindoff L, 1997, MITOCHONDRIAL MYOPAT, V0, P85
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DREVETS WC, 1992, J NEUROSCI, V12, P3628
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Fattal O, 2007, CNS SPECTRUMS, V12, P429, DOI 10.1017/S1092852900015303
   Gagnon C, 2007, J NEUROL NEUROSUR PS, V78, P800, DOI 10.1136/jnnp.2006.107185
   Graff-Guerrero A, 2004, J AFFECT DISORDERS, V80, P55, DOI 10.1016/S0165-0327(03)00049-1
   Harper PS, 2004, MYOTONIC DYSTROPHY: PRESENT MANAGEMENT, V0, P0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Hugdahl K, 2007, COGNITIVE THER RES, V31, P147, DOI 10.1007/s10608-006-9116-8
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Jacobs H M, 1990, NED TIJDSCHR GENEESKD, V134, P1950
   Kalkman JS, 2005, J NEUROL NEUROSUR PS, V76, P1406, DOI 10.1136/jnnp.2004.050005
   KALKMAN JS, 2006, PREVALENCE PREDICTOR, V0, P73
   Koene S, 2009, J AFFECT DISORDERS, V114, P327, DOI 10.1016/j.jad.2008.06.023
   LESTIENNE P, 1988, LANCET, V1, P885
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   MITSUMOTO H, 1983, NEUROLOGY, V33, P452, DOI 10.1212/WNL.33.4.452
   ROLAND PE, 1987, J NEUROSCI, V7, P2373
   Servaes P, 2002, ANN ONCOL, V13, P589, DOI 10.1093/annonc/mdf082
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X
   Willison HJ, 2001, BRAIN, V124, P1968, DOI 10.1093/brain/124.10.1968
NR 35
TC 26
Z9 27
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR 15
PY 2011
VL 21
IS 4
BP 272
EP 278
DI 10.1016/j.nmd.2010.12.008
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 753ED
UT WOS:000289747700005
PM 21236670
DA 2024-11-01
ER

PT J
AU Emmanuele, V
   Silvers, DS
   Sotiriou, E
   Tanji, K
   Dimauro, S
   Hirano, M
AF Emmanuele, Valentina
   Silvers, David S.
   Sotiriou, Evangelia
   Tanji, Kurenai
   Dimauro, Salvatore
   Hirano, Michio
TI MERRF AND KEARNS-SAYRE OVERLAP SYNDROME DUE TO THE MITOCHONDRIAL DNA M.3291T&gt;C MUTATION
SO MUSCLE & NERVE
LA English
DT Article
DE Kearns-Sayre syndrome; mitochondrial DNA; myoclonus epilepsy; point mutation; tRNA(Leu(UUR)); ragged-red fibers
ID deletions; deficiency; features; diseases; patient; genome; melas
AB A 48-year-old man presented with a complex phenotype of myoclonus epilepsy with ragged-red fibers (MERRF) syndrome and Kearns Sayre syndrome (KSS), which included progressive myoclonus epilepsy, cerebellar ataxia, hearing loss, myopathic weakness, ophthalmoparesis, pigmentary retinopathy, bifascicular heart block, and ragged-red fibers. The m.3291T>C mutation in the tRNA(Leu(UUR)) gene was found with 92% heteroplasmy in muscle. This mutation has been reported with MELAS, myopathy, and deafness with cognitive impairment. This is the first description with a MERRF/KSS syndrome. Muscle Nerve 44: 448-451, 2011
C1 [Emmanuele, Valentina; Sotiriou, Evangelia; Dimauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Silvers, David S.] Hartford Hosp, Dept Neurol, Hartford, CT 06115 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Hartford Hospital; Columbia University
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
FU National Institutes of Health (NIH) [NIH HD32062, R01HD57543, R01HD056103, RCNS070232]; Marriott Mitochondrial Disorders Clinical Research Fund (MMDCRF); Muscular Dystrophy Association
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   HARDING AE, 1992, J INHERIT METAB DIS, V15, P480, DOI 10.1007/BF01799606
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Naini A, 2007, METHOD CELL BIOL, V80, P437, DOI 10.1016/S0091-679X(06)80022-1
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   YONEDA M, 1990, BIOCHEM INT, V21, P789
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 16
TC 16
Z9 18
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0148-639X
EI 
J9 MUSCLE NERVE
JI Muscle Nerve
PD SEP 15
PY 2011
VL 44
IS 3
BP 448
EP 451
DI 10.1002/mus.22149
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 814IZ
UT WOS:000294443300022
PM 21996807
DA 2024-11-01
ER

PT J
AU Sundaram, C
   Meena, AK
   Uppin, MS
   Govindaraj, P
   Vanniarajan, A
   Thangaraj, K
   Kaul, S
   Kekunnaya, R
   Murthy, JMK
AF Sundaram, Challa
   Meena, A. K.
   Uppin, Megha S.
   Govindaraj, P.
   Vanniarajan, A.
   Thangaraj, K.
   Kaul, Subhash
   Kekunnaya, Ramesh
   Murthy, J. M. K.
TI Contribution of muscle biopsy and genetics to the diagnosis of chronic progressive external opthalmoplegia of mitochondrial origin
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Chronic progressive external; opthalmoplegia; Red ragged fiber; COX-SDH stain; Genetic study; tRNA
ID kearns-sayre-syndrome; ragged-red fibers; peripheral neuropathy; dna deletions; ophthalmoplegia; encephalomyopathy; diseases; cytopathy; pathology
AB Chronic progressive external opthalmoplegia (CPEO) is the most common phenotypic syndrome of the mitochondrial myopathies. Muscle biopsy, which provides important morphological clues for the diagnosis of mitochondrial disorders, is normal in approximately 25% of patients with CPEO, thus necessitating molecular genetic analysis for more accurate diagnosis. We aimed to study the utility of various histochemical stains in the diagnosis of CPEO on muscle biopsy and to correlate these results with genetic studies. Between May 2005 and November 2007 all 45 patients diagnosed with CPEO were included in the study (23 males; mean age at presentation, 35 years). Thirty-nine patients had CPEO only and six had CPEO plus; two had a positive family history but the remaining 39 patients had sporadic CPEO. Muscle biopsy samples were stained with hematoxylin and eosin, modified Gomori's trichrome stain, succinic dehydrogenase (SDH), cytochrome C oxidase (COX) and combined COX-SDH. Ragged red fibers were seen in 27 biopsies; seven showed characteristics of neurogenic atrophy only, and 11 were normal. The abnormal fibers were best identified on COX-SDH stain. A complete mitochondrial genome was amplified in muscle and blood samples of all patients. Mutations were found in transfer RNA, ribosomal RNA, ND, CYTB, COX I, II and III genes. Mitochondrial gene mutations were found in ten of the 11 patients with a normal muscle biopsy. The genetic mutations were classified according to their significance. The observed muscle biopsy findings were correlated with genetic mutations noted. Histological studies should be combined with genetic studies for the definitive diagnosis of CPEO syndrome. (c) 2010 Elsevier Ltd. All rights reserved.
C1 [Sundaram, Challa; Uppin, Megha S.] Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Andhra Pradesh, India.
   [Meena, A. K.; Kaul, Subhash] Nizams Inst Med Sci, Dept Neurol, Hyderabad 500082, Andhra Pradesh, India.
   [Govindaraj, P.; Vanniarajan, A.; Thangaraj, K.] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Kekunnaya, Ramesh] LV Prasad Eye Inst, Jasti V Ramanamma Childrens Eye Care Ctr, Hyderabad, Andhra Pradesh, India.
   [Murthy, J. M. K.] Care Hosp, Inst Neurol Sci, Hyderabad, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Nizam's Institute of Medical Sciences; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); L. V. Prasad Eye Institute
RP Sundaram, C (corresponding author), Nizams Inst Med Sci, Dept Pathol, Hyderabad 500082, Andhra Pradesh, India.
EM challa_sundaram@yahoo.com
CR Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   BROCKINGTON M, 1995, J NEUROL SCI, V131, P78, DOI 10.1016/0022-510X(95)00091-F
   Carry M R, 1989, BULL SOC BELGE OPHTALMOL, V237, P303
   Challa S, 2004, NEUROL INDIA, V52, P512
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Chu CC, 1997, EUR NEUROL, V37, P110, DOI 10.1159/000117420
   DeCoo IFM, 1997, J NEUROL SCI, V149, P37, DOI 10.1016/S0022-510X(97)05366-5
   DIMAURO S, 1990, NEUROL CLIN, V8, P483, DOI 10.1016/S0733-8619(18)30332-3
   FASSATI A, 1994, J NEUROL SCI, V123, P140, DOI 10.1016/0022-510X(94)90216-X
   Filosto M, 2007, BIOSCIENCE REP, V27, P23, DOI 10.1007/s10540-007-9034-3
   GEMIGNANI F, 1982, EUR NEUROL, V21, P181, DOI 10.1159/000115478
   GONATAS NK, 1965, EXCERPTA MED INT C S, V100, P606
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Caballero PEJ, 2007, NEUROLOGIST, V13, P33, DOI 10.1097/01.nrl.0000252953.49721.f5
   Johns D R, 1995, SEMIN OPHTHALMOL, V10, P295, DOI 10.3109/08820539509063800
   Kawashima S, 1993, NIHON RINSHO, V51, P2391
   Kornblum C, 2004, KLIN MONATSBL AUGENH, V221, P1057, DOI 10.1055/s-2004-813830
   Laforet P, 1997, REV NEUROL, V153, P51
   MANN CYY, 2005, NEUROMUSCULAR DISORD, V15, P17
   Mehndiratta MM, 2002, NEUROL INDIA, V50, P162
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   PETERSON PL, 1988, NEUROL CLIN, V6, P529, DOI 10.1016/S0733-8619(18)30859-4
   PEZESHKPOUR G, 1987, J NEUROL SCI, V77, P285, DOI 10.1016/0022-510X(87)90129-8
   RADHAKRISHNAN VV, 1998, J PATHOL MICROBIOL, V41, P5
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   SCHON EA, 1988, ANN NY ACAD SCI, V550, P348, DOI 10.1111/j.1749-6632.1988.tb35349.x
   Schoser BGH, 2006, STRABISMUS, V14, P107, DOI 10.1080/09273970600701218
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Thangaraj K, 2002, J ANDROL, V23, P815
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   YAMAMOTO M, 1988, ACTA NEUROPATHOL, V76, P558, DOI 10.1007/BF00689593
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
NR 35
TC 20
Z9 22
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 1532-2653
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD APR 15
PY 2011
VL 18
IS 4
BP 535
EP 538
DI 10.1016/j.jocn.2010.06.014
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 747MY
UT WOS:000289325300019
PM 21277779
DA 2024-11-01
ER

PT J
AU Suzuki, T
   Nagao, A
   Suzuki, T
AF Suzuki, Tsutomu
   Nagao, Asuteka
   Suzuki, Takeo
TI Human mitochondrial diseases caused by lack of taurine modification in mitochondrial tRNAs
SO WILEY INTERDISCIPLINARY REVIEWS-RNA
LA English
DT Review
ID wobble modification deficiency; transfer rnaleu(uur) gene; mutant transfer-rnas; lactic-acidosis; 1st position; codon recognition; mtdna mutation; transcription termination; modification defect; myoclonic epilepsy
AB Mitochondrial DNA mutations that cause mitochondrial dysfunction are responsible for a wide spectrum of human diseases, referred to as mitochondrial diseases. Pathogenic point mutations are found frequently in genes encoding mitochondrial (mt) tRNAs, indicating that impaired functioning of mutant mt tRNAs is the primary cause of mitochondrial dysfunction. Our previous studies revealed the absence of posttranscriptional taurine modification at the anticodon wobble uridine in mutant mt tRNAs isolated from cells derived from patients with two major classes of mitochondrial diseases, MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) and MERRF (myoclonus epilepsy associated with ragged red fibers). Defective taurine modification of the mutant mt tRNAs results in a deficiency in protein synthesis as the cognate codons of the mutant mt tRNA cannot be decoded. These findings represent the first evidence of a molecular pathogenesis caused by an RNA modification disorder. (C) 2011 John Wiley & Sons, Ltd. WIREs RNA 2011 2 376-386 DOI: 10.1002/wrna.65
C1 [Suzuki, Tsutomu; Nagao, Asuteka; Suzuki, Takeo] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo, Japan.
C3 University of Tokyo
RP Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo, Japan.
EM ts@chembio.t.u-tokyo.ac.jp
FU Grants-in-Aid for Scientific Research [21115003, 23710265, 23655153] Funding Source: KAKEN
CR AGRIS PF, 1973, BIOCHEMISTRY-US, V12, P4331, DOI 10.1021/bi00746a005
   ANDACHI Y, 1987, P NATL ACAD SCI USA, V84, P7398, DOI 10.1073/pnas.84.21.7398
   Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529
   BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164
   BONITZ SG, 1980, P NATL ACAD SCI-BIOL, V77, P3167, DOI 10.1073/pnas.77.6.3167
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Brulé H, 1998, NUCLEIC ACIDS RES, V26, P537, DOI 10.1093/nar/26.2.537
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   El Meziane A, 1998, NAT GENET, V18, P350
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Hino N, 2004, GENES CELLS, V9, P243, DOI 10.1111/j.1356-9597.2004.00718.x
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   INAGAKI Y, 1995, J MOL BIOL, V251, P486, DOI 10.1006/jmbi.1995.0450
   Janssen GMC, 2007, HUM MOL GENET, V16, P2472, DOI 10.1093/hmg/ddm203
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOGA Y, 1988, ANN NEUROL, V24, P749, DOI 10.1002/ana.410240609
   Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177
   Kurata S, 2008, J BIOL CHEM, V283, P18801, DOI 10.1074/jbc.M800233200
   Lehtinen SK, 2000, GENETICS, V154, P363
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Ling JQ, 2007, P NATL ACAD SCI USA, V104, P15299, DOI 10.1073/pnas.0704441104
   LUSTIG F, 1993, P NATL ACAD SCI USA, V90, P3343, DOI 10.1073/pnas.90.8.3343
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MORIYA J, 1994, BIOCHEMISTRY-US, V33, P2234, DOI 10.1021/bi00174a033
   Nagao A, 2009, P NATL ACAD SCI USA, V106, P16209, DOI 10.1073/pnas.0907602106
   Osborne A, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005636
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Suzuki T, 2005, TOP CURR GENET, V12, P23, DOI 10.1007/b106361
   Suzuki T, 2007, METHOD ENZYMOL, V425, P231, DOI 10.1016/S0076-6879(07)25010-4
   Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905
   YOKOYAMA S, 1979, NUCLEIC ACIDS RES, V6, P2611, DOI 10.1093/nar/6.7.2611
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 64
TC 89
Z9 100
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-7004
EI 1757-7012
J9 WIRES RNA
JI Wiley Interdiscip. Rev.-RNA
PD MAY-JUN 15
PY 2011
VL 2
IS 3
BP 376
EP 386
DI 10.1002/wrna.65
PG 11
WC Cell Biology
SC Cell Biology
GA 913GB
UT WOS:000301863400005
PM 21957023
DA 2024-11-01
ER

PT J
AU Safdar, A
   Bourgeois, JM
   Ogborn, DI
   Little, JP
   Hettinga, BP
   Akhtar, M
   Thompson, JE
   Melov, S
   Mocellin, NJ
   Kujoth, GC
   Prolla, TA
   Tarnopolsky, MA
AF Safdar, Adeel
   Bourgeois, Jacqueline M.
   Ogborn, Daniel I.
   Little, Jonathan P.
   Hettinga, Bart P.
   Akhtar, Mahmood
   Thompson, James E.
   Melov, Simon
   Mocellin, Nicholas J.
   Kujoth, Gregory C.
   Prolla, Tomas A.
   Tarnopolsky, Mark A.
TI Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice (Publication with Expression of Concern)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article; Publication with Expression of Concern
DE proliferator-activated receptor gamma coactivator-1 alpha; sarcopenia; cardiac hypertrophy
ID skeletal-muscle; point mutations; dna mutations; physical-activity; pgc-1-alpha; diseases; expression; apoptosis; deletions; atrophy
AB A causal role for mitochondrial DNA (mtDNA) mutagenesis in mammalian aging is supported by recent studies demonstrating that the mtDNA mutator mouse, harboring a defect in the proofreading-exonuclease activity of mitochondrial polymerase gamma, exhibits accelerated aging phenotypes characteristic of human aging, systemic mitochondrial dysfunction, multisystem pathology, and reduced lifespan. Epidemiologic studies in humans have demonstrated that endurance training reduces the risk of chronic diseases and extends life expectancy. Whether endurance exercise can attenuate the cumulative systemic decline observed in aging remains elusive. Here we show that 5 mo of endurance exercise induced systemic mitochondrial biogenesis, prevented mtDNA depletion and mutations, increased mitochondrial oxidative capacity and respiratory chain assembly, restored mitochondrial morphology, and blunted pathological levels of apoptosis in multiple tissues of mtDNA mutator mice. These adaptations conferred complete phenotypic protection, reduced multisystem pathology, and prevented premature mortality in these mice. The systemic mitochondrial rejuvenation through endurance exercise promises to be an effective therapeutic approach to mitigating mitochondrial dysfunction in aging and related comorbidities.
C1 [Safdar, Adeel; Hettinga, Bart P.; Akhtar, Mahmood; Mocellin, Nicholas J.; Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada.
   [Safdar, Adeel; Little, Jonathan P.] McMaster Univ, Dept Kinesiol, Hamilton, ON L8N 3Z5, Canada.
   [Safdar, Adeel; Tarnopolsky, Mark A.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada.
   [Bourgeois, Jacqueline M.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada.
   [Ogborn, Daniel I.] McMaster Univ, Dept Med Sci, Hamilton, ON L8N 3Z5, Canada.
   [Thompson, James E.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
   [Thompson, James E.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA.
   [Melov, Simon] Buck Inst Age Res, Novato, CA 94945 USA.
   [Kujoth, Gregory C.; Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.
   [Kujoth, Gregory C.; Prolla, Tomas A.] Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA.
C3 McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center; Buck Institute for Research on Aging; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
FU Canadian Institutes of Health Research [MOP97805]; Nathan Shock Award [P30AG025708]; Canadian Institutes of Health Research Institute of Aging; Canada PRESTIGE; National Sciences and Engineering Research Council
CR Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Balbuena L, 2009, FUTURE ONCOL, V5, P1051, DOI 10.2217/fon.09.65
   Balducci L, 2003, J AM GERIATR SOC, V51, P0
   Beal MF, 2009, PARKINSONISM RELAT D, V15, PS189, DOI 10.1016/S1353-8020(09)70812-0
   Boveris A, 2008, FREE RADICAL BIO MED, V44, P224, DOI 10.1016/j.freeradbiomed.2007.08.015
   Brenner Ingrid, 2009, PHYS SPORTSMED, V37, P84, DOI 10.3810/psm.2009.12.1746
   Buchner DM, 2009, CLIN GERIATR MED, V25, P661, DOI 10.1016/j.cger.2009.08.002
   Cantuti-Castelvetria I, 2005, NEUROBIOL AGING, V26, P1343, DOI 10.1016/j.neurobiolaging.2004.11.008
   Chakravarty EF, 2008, ARCH INTERN MED, V168, P1638, DOI 10.1001/archinte.168.15.1638
   Chaturvedi RK, 2009, HUM MOL GENET, V18, P3048, DOI 10.1093/hmg/ddp243
   Chen ML, 2009, BLOOD, V114, P4045, DOI 10.1182/blood-2008-08-169474
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   DellAgnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206
   Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785
   Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107
   Handschin C, 2009, TRENDS PHARMACOL SCI, V30, P322, DOI 10.1016/j.tips.2009.03.006
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hawley JA, 2009, NUTR REV, V67, P172, DOI 10.1111/j.1753-4887.2009.00185.x
   Herring MP, 2010, ARCH INTERN MED, V170, P321, DOI 10.1001/archinternmed.2009.530
   Hiona A, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0011468
   HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421
   ITO M, 1981, BRIT J RADIOL, V54, P384, DOI 10.1259/0007-1285-54-641-384
   Johannsen DL, 2009, CURR OPIN PHARMACOL, V9, P780, DOI 10.1016/j.coph.2009.09.002
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mott JL, 2005, REJUV RES, V8, P216, DOI 10.1089/rej.2005.8.216
   Mott JL, 2004, BIOCHEM BIOPH RES CO, V319, P1210, DOI 10.1016/j.bbrc.2004.05.104
   Nader GA, 2009, CURR OPIN RHEUMATOL, V21, P599, DOI 10.1097/BOR.0b013e3283319d53
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Safdar A, 2010, FREE RADICAL BIO MED, V49, P1487, DOI 10.1016/j.freeradbiomed.2010.08.010
   Safdar A, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0010778
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Seth A, 2007, CELL METAB, V6, P236, DOI 10.1016/j.cmet.2007.08.004
   Srivastava S, 2009, HUM MOL GENET, V18, P1805, DOI 10.1093/hmg/ddp093
   Stessman J, 2009, ARCH INTERN MED, V169, P1476, DOI 10.1001/archinternmed.2009.248
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Sutherland LN, 2009, J PHYSIOL-LONDON, V587, P1607, DOI 10.1113/jphysiol.2008.165464
   TATE EL, 1976, J GERONTOL, V31, P129, DOI 10.1093/geronj/31.2.129
   ten Hacken Nick H T, 2009, PROC AM THORAC SOC, V6, P663, DOI 10.1513/pats.200907-070DP
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Warburton DER, 2010, INT J BEHAV NUTR PHY, V7, P0, DOI 10.1186/1479-5868-7-39
   Wasilewski M, 2009, TRENDS ENDOCRIN MET, V20, P287, DOI 10.1016/j.tem.2009.03.007
   Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106
   Wenz T, 2009, J APPL PHYSIOL, V106, P1712, DOI 10.1152/japplphysiol.91571.2008
   Wohlgemuth SE, 2010, EXP GERONTOL, V45, P138, DOI 10.1016/j.exger.2009.11.002
NR 56
TC 255
Z9 289
U1 1
U2 43
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 8
PY 2011
VL 108
IS 10
BP 4135
EP 4140
DI 10.1073/pnas.1019581108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 731PA
UT WOS:000288120400060
PM 21368114
DA 2024-11-01
ER

PT J
AU Takata, A
   Kato, M
   Nakamura, M
   Yoshikawa, T
   Kanba, S
   Sano, A
   Kato, T
AF Takata, Atsushi
   Kato, Maiko
   Nakamura, Masayuki
   Yoshikawa, Takeo
   Kanba, Shigenobu
   Sano, Akira
   Kato, Tadafumi
TI Exome sequencing identifies a novel missense variant in <i>RRM2B</i> associated with autosomal recessive progressive external ophthalmoplegia
SO GENOME BIOLOGY
LA English
DT Article
ID mitochondrial-dna deletions; multiple deletions; bipolar disorder; mutations; features; disease; p53r2; cells
AB Background: Whole-exome sequencing using next-generation technologies has been previously demonstrated to be able to detect rare disease-causing variants. Progressive external ophthalmoplegia (PEO) is an inherited mitochondrial disease that follows either autosomal dominant or recessive forms of inheritance (adPEO or arPEO). AdPEO is a genetically heterogeneous disease and several genes, including POLG1 and C10orf2/Twinkle, have been identified as responsible genes. On the other hand, POLG1 was the only established gene causing arPEO with mitochondrial DNA deletions. We previously reported a case of PEO with unidentified genetic etiology. The patient was born of a first-cousin marriage. Therefore, the recessive form of inheritance was suspected. Results: To identify the disease-causing variant in this patient, we subjected the patient's DNA to whole-exome sequencing and narrowed down the candidate variants using public data and runs of homozygosity analysis. A total of 35 novel, putatively functional variants were detected in the homozygous segments. When we sorted these variants by the conservation score, a novel missense variant in RRM2B, whose heterozygous rare variant had been known to cause adPEO, was ranked at the top. The list of novel, putatively functional variants did not contain any other variant in genes encoding mitochondrial proteins registered in MitoCarta. Conclusions: Exome sequencing efficiently and effectively identified a novel, homozygous missense variant in RRM2B, which was strongly suggested to be causative for arPEO. The findings in this study indicate arPEO to be a genetically heterogeneous disorder, as is the case for adPEO.
C1 [Takata, Atsushi; Kato, Tadafumi] RIKEN Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan.
   [Takata, Atsushi; Kanba, Shigenobu] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Higashi Ku, Fukuoka 8128582, Japan.
   [Takata, Atsushi; Yoshikawa, Takeo] RIKEN Brain Sci Inst, Lab Mol Psychiat, Wako, Saitama 3510198, Japan.
   [Kato, Maiko; Nakamura, Masayuki; Sano, Akira] Kagoshima Univ, Dept Psychiat, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
C3 RIKEN; Kyushu University; RIKEN; Kagoshima University
RP Kato, T (corresponding author), RIKEN Brain Sci Inst, Lab Mol Dynam Mental Disorders, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.jp
FU Grants-in-Aid for Scientific Research [23659568, 23390291, 21591488] Funding Source: KAKEN
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Fattal O, 2007, CNS SPECTRUMS, V12, P429, DOI 10.1017/S1092852900015303
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Kakiuchi C, 2005, INT J NEUROPSYCHOPH, V8, P515, DOI 10.1017/S1461145705005213
   Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824
   Kato M, 2011, NEUROSCI RES, V69, P331, DOI 10.1016/j.neures.2010.12.013
   Kato T, 2008, TRENDS NEUROSCI, V31, P495, DOI 10.1016/j.tins.2008.07.007
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Ng SB, 2010, HUM MOL GENET, V19, PR119, DOI 10.1093/hmg/ddq390
   Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646
   Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Xue LJ, 2007, CANCER RES, V67, P16, DOI 10.1158/0008-5472.CAN-06-3200
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 32
TC 32
Z9 36
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
EI 
J9 GENOME BIOL
JI Genome Biol.
PD JUN 15
PY 2011
VL 12
IS 9
BP 
EP 
DI 10.1186/gb-2011-12-9-r92
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 874AH
UT WOS:000298926900009
PM 21951382
DA 2024-11-01
ER

PT J
AU Sato, K
   Yabe, I
   Yaguchi, H
   Nakano, F
   Kunieda, Y
   Saitoh, S
   Sasaki, H
AF Sato, Kazunori
   Yabe, Ichiro
   Yaguchi, Hiroaki
   Nakano, Fumihito
   Kunieda, Yasuyuki
   Saitoh, Shinji
   Sasaki, Hidenao
TI Genetic analysis of two Japanese families with progressive external ophthalmoplegia and parkinsonism
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE Progressive external ophthalmoplegia; DNA polymerase gamma gene; Parkinsonism; Mitochondria
ID polymerase-gamma mutations; mitochondrial-dna; polg1 mutations; disease; replication; deletions; twinkle
AB Mutations in the progressive external ophthalmoplegia 1 (PEO1), adenine nucleotide translocator 1 (ANT1) and DNA polymerase gamma (POLG) genes were reported in patients with progressive external ophthalmoplegia and parkinsonism. However, the genotype-phenotype correlation and pathophysiology of these syndromes are still unknown. In order to define the molecular basis of progressive external ophthalmoplegia and parkinsonism, we screened for mutations in PEO1, ANT1, POLG genes and the whole mitochondrial genome in two families. In results, we identified a compound heterozygous POLG substitutions, c.830A > T (p.H277L) and c.2827C > T (p.R943C) in one of the families. These two mutations in the coding region of POLG alter conserved amino acids in the exonuclease and polymerase domains, respectively, of the POLG protein. Neither of these substitutions was found in the 100 chromosomes of ethnically matched control subjects. In the other family, no mutations were detected in any of the three genes and the whole mitochondrial genome in the blood sample, although mitochondrial DNA deletions were observed in the muscle biopsy sample. Progressive external ophthalmoplegia and parkinsonism are genetically heterogenous disorders, and part of this syndrome may be caused by mutations in other, unknown genes.
C1 [Sato, Kazunori; Yabe, Ichiro; Yaguchi, Hiroaki; Nakano, Fumihito; Sasaki, Hidenao] Hokkaido Univ, Grad Sch Med, Dept Neurol, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
   [Kunieda, Yasuyuki] Wakkanai City Hosp, Dept Internal Med, Wakkanai, Hokkaido, Japan.
   [Saitoh, Shinji] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido 0608638, Japan.
C3 Hokkaido University; Hokkaido University
RP Yabe, I (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurol, Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan.
EM yabe@med.hokudai.ac.jp
FU Ministry of Health, Welfare and Labor, Japan; Ministry of Education, Science, Sports, and Culture, Japan
CR Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Errea JM, 1999, MOVEMENT DISORD, V14, P596, DOI 10.1002/1531-8257(199907)14:4<596::AID-MDS1008>3.0.CO;2-U
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   HARADA H, 1983, ARCH NEUROL-CHICAGO, V40, P151, DOI 10.1001/archneur.1983.04050030045008
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2009, MOVEMENT DISORD, V24, P1092, DOI 10.1002/mds.22310
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Miyako K, 1999, EUR J BIOCHEM, V259, P412, DOI 10.1046/j.1432-1327.1999.00056.x
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 27
TC 16
Z9 17
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 
J9 J NEUROL
JI J. Neurol.
PD JUL 15
PY 2011
VL 258
IS 7
BP 1327
EP 1332
DI 10.1007/s00415-011-5936-x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 789YE
UT WOS:000292554700017
PM 21301859
DA 2024-11-01
ER

PT J
AU Ben Ayed, I
   Chamkha, I
   Mkaouar-Rebai, E
   Kammoun, T
   Mezghani, N
   Chabchoub, I
   Aloulou, H
   Hachicha, M
   Fakhfakh, F
AF Ben Ayed, Imen
   Chamkha, Imen
   Mkaouar-Rebai, Emna
   Kammoun, Thouraya
   Mezghani, Najla
   Chabchoub, Imen
   Aloulou, Hajer
   Hachicha, Mongia
   Fakhfakh, Faiza
TI A Tunisian patient with Pearson syndrome harboring the 4.977 kb common deletion associated to two novel large-scale mitochondrial deletions
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Pearson syndrome; mtDNA deletions; Mitochondrial DNA; Heteroplasmy; Long range-PCR; Common deletion
ID marrow-pancreas-syndrome; kearns-sayre syndrome; dna deletion; mtdna deletion; pcr; rearrangements; duplication; myopathy; diseases; infant
AB Pearson syndrome (PS) is a multisystem disease including refractory anemia, vacuolization of marrow precursors and pancreatic fibrosis. The disease starts during infancy and affects various tissues and organs, and most affected children die before the age of 3 years. Pearson syndrome is caused by de novo large-scale deletions or, more rarely, duplications in the mitochondrial genome. In the present report, we described a Pearson syndrome patient harboring multiple mitochondrial deletions which is, in our knowledge, the first case described and studied in Tunisia. In fact, we reported the common 4.977 kb deletion and two novel heteroplasmic deletions (5.030 and 5.234 kb) of the mtDNA. These deletions affect several protein-coding and tRNAs genes and could strongly lead to defects in mitochondrial polypeptides synthesis, and impair oxidative phosphorylation and energy metabolism in the respiratory chain in the studied patient. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ben Ayed, Imen; Chamkha, Imen; Mkaouar-Rebai, Emna; Mezghani, Najla; Fakhfakh, Faiza] Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Sfax 3029, Tunisia.
   [Kammoun, Thouraya; Chabchoub, Imen; Aloulou, Hajer; Hachicha, Mongia] CHU Habib Bourguiba Sfax, Serv Pediat, Sfax, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Hedi Chaker; Hopital Habib Bourguiba
RP Ben Ayed, I (corresponding author), Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Ave Magida Boulila, Sfax 3029, Tunisia.
EM imenbenayed60@yahoo.fr; emna_m@yahoo.fr
FU Tunisian Ministry of Higher Education and Scientific Research
CR BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   BLAW ME, 1990, J CHILD NEUROL, V5, P186, DOI 10.1177/088307389000500305
   BLOK RB, 1995, HUM GENET, V95, P75
   Coulter-Mackie MB, 1998, CLIN BIOCHEM, V31, P627, DOI 10.1016/S0009-9120(98)00074-5
   DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   HARDING AE, 1992, J INHERIT METAB DIS, V15, P480, DOI 10.1007/BF01799606
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   KAPSA R, 1994, J INHERIT METAB DIS, V17, P521, DOI 10.1007/BF00711584
   KIYOMOTO BH, 1997, J NEUROL SCI, V25, P160
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   Knerr I, 2003, J PEDIAT HEMATOL ONC, V25, P948, DOI 10.1097/00043426-200312000-00008
   Lacbawan F, 2000, AM J MED GENET, V95, P266, DOI 10.1002/1096-8628(20001127)95:3<266::AID-AJMG13>3.3.CO;2-S
   Lee HF, 2007, EUR J PAEDIATR NEURO, V11, P208, DOI 10.1016/j.ejpn.2006.12.008
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Mkaouar-Rebai E, 2007, BIOCHEM BIOPH RES CO, V355, P1031, DOI 10.1016/j.bbrc.2007.02.083
   Mohri I, 1998, J NEUROL SCI, V158, P106, DOI 10.1016/S0022-510X(98)00082-3
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NIAUDET P, 1994, PEDIATR NEPHROL, V8, P164, DOI 10.1007/BF00865468
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Ro LS, 2003, MUSCLE NERVE, V28, P737, DOI 10.1002/mus.10504
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   ROTIG A, 1989, LANCET, V1, P902
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SANO T, 1993, PEDIATR RES, V34, P105, DOI 10.1203/00006450-199307000-00024
   Santorelli FM, 1996, NEUROLOGY, V47, P1320, DOI 10.1212/WNL.47.5.1320
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Seneca S, 1997, CLIN GENET, V51, P338
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SUPERTIFURGA A, 1993, EUR J PEDIATR, V152, P44, DOI 10.1007/BF02072515
   Toth T, 1998, CLIN GENET, V53, P210
   van den Ouweland JMW, 2000, EUR J HUM GENET, V8, P195, DOI 10.1038/sj.ejhg.5200444
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 37
TC 5
Z9 6
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 29
PY 2011
VL 411
IS 2
BP 381
EP 386
DI 10.1016/j.bbrc.2011.06.154
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 806LS
UT WOS:000293809900027
PM 21741369
DA 2024-11-01
ER

PT J
AU Campbell, GR
   Ziabreva, I
   Reeve, AK
   Krishnan, KJ
   Reynolds, R
   Howell, O
   Lassmann, H
   Turnbull, DM
   Mahad, DJ
AF Campbell, Graham R.
   Ziabreva, Iryna
   Reeve, Amy K.
   Krishnan, Kim J.
   Reynolds, Richard
   Howell, Owen
   Lassmann, Hans
   Turnbull, Doug M.
   Mahad, Don J.
TI Mitochondrial DNA Deletions and Neurodegeneration in Multiple Sclerosis
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID substantia-nigra neurons; inclusion-body myositis; gray-matter atrophy; real-time pcr; nitric-oxide; clonal expansion; individual cells; muscle-fibers; disease; mutations
AB Objective: Cerebral atrophy is a correlate of clinical progression in multiple sclerosis (MS). Mitochondria are now established to play a part in the pathogenesis of MS. Uniquely, mitochondria harbor their own mitochondrial DNA (mtDNA), essential for maintaining a healthy central nervous system. We explored mitochondrial respiratory chain activity and mtDNA deletions in single neurons from secondary progressive MS (SPMS) cases. Methods: Ninety-eight snap-frozen brain blocks from 13 SPMS cases together with complex IV/complex II histochemistry, immunohistochemistry, laser dissection microscopy, long-range and real-time PCR and sequencing were used to identify and analyze respiratory-deficient neurons devoid of complex IV and with complex II activity. Results: The density of respiratory-deficient neurons in SPMS was strikingly in excess of aged controls. The majority of respiratory-deficient neurons were located in layer VI and immediate subcortical white matter (WM) irrespective of lesions. Multiple deletions of mtDNA were apparent throughout the gray matter (GM) in MS. The respiratory-deficient neurons harbored high levels of clonally expanded mtDNA deletions at a single-cell level. Furthermore, there were neurons lacking mtDNA-encoded catalytic subunits of complex IV. mtDNA deletions sufficiently explained the biochemical defect in the majority of respiratory-deficient neurons. Interpretation: These findings provide evidence that neurons in MS are respiratory-deficient due to mtDNA deletions, which are extensive in GM and may be induced by inflammation. We propose induced multiple deletions of mtDNA as an important contributor to neurodegeneration in MS. ANN NEUROL 2011;69:481-492
C1 [Campbell, Graham R.; Ziabreva, Iryna; Reeve, Amy K.; Krishnan, Kim J.; Turnbull, Doug M.; Mahad, Don J.] Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Reynolds, Richard; Howell, Owen] Univ London Imperial Coll Sci Technol & Med, Fac Med, Wolfson Neurosci Labs, London, England.
   [Lassmann, Hans] Med Univ Vienna, Ctr Brain Res, Dept Neuroimmunol, Vienna, Austria.
C3 Newcastle University - UK; Imperial College London; Medical University of Vienna
RP Mahad, DJ (corresponding author), Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.j.mahad@ncl.ac.uk
FU Wellcome Trust; MS Society; Wissenschaftsfonds Austria [P 19854]
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bender A, 2008, J NEUROL, V255, P1231, DOI 10.1007/s00415-008-0892-9
   Betts J, 2004, NEUROCHEM RES, V29, P505, DOI 10.1023/B:NERE.0000014821.07269.8d
   Blokhin A, 2008, NEUROMOL MED, V10, P187, DOI 10.1007/s12017-008-8025-2
   Bo L, 2003, J NEUROPATH EXP NEUR, V62, P723, DOI 10.1093/jnen/62.7.723
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chang A, 2008, BRAIN, V131, P2366, DOI 10.1093/brain/awn157
   Coller HA, 2002, ANN NY ACAD SCI, V959, P434, DOI 10.1111/j.1749-6632.2002.tb02113.x
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   Cooper CE, 2008, J BIOENERG BIOMEMBR, V40, P533, DOI 10.1007/s10863-008-9166-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Druzhyna NM, 2008, MECH AGEING DEV, V129, P383, DOI 10.1016/j.mad.2008.03.002
   Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736
   Dutta R, 2007, NEUROLOGY, V68, PS22, DOI 10.1212/01.wnl.0000275229.13012.32
   Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, PH22, DOI 10.1152/ajpheart.00766.2003
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fisher E, 2008, ANN NEUROL, V64, P255, DOI 10.1002/ana.21436
   Fisniku LK, 2008, ANN NEUROL, V64, P247, DOI 10.1002/ana.21423
   Hauser SL, 2006, NEURON, V52, P61, DOI 10.1016/j.neuron.2006.09.011
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Kalman B, 2007, J NEUROIMMUNOL, V188, P1, DOI 10.1016/j.jneuroim.2007.03.020
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krieger C, 2002, EUR J PHARMACOL, V447, P177, DOI 10.1016/S0014-2999(02)01842-3
   Krishnan KJ, 2007, NUCLEIC ACIDS RES, V35, P7399, DOI 10.1093/nar/gkm635
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9
   Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046
   Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474
   Nicholas A, 2009, EXP NEUROL, V218, P316, DOI 10.1016/j.expneurol.2009.04.029
   Nicholls DG, 1999, BIOCHEM SOC SYMP, V66, P55, DOI 10.1042/bss0660055
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Pandit A, 2009, J NEUROL SCI, V279, P14, DOI 10.1016/j.jns.2009.01.009
   Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Reeve AK, 2008, ANN NY ACAD SCI, V1147, P21, DOI 10.1196/annals.1427.016
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Tanji K, 2007, METHOD CELL BIOL, V80, P135, DOI 10.1016/S0091-679X(06)80006-3
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trevelyan AJ, 2010, BRAIN, V133, P787, DOI 10.1093/brain/awq023
   Wei JP, 2002, J IMMUNOL, V168, P4721, DOI 10.4049/jimmunol.168.9.4721
   WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419
   Witte ME, 2009, J PATHOL, V219, P193, DOI 10.1002/path.2582
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 46
TC 272
Z9 295
U1 0
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 
J9 ANN NEUROL
JI Ann. Neurol.
PD MAR 15
PY 2011
VL 69
IS 3
BP 481
EP 492
DI 10.1002/ana.22109
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 744FW
UT WOS:000289081300011
PM 21446022
DA 2024-11-01
ER

PT J
AU Dorado, B
   Area, E
   Akman, HO
   Hirano, M
AF Dorado, Beatriz
   Area, Estela
   Akman, Hasan O.
   Hirano, Michio
TI Onset and organ specificity of Tk2 deficiency depends on Tk1 down-regulation and transcriptional compensation
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID mitochondrial-dna depletion; thymidine kinase 2; nuclear respiratory factors; developing rat-brain; mtdna depletion; human-cells; deoxynucleotide pools; triphosphate pools; gene; biogenesis
AB Deficiency of thymidine kinase 2 (TK2) is a frequent cause of isolated myopathy or encephalomyopathy in children with mitochondrial DNA (mtDNA) depletion. To determine the bases of disease onset, organ specificity and severity of TK2 deficiency, we have carefully characterized Tk2 H126N knockin mice (Tk2(-/-)). Although normal until postnatal day 8, Tk2(-/-) mice rapidly develop fatal encephalomyopathy between postnatal days 10 and 13. We have observed that wild-type Tk2 activity is constant in the second week of life, while Tk1 activity decreases significantly between postnatal days 8 and 13. The down-regulation of Tk1 activity unmasks Tk2 deficiency in Tk2(-/-) mice and correlates with the onset of mtDNA depletion in the brain and the heart. Resistance to pathology in Tk2 mutant organs depends on compensatory mechanisms to the reduced mtDNA level. Our analyses at postnatal day 13 have revealed that Tk2(-/-) heart significantly increases mitochondrial transcript levels relative to the mtDNA content. This transcriptional compensation allows the heart to maintain normal levels of mtDNA-encoded proteins. The up-regulation in mitochondrial transcripts is not due to increased expression of the master mitochondrial biogenesis regulators peroxisome proliferator-activated receptor-gamma coactivator 1 alpha and nuclear respiratory factors 1 and 2, or to enhanced expression of the mitochondrial transcription factors A, B1 or B2. Instead, Tk2(-/-) heart compensates for mtDNA depletion by down-regulating the expression of the mitochondrial transcriptional terminator transcription factor 3 (MTERF3). Understanding the molecular mechanisms that allow Tk2 mutant organs to be spared may help design therapies for Tk2 deficiency.
C1 [Dorado, Beatriz; Area, Estela; Akman, Hasan O.; Hirano, Michio] Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA.
C3 Columbia University
RP Hirano, M (corresponding author), Columbia Univ, Dept Neurol, Med Ctr, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
FU Muscular Dystrophy Association, USA; FUNDISMUN Foundation; Muscular Dystrophy Association; National Institutes of Health [R01 HD057543, R01 HD056103, RC1 NS070232, P01 HD032062]; Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF)
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Asin-Cayuela J, 2007, TRENDS BIOCHEM SCI, V32, P111, DOI 10.1016/j.tibs.2007.01.003
   Bartesaghi S, 2010, HUM MOL GENET, V19, P1669, DOI 10.1093/hmg/ddq043
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Bruni F, 2010, J BIOL CHEM, V285, P3939, DOI 10.1074/jbc.M109.044305
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Ferraro P, 2010, NUCLEIC ACIDS RES, V38, P0, DOI 10.1093/nar/gkp1141
   Franzolin E, 2006, BIOCHEM BIOPH RES CO, V344, P30, DOI 10.1016/j.bbrc.2006.03.147
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   HAAS RJ, 1970, J ANAT, V107, P421
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Ke PY, 2004, MOL CELL BIOL, V24, P514, DOI 10.1128/MCB.24.2.514-526.2004
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Leanza L, 2008, J BIOL CHEM, V283, P16437, DOI 10.1074/jbc.M801572200
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   LI K, 1995, AM J PHYSIOL-CELL PH, V269, PC1265, DOI 10.1152/ajpcell.1995.269.5.C1265
   Liu ZC, 2006, ANNU REV GENET, V40, P159, DOI 10.1146/annurev.genet.40.110405.090613
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   Martin M, 2005, CELL, V123, P1227, DOI 10.1016/j.cell.2005.09.040
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   MORI K, 1970, J NEUROCHEM, V17, P835, DOI 10.1111/j.1471-4159.1970.tb02237.x
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Park CB, 2007, CELL, V130, P273, DOI 10.1016/j.cell.2007.05.046
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   RAMPAZZO C, 2010, MUTAT RES, V0, P0
   Rampazzo C, 2007, J BIOL CHEM, V282, P34758, DOI 10.1074/jbc.M705923200
   REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006
   Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, P0
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Villarroya J, 2009, EXP CELL RES, V315, P1429, DOI 10.1016/j.yexcr.2009.02.018
   VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309
   Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309
   Wang L, 2010, NUCLEOS NUCLEOT NUCL, V29, P400, DOI 10.1080/15257771003741042
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Wang LY, 2008, NUCLEOS NUCLEOT NUCL, V27, P858, DOI 10.1080/15257770802146510
   Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wenz T, 2009, CELL METAB, V9, P499, DOI 10.1016/j.cmet.2009.04.010
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   YAMAGAMI S, 1972, J NEUROCHEM, V19, P369, DOI 10.1111/j.1471-4159.1972.tb01346.x
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
   Zhou XS, 2010, J INHERIT METAB DIS, V33, P231, DOI 10.1007/s10545-010-9102-x
NR 61
TC 28
Z9 34
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 15
PY 2011
VL 20
IS 1
BP 155
EP 164
DI 10.1093/hmg/ddq453
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 692ZE
UT WOS:000285193600013
PM 20940150
DA 2024-11-01
ER

PT J
AU Estep, PA
   Johnson, KA
AF Estep, Patricia A.
   Johnson, Kenneth A.
TI Effect of the Y955C Mutation on Mitochondrial DNA Polymerase Nucleotide Incorporation Efficiency and Fidelity
SO BIOCHEMISTRY
LA English
DT Article
ID replication; mechanism; gamma; discrimination; consequences; specificity; explorer; defects
AB The human mitochondrial DNA polymerase (pol gamma) is responsible for the replication of the mitochondrial genome. Mutation Y955C in the active site of pol gamma results in early onset progressive external ophthalmoplegia, premature ovarian failure, and Parkinson's disease. In single-turnover kinetic studies, we show that the Y955C mutation results in a decrease in the maximal rate of polymerization and an increase in the K-m for correct incorporation. The mutation decreased the specificity constant for correct incorporation of dGTP, TTP, and ATP to values of 1.5, 0.35, and 0.044 mu M-1 s(-1), respectively, representing reductions of 30-, 110-, and 1300-fold, respectively, relative to the value for the wild-type enzyme. The fidelity of incorporation was reduced 6-130-fold, largely because of the significant decrease in the specificity constant for correct dATP:T incorporation. For example, K-cat/K-m for forming a TTP:T mismatch was decreased 10-fold from 0.0002 to 0.00002 mu M-1 s(-1) by the Y955C mutant, but the 1300-fold slower incorporation of the correct dATP:T relative to that of the wild type led to a 130-fold lower fidelity. While correct incorporation of 8-oxo-dGTP was largely unchanged, the level of incorporation of 8-oxo-dG with dA in the template strand was reduced 500-fold. These results support a role for Y955 in stabilizing A:T base pairs at the active site of pol gamma and suggest that the severe clinical symptoms of patients with this mutation may be due, in part, to the reduced efficiency of incorporation of dATP opposite T, and that the autosomal dominant phenotype may arise from the resulting higher mutation frequency.
C1 [Estep, Patricia A.; Johnson, Kenneth A.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA.
C3 University of Texas System; University of Texas Austin
RP Johnson, KA (corresponding author), Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, 2500 Speedway, Austin, TX 78712 USA.
EM kajohnson@mail.utexas.edu
FU National Institutes of Health [GM044613]; Welch Foundation [F-1604]
CR Atanassova N, 2011, HUM MOL GENET, V20, P1212, DOI 10.1093/hmg/ddq565
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Batabyal D, 2010, J BIOL CHEM, V285, P34191, DOI 10.1074/jbc.M110.156182
   Bertram JG, 2010, BIOCHEMISTRY-US, V49, P20, DOI 10.1021/bi901653g
   BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689
   Copeland WC, 2004, ENVIRON MOL MUTAGEN, V44, P193
   DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P9
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hanes JW, 2007, NUCLEIC ACIDS RES, V35, P6973, DOI 10.1093/nar/gkm695
   Hanes JW, 2008, ANAL BIOCHEM, V372, P125, DOI 10.1016/j.ab.2007.08.004
   Hanes JW, 2006, J BIOL CHEM, V281, P36241, DOI 10.1074/jbc.M607965200
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345
   Johnson KA, 2008, J BIOL CHEM, V283, P26297, DOI 10.1074/jbc.R800034200
   Johnson KA, 2010, BBA-PROTEINS PROTEOM, V1804, P1041, DOI 10.1016/j.bbapap.2010.01.006
   Johnson KA, 2009, ANAL BIOCHEM, V387, P30, DOI 10.1016/j.ab.2008.12.025
   Johnson KA, 2009, ANAL BIOCHEM, V387, P20, DOI 10.1016/j.ab.2008.12.024
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   Kellinger MW, 2010, P NATL ACAD SCI USA, V107, P7734, DOI 10.1073/pnas.0913946107
   Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029
   PONAMEREV MV, 2002, J BIOL CHEM, V277, P3
   PURSELL ZF, 2008, NUCLEIC ACIDS RES, V36, P7
   TAYLOR RW, 2005, NAT REV, V6, P14
   Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 38
TC 21
Z9 23
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
EI 
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUL 26
PY 2011
VL 50
IS 29
BP 6376
EP 6386
DI 10.1021/bi200280r
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 793UO
UT WOS:000292849600012
PM 21696159
DA 2024-11-01
ER

PT J
AU Milone, M
   Wang, J
   Liewluck, T
   Chen, LC
   Leavitt, JA
   Wong, LJ
AF Milone, Margherita
   Wang, Jing
   Liewluck, Teerin
   Chen, Li-Chieh
   Leavitt, Jacqueline A.
   Wong, Lee-Jun
TI Novel <i>POLG</i> Splice Site Mutation and Optic Atrophy
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID molecular diagnosis; polymerase-gamma; opa1 mutations; mitochondrial; disease
AB Objective: To investigate the molecular etiology of 2 unrelated patients with a multisystem mitochondrial disorder accompanied by optic atrophy in one of them. Design: Clinical examination and neurophysiological, radiological, morphological, and molecular analyses. Setting: Tertiary care neuromuscular clinic and molecular genetics laboratory. Patients: A 65-year-old man (patient 1) with dyschromatopsia and vision loss since childhood developed progressive external ophthalmoplegia, ptosis, and myopathy in the seventh decade of life and was found to have optic atrophy. A 63-year-old man (patient 2) with a similar phenotype, without visual symptoms, experienced also hearing loss and parkinsonism. Main Outcome Measures: Description of the clinical and molecular findings. Results: A muscle biopsy specimen showed ragged-red, ragged-blue, and cytochrome c oxidase-negative fibers in both patients. Because optic atrophy in patient 1 suggested an autosomal dominant OPA1-related disorder, the OPA1 gene was first sequenced, the results of which did not detect any mutations. Southern blot and polymerase chain reaction analyses of muscle mitochondrial DNA revealed multiple deletions. Sequencing of POLG detected a novel variant, c.3104 + 3A>T, in both patients. Patient 1 was compound heterozygous for a known p. F749S mutation; patient 2 had p.G848S as the second mutation. Analysis of POLG complementary DNA showed that c.3104 + 3A>T results in skipping of exon 18. Conclusion: Early-onset dyschromatopsia and optic atrophy can occur not only in OPA1-related but also in POLG-related disorders with significant impact on genetic counseling.
C1 [Milone, Margherita; Liewluck, Teerin] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Leavitt, Jacqueline A.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Wang, Jing; Chen, Li-Chieh; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Mayo Clinic; Mayo Clinic; Baylor College of Medicine
RP Milone, M (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.
EM Milone.Margherita@mayo.edu
FU National Institutes of Health/National Center for Research Resources [UL1 RR024150]
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   [Anonymous], 2010, GENEREVIEWS, V0, P0
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 11
TC 23
Z9 24
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JUN 15
PY 2011
VL 68
IS 6
BP 806
EP 811
DI 
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 776ON
UT WOS:000291546100019
PM 21670405
DA 2024-11-01
ER

PT J
AU Moreno-Loshuertos, R
   Ferrín, G
   Acín-Pérez, R
   Gallardo, ME
   Viscomi, C
   Pérez-Martos, A
   Zeviani, M
   Fernández-Silva, P
   Enríquez, JA
AF Moreno-Loshuertos, Raquel
   Ferrin, Gustavo
   Acin-Perez, Rebeca
   Esther Gallardo, M.
   Viscomi, Carlo
   Perez-Martos, Acisclo
   Zeviani, Massimo
   Fernandez-Silva, Patricio
   Antonio Enriquez, Jose
TI Evolution Meets Disease: Penetrance and <i>Functional Epistasis</i> of Mitochondrial tRNA Mutations
SO PLOS GENETICS
LA English
DT Article
ID ragged-red fibers; progressive external ophthalmoplegia; mtdna mutation; point mutation; human-cells; compensatory evolution; molecular phenotype; trna(leu(uur)) gene; myoclonic epilepsy; protein-synthesis
AB About half of the mitochondrial DNA (mtDNA) mutations causing diseases in humans occur in tRNA genes. Particularly intriguing are those pathogenic tRNA mutations than can reach homoplasmy and yet show very different penetrance among patients. These mutations are scarce and, in addition to their obvious interest for understanding human pathology, they can be excellent experimental examples to model evolution and fixation of mitochondrial tRNA mutations. To date, the only source of this type of mutations is human patients. We report here the generation and characterization of the first mitochondrial tRNA pathological mutation in mouse cells, an m. 3739G > A transition in the mitochondrial mt-Ti gene. This mutation recapitulates the molecular hallmarks of a disease-causing mutation described in humans, an m. 4290T > C transition affecting also the human mt-Ti gene. We could determine that the pathogenic molecular mechanism, induced by both the mouse and the human mutations, is a high frequency of abnormal folding of the tRNA(Ile) that cannot be charged with isoleucine. We demonstrate that the cells harboring the mouse or human mutant tRNA have exacerbated mitochondrial biogenesis triggered by an increase in mitochondrial ROS production as a compensatory response. We propose that both the nature of the pathogenic mechanism combined with the existence of a compensatory mechanism can explain the penetrance pattern of this mutation. This particular behavior can allow a scenario for the evolution of mitochondrial tRNAs in which the fixation of two alleles that are individually deleterious can proceed in two steps and not require the simultaneous mutation of both.
C1 [Moreno-Loshuertos, Raquel; Ferrin, Gustavo; Acin-Perez, Rebeca; Perez-Martos, Acisclo; Fernandez-Silva, Patricio; Antonio Enriquez, Jose] Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, Zaragoza, Spain.
   [Esther Gallardo, M.] Univ Autonoma Madrid, Fac Med, CSIC,CIBERER, Dept Bioquim,Inst Invest Biomed Alberto Sols,ISCI, E-28029 Madrid, Spain.
   [Viscomi, Carlo; Zeviani, Massimo] Ist Neurol Carlo Besta, Div Mol Neurogenet, Milan, Italy.
   [Antonio Enriquez, Jose] Ctr Nacl Invest Cardiovasc Carlos III, Regenerat Cardiol Dept, Madrid, Spain.
C3 University of Zaragoza; Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Fondazione IRCCS Istituto Neurologico Carlo Besta; Centro Nacional de Investigaciones Cardiovasculares (CNIC)
RP Moreno-Loshuertos, R (corresponding author), Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, Zaragoza, Spain.
EM jaenriquez@cnic.es
FU Spanish Ministry of Education [SAF2009-08007, CSD2007-00020]; EU [EUMITOCOMBAT-LSHM-CT-2004-503116]; Group of Excellence grant DGA [B55]; Spanish Ministry of Science and Innovation; Pro-CNIC Foundation
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   Acín-Pérez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021
   Bayona-Bafaluy Maria Pilar, 2008, V457, V0, PP379, DOI 10.1007/978-1-59745-261-8-28
   Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Bornstein B, 2005, BIOCHEM J, V387, P773, DOI 10.1042/BJ20040949
   Bornstein B, 2002, HUM MUTAT, V19, P234, DOI 10.1002/humu.10050
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   CHOMYN A, 1994, AM J HUM GENET, V54, P966
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Enriquez J A, 1996, METHODS ENZYMOL, V264, P183, DOI 10.1016/S0076-6879(96)64019-1
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300
   Fernández-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8
   Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165
   Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338
   Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868
   Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1994, J BIOL CHEM, V269, P19060
   Hino N, 2004, GENES CELLS, V9, P243, DOI 10.1111/j.1356-9597.2004.00718.x
   Hofhaus G, 1996, METHODS ENZYMOL, V264, P476, DOI 10.1016/S0076-6879(96)64043-9
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Kern AD, 2004, NAT GENET, V36, P1207, DOI 10.1038/ng1451
   Kondrashov FA, 2005, HUM MOL GENET, V14, P2415, DOI 10.1093/hmg/ddi243
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Meer MV, 2010, NATURE, V464, P279, DOI 10.1038/nature08691
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Park H, 2008, RNA, V14, P2407, DOI 10.1261/rna.1208808
   Porcelli AM, 2010, HUM MOL GENET, V19, P1019, DOI 10.1093/hmg/ddp566
   Reid FM, 1997, HUM MOL GENET, V6, P443, DOI 10.1093/hmg/6.3.443
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P3065, DOI 10.1093/nar/gkn147
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Sasarman F, 2008, HUM MOL GENET, V17, P3697, DOI 10.1093/hmg/ddn265
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Sun T, 2008, NUCLEIC ACIDS RES, V36, P1654, DOI 10.1093/nar/gkm1180
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Tiranti V, 1999, NEUROMUSCULAR DISORD, V9, P66, DOI 10.1016/S0960-8966(98)00103-5
   Tomari Y, 2003, J BIOL CHEM, V278, P16828, DOI 10.1074/jbc.M213216200
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Tuppen HAL, 2008, J MED GENET, V45, P55, DOI 10.1136/jmg.2007.051185
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
NR 54
TC 49
Z9 51
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
EI 
J9 PLOS GENET
JI PLoS Genet.
PD APR 15
PY 2011
VL 7
IS 4
BP 
EP 
DI 10.1371/journal.pgen.1001379
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000018
PM 21533077
DA 2024-11-01
ER

PT J
AU Swalwell, H
   Kirby, DM
   Blakely, EL
   Mitchell, A
   Salemi, R
   Sugiana, C
   Compton, AG
   Tucker, EJ
   Ke, X
   Lamont, PJ
   Turnbull, DM
   McFarland, R
   Taylor, RW
   Thorburn, DR
AF Swalwell, Helen
   Kirby, Denise M.
   Blakely, Emma L.
   Mitchell, Anna
   Salemi, Renato
   Sugiana, Canny
   Compton, Alison G.
   Tucker, Elena J.
   Ke, Xia
   Lamont, Phillipa J.
   Turnbull, Douglass M.
   McFarland, Robert
   Taylor, Robert W.
   Thorburn, David R.
TI Respiratory chain complex I deficiency caused by mitochondrial DNA mutations
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE respiratory chain; complex I; mitochondrial DNA; mutation; genetic counselling
ID leigh-syndrome; ubiquinone oxidoreductase; g13513a mutation; lactic-acidosis; common-cause; nd3 gene; disease; disorders; children; myopathy
AB Defects of the mitochondrial respiratory chain are associated with a diverse spectrum of clinical phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)). Isolated complex I deficiency is the most common enzyme defect in mitochondrial disorders, particularly in children in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause. In contrast, although a number of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric complex I deficiency. We reviewed the clinical and genetic findings in a large cohort of 109 paediatric patients with isolated complex I deficiency from 101 families. Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in MTND subunit genes and 8 in mtDNA tRNA genes. Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation analysis (nuclear gene mutations were identified in 22 probands). Leigh or Leigh-like disease was the most common clinical presentation in both mtDNA and nuclear genetic defects. The median age at onset was higher in mtDNA patients (12 months) than in patients with a nuclear gene defect (3 months). However, considerable overlap existed, with onset varying from 0 to 460 months in both groups. Our findings confirm that pathogenic mtDNA mutations are a significant cause of complex I deficiency in children. In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying molecular genetic abnormality. European Journal of Human Genetics (2011) 19, 769-775; doi:10.1038/ejhg.2011.18; published online 2 March 2011
C1 [Kirby, Denise M.; Salemi, Renato; Sugiana, Canny; Compton, Alison G.; Tucker, Elena J.; Ke, Xia; Thorburn, David R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Swalwell, Helen; Blakely, Emma L.; Mitchell, Anna; Turnbull, Douglass M.; McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Sugiana, Canny; Tucker, Elena J.; Thorburn, David R.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Lamont, Phillipa J.] Royal Perth Hosp, Dept Neurol, Neurogenet Unit, Perth, WA, Australia.
   [Thorburn, David R.] Royal Childrens Hosp, Genet Hlth Serv Victoria, Melbourne, Vic, Australia.
C3 Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Newcastle University - UK; University of Melbourne; East Metropolitan Health Service; Royal Perth Hospital; University of Western Australia; Royal Children's Hospital Melbourne
RP Thorburn, DR (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM david.thorburn@mcri.edu.au
FU Australian National Health and Medical Research Council; Muscular Dystrophy Association, USA; Medical Research Council, UK; Wellcome Trust, UK; UK National Commissioning Group; MRC [G0800674, G0601943, G0900390] Funding Source: UKRI
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Blok MJ, 2007, J MED GENET, V44, P0, DOI 10.1136/jmg.2006.045716
   Bruno C, 1999, J PEDIATR-US, V135, P197, DOI 10.1016/S0022-3476(99)70022-3
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200
   Chae JH, 2007, PEDIATR RES, V61, P622, DOI 10.1203/pdr.0b013e3180459f2d
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Dinopoulos A, 2005, ACTA NEUROPATHOL, V110, P199, DOI 10.1007/s00401-005-1036-2
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   Hoefs SJG, 2008, AM J HUM GENET, V82, P1306, DOI 10.1016/j.ajhg.2008.05.007
   HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066
   Kirby DM, 2008, TWIN RES HUM GENET, V11, P395, DOI 10.1375/twin.11.4.395
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lazarou M, 2007, MOL CELL BIOL, V27, P4228, DOI 10.1128/MCB.00074-07
   Lazarou M, 2009, FEBS J, V276, P6701, DOI 10.1111/j.1742-4658.2009.07384.x
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057
   MOREADITH RW, 1984, J CLIN INVEST, V74, P685, DOI 10.1172/JCI111484
   Moslemi AR, 2008, NEUROPEDIATRICS, V39, P24, DOI 10.1055/s-2008-1076739
   Naess K, 2009, BBA-BIOENERGETICS, V1787, P484, DOI 10.1016/j.bbabio.2008.11.014
   Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002
   Ogle RF, 1997, J PEDIATR-US, V130, P138, DOI 10.1016/S0022-3476(97)70323-8
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4
   ROBINSON BH, 1985, AM J HUM GENET, V37, P938
   Rötig A, 2004, BBA-BIOENERGETICS, V1659, P129, DOI 10.1016/j.bbabio.2004.07.007
   Ruitenbeek W, 1996, J INHERIT METAB DIS, V19, P581, DOI 10.1007/BF01799118
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Schägger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Sugiana C, 2008, AM J HUM GENET, V83, P468, DOI 10.1016/j.ajhg.2008.09.009
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Vasta V, 2009, GENOME MED, V1, P0, DOI 10.1186/gm100
NR 51
TC 99
Z9 107
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JUL 15
PY 2011
VL 19
IS 7
BP 769
EP 775
DI 10.1038/ejhg.2011.18
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 778DA
UT WOS:000291678400011
PM 21364701
DA 2024-11-01
ER

PT J
AU Malik, AN
   Shahni, R
   Rodriguez-De-Ledesma, A
   Laftah, A
   Cunningham, P
AF Malik, Afshan N.
   Shahni, Rojeen
   Rodriguez-de-Ledesma, Ana
   Laftah, Abas
   Cunningham, Phil
TI Mitochondrial DNA as a non-invasive biomarker: Accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondrial DNA; Copy numbers; Pseudogenes; Real time qPCR; Dilution bias
ID hiv-infected patients; copy number; peripheral-blood; skeletal-muscle; cancer; association; biogenesis; hyperglycemia; expression; depletion
AB Circulating mitochondrial DNA (MtDNA) is a potential non-invasive biomarker of cellular mitochondrial dysfunction, the latter known to be central to a wide range of human diseases. Changes in MtDNA are usually determined by quantification of MtDNA relative to nuclear DNA (Mt/N) using real time quantitative PCR. We propose that the methodology for measuring Mt/N needs to be improved and we have identified that current methods have at least one of the following three problems: (1) As much of the mitochondrial genome is duplicated in the nuclear genome, many commonly used MtDNA primers co-amplify homologous pseudogenes found in the nuclear genome; (2) use of regions from genes such as beta-actin and 18S rRNA which are repetitive and/or highly variable for qPCR of the nuclear genome leads to errors; and (3) the size difference of mitochondrial and nuclear genomes cause a "dilution bias" when template DNA is diluted. We describe a PCR-based method using unique regions in the human mitochondrial genome not duplicated in the nuclear genome; unique single copy region in the nuclear genome and template treatment to remove dilution bias, to accurately quantify MtDNA from human samples. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Malik, Afshan N.; Shahni, Rojeen; Rodriguez-de-Ledesma, Ana; Laftah, Abas; Cunningham, Phil] Kings Coll London, Diabet Res Grp, Div Diabet & Nutr Sci, Sch Med, London SE1 1UL, England.
C3 University of London; King's College London
RP Malik, AN (corresponding author), Kings Coll London, Diabet Res Grp, Div Diabet & Nutr Sci, Sch Med, Hodgkin Bldg,Guys Campus, London SE1 1UL, England.
EM afshan.malik@kcl.ac.uk
CR Abu-Amero KK, 2009, MOL VIS, V15, P1594
   Al-Kafaji G, 2010, BIOCHEM BIOPH RES CO, V391, P1585, DOI 10.1016/j.bbrc.2009.12.061
   Alcolea MP, 2007, AM J PHYSIOL-ENDOC M, V293, PE636, DOI 10.1152/ajpendo.00120.2007
   Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006
   Asmann YW, 2006, DIABETES, V55, P3309, DOI 10.2337/db05-1230
   Cavelier L, 2000, EXP CELL RES, V259, P79, DOI 10.1006/excr.2000.4949
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509
   Chêne G, 2007, AIDS RES HUM RETROV, V23, P54, DOI 10.1089/aid.2006.0039
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   Cree LM, 2008, DIABETOLOGIA, V51, P1440, DOI 10.1007/s00125-008-1054-4
   ELLINGER J, 2010, UROL ONCOL, V0, P0
   Ellinger J, 2009, BJU INT, V104, P48, DOI 10.1111/j.1464-410X.2008.08289.x
   ELSNER HI, 1989, DNA-J MOLEC CELL BIO, V8, P697, DOI 10.1089/dna.1989.8.697
   Flicek P, 2010, NUCLEIC ACIDS RES, V38, PD557, DOI 10.1093/nar/gkp972
   Gourlain K, 2003, HIV MED, V4, P287, DOI 10.1046/j.1468-1293.2003.00158.x
   Guo W, 2009, MITOCHONDRION, V9, P261, DOI 10.1016/j.mito.2009.03.003
   Hazkani-Covo E, 2010, PLOS GENET, V6, P0, DOI 10.1371/journal.pgen.1000834
   Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119
   Jiang WW, 2005, CLIN CANCER RES, V11, P2486, DOI 10.1158/1078-0432.CCR-04-2147
   Kaaman M, 2007, DIABETOLOGIA, V50, P2526, DOI 10.1007/s00125-007-0818-6
   Kao SH, 2004, FERTIL STERIL, V82, P66, DOI 10.1016/j.fertnstert.2003.11.056
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   Kim MJ, 2008, ANTIMICROB AGENTS CH, V52, P1670, DOI 10.1128/AAC.01449-07
   Lanktree MB, 2009, J LIPID RES, V50, P768, DOI 10.1194/jlr.D800050-JLR200
   Lim S, 2000, EUR J APPL PHYSIOL, V82, P407, DOI 10.1007/s004210000238
   LTSCHUL SF, 1990, J MOL BIOL, V215, P403
   Malik AN, 2007, BIOCHEM BIOPH RES CO, V357, P237, DOI 10.1016/j.bbrc.2007.03.132
   Malik Afshan N, 2009, DIABETES RES CLIN PRACT, V86, Pe22, DOI 10.1016/j.diabres.2009.07.002
   Marcuello A, 2005, J APPL PHYSIOL, V99, P1372, DOI 10.1152/japplphysiol.00289.2005
   Masayesva BG, 2006, CANCER EPIDEM BIOMAR, V15, P19, DOI 10.1158/1055-9965.EPI-05-0210
   May-Panloup P, 2003, HUM REPROD, V18, P550, DOI 10.1093/humrep/deg096
   Mitsuishi M, 2009, DIABETES, V58, P710, DOI 10.2337/db08-0949
   Mizumachi T, 2008, ONCOGENE, V27, P831, DOI 10.1038/sj.onc.1210681
   Mizumachi T, 2008, PROSTATE, V68, P408, DOI 10.1002/pros.20697
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   Mussini C, 2005, AIDS, V19, P1627, DOI 10.1097/01.aids.0000186019.47297.0d
   Myers MB, 2009, BIOTECHNIQUES, V47, P867, DOI 10.2144/000113222
   Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666
   Park JY, 2009, CIRC RES, V105, P705, DOI 10.1161/CIRCRESAHA.109.205310
   Park KS, 2001, DIABETES RES CLIN PR, V52, P97, DOI 10.1016/S0168-8227(00)00237-0
   Park SY, 2009, MITOCHONDRION, V9, P318, DOI 10.1016/j.mito.2009.04.006
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   Pejznochova M, 2010, MITOCHONDRION, V10, P321, DOI 10.1016/j.mito.2010.01.006
   Reynier P, 2001, MOL HUM REPROD, V7, P425, DOI 10.1093/molehr/7.5.425
   Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Shen J, 2010, MITOCHONDRION, V10, P62, DOI 10.1016/j.mito.2009.09.004
   Stuart JA, 2006, BBA-BIOENERGETICS, V1757, P79, DOI 10.1016/j.bbabio.2006.01.003
   Tourmen Y, 2002, GENOMICS, V80, P71, DOI 10.1006/geno.2002.6798
   Wang Y, 2005, GYNECOL ONCOL, V98, P104, DOI 10.1016/j.ygyno.2005.04.015
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390
   Xing JL, 2008, JNCI-J NATL CANCER I, V100, P1104, DOI 10.1093/jnci/djn213
   Xu SC, 2010, BRAIN RES, V1311, P189, DOI 10.1016/j.brainres.2009.10.062
   Yamada S, 2006, EJSO-EUR J SURG ONC, V32, P303, DOI 10.1016/j.ejso.2006.01.002
   Yu M, 2007, TOXICOL LETT, V170, P83, DOI 10.1016/j.toxlet.2007.02.013
NR 54
TC 107
Z9 127
U1 0
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 19
PY 2011
VL 412
IS 1
BP 1
EP 7
DI 10.1016/j.bbrc.2011.06.067
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 815EN
UT WOS:000294509000001
PM 21703239
DA 2024-11-01
ER

PT J
AU Chen, T
   He, J
   Huang, YS
   Zhao, WW
AF Chen, Tao
   He, Jing
   Huang, Yushan
   Zhao, Weiwei
TI The generation of mitochondrial DNA large-scale deletions in human cells
SO JOURNAL OF HUMAN GENETICS
LA English
DT Review
DE generation; large-scale deletions; mitochondrial DNA; repair; replication
ID human skeletal-muscle; strand break repair; external ophthalmoplegia; degenerative diseases; mutations; replication; mtdna; sequence; pathways; cancer
AB Large-scale deletions of human mitochondrial DNA (mtDNA) are a common cause of mitochondrial diseases. In order to prevent and treat these mitochondrial diseases, it is important and necessary to understand the mechanisms behind the generation of these deletions. Generally, there exist three kinds of large-scale deletions: deletions almost occur within two direct repeats with identical sequences (class I deletions), deletions are flanked by imperfect repeats (class II deletions) and by no direct repeats (class III deletions). Two major hypotheses are suggested to generate these deletions: replication for class I/II deletions through slipped mispairing between two repeats, and repair mainly for class II/III deletions mediated by mtDNA double-strand breaks. It seems possible that these two mechanisms work together as a powerful and complementary system to compensate for their defects in the generation of all these deletions, not respectively. Journal of Human Genetics (2011) 56, 689-694; doi:10.1038/jhg.2011.97; published online 25 August 2011
C1 [Chen, Tao; Huang, Yushan; Zhao, Weiwei] Guangzhou Kingmed Ctr Clin Lab, Dept Mol Pathol, Guangzhou 510330, Guangdong, Peoples R China.
   [Chen, Tao] Guangzhou Kingmed Ctr Clin Lab, Dept Mol Genet, Guangzhou 510330, Guangdong, Peoples R China.
   [He, Jing] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China.
C3 Fudan University
RP Chen, T (corresponding author), Guangzhou Kingmed Ctr Clin Lab, Dept Mol Pathol, Guangzhou 510330, Guangdong, Peoples R China.
EM ct19840796@126.com
CR Abnet CC, 2004, BMC CANCER, V4, P0, DOI 10.1186/1471-2407-4-30
   ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351
   Chen J, 2007, NUCLEIC ACIDS RES, V35, P1377, DOI 10.1093/nar/gkm010
   Chen T, 2011, BMC MED GENET, V12, P0, DOI 10.1186/1471-2350-12-8
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493
   Eshaghian A, 2006, J INVEST DERMATOL, V126, P336, DOI 10.1038/sj.jid.5700088
   Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703
   Fishel ML, 2007, MUTAT RES-FUND MOL M, V614, P24, DOI 10.1016/j.mrfmmm.2006.06.007
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Fukui H, 2009, HUM MOL GENET, V18, P1028, DOI 10.1093/hmg/ddn437
   GROSS NJ, 1969, J BIOL CHEM, V244, P1552
   Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059
   Kamalidehghan B, 2006, ARCH MED RES, V37, P848, DOI 10.1016/j.arcmed.2006.03.007
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   MITONIAP, 2010, MITOMAP HUM MIT GEN, V0, P0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Muqit MMK, 2008, J NEUROL NEUROSUR PS, V79, P68, DOI 10.1136/jnnp.2006.112250
   Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   ROBBERSODL, 1972, P NATL ACAD SCI USA, V69, P3810, DOI 10.1073/pnas.69.12.3810
   Rocher C, 2002, MOL GENET METAB, V76, P123, DOI 10.1016/S1096-7192(02)00024-0
   Rogounovitch T, 2004, ENDOCR J, V51, P265, DOI 10.1507/endocrj.51.265
   Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Shen LJ, 2010, ANN NY ACAD SCI, V1201, P26, DOI 10.1111/j.1749-6632.2010.05635.x
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Solano A, 2003, J MED GENET, V40, P0, DOI 10.1136/jmg.40.7.e86
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049
   WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WELTER C, 1989, NUCLEIC ACIDS RES, V17, P6077
   Wong LJC, 2003, J MED GENET, V40, P0
   Wu CW, 2005, GENE CHROMOSOME CANC, V44, P19, DOI 10.1002/gcc.20213
   Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   Ye CZ, 2008, BREAST CANCER RES TR, V108, P427, DOI 10.1007/s10549-007-9613-9
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZHANG CF, 1995, HUM MOL GENET, V4, P751, DOI 10.1093/hmg/4.4.751
NR 61
TC 47
Z9 58
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD OCT 15
PY 2011
VL 56
IS 10
BP 689
EP 694
DI 10.1038/jhg.2011.97
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 842DM
UT WOS:000296569900001
PM 21866113
DA 2024-11-01
ER

PT J
AU Kemp, JP
   Smith, PM
   Pyle, A
   Neeve, VCM
   Tuppen, HAL
   Schara, U
   Talim, B
   Topaloglu, H
   Holinski-Feder, E
   Abicht, A
   Czermin, B
   Lochmüller, H
   McFarland, R
   Chinnery, PF
   Chrzanowska-Lightowlers, ZM
   Lightowlers, RN
   Taylor, RW
   Horvath, R
AF Kemp, John P.
   Smith, Paul M.
   Pyle, Angela
   Neeve, Vivienne C. M.
   Tuppen, Helen A. L.
   Schara, Ulrike
   Talim, Beril
   Topaloglu, Haluk
   Holinski-Feder, Elke
   Abicht, Angela
   Czermin, Birgit
   Lochmueller, Hanns
   McFarland, Robert
   Chinnery, Patrick F.
   Chrzanowska-Lightowlers, Zofia M. A.
   Lightowlers, Robert N.
   Taylor, Robert W.
   Horvath, Rita
TI Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency
SO BRAIN
LA English
DT Article
DE mitochondrial translation; combined respiratory chain deficiency; early-onset encephalomyopathy
ID sideroblastic anemia-mlasa; c-oxidase deficiency; rna-synthetase gene; dna depletion; molecular-basis; mutation; disease; myopathy; leukoencephalopathy; encephalomyopathy
AB Mutations in several mitochondrial DNA and nuclear genes involved in mitochondrial protein synthesis have recently been reported in combined respiratory chain deficiency, indicating a generalized defect in mitochondrial translation. However, the number of patients with pathogenic mutations is small, implying that nuclear defects of mitochondrial translation are either underdiagnosed or intrauterine lethal. No comprehensive studies have been reported on large cohorts of patients with combined respiratory chain deficiency addressing the role of nuclear genes affecting mitochondrial protein synthesis to date. We investigated a cohort of 52 patients with combined respiratory chain deficiency without causative mitochondrial DNA mutations, rearrangements or depletion, to determine whether a defect in mitochondrial translation defines the pathomechanism of their clinical disease. We followed a combined approach of sequencing known nuclear genes involved in mitochondrial protein synthesis (EFG1, EFTu, EFTs, MRPS16, TRMU), as well as performing in vitro functional studies in 22 patient cell lines. The majority of our patients were children (< 15 years), with an early onset of symptoms < 1 year of age (65%). The most frequent clinical presentation was mitochondrial encephalomyopathy (63%); however, a number of patients showed cardiomyopathy (33%), isolated myopathy (15%) or hepatopathy (13%). Genomic sequencing revealed compound heterozygous mutations in the mitochondrial transfer ribonucleic acid modifying factor (TRMU) in a single patient only, presenting with early onset, reversible liver disease. No pathogenic mutation was detected in any of the remaining 51 patients in the other genes analysed. In vivo labelling of mitochondrial polypeptides in 22 patient cell lines showed overall (three patients) or selective (four patients) defects of mitochondrial translation. Immunoblotting for mitochondrial proteins revealed decreased steady state levels of proteins in some patients, but normal or increased levels in others, indicating a possible compensatory mechanism. In summary, candidate gene sequencing in this group of patients has a very low detection rate (1/52), although in vivo labelling of mitochondrial translation in 22 patient cell lines indicate that a nuclear defect affecting mitochondrial protein synthesis is responsible for about one-third of combined respiratory chain deficiencies (7/22). In the remaining patients, the impaired respiratory chain activity is most likely the consequence of several different events downstream of mitochondrial translation. Clinical classification of patients with biochemical analysis, genetic testing and, more importantly, in vivo labelling and immunoblotting of mitochondrial proteins show incoherent results, but a systematic review of these data in more patients may reveal underlying mechanisms, and facilitate the identification of novel factors involved in combined respiratory chain deficiency.
C1 [Horvath, Rita] Newcastle Univ, Inst Human Genet, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Kemp, John P.; Smith, Paul M.; Pyle, Angela; Neeve, Vivienne C. M.; Tuppen, Helen A. L.; McFarland, Robert; Chinnery, Patrick F.; Chrzanowska-Lightowlers, Zofia M. A.; Lightowlers, Robert N.; Taylor, Robert W.; Horvath, Rita] Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Pyle, Angela; Neeve, Vivienne C. M.; Holinski-Feder, Elke; Abicht, Angela; Czermin, Birgit; Horvath, Rita] Ctr Med Genet, Munich, Germany.
   [Schara, Ulrike] Univ Essen Gesamthsch, Dept Paediat Neurol, Essen, Germany.
   [Talim, Beril; Topaloglu, Haluk] Hacettepe Univ, Paediat Pathol Unit, Dept Paediat, Ankara, Turkey.
C3 Newcastle University - UK; Newcastle University - UK; University of Duisburg Essen; Hacettepe University
RP Horvath, R (corresponding author), Newcastle Univ, Inst Human Genet, Mitochondrial Res Grp, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM Rita.Horvath@ncl.ac.uk
FU Newcastle upon Tyne Hospitals NHS Charity [RES0211/7262]; Academy of Medical Sciences, UK [BH090164]; Parkinson's Disease Society (UK); Medical Research Council Translational Muscle Centre; UK NIHR Biomedical Research Centre in Aging and Age-related disease; Wellcome Trust [074454/Z/04/Z]; Biotechnology and Biological Sciences Research Council [BB/F011520/1]; Medical Research Council [G0700718]; German ministry of education and research (BMBF, Bonn, Germany); UK National Commissioning Group; MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (UK); BBSRC [BB/F011520/1] Funding Source: UKRI; MRC [G0800674, G0700718, G0601943] Funding Source: UKRI
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Antonicka H, 2010, AM J HUM GENET, V87, P115, DOI 10.1016/j.ajhg.2010.06.004
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   Isohanni P, 2010, J MED GENET, V47, P66, DOI 10.1136/jmg.2009.068221
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Munaro M, 1997, HUM MOL GENET, V6, P221, DOI 10.1093/hmg/6.2.221
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Numata T, 2006, NATURE, V442, P419, DOI 10.1038/nature04896
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P5787, DOI 10.1093/nar/gkn576
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Smits P, 2010, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2010/737385
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Soleimanpour-Lichaei HR, 2007, MOL CELL, V27, P745, DOI 10.1016/j.molcel.2007.06.031
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 41
TC 59
Z9 69
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JAN 15
PY 2011
VL 134
IS 
BP 183
EP 195
DI 10.1093/brain/awq320
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 698WK
UT WOS:000285625000017
PM 21169334
DA 2024-11-01
ER

PT J
AU Szántó, M
   Rutkai, I
   Hegedus, C
   Czikora, A
   Rózsahegyi, M
   Kiss, B
   Virág, L
   Gergely, P
   Tóth, A
   Bai, P
AF Szanto, Magdolna
   Rutkai, Ibolya
   Hegedus, Csaba
   Czikora, Agnes
   Rozsahegyi, Mate
   Kiss, Borbala
   Virag, Laszlo
   Gergely, Pal
   Toth, Attila
   Bai, Peter
TI Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction
SO CARDIOVASCULAR RESEARCH
LA English
DT Article
DE PARP-2; Doxorubicin; SIRT1; Mitochondria; Vascular smooth muscle
ID oxidative stress; heart-failure; mitochondrial-function; regulates sirt1; renal damage; dna damage; resveratrol; parp-2; mice; activation
AB Aims Doxorubicin (DOX) is widely used in cytostatic treatments, although it may cause cardiovascular dysfunction as a side effect. DOX treatment leads to enhanced free radical production that in turn causes DNA strand breakage culminating in poly(ADP-ribose) polymerase (PARP) activation and mitochondrial and cellular dysfunction. DNA nicks can activate numerous enzymes, such as PARP-2. Depletion of PARP-2 has been shown to result in a protective phenotype against free radical-mediated diseases, suggesting similar properties in the case of DOX-induced vascular damage. Methods and results PARP-2(+/+) and PARP-2(-/-) mice and aortic smooth muscle (MOVAS) cells were treated with DOX (25 mg/kg or 3 mu M, respectively). Aortas were harvested 2-day post-treatment while MOVAS cells were treated with DOX for 7 hours. Aortas from PARP-2(-/-) mice displayed partial protection against DOX toxicity, and the protection depended on the conservation of smooth muscle but not on the conservation of endothelial function. DOX treatment evoked free radical production, DNA breakage and PARP activation. Importantly, depletion of PARP-2 did not quench any of these phenomena, suggesting an alternative mechanism. Depletion of PARP-2 prevented DOX-induced mitochondrial dysfunction through SIRT1 activation. Genetic deletion of PARP-2 resulted in the induction of the SIRT1 promoter and consequently increased SIRT1 expression both in aortas and in MOVAS cells. SIRT1 activation enhanced mitochondrial biogenesis, which provided protection against DOX-induced mitochondrial damage. Conclusion Our data identify PARP-2 as a mediator of DOX toxicity by regulating vascular SIRT1 activity and mitochondrial biogenesis. Moreover, to the best of our knowledge, this is the first report of SIRT1 as a protective factor in the vasculature upon oxidative stress.
C1 [Szanto, Magdolna; Hegedus, Csaba; Rozsahegyi, Mate; Virag, Laszlo; Gergely, Pal; Bai, Peter] Univ Debrecen, Dept Med Chem, Med & Hlth Sci Ctr, H-4032 Debrecen, Hungary.
   [Rutkai, Ibolya; Czikora, Agnes; Toth, Attila] Univ Debrecen, Med & Hlth Sci Ctr, Inst Cardiol, Div Clin Physiol, Debrecen, Hungary.
   [Hegedus, Csaba; Virag, Laszlo; Gergely, Pal; Bai, Peter] Hungarian Acad Sci, Cell Biol & Signaling Res Grp, Debrecen, Hungary.
   [Kiss, Borbala] Univ Debrecen, Dept Dermatol, Med & Hlth Sci Ctr, Debrecen, Hungary.
C3 University of Debrecen; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen
RP Bai, P (corresponding author), Univ Debrecen, Dept Med Chem, Med & Hlth Sci Ctr, Nagyerdei Krt 98 Pf 7, H-4032 Debrecen, Hungary.
EM baip@med.unideb.hu
FU Bolyai fellowship; National Innovation Office [FR-26/2009]; Hungarian National Science Foundation [CNK80709, IN80481, K60780, K84300, K73003, K82009, PD83473]; University of Debrecen, Medical and Health Science Center [Mecenatura Mec-8/2011]; Hungarian Ministry of Health [ETT 430/2006]; European Social Fund;  [TAMOP 4.2.1./B-09/1/KONV-2010-0007];  [TAMOP-4.2.2/B-10/1-2010-0024];  [TAMOP-4.2.2-08/1-2008-0019]
CR Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a
   Amé JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860
   Bai P, 2004, ONCOL REP, V11, P505
   Bai P, 2007, J BIOL CHEM, V282, P37738, DOI 10.1074/jbc.M701021200
   Bai P, 2007, TOXICOL LETT, V170, P203, DOI 10.1016/j.toxlet.2007.03.007
   Bai P, 2011, CELL METAB, V13, P450, DOI 10.1016/j.cmet.2011.03.013
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299
   Borradaile NM, 2009, CURR PHARM DESIGN, V15, P110, DOI 10.2174/138161209787185742
   BRISTOW MR, 1981, LAB INVEST, V45, P157
   Brunyánszki A, 2010, J INVEST DERMATOL, V130, P2629, DOI 10.1038/jid.2010.190
   Danz EDB, 2009, FREE RADICAL BIO MED, V46, P1589, DOI 10.1016/j.freeradbiomed.2009.03.011
   DAWER S P, 1988, HEART AND VESSELS, V4, P237, DOI 10.1007/BF02058592
   de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206
   DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068
   Erdélyi K, 2009, FASEB J, V23, P3553, DOI 10.1096/fj.09-133264
   Hasinoff Brian B, 2003, CARDIOVASC TOXICOL, V3, P89, DOI 10.1385/CT:3:2:89
   Kofler J, 2006, J CEREBR BLOOD F MET, V26, P135, DOI 10.1038/sj.jcbfm.9600173
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lorenz P, 2003, NITRIC OXIDE-BIOL CH, V9, P64, DOI 10.1016/j.niox.2003.09.005
   Moroni F, 2009, BRIT J PHARMACOL, V157, P854, DOI 10.1111/j.1476-5381.2009.00232.x
   Murata T, 2001, LIFE SCI, V69, P2685, DOI 10.1016/S0024-3205(01)01352-2
   Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731
   Ochodnicky P, 2009, NEPHROL DIAL TRANSPL, V24, P413, DOI 10.1093/ndt/gfn483
   Pacher P, 2006, INT J MOL MED, V17, P369
   Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD
   Pacher P, 2002, J PHARMACOL EXP THER, V300, P862, DOI 10.1124/jpet.300.3.862
   Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682
   Pedrycz Agnieszka, 2004, ANN UNIV MARIAE CURIE SKLODOWSKA MED, V59, P319
   Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200
   Popoff I, 2002, J PHARMACOL EXP THER, V303, P1145, DOI 10.1124/jpet.102.039768
   Rajamohan SB, 2009, MOL CELL BIOL, V29, P4116, DOI 10.1128/MCB.00121-09
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354
   Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0
   Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1
   Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307
   TAGA I, 1987, JOURNAL OF RECONSTRUCTIVE MICROSURGERY, V3, P153, DOI 10.1055/s-2007-1006979
   Tao R, 2007, BIOCHEM BIOPH RES CO, V363, P257, DOI 10.1016/j.bbrc.2007.08.041
   Xu MF, 2002, J MOL CELL CARDIOL, V34, P75, DOI 10.1006/jmcc.2001.1485
   Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909
   Zhang C, 2011, CARDIOVASC RES, V90, P538, DOI 10.1093/cvr/cvr022
NR 41
TC 51
Z9 52
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD DEC 1
PY 2011
VL 92
IS 3
BP 430
EP 438
DI 10.1093/cvr/cvr246
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 847MM
UT WOS:000296977000012
PM 21921080
DA 2024-11-01
ER

PT J
AU Baruffini, E
   Horvath, R
   Dallabona, C
   Czermin, B
   Lamantea, E
   Bindoff, L
   Invernizzi, F
   Ferrero, I
   Zeviani, M
   Lodi, T
AF Baruffini, Enrico
   Horvath, Rita
   Dallabona, Cristina
   Czermin, Birgit
   Lamantea, Eleonora
   Bindoff, Laurence
   Invernizzi, Federica
   Ferrero, Iliana
   Zeviani, Massimo
   Lodi, Tiziana
TI Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model
SO MITOCHONDRION
LA English
DT Article
DE Yeast model; POLG; Mitochondrial diseases; MIPI; mtDNA mutability; ROS scavengers
ID dna-polymerase-gamma; progressive external ophthalmoplegia; mitochondrial-dna; saccharomyces-cerevisiae; rib2 locus; defects; gene; replication; mtdna; erythromycin
AB The yeast Saccharomyces cerevisiae was used to validate the pathogenic significance of eight human mutations in the gene encoding for the mitochondrial DNA polymerase gamma, namely C303R, S305R, R386H, R574W, P625R, D930N, K947R and P1073L, among which three are novel and four are of unclear pathological significance. Mitochondrial DNA extended and point mutability as well as dominance/recessivity of each mutation has been evaluated. The analysis in yeast revealed that two mutations. S305R and R386H, cannot be the sole cause of pathology observed in patients. These data led us to search for a second mutation in compound with S305R and we found a mutation. P1073L, missed in the first genetic analysis. Finally, a significant rescue of extended mutability has been observed for several dominant mutations by treatment with mitochondrial antioxidants. (C) 2010 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Baruffini, Enrico; Dallabona, Cristina; Ferrero, Iliana; Lodi, Tiziana] Univ Parma, Dept Genet, I-43124 Parma, Italy.
   [Horvath, Rita] Newcastle Univ, Mitochondrial Res Grp, Inst Hlth & Aging, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Horvath, Rita; Czermin, Birgit] Ctr Med Genet, Munich, Germany.
   [Lamantea, Eleonora; Invernizzi, Federica; Zeviani, Massimo] Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Milan, Italy.
   [Bindoff, Laurence] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
C3 University of Parma; Newcastle University - UK; University of Bergen; Haukeland University Hospital
RP Lodi, T (corresponding author), Univ Parma, Dept Genet, I-43124 Parma, Italy.
EM tiziana.lodi@unipr.it
FU Fondazione Pierfranco and Luisa Mariani; Fondazione Telethon-Italy [GGP07019]; Ricerca Finalizzata of the Italian Ministry of Health [RF-IN-2007-634163]; Academy of Medical Sciences UK [BH090164]
CR Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2010, METHODS, V51, P426, DOI 10.1016/j.ymeth.2010.02.023
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   CUI Z, 1989, CURR GENET, V16, P273, DOI 10.1007/BF00422114
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Fontanesi F, 2009, CURR PROTOC HUM GENE, V0, P0
   Foury Francoise, 2007, METHODS MOL BIOL, V372, P167, DOI 10.1007/978-1-59745-365-3_12
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   Kurt B, 2010, ARCH NEUROL-CHICAGO, V67, P239, DOI 10.1001/archneurol.2009.332
   Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   SLONIMSKI PP, 1976, EUR J BIOCHEM, V61, P27, DOI 10.1111/j.1432-1033.1976.tb09994.x
   SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313
   SOR F, 1982, NUCLEIC ACIDS RES, V11, P1625
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   STEWART JD, 1900, DOI 10.1002/HEP.23891, V0, P0
   Stricker S, 2009, J NEUROL NEUROSUR PS, V80, P1181, DOI 10.1136/jnnp.2008.166066
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Tzoulis C, 2010, BRAIN, V133, P1428, DOI 10.1093/brain/awq067
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 36
TC 21
Z9 23
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN 15
PY 2011
VL 11
IS 1
BP 182
EP 190
DI 10.1016/j.mito.2010.09.007
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 709OP
UT WOS:000286450300025
PM 20883824
DA 2024-11-01
ER

PT J
AU Houshmand, M
   Montazeri, M
   Kuchekian, N
   Noohi, F
   Nozar, G
   Zamani, A
AF Houshmand, Massoud
   Montazeri, Maryam
   Kuchekian, Nafiseh
   Noohi, Freidoon
   Nozar, Givtaj
   Zamani, Akram
TI Is 8860 variation a rare polymorphism or associated as a secondary effect in HCM disease?
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE hypertrophic cardiomyopathy; mtDNA mutation disease
ID human mitochondrial-dna; red fibers merrf; hypertrophic cardiomyopathy; idiopathic cardiomyopathy; myoclonic epilepsy; skeletal-muscle; lactic-acidosis; episodes melas; mutation; gene
AB Introduction: mtDNA defects, both deletions and point mutations, have been associated with hypertrophic cardiomyopathies. The aim of this study was to establish a spectrum for mtDNA mutations in Iranian hypertrophic cardiomyopathy (HCM) patients. Material and methods: The control group was chosen among the special medical centre visitors who did not have hypertrophic cardiomyopathy or any related heart disease. Hypertrophic cardiomyopathy (HCM) is widely accepted as a pluricausal or multifactorial disease. Because of the linkage between energy metabolism in the mitochondria and cardiac muscle contraction, it is reasonable to assume that mitochondrial abnormalities may be responsible for some forms of HCM. Point mutations and deletions in the two hot spot regions of mtDNA were investigated by PCR and sequencing methods. Results: Some unreported point mutations have been found in this study but no deletion was detected. Meanwhile some of these point mutations have been investigated among HCM patients for the first time. Conclusions: A8860G transition was detected in a high proportion, raising the question whether this rare polymorphism is associated as a secondary effect in HCM disease.
C1 [Houshmand, Massoud; Montazeri, Maryam] Natl Inst Genet Engn & Biotechnol, Tehran, Iran.
   [Kuchekian, Nafiseh; Zamani, Akram] Special Med Ctr, Tehran, Iran.
   [Noohi, Freidoon; Nozar, Givtaj] Iran Univ Med Sci, Shaheed Rajaei Cardiovasc Med Ctr, Tehran, Iran.
C3 Iran University of Medical Sciences; Rajaei Cardiovascular Medical & Research Center
RP Houshmand, M (corresponding author), Natl Inst Genet Engn & Biotechnol, Tehran, Iran.
EM massoudh@nigeb.ac.ir
FU National Institute for Genetic Engineering and Biotechnology, Ministry of Science, Research and Technology, Tehran, Iran [227]
CR Ahari SE, 2007, CELL MOL NEUROBIOL, V27, P695, DOI 10.1007/s10571-007-9160-2
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Fauser S, 2002, BIOCHEM BIOPH RES CO, V295, P342, DOI 10.1016/S0006-291X(02)00672-1
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Houshmand M, 2006, MITOCHONDRION, V6, P82, DOI 10.1016/j.mito.2006.01.005
   Kirk R, 1999, AM J HUM GENET, V65, P508, DOI 10.1086/302507
   KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107
   Lee MS, 2002, MITOCHONDRION, V1, P321, DOI 10.1016/S1567-7249(01)00031-9
   Marian AJ, 2002, CURR OPIN CARDIOL, V17, P242, DOI 10.1097/00001573-200205000-00006
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Montazeri Maryam, 2005, IRANIAN JOURNAL OF BIOTECHNOLOGY, V3, P157
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Mostafaie N, 2004, J NEURAL TRANSM, V111, P1155, DOI 10.1007/s00702-004-0161-8
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Turner LF, 1998, EUR HEART J, V19, P1725, DOI 10.1053/euhj.1998.1125
NR 19
TC 17
Z9 17
U1 0
U2 1
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA WENEDOW ST 9-1, POZNAN, 61-614, POLAND
SN 1734-1922
EI 
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD APR 15
PY 2011
VL 7
IS 2
BP 242
EP 246
DI 10.5114/aoms.2011.22074
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 768EU
UT WOS:000290915100009
PM 22291763
DA 2024-11-01
ER

PT J
AU Marazziti, D
   Baroni, S
   Picchetti, M
   Landi, P
   Silvestri, S
   Vatteroni, E
   Dell'Osso, MC
AF Marazziti, D.
   Baroni, S.
   Picchetti, M.
   Landi, P.
   Silvestri, S.
   Vatteroni, E.
   Dell'Osso, M. Catena
TI Mitochondrial Alterations and Neuropsychiatric Disorders
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Mitochondria; ATP; Genetics; Mitochondrial Diseases; Schizophrenia; Mood Disorders; Anxiety Disorders; Autism; ADHD; Alzheimer's disease
ID complex-i activity; progressive external ophthalmoplegia; magnetic-resonance-spectroscopy; cytochrome-c-oxidase; stroke-like episodes; alzheimers-disease; oxidative damage; psychiatric-symptoms; multiple deletions; bipolar disorder
AB Mitochondria are membrane-enclosed organelle found in most eukaryotic cells, where they generate the majority of the cell's supply of adenosine triphosphate (ATP), used as a source of chemical energy. In addition, they are involved in a range of other processes, such as signalling, cellular differentiation, cell death, as well as the control of the cell cycle and cell growth. Mitochondria have been implicated in several neuropsychiatric disorders, in particular, depression, anxiety, schizophrenia, autism, and Alzheimer's dementia. Furthermore, the presence of mutations at the level of mitochondrial or nuclear DNA (mtDNA and nDNA, respectively) has been linked to personality disorders, behavioral disturbances, thought alterations, impulsivity, learning impairment, cognitive failures until dementia. The aim of this paper is to review the literature on the relationship between psychiatric symptoms or syndromes and mtDNA mutations or mitochondrial alterations, while highlighting novel therapeutic targets for a broad range of disorders.
C1 [Marazziti, D.; Baroni, S.; Picchetti, M.; Landi, P.; Silvestri, S.; Vatteroni, E.; Dell'Osso, M. Catena] Univ Pisa, Dipartimento Psichiatria Neurobiol Farmacol & Bio, I-56100 Pisa, Italy.
C3 University of Pisa
RP Marazziti, D (corresponding author), Univ Pisa, Dipartimento Psichiatria Neurobiol Farmacol & Bio, Via Roma 67, I-56100 Pisa, Italy.
EM dmarazzi@psico.med.unipi.it
CR Alberts B, 1983, MOL BIOL CELL 2, V0, P321
   ALTMANN R, 1890, ELEMENTARORGANISMEN, V0, P0
   Amemiya S, 2000, NEUROLOGY, V55, P600, DOI 10.1212/WNL.55.4.600
   Andreazza AC, 2010, ARCH GEN PSYCHIAT, V67, P360, DOI 10.1001/archgenpsychiatry.2010.22
   BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61
   BARON M, 1994, BIOL PSYCHIAT, V35, P757, DOI 10.1016/0006-3223(94)91135-5
   Beal MF, 2005, NEUROBIOL AGING, V26, P585, DOI 10.1016/j.neurobiolaging.2004.09.022
   Ben-Shachar D, 1999, INT J NEUROPSYCHOPH, V2, P245, DOI 10.1017/S1461145799001649
   Ben-Shachar D, 2004, BIOCHEM PHARMACOL, V67, P1965, DOI 10.1016/j.bcp.2004.02.015
   Benda C, 1898, ARCH ANAT PHYSIOL, V73, P393
   Berio A, 2002, PANMINERVA MED, V44, P265
   Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   Boles RG, 2005, AM J MED GENET B, V137B, P20, DOI 10.1002/ajmg.b.30199
   BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605
   Burnett BB, 2005, J AFFECT DISORDERS, V88, P109, DOI 10.1016/j.jad.2005.05.009
   Campos Y, 2001, J INHERIT METAB DIS, V24, P685, DOI 10.1023/A:1012719211505
   Castellani R, 2002, J NEUROSCI RES, V70, P357, DOI 10.1002/jnr.10389
   CAVELIER L, 1995, GENOMICS, V29, P217, DOI 10.1006/geno.1995.1234
   CHANG TS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1254, DOI 10.1001/archopht.1993.01090090106028
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   Chinnery PF, 1997, QJM-INT J MED, V90, P657, DOI 10.1093/qjmed/90.11.657
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   CORTOPASSI G, 1995, BBA-MOL BASIS DIS, V1271, P171, DOI 10.1016/0925-4439(95)00025-Y
   Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149
   Cutter WJ, 2003, J NEUROL NEUROSUR PS, V74, P837, DOI 10.1136/jnnp.74.7.837
   DEICKEN RF, 1995, J AFFECT DISORDERS, V33, P195, DOI 10.1016/0165-0327(94)00089-R
   DiMauro S, 1998, NEUROSCIENTIST, V4, P53, DOI 10.1177/107385849800400113
   Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116
   ELEFF SM, 1990, ANN NEUROL, V27, P626, DOI 10.1002/ana.410270607
   Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954
   Friedrich T, 2004, BBA-BIOENERGETICS, V1608, P1, DOI 10.1016/j.bbabio.2003.10.002
   Gardner A, 2003, ACTA PSYCHIAT SCAND, V107, P233, DOI 10.1034/j.1600-0447.2003.02188.x
   Giulivi C, 2010, JAMA-J AM MED ASSOC, V304, P2389, DOI 10.1001/jama.2010.1706
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6
   György H, 2006, CELL CALCIUM, V40, P553, DOI 10.1016/j.ceca.2006.08.016
   HART ZH, 1977, ARCH NEUROL-CHICAGO, V34, P180, DOI 10.1001/archneur.1977.00500150066013
   Henze K, 2003, NATURE, V426, P127, DOI 10.1038/426127a
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horsefield R, 2004, CURR PROTEIN PEPT SC, V5, P107, DOI 10.2174/1389203043486847
   Houshmand M, 2004, NEUROMUSCULAR DISORD, V14, P195, DOI 10.1016/j.nmd.2003.12.002
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Inagaki T, 1997, BIOL PSYCHIAT, V42, P1067, DOI 10.1016/S0006-3223(97)00351-X
   Iwamoto K, 2005, HUM MOL GENET, V14, P241, DOI 10.1093/hmg/ddi022
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   KALCKAR HERMAN, 1937, ENZYMOLOGIA HAGUE, V2, P47
   Kandel ER, 2021, PRINCIPLES OF NEURAL SCIENCE, VSixth, P0
   Karry R, 2004, BIOL PSYCHIAT, V55, P676, DOI 10.1016/j.biopsych.2003.12.012
   KATO T, 1995, PSYCHOL MED, V25, P557, DOI 10.1017/S003329170003347X
   Kato T, 1996, J AFFECT DISORDERS, V37, P67, DOI 10.1016/0165-0327(95)00050-X
   Kato T, 1998, J NEUROPSYCH CLIN N, V10, P133, DOI 10.1176/jnp.10.2.133
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   KENNEDY EP, 1949, J BIOL CHEM, V179, P957
   Kiejna A, 2002, MED SCI MONITOR, V8, P66
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Lambert JC, 2004, J MED GENET, V41, P104, DOI 10.1136/jmg.2003.005033
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Lindholm E, 1997, EUR J HUM GENET, V5, P406, DOI 10.1159/000484799
   Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066
   MARCHBANKS RM, 1995, BRIT J PSYCHIAT, V167, P293, DOI 10.1192/bjp.167.3.293
   McBride HM, 2006, CURR BIOL, V16, PR551, DOI 10.1016/j.cub.2006.06.054
   Melov S, 1999, NEUROBIOL AGING, V20, P565, DOI 10.1016/S0197-4580(99)00092-5
   Mendlewicz J, 1994, GENETIC STUDIES AFFE, V0, P0
   Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Miyaoka H, 1997, BIOL PSYCHIAT, V42, P524, DOI 10.1016/S0006-3223(97)00280-1
   Newman-Toker DE, 2003, ARCH OPHTHALMOL-CHIC, V121, P288
   Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003
   Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905
   Onishi H, 1997, BIOL PSYCHIAT, V41, P1137, DOI 10.1016/S0006-3223(97)00005-X
   Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425
   PALADE GE, 1952, ANAT RECORD, V114, P427, DOI 10.1002/ar.1091140304
   Pantelis C, 2005, SCHIZOPHRENIA BULL, V31, P672, DOI 10.1093/schbul/sbi034
   Praticò D, 2005, NEUROBIOL AGING, V26, P581, DOI 10.1016/j.neurobiolaging.2004.09.020
   Prayson RA, 1998, ARCH PATHOL LAB MED, V122, P978
   Prince JA, 2000, NEUROPSYCHOPHARMACOL, V22, P284, DOI 10.1016/S0893-133X(99)00111-6
   Rossier MF, 2006, CELL CALCIUM, V40, P155, DOI 10.1016/j.ceca.2006.04.020
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Schwartz M, 2003, BIOCHEM BIOPH RES CO, V310, P247, DOI 10.1016/j.bbrc.2003.09.037
   Shah NS, 2002, J CHILD NEUROL, V17, P369, DOI 10.1177/088307380201700511
   SHANSKE AL, 1993, NEUROMUSCULAR DISORD, V3, P191, DOI 10.1016/0960-8966(93)90058-R
   Sherwin BB, 2003, ENDOCR REV, V24, P133, DOI 10.1210/er.2001-0016
   Shinkai T, 2000, AUST NZ J PSYCHIAT, V34, P1034, DOI 10.1080/000486700286
   SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942
   Spellberg B, 2001, ARCH INTERN MED, V161, P2497, DOI 10.1001/archinte.161.20.2497
   STEWART J B, 1990, MEDICAL SCIENCE RESEARCH, V18, P265
   Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0
   Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suzuki Y, 1997, MOL ASPECTS MED, V18, P0
   SWEENEY MG, 1993, Q J MED, V86, P709
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   TOROK TL, 1989, PROG NEUROBIOL, V32, P11, DOI 10.1016/0301-0082(89)90027-0
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Varvogli L, 1999, J INHERIT METAB DIS, V22, P615, DOI 10.1023/A:1005521828360
   Voet D, 2006, FUNDAMENTALS BIOCH, V0, P0
   WALLACE DC, 1994, EPILEPSIA, V35, PS43, DOI 10.1111/j.1528-1157.1994.tb05928.x
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace DC, 1997, MITOCHONDRIA FREE RA, V0, P283
   Wang XL, 2008, P NATL ACAD SCI USA, V105, P19318, DOI 10.1073/pnas.0804871105
   Warburg O, 1913, PFLUG ARCH GES PHYS, V154, P599, DOI 10.1007/BF01681207
   Wei YH, 1996, ANN NY ACAD SCI, V786, P24, DOI 10.1111/j.1749-6632.1996.tb39049.x
   WOLFF DJ, 1977, J BIOL CHEM, V252, P4108
   Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 114
TC 36
Z9 38
U1 1
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD OCT 15
PY 2011
VL 18
IS 30
BP 4715
EP 4721
DI 10.2174/092986711797379221
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 875EC
UT WOS:000299012200009
PM 21864278
DA 2024-11-01
ER

PT J
AU Greaves, LC
   Barron, MJ
   Campbell-Shiel, G
   Kirkwood, TBL
   Turnbull, DM
AF Greaves, Laura C.
   Barron, Martin J.
   Campbell-Shiel, George
   Kirkwood, Thomas B. L.
   Turnbull, Douglass M.
TI Differences in the accumulation of mitochondrial defects with age in mice and humans
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Mitochondria; Colonic epithelium; Ciliary epithelium; Ageing
ID dna mutations; stem-cells; intestinal crypts; deletions; disease; cancer; fibers; muscle; mouse
AB Mitochondrial DNA mutations and associated defects in cytochrome c oxidase (COX) are proposed to play an important role in human ageing; however there have been limited studies on the frequency of these defects in normal mouse ageing. Here we compare COX-deficiency in two epithelial tissues; the colon and the ciliary epithelium, from human and mouse. The pattern of accumulation of COX-deficiency is similar in both tissues in the two species; however the frequency of colonic crypts with COX-deficiency in aged humans is significantly higher than in aged mice, whereas the levels of COX-deficiency in the ciliary epithelium are higher in the mouse than in humans. This suggests the impact of mitochondrial defects on normal ageing may differ significantly between species. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Greaves, Laura C.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Kirkwood, Thomas B. L.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Greaves, LC (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM laura.greaves@ncl.ac.uk; Martin.Barron@manchester.ac.uk; g.r.campbell-shiel@ncl.ac.uk; tom.kirkwood@ncl.ac.uk; doug.turnbull@newcastle.ac.uk
FU Wellcome Trust; Medical Research Council; Newcastle University Centre for Brain Ageing Vitality; BBSRC; EPSRC; ESRC; MRC as part of the crosscouncil Lifelong Health and Wellbeing Initiative; BBSRC Centre for Integrated Systems Biology of Ageing and Nutrition; MRC [G0601943, G0700718] Funding Source: UKRI
CR Blasco MA, 2005, EMBO J, V24, P1095, DOI 10.1038/sj.emboj.7600598
   Cottrell DA, 2001, NEUROPATH APPL NEURO, V27, P206, DOI 10.1046/j.1365-2990.2001.00315.x
   Fellous TG, 2009, HEPATOLOGY, V49, P1655, DOI 10.1002/hep.22791
   Guo XH, 2010, BBA-BIOENERGETICS, V1797, P1159, DOI 10.1016/j.bbabio.2010.04.005
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Martin K, 1998, EXP CELL RES, V241, P316, DOI 10.1006/excr.1998.4001
   Martin K, 1998, J CELL SCI, V111, P2297
   Mcdonald SAC, 2008, GASTROENTEROLOGY, V134, P500, DOI 10.1053/j.gastro.2007.11.035
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   OSullivan J, 2006, CANCER EPIDEM BIOMAR, V15, P573, DOI 10.1158/1055-9965.EPI-05-0542
   ROWLATT C, 1976, LABORATORY ANIMALS (LONDON), V10, P419, DOI 10.1258/002367776780956917
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
NR 16
TC 24
Z9 24
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0047-6374
EI 
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD NOV-DEC 15
PY 2011
VL 132
IS 11-12
BP 588
EP 591
DI 10.1016/j.mad.2011.10.004
PG 4
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 888CG
UT WOS:000299980800008
PM 22015485
DA 2024-11-01
ER

PT J
AU Smith, PM
   Lightowlers, RN
AF Smith, Paul M.
   Lightowlers, Robert N.
TI Altering the balance between healthy and mutated mitochondrial DNA
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID targeted restriction-endonuclease; human-cells; heteroplasmy; expression; disease; single; gene; myopathy; disorders; deletions
AB Pathogenic mutations of the mitochondrial genome are frequently found to co-exist with wild-type mtDNA molecules, a state known as heteroplasmy. In most disease cases, the mutation is recessive with manifestation of a clinical phenotype occurring when the proportion of mutated mtDNA exceeds a high threshold. The concept of increasing the ratio of healthy to mutated mtDNA as a means to correcting the biochemical defect has received much attention. A number of strategies are highlighted in this article, including manipulation of the mitochondrial genome by antigenomic drugs or restriction endonucleases, zinc finger peptide-targeted nucleases and exercise-induced gene shifting. The feasibility of these approaches has been demonstrated in a number of models, however more work is necessary before use in human patients.
C1 [Smith, Paul M.; Lightowlers, Robert N.] Med Sch Newcastle Upon Tyne, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Smith, PM (corresponding author), Med Sch Newcastle Upon Tyne, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM Paul.smith@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bacman SR, 2007, GENE THER, V14, P1309, DOI 10.1038/sj.gt.3302981
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Dassa EP, 2009, EMBO MOL MED, V1, P30, DOI 10.1002/emmm.200900001
   KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Minczuk M, 2008, NUCLEIC ACIDS RES, V36, P3926, DOI 10.1093/nar/gkn313
   Minczuk M, 2006, P NATL ACAD SCI USA, V103, P19689, DOI 10.1073/pnas.0609502103
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Ross GF, 2003, BIOCONJUGATE CHEM, V14, P962, DOI 10.1021/bc034050f
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Smith PM, 2004, BBA-BIOENERGETICS, V1659, P232, DOI 10.1016/j.bbabio.2004.09.003
   Spelbrink JN, 1997, CURR GENET, V32, P115, DOI 10.1007/s002940050255
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Srivastava S, 2009, HUM MOL GENET, V18, P1805, DOI 10.1093/hmg/ddp093
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
NR 25
TC 22
Z9 26
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD APR 15
PY 2011
VL 34
IS 2
BP 309
EP 313
DI 10.1007/s10545-010-9122-6
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 739YI
UT WOS:000288757700008
PM 20506041
DA 2024-11-01
ER

PT J
AU Compton, AG
   Troedson, C
   Wilson, M
   Procopis, PG
   Li, FY
   Brundage, EK
   Yamazaki, T
   Thorburn, DR
   Wong, LJC
AF Compton, Alison G.
   Troedson, Christopher
   Wilson, Meredith
   Procopis, Peter G.
   Li, Fang-Yuan
   Brundage, Ellen K.
   Yamazaki, Taro
   Thorburn, David R.
   Wong, Lee-Jun C.
TI Application of oligonucleotide array CGH in the detection of a large intragenic deletion in <i>POLG</i> associated with Alpers Syndrome
SO MITOCHONDRION
LA English
DT Article
DE POLG; Array CGH; Intragenic deletion; Alpers syndrome
ID progressive external ophthalmoplegia; comparative genomic hybridization; mitochondrial-dna depletion; polymerase-gamma; mutations
AB Mutations in the polymerase gamma (POLG) gene are among the most common causes of mitochondrial disease and more than 160 POLG mutations have been reported. However, a large proportion of patients suspected of having POLG mutations only have one (heterozygous) definitive pathogenic mutation identified. Using oligonucleotide array CGH, we identified a compound heterozygous large intragenic deletion encompassing exons 15-21 of this gene in a child with Alpers syndrome due to mtDNA depletion. This is the first large POLG deletion reported and the findings show the clinical utility of using array CGH in cases where a single heterozygous mutation has been identified in POLG. (C) 2010 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Compton, Alison G.; Yamazaki, Taro; Thorburn, David R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   [Compton, Alison G.; Yamazaki, Taro; Thorburn, David R.] Royal Childrens Hosp, Genet Hlth Serv Victoria, Parkville, Vic 3052, Australia.
   [Troedson, Christopher; Procopis, Peter G.] Childrens Hosp Westmead, TY Nelson Dept Neurol, Sydney, NSW, Australia.
   [Wilson, Meredith] Univ Sydney, Western Sydney Genet Program, Childrens Hosp Westmead, Sydney, NSW 2006, Australia.
   [Wilson, Meredith] Univ Sydney, Discipline Paediat, Sydney, NSW 2006, Australia.
   [Wilson, Meredith] Univ Sydney, Discipline Child Hlth & Genet Med, Sydney, NSW 2006, Australia.
   [Li, Fang-Yuan; Brundage, Ellen K.; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Yamazaki, Taro] Saitama Med Univ, Dept Pediat, Sch Med, Saitama, Japan.
   [Thorburn, David R.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
C3 Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; NSW Health; The Children's Hospital at Westmead; University of Sydney; University of Sydney; NSW Health; The Children's Hospital at Westmead; University of Sydney; University of Sydney; Baylor College of Medicine; Saitama Medical University; University of Melbourne
RP Thorburn, DR (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM david.thorburn@mcri.edu.au
FU Australian National Health and Medical Research Council
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Lamandé SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 13
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN 15
PY 2011
VL 11
IS 1
BP 104
EP 107
DI 10.1016/j.mito.2010.07.012
PG 4
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 709OP
UT WOS:000286450300015
PM 20708716
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Inherited mitochondrial neuropathies
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Review
DE Neuromuscular; Encephalomyopathy; Metabolic disease; Multisystem disease; Mitochondrial DNA; Neuropathy; Nerve conduction
ID kearns-sayre-syndrome; marie-tooth-disease; onset spinocerebellar ataxia; hereditary optic neuropathy; progressive external ophthalmoplegia; neurogastrointestinal encephalomyopathy mngie; sensory-motor neuropathy; c-oxidase deficiency; leigh-syndrome; peripheral neuropathy
AB Mitochondrial disorders (MIDs) occasionally manifest as polyneuropathy either as the dominant feature or as one of many other manifestations (inherited mitochondrial neuropathy). MIDs in which polyneuropathy is the dominant feature, include NARP syndrome due to the transition m.8993T>, CMT2A due to MFN2 mutations, CMT2K and CMT4A due to GDAP1 mutations, and axonal/demyelinating neuropathy with external ophthalmoplegia due to POLG1 mutations. MIDs in which polyneuropathy is an inconstant feature among others is the MELAS syndrome, MERRF syndrome, LHON, Mendelian PEO, KSS, Leigh syndrome, MNGIE, SANDO; MIRAS, MEMSA, AHS, MDS (hepato-cerebral form), IOSCA, and ADOA syndrome. In the majority of the cases polyneuropathy presents in a multiplex neuropathy distribution. Nerve conduction studies may reveal either axonal or demyelinated or mixed types of neuropathies. If a hereditary neuropathy is due to mitochondrial dysfunction, the management of these patients is at variance from non-mitochondrial hereditary neuropathies. Patients with mitochondrial hereditary neuropathy need to be carefully investigated for clinical or subclinical involvement of other organs or systems. Supportive treatment with co-factors, antioxidants, alternative energy sources, or lactate lowering agents can be tried. Involvement of other organs may require specific treatment. Mitochondrial neuropathies should be included in the differential diagnosis of hereditary neuropathies. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Al-Dosary M, 2009, NEUROMUSCULAR DISORD, V19, P841, DOI 10.1016/j.nmd.2009.10.001
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   [Anonymous], 2003, GENEREVIEWS, V0, P0
   [Anonymous], 2000, GENEREVIEWS, V0, P0
   APPENZELLER O, 1976, ARCH NEUROL-CHICAGO, V33, P733, DOI 10.1001/archneur.1976.00500110001001
   Bedlack RS, 2004, MUSCLE NERVE, V29, P364, DOI 10.1002/mus.10546
   Bhatti MT, 1999, J NEURO-OPHTHALMOL, V19, P28
   Cassereau J, 2011, EXP NEUROL, V227, P31, DOI 10.1016/j.expneurol.2010.09.006
   Cassereau J, 2009, NEUROGENETICS, V10, P145, DOI 10.1007/s10048-008-0166-9
   CHABROL B, 1994, J CHILD NEUROL, V9, P52, DOI 10.1177/088307389400900113
   Childs AM, 2007, NEUROPEDIATRICS, V38, P313, DOI 10.1055/s-2008-1065355
   Chu CC, 1997, EUR NEUROL, V37, P110, DOI 10.1159/000117420
   COKER SB, 1993, PEDIATR NEUROL, V9, P61, DOI 10.1016/0887-8994(93)90013-3
   Colomer J, 2000, REV NEUROLOGIA, V30, P1117, DOI 10.33588/rn.3012.2000079
   Consalvo D, 1997, MEDICINA-BUENOS AIRE, V57, P67
   Corrado G, 2006, CARDIOLOGY, V105, P142, DOI 10.1159/000091152
   Crimella C, 2010, J MED GENET, V47, P712, DOI 10.1136/jmg.2010.077909
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Debouverie M, 1997, REV NEUROL, V153, P547
   Debray FG, 2007, AM J MED GENET A, V143A, P2046, DOI 10.1002/ajmg.a.31880
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   DiTrapani G, 1997, CLIN NEUROPATHOL, V16, P195
   Erol I, 2009, NEUROMUSCULAR DISORD, V19, P275, DOI 10.1016/j.nmd.2009.01.012
   EYMARD B, 1991, REV NEUROL, V147, P508
   Finsterer J, 2005, CLIN NEUROL NEUROSUR, V107, P181, DOI 10.1016/j.clineuro.2004.07.001
   Finsterer J, 2009, EUR J NEUROL, V16, P1255, DOI 10.1111/j.1468-1331.2009.02811.x
   Funalot B, 2009, REV NEUROL-FRANCE, V165, P1118, DOI 10.1016/j.neurol.2009.10.001
   Funalot B, 2009, B ACAD NAT MED PARIS, V193, P151, DOI 10.1016/S0001-4079(19)32613-5
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Gelfand JM, 2011, J NEUROL, V258, P440, DOI 10.1007/s00415-010-5775-1
   Gilhuis HJ, 2006, NEUROMUSCULAR DISORD, V16, P394, DOI 10.1016/j.nmd.2006.03.006
   GOEBEL HH, 1986, MUSCLE NERVE, V9, P165, DOI 10.1002/mus.880090210
   Gómez-Zaera M, 2001, MOL GENET METAB, V72, P72, DOI 10.1006/mgme.2000.3107
   Gordon N, 2006, DEV MED CHILD NEUROL, V48, P1001, DOI 10.1017/S0012162206002209
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hakonen Anna H, 2010, DUODECIM, V126, P1552
   Hamano H, 1997, RINSHO SHINKEIGAKU, V37, P917
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   HIRANO M, 1996, HDB MUSCLE DIS, V1, P479
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hourani RG, 2006, NEUROPEDIATRICS, V37, P110, DOI 10.1055/s-2006-924226
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   JACOBS JM, 1990, BRAIN, V113, P447, DOI 10.1093/brain/113.2.447
   JOHNSEN SD, 1993, NEUROLOGY, V43, P1120, DOI 10.1212/WNL.43.6.1120
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Klimek Andrzej, 1997, POLISH JOURNAL OF PATHOLOGY, V48, P197
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Lamperti C, 2009, ACTA MYOL, V28, P2
   Lawlor M W, 2000, ELECTROMYOGR CLIN NEUROPHYSIOL, V40, P211
   Liguori M, 2008, J NEUROL, V255, P127, DOI 10.1007/s00415-008-0571-x
   Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.3.CO;2-B
   Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Malandrini A, 1998, J NEUROL SCI, V155, P218, DOI 10.1016/S0022-510X(98)00014-8
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mano Atsushi, 2003, RINSHO SHINKEIGAKU, V43, P564
   McDonald DGM, 2002, AM J MED GENET, V111, P191, DOI 10.1002/ajmg.10522
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Misko A, 2010, J NEUROSCI, V30, P4232, DOI 10.1523/JNEUROSCI.6248-09.2010
   MIZUSAWA H, 1991, REV NEUROL, V147, P501
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Nagashima T, 2001, NEUROMUSCULAR DISORD, V11, P470, DOI 10.1016/S0960-8966(01)00190-0
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   Naumann M, 1997, MUSCLE NERVE, V20, P833, DOI 10.1002/(SICI)1097-4598(199707)20:7<833::AID-MUS7>3.0.CO;2-8
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Niemann A, 2009, NEUROBIOL DIS, V36, P509, DOI 10.1016/j.nbd.2009.09.011
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   Okun MS, 2004, AM J OPHTHALMOL, V137, P951, DOI 10.1016/j.ajo.2003.10.046
   Pedrola L, 2005, HUM MOL GENET, V14, P1087, DOI 10.1093/hmg/ddi121
   Peng Y, 2003, MOVEMENT DISORD, V18, P716, DOI 10.1002/mds.10428
   Riera ARP, 2008, J ELECTROCARDIOL, V41, P675, DOI 10.1016/j.jelectrocard.2008.04.001
   Posada IJ, 2010, MED CLIN-BARCELONA, V135, P452, DOI 10.1016/j.medcli.2010.03.031
   Poulton J, 1998, AM J HUM GENET, V62, P752, DOI 10.1086/301811
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Reilly MM, 2009, J NEUROL NEUROSUR PS, V80, P1304, DOI 10.1136/jnnp.2008.158295
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   RUSANEN H, 1995, NEUROLOGY, V45, P1188, DOI 10.1212/WNL.45.6.1188
   Sahin-Calapoglu N, 2009, NEUROMOL MED, V11, P106, DOI 10.1007/s12017-009-8062-5
   Said G, 2005, J NEUROL, V252, P655, DOI 10.1007/s00415-005-0712-4
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   Santoro L, 2006, J NEUROL, V253, P869, DOI 10.1007/s00415-006-0082-6
   Schoffer K, 2006, MUSCLE NERVE, V33, P142, DOI 10.1002/mus.20406
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spiegel R, 2009, ANN NEUROL, V66, P419, DOI 10.1002/ana.21752
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Stickler DE, 2003, J CHILD NEUROL, V18, P574, DOI 10.1177/08830738030180081101
   Tsao CY, 2001, J CHILD NEUROL, V16, P533, DOI 10.1177/088307380101600716
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Uusimaa J, 2003, PEDIATRICS, V111, P0, DOI 10.1542/peds.111.3.e262
   van de Glind G, 2007, EUR J PAEDIATR NEURO, V11, P243, DOI 10.1016/j.ejpn.2007.01.004
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Voo I, 2003, AM J OPHTHALMOL, V136, P670, DOI 10.1016/S0002-9394(03)00390-8
   Wagner KM, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005160
   Watanabe Yuka, 2009, BRAIN AND NERVE (TOKYO), V61, P309
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   Wiedemann FR, 2008, CLIN NEUROL NEUROSUR, V110, P859, DOI 10.1016/j.clineuro.2008.06.010
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Zanssen S, 1998, CLIN NEUROPATHOL, V17, P291
   Zoccolella S, 2006, FUNCT NEUROL, V21, P39
NR 121
TC 46
Z9 49
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAY 15
PY 2011
VL 304
IS 1-2
BP 9
EP 16
DI 10.1016/j.jns.2011.02.012
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 757GD
UT WOS:000290072600002
PM 21402391
DA 2024-11-01
ER

PT J
AU Alway, SE
   Siu, PM
AF Alway, Stephen E.
   Siu, Parco M.
TI Nuclear Apoptosis and Sarcopenia
SO SARCOPENIA-AGE-RELATED MUSCLE WASTING AND WEAKNESS: MECHANISMS AND TREATMENTS
LA English
DT Article; Book Chapter
DE Nuclear cell death; Apoptosis; Skeletal myofiber; Satellite cell; Mitochondria; Muscle atrophy
ID necrosis-factor-alpha; nf-kappa-b; cytochrome-c release; permeability transition pore; mitochondrial-dna mutations; skeletal-muscle apoptosis; programmed cell-death; bcl-2 family proteins; chronic heart-failure; x-linked inhibitor
AB Apoptosis is a well-conserve cellular disassembly process, which has been implicated in a variety of diseases. Unlike cells with a single nucleus, apoptotic signaling can target individual nuclei in multi-nucleated skeletal muscle cells without necessarily eliminating the entire cell (muscle fiber). This targeted apoptosis or "nuclear apoptosis" appears to have a role in regulating aging-induced muscle loss (sarcopenia) by reducing the myofiber volume (i.e. cytoplasm) that can be supported in a single muscle fibre. Recent investigations indicate that apoptotic signaling in aged skeletal muscles occurs through three apoptotic pathways. The intrinsic or mitochondria apoptotic pathway has been most widely studied in muscle. Mitochondria dysfunction and increased mitochondria permeability lead to activation of cysteine-aspartic acid proteases (caspases) and eventually DNA fragmentation in sarcopenia. The death receptor (extrinsic) apoptotic pathway has been strongly implicated in sarcopenia and other conditions of muscle loss with aging or disuse. TNF-alpha is thought to initiate apoptotic signaling via the death receptor, and this can proceed to activate the effort proteases (e.g., caspase 3) independent from mitochondria signaling. Nevertheless, there is some cross-talk between the intrinsic and the extrinsic apoptotic pathways. Finally, a few studies have shown data to suggest that the endoplasmic reticulum-stress apoptotic pathway may also have a role in sarcopenia, although the importance of this pathway relative to the other two pathways is less clear. Both myonuclei and satellite cells appear to be susceptible to nuclear apoptosis in sarcopenia.
C1 [Alway, Stephen E.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Exercise Physiol, Morgantown, WV 26506 USA.
   [Alway, Stephen E.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Ctr Cardiovasc & Resp Sci, Morgantown, WV 26506 USA.
   [Siu, Parco M.] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China.
C3 West Virginia University; West Virginia University; Hong Kong Polytechnic University
RP Alway, SE (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Exercise Physiol, 1 Med Ctr Dr, Morgantown, WV 26506 USA.
EM salway@hsc.wvu.edu; htpsiu@inet.polyu.edu.hk
CR Abmayr S, 2004, HUM MOL GENET, V13, P213, DOI 10.1093/hmg/ddh018
   Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2
   Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, PC1182, DOI 10.1152/ajpcell.00173.2002
   Adams V, 1999, J AM COLL CARDIOL, V33, P959, DOI 10.1016/S0735-1097(98)00626-3
   Adams V, 2008, FRONT BIOSCI-LANDMRK, V13, P302, DOI 10.2741/2680
   Adhihetty PJ, 2008, EXERC SPORT SCI REV, V36, P116, DOI 10.1097/JES.0b013e31817be7b7
   Adhihetty PJ, 2007, J APPL PHYSIOL, V102, P1143, DOI 10.1152/japplphysiol.00768.2006
   Adhihetty PJ, 2007, AM J PHYSIOL-ENDOC M, V292, PE748, DOI 10.1152/ajpendo.00311.2006
   Adhihetty PJ, 2009, AM J PHYSIOL-CELL PH, V297, PC217, DOI 10.1152/ajpcell.00070.2009
   Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505
   Adhihetty PJ, 2003, BAM PADOVA, V13, P171
   Allen DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8
   Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, PC579, DOI 10.1152/ajpcell.1997.273.2.C579
   ALWAY SE, 1989, J APPL PHYSIOL, V66, P2725, DOI 10.1152/jappl.1989.66.6.2725
   Alway SE, 1996, J GERONTOL A-BIOL, V51, PB195, DOI 10.1093/gerona/51A.3.B195
   Alway SE, 2003, J GERONTOL A-BIOL, V58, P687
   Alway SE, 2003, AM J PHYSIOL-REG I, V284, PR540, DOI 10.1152/ajpregu.00550.2002
   Alway SE, 2002, AM J PHYSIOL-REG I, V282, PR411, DOI 10.1152/ajpregu.00332.2001
   Alway SE, 2002, AM J PHYSIOL-CELL PH, V283, PC66, DOI 10.1152/ajpcell.00598.2001
   ALWAY SE, 1991, J APPL PHYSIOL, V70, P2111, DOI 10.1152/jappl.1991.70.5.2111
   Alway SE, 2008, EXERC SPORT SCI REV, V36, P51, DOI 10.1097/JES.0b013e318168e9dc
   Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271
   Attaix D, 2005, ESSAYS BIOCHEM, V41, P173, DOI 10.1042/EB0410173
   Basañez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492
   Benayoun B, 2008, FASEB J, V22, P1521, DOI 10.1096/fj.07-8701com
   Bernardi P, 1999, ITAL J NEUROL SCI, V20, P395
   Bhuiyan MS, 2007, EUR J PHARMACOL, V557, P168, DOI 10.1016/j.ejphar.2006.10.067
   Blink E, 2004, CELL DEATH DIFFER, V11, P937, DOI 10.1038/sj.cdd.4401409
   Bourdel-Marchasson I, 2007, J NUTR HEALTH AGING, V11, P215
   Brack AS, 2007, STEM CELL REV, V3, P226, DOI 10.1007/s12015-007-9000-2
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Brack AS, 2005, J CELL SCI, V118, P4813, DOI 10.1242/jcs.02602
   Bruunsgaard H, 1999, J GERONTOL A-BIOL, V54, PM357, DOI 10.1093/gerona/54.7.M357
   Bruunsgaard H, 2002, EUR CYTOKINE NETW, V13, P389
   Bruunsgaard H, 2003, CLIN EXP IMMUNOL, V132, P24, DOI 10.1046/j.1365-2249.2003.02137.x
   Bruunsgaard H, 2003, AM J MED, V115, P278, DOI 10.1016/S0002-9343(03)00329-2
   Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001
   Bruusgaard JC, 2006, J APPL PHYSIOL, V100, P2024, DOI 10.1152/japplphysiol.00913.2005
   Burstein E, 2003, CURR OPIN CELL BIOL, V15, P732, DOI 10.1016/j.ceb.2003.10.005
   Cacciapaglia F, 2009, EUR REV MED PHARMACO, V13, P23
   Campisi J, 2009, J GERONTOL A-BIOL, V64, P164, DOI 10.1093/gerona/gln073
   Candé C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210
   Candé C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3
   Carbó N, 2002, BRIT J CANCER, V86, P1012, DOI 10.1038/sj.bjc.6600167
   Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5
   Chabi B, 2008, AGING CELL, V7, P2, DOI 10.1111/j.1474-9726.2007.00347.x
   Chakravarthy MV, 2001, CELL MOL LIFE SCI, V58, P1150, DOI 10.1007/PL00000929
   Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000
   Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395
   CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821
   CHARETTE SL, 1991, J APPL PHYSIOL, V70, P1912, DOI 10.1152/jappl.1991.70.5.1912
   Chipuk JE, 2009, CELL CYCLE, V8, P2692, DOI 10.4161/cc.8.17.9412
   Chowdhury I, 2008, COMP BIOCHEM PHYS B, V151, P10, DOI 10.1016/j.cbpb.2008.05.010
   Combaret L, 2009, CURR OPIN CLIN NUTR, V12, P37, DOI 10.1097/MCO.0b013e32831b9c31
   Conley KE, 2007, EXERC SPORT SCI REV, V35, P43
   Conley KE, 2007, EXP PHYSIOL, V92, P333, DOI 10.1113/expphysiol.2006.034330
   Conraads VM, 2009, EUR J CARDIOV PREV R, V16, P325, DOI 10.1097/HJR.0b013e3283244436
   Dali-Youcef N, 2007, ANN MED, V39, P335, DOI 10.1080/07853890701408194
   DALLA L, 2009, INT J CARDIOL, V143, P192
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Daussin FN, 2008, J APPL PHYSIOL, V104, P1436, DOI 10.1152/japplphysiol.01135.2007
   Degens H, 2007, JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, V7, P246
   Degens H, 2003, MUSCLE NERVE, V27, P339, DOI 10.1002/mus.10314
   Degens H, 2007, AM J PHYSIOL-REG I, V293, PR135, DOI 10.1152/ajpregu.00046.2007
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Dejean LM, 2006, CELL DEATH DIFFER, V13, P1387, DOI 10.1038/sj.cdd.4401949
   Dejean LM, 2006, BBA-MOL BASIS DIS, V1762, P191, DOI 10.1016/j.bbadis.2005.07.002
   Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.e04-12-1111
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   Deschenes MR, 2002, AM J PHYS MED REHAB, V81, PS3, DOI 10.1097/01.PHM.0000029722.06777.E9
   Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215
   Dirks A, 2002, AM J PHYSIOL-REG I, V282, PR519, DOI 10.1152/ajpregu.00458.2001
   Dirks AJ, 2005, SPORTS MED, V35, P473, DOI 10.2165/00007256-200535060-00002
   Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003
   Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, PC1208, DOI 10.1152/ajpcell.00226.2006
   Dirks AJ, 2006, J NUTR BIOCHEM, V17, P501, DOI 10.1016/j.jnutbio.2005.11.002
   Dirks AJ, 2006, AGEING RES REV, V5, P179, DOI 10.1016/j.arr.2006.03.002
   Duke RC, 1996, SCI AM, V275, P80, DOI 10.1038/scientificamerican1296-80
   Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938
   Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383
   ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663
   Er E, 2007, J BIOL CHEM, V282, P24938, DOI 10.1074/jbc.M703823200
   Fan YJ, 2008, ADV EXP MED BIOL, V615, P223, DOI 10.1007/978-1-4020-6554-5_11
   Ferketich AK, 1998, ACTA PHYSIOL SCAND, V164, P259
   Figueras M, 2005, INT J ONCOL, V27, P855
   Forsey RJ, 2003, MECH AGEING DEV, V124, P487, DOI 10.1016/S0047-6374(03)00025-3
   Forte M, 2006, CELL DEATH DIFFER, V13, P1287, DOI 10.1038/sj.cdd.4401957
   Foulstone EJ, 2001, J CELL PHYSIOL, V189, P207, DOI 10.1002/jcp.10017
   GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V
   GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829
   GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848
   Ghosh AP, 2009, J NEUROPATH EXP NEUR, V68, P747, DOI 10.1097/NEN.0b013e3181a9d524
   Gorman AM, 2000, DEV NEUROSCI-BASEL, V22, P348, DOI 10.1159/000017460
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005
   Grütter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9
   Gustafsson ÅB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200
   Hagen JL, 2004, J GERONTOL A-BIOL, V59, P1099, DOI 10.1093/gerona/59.11.1099
   Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HARMAN D, 1992, ANN NY ACAD SCI, V673, P126, DOI 10.1111/j.1749-6632.1992.tb27444.x
   Harman D, 2009, BIOGERONTOLOGY, V10, P773, DOI 10.1007/s10522-009-9234-2
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200
   Heikaus S, 2008, APOPTOSIS, V13, P938, DOI 10.1007/s10495-008-0225-6
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   Hu AH, 2008, REJUV RES, V11, P215, DOI 10.1089/rej.2007.0609
   Huang ZT, 2008, FREE RADICAL BIO MED, V44, P1935, DOI 10.1016/j.freeradbiomed.2008.02.016
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Jejurikar SS, 2002, PLAST RECONSTR SURG, V110, P160, DOI 10.1097/00006534-200207000-00027
   Jin HM, 2001, J TRAUMA, V50, P31, DOI 10.1097/00005373-200101000-00005
   Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13
   Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005
   Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004
   Jubrias SA, 2001, J APPL PHYSIOL, V90, P1663, DOI 10.1152/jappl.2001.90.5.1663
   Kadenbach B, 2009, TRENDS MOL MED, V15, P139, DOI 10.1016/j.molmed.2009.02.004
   Kearns JD, 2009, J BIOL CHEM, V284, P5439, DOI 10.1074/jbc.R800008200
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Knudson CMichael, 2008, V414, V0, P95
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Korsmeyer SJ, 1999, CANCER RES, V59, P0
   KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1
   KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R
   Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156
   Krajnak K, 2006, MUSCLE NERVE, V34, P720, DOI 10.1002/mus.20656
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kujoth GC, 2006, CANCER RES, V66, P7386, DOI 10.1158/0008-5472.CAN-05-4670
   Kwak HB, 2006, FASEB J, V20, P791, DOI 10.1096/fj.05-5116fje
   Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1
   Lanza IR, 2008, DIABETES, V57, P2933, DOI 10.2337/db08-0349
   Lee DH, 2009, BRIT J PHARMACOL, V157, P1189, DOI 10.1111/j.1476-5381.2009.00245.x
   Lee HC, 2007, EXP BIOL MED, V232, P592
   Lee SC, 2007, INT J BIOCHEM CELL B, V39, P497, DOI 10.1016/j.biocel.2006.09.007
   Lees SJ, 2009, AGING CELL, V8, P26, DOI 10.1111/j.1474-9726.2008.00445.x
   Leeuwenburgh C, 2005, AM J PHYSIOL-REG I, V288, PR1288, DOI 10.1152/ajpregu.00576.2004
   Leeuwenburgh C, 2003, J GERONTOL A-BIOL, V58, P999
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Libera LD, 2001, J MOL CELL CARDIOL, V33, P1871, DOI 10.1006/jmcc.2001.1453
   Linke A, 2005, CIRCULATION, V111, P1763, DOI 10.1161/01.CIR.0000165503.08661.E5
   Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2
   Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827
   LLovera M, 1998, INT J MOL MED, V2, P69
   Ma YS, 2009, BBA-GEN SUBJECTS, V1790, P1021, DOI 10.1016/j.bbagen.2009.04.012
   Malinska D, 2009, METHOD ENZYMOL, V456, P419, DOI 10.1016/S0076-6879(08)04423-6
   Martin C, 2007, AGING CELL, V6, P165, DOI 10.1111/j.1474-9726.2007.00271.x
   Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005
   Marzetti E, 2008, FREE RADICAL BIO MED, V44, P160, DOI 10.1016/j.freeradbiomed.2007.05.028
   Marzetti E, 2008, AM J PHYSIOL-REG I, V294, PR558, DOI 10.1152/ajpregu.00620.2007
   Marzetti E, 2009, MECH AGEING DEV, V130, P272, DOI 10.1016/j.mad.2008.12.008
   MAYHEW DL, 2009, J APPL PHYS IN PRESS, V0, P0
   McCall GE, 1998, J APPL PHYSIOL, V84, P1407, DOI 10.1152/jappl.1998.84.4.1407
   McMullen CA, 2009, EXP GERONTOL, V44, P420, DOI 10.1016/j.exger.2009.03.006
   Meadows KA, 2000, J CELL PHYSIOL, V183, P330, DOI 10.1002/(SICI)1097-4652(200006)183:3<330::AID-JCP5>3.0.CO;2-N
   Meissner C, 2007, Z GERONTOL GERIATR, V40, P325, DOI 10.1007/s00391-007-0481-z
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Melov S, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000465
   Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200
   Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200
   Molina EJ, 2009, J SURG RES, V153, P287, DOI 10.1016/j.jss.2008.03.043
   Murray AJ, 2007, CURR OPIN CLIN NUTR, V10, P704, DOI 10.1097/MCO.0b013e3282f0ecbe
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887
   Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681
   Naylor AJD, 2008, EXERC SPORT SCI REV, V36, P19, DOI 10.1097/jes.0b013e31815ddd9d
   Nickson P, 2007, CARDIOVASC RES, V73, P48, DOI 10.1016/j.cardiores.2006.10.001
   Parise G, 2005, FREE RADICAL BIO MED, V39, P289, DOI 10.1016/j.freeradbiomed.2005.03.024
   Parise G, 2000, CURR OPIN CLIN NUTR METAB CARE, V3, P489, DOI 10.1097/00075197-200011000-00012
   Pedersen M, 2003, MECH AGEING DEV, V124, P495, DOI 10.1016/S0047-6374(03)00027-7
   Peterson JM, 2008, J APPL PHYSIOL, V105, P1934, DOI 10.1152/japplphysiol.00037.2008
   Phaneuf S, 2002, AM J PHYSIOL-REG I, V282, PR423, DOI 10.1152/ajpregu.00296.2001
   Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T
   Phillips T, 2005, FASEB J, V19, P668, DOI 10.1096/fj.04-2870fje
   Pistilli EE, 2006, J GERONTOL A-BIOL, V61, P245, DOI 10.1093/gerona/61.3.245
   Pistilli EE, 2008, BIOCHEM BIOPH RES CO, V373, P20, DOI 10.1016/j.bbrc.2008.05.188
   Pistilli EE, 2007, AM J PHYSIOL-CELL PH, V292, PC1298, DOI 10.1152/ajpcell.00496.2006
   Pistilli EE, 2006, APOPTOSIS, V11, P2115, DOI 10.1007/s10495-006-0194-6
   Podhorska-Okolow M, 1998, NEUROPATH APPL NEURO, V24, P518
   Podhorska-Okolow M, 1999, FOLIA HISTOCHEM CYTO, V37, P127
   Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x
   Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552
   Primeau AJ, 2002, CAN J APPL PHYSIOL, V27, P349, DOI 10.1139/h02-020
   Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y
   Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867
   Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X
   Renault V, 2002, EXP GERONTOL, V37, P1229, DOI 10.1016/S0531-5565(02)00129-8
   Ricci C, 2007, CAN J PHYSIOL PHARM, V85, P455, DOI 10.1139/Y07-029
   ROMAN WJ, 1993, J APPL PHYSIOL, V74, P750, DOI 10.1152/jappl.1993.74.2.750
   ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607
   Ryan MJ, 2008, J GERONTOL A-BIOL, V63, P1015, DOI 10.1093/gerona/63.10.1015
   Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830
   Sandmand M, 2003, GERONTOLOGY, V49, P155, DOI 10.1159/000069174
   Sandri M, 1997, J NEUROPATH EXP NEUR, V56, P45, DOI 10.1097/00005072-199701000-00005
   Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002
   Schaap LA, 2006, AM J MED, V119, P0, DOI 10.1016/j.amjmed.2005.10.049
   Schaap LA, 2009, J GERONTOL A-BIOL, V64, P1183, DOI 10.1093/gerona/glp097
   SCHULTZ E, 1989, MED SCI SPORT EXER, V21, P0
   Schultz E, 1996, DEV BIOL, V175, P84, DOI 10.1006/dbio.1996.0097
   SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904
   Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200
   Seo AY, 2008, AGING CELL, V7, P706, DOI 10.1111/j.1474-9726.2008.00418.x
   Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3
   Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804
   Shi YG, 2002, STRUCTURE, V10, P285, DOI 10.1016/S0969-2126(02)00732-3
   Shiha VFS, 2009, P NATL ACAD SCI USA, V106, P9619, DOI 10.1073/pnas.0812367106
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003
   Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399
   Siu PM, 2006, APOPTOSIS, V11, P967, DOI 10.1007/s10495-006-6315-4
   Siu PM, 2007, J MOL CELL CARDIOL, V42, P678, DOI 10.1016/j.yjmcc.2007.01.001
   Siu PM, 2009, FRONT BIOSCI-LANDMRK, V14, P432, DOI 10.2741/3253
   Siu PM, 2008, J APPL PHYSIOL, V105, P1695, DOI 10.1152/japplphysiol.90800.2008
   Siu PM, 2006, EXP GERONTOL, V41, P175, DOI 10.1016/j.exger.2005.11.004
   Siu PM, 2006, J APPL PHYSIOL, V100, P907, DOI 10.1152/japplphysiol.01012.2005
   Siu PM, 2005, AM J PHYSIOL-REG I, V289, PR1015, DOI 10.1152/ajpregu.00198.2005
   Siu PM, 2005, J GERONTOL A-BIOL, V60, P976, DOI 10.1093/gerona/60.8.976
   Siu PM, 2005, J APPL PHYSIOL, V99, P204, DOI 10.1152/japplphysiol.00084.2005
   Siu PM, 2005, J PHYSIOL-LONDON, V565, P309, DOI 10.1113/jphysiol.2004.081083
   Siu PM, 2005, AM J PHYSIOL-CELL PH, V288, PC338, DOI 10.1152/ajpcell.00239.2004
   Siu PM, 2004, FASEB J, V18, P0
   Smith MI, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005097
   Song W, 2006, ANTIOXID REDOX SIGN, V8, P517, DOI 10.1089/ars.2006.8.517
   Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105
   Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002
   Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359
   Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599
   Stewart CEH, 2004, J CELL PHYSIOL, V198, P237, DOI 10.1002/jcp.10387
   SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0
   Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053
   Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343
   Tamilselvan J, 2007, FREE RADICAL BIO MED, V43, P1656, DOI 10.1016/j.freeradbiomed.2007.08.028
   Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303
   Tarnopolsky MA, 2009, APPL PHYSIOL NUTR ME, V34, P348, DOI 10.1139/H09-022
   Tews DS, 2005, MUSCLE NERVE, V32, P443, DOI 10.1002/mus.20348
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780
   Tsujimoto Y, 2006, BBA-BIOENERGETICS, V1757, P1297, DOI 10.1016/j.bbabio.2006.03.017
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Vescovo G, 2000, HEART, V84, P431, DOI 10.1136/heart.84.4.431
   Vescovo G, 2006, CURR OPIN CLIN NUTR, V9, P416, DOI 10.1097/01.mco.0000232902.97286.35
   Visser M, 2002, J GERONTOL A-BIOL, V57, PM326, DOI 10.1093/gerona/57.5.M326
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Wajant H, 2009, RESULTS PROBL CELL D, V49, P1, DOI 10.1007/400_2008_26
   Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51
   Wang W, 2008, CELL, V134, P279, DOI 10.1016/j.cell.2008.06.017
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, PE422, DOI 10.1152/ajpendo.1995.268.3.E422
   WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
   Yang F, 2009, NEUROSCI LETT, V454, P203, DOI 10.1016/j.neulet.2009.03.027
   Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836
   YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0
   Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196
   Yu J, 2008, ONCOGENE, V27, PS71, DOI 10.1038/onc.2009.45
   Yu JG, 2009, J ATHEROSCLER THROMB, V16, P21, DOI 10.5551/jat.E551
   Yu JW, 2009, P NATL ACAD SCI USA, V106, P8169, DOI 10.1073/pnas.0812453106
   Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739
   Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1
   Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440
   Zheng A, 2005, P NATL ACAD SCI USA, V102, P12083, DOI 10.1073/pnas.0503374102
NR 265
TC 1
Z9 1
U1 0
U2 6
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 
EI 
J9 
PD JUN 15
PY 2011
VL 0
IS 
BP 173
EP 206
DI 10.1007/978-90-481-9713-2_9
PG 34
WC Geriatrics & Gerontology; Sport Sciences
SC Geriatrics & Gerontology; Sport Sciences
GA BSR26
UT WOS:000285535100009
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, Salvatore
TI A history of mitochondrial diseases
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID cytochrome-c-oxidase; dominant optic atrophy; progressive external ophthalmoplegia; coenzyme-q deficiency; ragged-red fibers; oxidative-phosphorylation; cerebellar-ataxia; lactic-acidosis; skeletal-muscle; barth-syndrome
AB This articles reviews the development of mitochondrial medicine from the premolecular era (1962-1988), when mitochondrial diseases were defined on the basis of clinical examination, muscle biopsy, and biochemical criteria, through the molecular era, when the full complexity of these disorders became evident. In a chronological order, I have followed the introduction of new pathogenic concepts that have shaped a rational genetic classification of these clinically heterogeneous disorders. Thus, mitochondrial DNA (mtDNA)-related diseases can be divided into two main groups: those that impair mitochondrial protein synthesis in toto, and those that affect specific respiratory chain proteins. Mutations in nuclear DNA can affect components of respiratory chain complexes (direct hits) or assembly proteins (indirect hits), but they can also impair mtDNA integrity (multiple mtDNA mutations), replication (mtDNA depletion), or mtDNA translation. Besides these disorders that affect the respiratory chain directly, defects in other mitochondrial functions may also affect oxidative phosphorylation, including problems in mitochondrial protein import, alterations of the inner mitochondrial membrane lipid composition, and defects of mitochondrial dynamics. The enormous and still ongoing progress in our understanding of mitochondrial medicine was made possible by the intense collaboration of an international cadre of "mitochondriacs." Having published my first paper on a patient with mitochondrial myopathy 37 years ago (DiMauro et al., 1973), I feel qualified to write a history of the mitochondrial diseases, a fascinating, still evolving, and continuously puzzling area of medicine. In each section, I follow a chronological order of the salient discoveries and I show only the portraits of distinguished deceased mitochondriacs and those whose names became eponyms of mitochondrial diseases.
C1 Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, Room 4-424B,630 West 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NIH [HD032062]; Marriott Mitochondrial Clinical Research Fund (MMCRF)
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Area-Gomez E, 2009, AM J PATHOL, V175, P1810, DOI 10.2353/ajpath.2009.090219
   Auré K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2
   BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5
   Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385
   BLASS J P, 1970, JOURNAL OF CLINICAL INVESTIGATION, V49, P423, DOI 10.1172/JCI106251
   Bolender N, 2008, EMBO REP, V9, P42, DOI 10.1038/sj.embor.7401126
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Cao LQ, 2009, PLOS GENET, V5, P0, DOI 10.1371/journal.pgen.1000756
   Carelli V, 2006, MITOCHONDRIAL MEDICINE, V0, P105
   Chan DC, 2007, NEW ENGL J MED, V356, P1707, DOI 10.1056/NEJMp078040
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CIZKOVA A, 2009, NAT GENET, V40, P0
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Davey KM, 2006, J MED GENET, V43, P385, DOI 10.1136/jmg.2005.036657
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   DEFRANCESCO L, 1976, J BIOL CHEM, V251, P4588
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163
   DIMAURO S, 1973, ARCH NEUROL-CHICAGO, V29, P170, DOI 10.1001/archneur.1973.00490270052008
   DIMAURO S, 1973, SCIENCE, V182, P929, DOI 10.1126/science.182.4115.929
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   DIMAURO S, 2006, MITOCHONDRIAL MED, V0, P0
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   ENGEL AG, 1973, SCIENCE, V179, P899, DOI 10.1126/science.179.4076.899
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   FENTON WA, 1995, AM J HUM GENET, V57, P235
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Ghezzi D, 2009, NAT GENET, V41, P654, DOI 10.1038/ng.378
   Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7
   GONATAS NK, 1965, EXCERPTA MED INT C S, V100, P606
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935
   Haut S, 2003, HUM GENET, V113, P118, DOI 10.1007/s00439-003-0946-0
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   HERS HG, 1965, GASTROENTEROLOGY, V48, P625
   Hinson JT, 2007, NEW ENGL J MED, V356, P809, DOI 10.1056/NEJMoa055262
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   KARPATI G, 1975, NEUROLOGY, V25, P16, DOI 10.1212/WNL.25.1.16
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   LEDLEY FD, 1990, P NATL ACAD SCI USA, V87, P3147, DOI 10.1073/pnas.87.8.3147
   LESTIENNE P, 1988, LANCET, V1, P885
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Magen D, 2008, AM J HUM GENET, V83, P30, DOI 10.1016/j.ajhg.2008.05.016
   Mangiullo R, 2008, BBA-BIOENERGETICS, V1777, P1326, DOI 10.1016/j.bbabio.2008.08.003
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORAIS R, 1988, IN VITRO CELL DEV B, V24, P649, DOI 10.1007/BF02623602
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   NASS S, 1963, J CELL BIOL, V19, P613, DOI 10.1083/jcb.19.3.613
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Ravera S, 2009, INT J BIOCHEM CELL B, V41, P1581, DOI 10.1016/j.biocel.2009.01.009
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Rowland LP, 1994, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V0, P116
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Scheffler IE, 1986, CARBOHYDRATE METABOLISM IN CULTURED CELLS, V0, P77
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Schlame M, 2006, FEBS LETT, V580, P5450, DOI 10.1016/j.febslet.2006.07.022
   Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Shankar SP, 2008, OPHTHALMIC GENET, V29, P17, DOI 10.1080/13816810701867607
   SHAPIRA Y, 1977, ISRAEL J MED SCI, V13, P161
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHY GM, 1966, BRAIN, V89, P133, DOI 10.1093/brain/89.1.133
   SHY GM, 1964, SCIENCE, V145, P493, DOI 10.1126/science.145.3631.493
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sperl W, 2006, NEUROMUSCULAR DISORD, V16, P821, DOI 10.1016/j.nmd.2006.08.008
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   SPIRO AJ, 1970, ARCH NEUROL-CHICAGO, V23, P103, DOI 10.1001/archneur.1970.00480260009002
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   TAKAKUBO F, 1995, AM J HUM GENET, V57, P772
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tiranti V, 2006, J MED GENET, V43, P340, DOI 10.1136/jmg.2005.036210
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Tiranti V, 2009, NAT MED, V15, P200, DOI 10.1038/nm.1907
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Yu YM, 2006, J BIOL CHEM, V281, P36929, DOI 10.1074/jbc.M607703200
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 175
TC 58
Z9 67
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD APR 15
PY 2011
VL 34
IS 2
BP 261
EP 276
DI 10.1007/s10545-010-9082-x
PG 16
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 739YI
UT WOS:000288757700004
PM 20490929
DA 2024-11-01
ER

PT J
AU Tulinius, M
   Oldfors, A
AF Tulinius, Mar
   Oldfors, Anders
TI Neonatal muscular manifestations in mitochondrial disorders
SO SEMINARS IN FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Genetic diseases; Infant; Mitochondrial respiratory chain deficiency; Myopathies; Neonate
ID c-oxidase deficiency; thymidine kinase; lactic-acidosis; iron-overload; dna depletion; mutations; gene; encephalomyopathy; translation; subunit
AB During the last decade rapid development has occurred in defining nuclear gene mutations causing mitochondrial disease. Some of these newly defined gene mutations cause neonatal or early infantile onset of disease, often associated with severe progressive encephalomyopathy combined with other multi-organ involvement such as cardiomyopathy or hepatopathy and with early death. Findings suggesting myopathy in neonates are hypotonia, muscle weakness and wasting, and arthrogryposis. We aim to describe the clinical findings of patients with mitochondrial disease presenting with muscular manifestations in the neonatal period or in early infancy and in whom the genetic defect has been characterized. The majority of patients with neonatal onset of mitochondrial disease have mutations in nuclear genes causing dysfunction of the mitochondrial respiratory chain, leading to defective oxidative phosphorylation. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Tulinius, Mar] Univ Gothenburg, Dept Pediat, Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
   [Oldfors, Anders] Univ Gothenburg, Dept Pathol, Sahlgrenska Univ Hosp, S-41685 Gothenburg, Sweden.
C3 University of Gothenburg; Queen Silvia Children's Hospital; Sahlgrenska University Hospital; University of Gothenburg
RP Tulinius, M (corresponding author), Univ Gothenburg, Dept Pediat, Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
EM mar.tulinius@gu.se
CR Bodensteiner JB, 2008, SEMIN PEDIATR NEUROL, V15, P10, DOI 10.1016/j.spen.2008.01.003
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Cameron JM, 2011, MITOCHONDRION, V11, P191, DOI 10.1016/j.mito.2010.09.008
   Cizková A, 2008, NAT GENET, V40, P1288, DOI 10.1038/ng.246
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Damian MS, 1996, AM J MED GENET, V62, P398, DOI 10.1002/(SICI)1096-8628(19960424)62:4<398::AID-AJMG13>3.0.CO;2-J
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   DEMAUGRE F, 1991, J CLIN INVEST, V87, P859, DOI 10.1172/JCI115090
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   Dimauro Salvatore, 2007, HANDB CLIN NEUROL, V86, P167, DOI 10.1016/S0072-9752(07)86007-6
   Dubowitz V, 1980, FLOPPY INFANT, V0, P0
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fellman V, 1998, LANCET, V351, P490, DOI 10.1016/S0140-6736(97)09272-6
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Gurgey A, 1996, PEDIATR NEPHROL, V10, P637
   HALL JG, 2007, EMERY RIMOINS PRINCI, V0, P3785
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Houstek J, 2009, BBA-BIOENERGETICS, V1787, P529, DOI 10.1016/j.bbabio.2008.11.013
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   Morava E, 2006, AM J MED GENET A, V140A, P863, DOI 10.1002/ajmg.a.31194
   Morava E, 2009, MITOCHONDRION, V9, P438, DOI 10.1016/j.mito.2009.08.003
   Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Ostergaard E, 2010, EUR J PEDIATR, V169, P201, DOI 10.1007/s00431-009-1007-z
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   PRASAD AN, 2011, SEMIN FETAL NEO 1203, V0, P0
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   SCHIFF M, 2011, SEMIN FETAL NEONATAL, V16, P0
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   SMITS P, 2010, EUR J HUM GENET 1201, V0, P0
   SOKOL R, 2011, SEMIN FETAL NEONATAL, V16, P0
   SPIEGEL R, 2010, J MED GENET 1208, V0, P0
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tuppen HAL, 2010, MOL GENET METAB, V100, P345, DOI 10.1016/j.ymgme.2010.04.010
   UZIEL G, 2011, SEMIN FETAL NEONATAL, V16, P0
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
NR 52
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-165X
EI 1878-0946
J9 SEMIN FETAL NEONAT M
JI Semin. Fetal Neonatal Med.
PD AUG 15
PY 2011
VL 16
IS 4
BP 229
EP 235
DI 10.1016/j.siny.2011.04.001
PG 7
WC Pediatrics
SC Pediatrics
GA 799DI
UT WOS:000293263300009
PM 21596636
DA 2024-11-01
ER

PT J
AU Euro, L
   Farnum, GA
   Palin, E
   Suomalainen, A
   Kaguni, LS
AF Euro, Liliya
   Farnum, Gregory A.
   Palin, Eino
   Suomalainen, Anu
   Kaguni, Laurie S.
TI Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol γ
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID dna-polymerase-gamma; progressive external ophthalmoplegia; virion rna-polymerase; accessory subunit; structural basis; saccharomyces-cerevisiae; multiple deletions; crystal-structure; escherichia-coli; w748s mutation
AB Mutations in Pol gamma represent a major cause of human mitochondrial diseases, especially those affecting the nervous system in adults and in children. Recessive mutations in Pol gamma represent nearly half of those reported to date, and they are nearly uniformly distributed along the length of the POLG1 gene (Human DNA Polymerase gamma Mutation Database); the majority of them are linked to the most severe form of POLG syndrome, Alpers-Huttenlocher syndrome. In this report, we assess the structure-function relationships for recessive disease mutations by reviewing existing biochemical data on site-directed mutagenesis of the human, Drosophila and yeast Pol gamma s, and their homologs from the family A DNA polymerase group. We do so in the context of a molecular model of Pol gamma in complex with primer-template DNA, which we have developed based upon the recently solved crystal structure of the apoenzyme form. We present evidence that recessive mutations cluster within five distinct functional modules in the catalytic core of Pol gamma. Our results suggest that cluster prediction can be used as a diagnosis-supporting tool to evaluate the pathogenic role of new Pol gamma variants.
C1 [Farnum, Gregory A.; Kaguni, Laurie S.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   [Farnum, Gregory A.; Kaguni, Laurie S.] Michigan State Univ, Ctr Mitochondrial Sci & Med, E Lansing, MI 48824 USA.
   [Euro, Liliya; Palin, Eino; Suomalainen, Anu] Univ Helsinki, Biomedicum Helsinki, Res Programs Unit, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland.
C3 Michigan State University; Michigan State University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
EM lskaguni@msu.edu
FU National Institutes of Health [GM45295]; Academy of Finland; University of Helsinki; Jane, and Aatos Erkko Foundation; Sigrid Juselius Foundation
CR Atanassova N, 2011, HUM MOL GENET, V20, P1212, DOI 10.1093/hmg/ddq565
   Baqri RM, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0007874
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   Baruffini E, 2010, MITOCHONDRION, V10, P183, DOI 10.1016/j.mito.2009.10.002
   Berdis AJ, 2009, CHEM REV, V109, P2862, DOI 10.1021/cr800530b
   Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Gleghorn ML, 2008, MOL CELL, V32, P707, DOI 10.1016/j.molcel.2008.11.010
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Iyengar B, 1999, GENETICS, V153, P1809
   Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101
   Jin ZN, 2011, J BIOL CHEM, V286, P1312, DOI 10.1074/jbc.M110.156737
   Johnson KA, 2010, BBA-PROTEINS PROTEOM, V1804, P1041, DOI 10.1016/j.bbapap.2010.01.006
   Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Lee HR, 2008, J BIOL CHEM, V283, P14411, DOI 10.1074/jbc.M705006200
   Lee HR, 2008, J BIOL CHEM, V283, P14402, DOI 10.1074/jbc.M705007200
   Lee YS, 2010, J BIOL CHEM, V285, P28105, DOI 10.1074/jbc.M110.122283
   Lee YS, 2010, J BIOL CHEM, V285, P1490, DOI 10.1074/jbc.M109.062752
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Murakami KS, 2008, P NATL ACAD SCI USA, V105, P5046, DOI 10.1073/pnas.0712325105
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Palin EJH, 2010, BBA-MOL BASIS DIS, V1802, P545, DOI 10.1016/j.bbadis.2010.02.003
   POLESKY AH, 1992, J BIOL CHEM, V267, P8417
   POLESKY AH, 1990, J BIOL CHEM, V265, P14579
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 51
TC 38
Z9 41
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD NOV 15
PY 2011
VL 39
IS 21
BP 9072
EP 9084
DI 10.1093/nar/gkr618
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 852RR
UT WOS:000297375700009
PM 21824913
DA 2024-11-01
ER

PT J
AU Pitceathly, RDS
   Fassone, E
   Taanman, JW
   Sadowski, M
   Fratter, C
   Mudanohwo, EE
   Woodward, CE
   Sweeney, MG
   Holton, JL
   Hanna, MG
   Rahman, S
AF Pitceathly, Robert D. S.
   Fassone, Elisa
   Taanman, Jan-Willem
   Sadowski, Michael
   Fratter, Carl
   Mudanohwo, Ese E.
   Woodward, Cathy E.
   Sweeney, Mary G.
   Holton, Janice L.
   Hanna, Michael G.
   Rahman, Shamima
TI Kearns-Sayre syndrome caused by defective R1/p53R2 assembly
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID mitochondrial-dna deletions; ribonucleotide reduction; external ophthalmoplegia; depletion; mutations; p53r2; replication; rrm2b
AB Background Mutations in RRM2B encoding ribonucleotide reductase (RNR) p53R2 subunit usually cause paediatric-onset mitochondrial disease associated with mitochondrial DNA (mtDNA) depletion. The importance of RNR dysfunction in adult mitochondrial disease is unclear. Objective To report the RRM2B mutation frequency in adults with multiple mtDNA deletions and examine RNR assembly in a patient with Kearns-Sayre syndrome (KSS) caused by two novel RRM2B mutations. Methods 50 adult patients with multiple mtDNA deletions in skeletal muscle were studied. DNA sequencing of RRM2B was performed in patients without mutations in mtDNA maintenance genes POLG and C10orf2. RNR protein was studied using western blot and Blue-native polyacrylamide gel electrophoresis (BN-PAGE). Results Four per cent (two unrelated cases) of this adult cohort harboured RRM2B mutations. Patient 1 had KSS and two novel missense mutations: c.122G -> A; p.Arg41Gln and c.391G -> A; p.Glu131Lys. BN-PAGE demonstrated reduced heterotetrameric R1/p53R2 RNR levels compared with controls, despite normal steady-state p53R2 levels on western blot, suggesting failed assembly of functional RNR as a potential disease mechanism. Patient 2 had late-onset progressive external ophthalmoplegia and fatigue. A heterozygous deletion c. 253_255delGAG; p.Glu85del was identified. Muscle histology in both cases showed significant numbers of necrotic muscle fibres, possibly indicating enhanced apoptotic cell death. Conclusion These data indicate that 4% of adult mitochondrial disease with multiple deletions is caused by RNR dysfunction. KSS has not previously been linked to a nuclear gene defect. Evidence that disease pathogenesis may be caused by defective RNR assembly is given. RRM2B screening should be considered early in the differential diagnosis of adults with multiple mtDNA deletions.
C1 [Rahman, Shamima] Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
   [Pitceathly, Robert D. S.; Holton, Janice L.; Hanna, Michael G.; Rahman, Shamima] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England.
   [Fassone, Elisa; Rahman, Shamima] UCL Inst Child Hlth, Mitochondrial Res Grp, Clin & Mol Genet Unit, London, England.
   [Fassone, Elisa] Univ Milan, Dino Ferrari Ctr, Dept Neurol Sci, Osped Maggiore Policlin,IRCCS Fdn Ca Granda, Milan, Italy.
   [Taanman, Jan-Willem] UCL Inst Neurol, Dept Clin Neurosci, London, England.
   [Sadowski, Michael] Natl Inst Med Res, Div Math Biol, London NW7 1AA, England.
   [Fratter, Carl] Oxford Radcliffe Hosp NHS Trust, Oxford Reg Mol Genet Lab, Oxford, England.
   [Mudanohwo, Ese E.; Woodward, Cathy E.; Sweeney, Mary G.] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London WC1N 3BG, England.
   [Holton, Janice L.; Hanna, Michael G.] UCL Inst Neurol, Dept Mol Neurosci, London, England.
   [Rahman, Shamima] Great Ormond St Hosp Sick Children, Metab Unit, London WC1N 3JH, England.
C3 University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of London; University College London; MRC National Institute for Medical Research; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust
RP Rahman, S (corresponding author), Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, 8-11 Queen Sq, London WC1N 3BG, England.
EM s.rahman@ich.ucl.ac.uk
FU MRC [G0800674]; MRC Centre [G0601943]; Great Ormond Street Hospital Children's Charity; Myositis Support Group; Reta Lila Weston Institute for Neurological Studies; NIHR UCLH/UCL Comprehensive Biomedical Research Centre; Department of Health's National Institute for Health Research Biomedical Research Centres; MRC [G0800674, G0200335, G0601943] Funding Source: UKRI
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105
   DeLano WL, 2002, THE PYMOL MOLECULAR GRAPHICS SYSTEM, V0, P0
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71
   Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774
   Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOFFNER JM, 2001, DISORDERS VOLUNTARY, V0, P580
   Smith P, 2009, BIOCHEMISTRY-US, V48, P11134, DOI 10.1021/bi9001425
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Yamaguchi T, 2001, CANCER RES, V61, P8256
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 26
TC 36
Z9 37
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP 15
PY 2011
VL 48
IS 9
BP 610
EP 617
DI 10.1136/jmg.2010.088328
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 810WQ
UT WOS:000294160000009
PM 21378381
DA 2024-11-01
ER

PT J
AU Cameron, JM
   Levandovskiy, V
   MacKay, N
   Ackerley, C
   Chitayat, D
   Raiman, J
   Halliday, WH
   Schulze, A
   Robinson, BH
AF Cameron, Jessie M.
   Levandovskiy, Valeriy
   MacKay, Nevena
   Ackerley, Cameron
   Chitayat, David
   Raiman, Julian
   Halliday, W. H.
   Schulze, Andreas
   Robinson, Brian H.
TI Complex V TMEM70 deficiency results in mitochondrial nucleoid disorganization
SO MITOCHONDRION
LA English
DT Article
DE ATP synthase; Mitochondria; TMEM70; Nucleoids
ID skin fibroblast-cultures; atp-synthase deficiency; inner membrane; saccharomyces-cerevisiae; dna nucleoids; mutation; gene; subunit-6; morphology; cristae
AB Mutations in the TMEM70 gene are responsible for a familial form of complex V deficiency presenting with 3-methylglutaconic aciduria, lactic acidosis, cardiomyopathy and mitochondria! myopathy. Here we present a case of TMEM70 deficiency due to compound heterozygous mutations, who displayed abnormal mitochondria with whorled cristae in muscle. Immunogold electron microscopy and tomography shows for the first time that nucleoid clusters of mtDNA are disrupted in the abnormal mitochondria, with both nucleoids and mitochondrial respiratory chain complexes confined to the outer rings of the whorls. This could explain the differential effects on the expression and assembly of complex V in different tissues. (C) 2010 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Cameron, Jessie M.; Levandovskiy, Valeriy; MacKay, Nevena; Robinson, Brian H.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada.
   [Ackerley, Cameron; Halliday, W. H.] Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada.
   [Chitayat, David; Raiman, Julian; Schulze, Andreas] Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada.
   [Robinson, Brian H.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A8, Canada.
   [Robinson, Brian H.] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto
RP Robinson, BH (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM bhr@sickkids.ca
FU MitoMarch for Kirkland
CR Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170
   Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200
   BREEN GAM, 1986, J BIOL CHEM, V261, P1680
   Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729
   Cizková A, 2008, NAT GENET, V40, P1288, DOI 10.1038/ng.246
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1
   HOLME E, 1992, PEDIATR RES, V32, P731, DOI 10.1203/00006450-199212000-00022
   Houstek J, 1999, HUM MOL GENET, V8, P1967
   HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A
   John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.E04-08-0697
   JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3
   Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Margineantu DH, 2002, MITOCHONDRION, V1, P327, DOI 10.1016/S1567-7249(01)00033-2
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   Mun JY, 2010, J CELL PHYSIOL, V224, P748, DOI 10.1002/jcp.22177
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   OZAWA T, 1973, J BIOENERG, V4, P507, DOI 10.1007/BF01515942
   Pitkanen S, 1996, BIOCHEM MOL MED, V59, P134, DOI 10.1006/bmme.1996.0078
   Rak M, 2007, J BIOL CHEM, V282, P10853, DOI 10.1074/jbc.M608692200
   Robinson B H, 1996, METHODS ENZYMOL, V264, P454, DOI 10.1016/S0076-6879(96)64041-5
   ROBINSON BH, 1990, PEDIATR RES, V28, P549, DOI 10.1203/00006450-199011000-00027
   ROBINSON BH, 1983, EUR J PEDIATR, V140, P98, DOI 10.1007/BF00441651
   Spelbrink JN, 2010, IUBMB LIFE, V62, P19, DOI 10.1002/iub.282
   Sperl W, 2006, NEUROMUSCULAR DISORD, V16, P821, DOI 10.1016/j.nmd.2006.08.008
   Strauss M, 2008, EMBO J, V27, P1154, DOI 10.1038/emboj.2008.35
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tatuch Yuriy, 1994, EUROPEAN JOURNAL OF HUMAN GENETICS, V2, P35
   Wang YS, 2006, J BIOL CHEM, V281, P25791, DOI 10.1074/jbc.M604501200
   Wittig I, 2007, MOL CELL PROTEOMICS, V6, P1215, DOI 10.1074/mcp.M700076-MCP200
   Xu F, 2008, BIOCHEM J, V416, P15, DOI 10.1042/BJ20080847
   YOTSUYANAGI Y, 1962, J ULTRA MOL STRUCT R, V7, P141, DOI 10.1016/S0022-5320(62)80032-X
   YOTSUYANAGI Y, 1988, J ULTRA MOL STRUCT R, V98, P254, DOI 10.1016/S0889-1605(88)80918-2
   Zeng XM, 2007, MOL BIOL CELL, V18, P617, DOI 10.1091/mbc.E06-09-0801
NR 36
TC 37
Z9 38
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN 15
PY 2011
VL 11
IS 1
BP 191
EP 199
DI 10.1016/j.mito.2010.09.008
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 709OP
UT WOS:000286450300026
PM 20920610
DA 2024-11-01
ER

PT J
AU Al-Jasmi, F
   Penefsky, HS
   Souid, AK
AF Al-Jasmi, Fatma
   Penefsky, Harvey S.
   Souid, Abdul-Kader
TI The phosphorescence oxygen analyzer as a screening tool for disorders with impaired lymphocyte bioenergetics
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Oxygen; Respiration; Mitochondria; Respiratory chain
ID oxidative-phosphorylation disorders; mitochondrial-dna depletion; cellular respiration; dehydrogenase-deficiency; anticancer drugs; cells; consumption; doxorubicin; capacity; mutation
AB This study aimed to show the feasibility of using the phosphorescence oxygen analyzer to screen for clinical disorders with impaired cellular bioenergetics. [O(2)] was determined as function of time from the phosphorescence decay of Pd (II) meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin. In sealed vials, O(2) consumption by peripheral blood mononuclear cells was linear with time, confirming its zero-order kinetics. Cyanide inhibited O(2) consumption, confirming the oxidation occurred in the mitochondrial respiratory chain. The rate of respiration (mean +/- SD, in mu M O(2) per min per 10(7) cells, set as the negative of the slope of [O(2)] vs. t) for adults was 2.1 +/- 0.8 (n=18), for children 2.0 +/- 0.9 (n=20), and for newborns (umbilical cord samples) 0.8 +/- 0.4 (n=18), p<0.0001. For an 8-year-old patient with reduced NADH dehydrogenase and pyruvate dehydrogenase activities in the muscle, the rate was 0.7 +/- 0.2 (n=3) mu M O(2) per min per 10(7) cells. For a 3-month-old patient with hepatocerebral mitochondrial DNA depletion syndrome (MDS) with confirmed mutations in the MPV17 gene, the rate was 0.6 mu M O(2) per min per 10(7) cells. For an 18 month-old patient with MDS and confirmed mutations in the POLG gene, the rate was 0.5 mu M O(2) per min per 10(7) cells. For a 6-year-old patient with MDS and confirmed mutations in the POLG gene, the rate was 0.6 mu M O(2) per min per 10(7) cells. For 1-week-old patient with congenital lactic acidemia and hypotonia (confirmed mutations in DLD gene), the rate was 1.5 mu M O(2) per min per 10(7) cells. For three siblings (9-year-old male, 8-year-old male and 2-month-old female) with congenital progressive myopathy, the rates were 0.9, 0.6 and 12 mu M O(2) per min per 10(7) cells, respectively. Four patients with congenital lactic acidemia (with inadequate work-up) were also studied; their rates were 0.2, 1.5, 0.3 and 1.7 mu M O(2) per min per 10(7) cells. This novel approach permits non-invasive, preliminary assessment of cellular bioenergetics. Potential applications and limitations of this technique are discussed. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Al-Jasmi, Fatma; Penefsky, Harvey S.; Souid, Abdul-Kader] United Arab Emirates Univ, Dept Pediat, Fac Med & Hlth Sci, Al Ain, U Arab Emirates.
C3 United Arab Emirates University
RP Al-Jasmi, F (corresponding author), United Arab Emirates Univ, Dept Pediat, Fac Med & Hlth Sci, POB 17666, Al Ain, U Arab Emirates.
EM aljasmif@uaeu.ac.ae
FU United Arab Emirates University
CR Al Jasmi AS, 2011, BIOENERGETICS, V0, P0
   Anderson NR, 2007, J AM MED INFORM ASSN, V14, P478, DOI 10.1197/jamia.M2114
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   CHRETIEN D, 1994, CLIN CHIM ACTA, V228, P53, DOI 10.1016/0009-8981(94)90056-6
   Chretien D, 2003, J INHERIT METAB DIS, V26, P189, DOI 10.1023/A:1024437201166
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008
   HEDESKOV CJ, 1966, BLOOD-J HEMATOL, V28, P163, DOI 10.1182/blood.V28.2.163.163
   ITO M, 1995, J INHERIT METAB DIS, V18, P547, DOI 10.1007/BF02435999
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Jonckheere AI, 2010, CLIN CHEM, V56, P424, DOI 10.1373/clinchem.2009.131441
   Kogelnik AM, 1997, NUCLEIC ACIDS RES, V25, P196, DOI 10.1093/nar/25.1.196
   Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144
   Marriage BJ, 2004, MOL GENET METAB, V81, P263, DOI 10.1016/j.ymgme.2003.12.008
   Marriage BJ, 2003, ANAL BIOCHEM, V313, P137, DOI 10.1016/S0003-2697(02)00539-0
   PACHMAN LM, 1967, BLOOD-J HEMATOL, V30, P691, DOI 10.1182/blood.V30.6.691.691
   Posh BD-VLeta, 1994, J NUTR BIOCH, V5, P284
   Robinson B H, 1996, METHODS ENZYMOL, V264, P454, DOI 10.1016/S0076-6879(96)64041-5
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Shaban S, 2010, COMPUT METHODS PROGR, V0, P0
   Shany E, 1999, BIOCHEM BIOPH RES CO, V262, P163, DOI 10.1006/bbrc.1999.1133
   Souid AK, 2006, MOL PHARMACEUT, V3, P307, DOI 10.1021/mp050080j
   Souid AK, 2003, BIOCHEM PHARMACOL, V66, P977, DOI 10.1016/S0006-2952(03)00418-0
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Tacka KA, 2004, CHEM RES TOXICOL, V17, P1434, DOI 10.1021/tx0498760
   Tao ZM, 2008, ANAL BIOCHEM, V381, P43, DOI 10.1016/j.ab.2008.06.020
   Tao ZM, 2008, NANO LETT, V8, P1517, DOI 10.1021/nl080250u
   Tao ZM, 2006, CHEM RES TOXICOL, V19, P1051, DOI 10.1021/tx050315y
   Tao ZM, 2009, BIOPHYS J, V96, P2977, DOI 10.1016/j.bpj.2008.11.071
   WEISS RF, 1970, DEEP-SEA RES, V17, P721, DOI 10.1016/0011-7471(70)90037-9
NR 31
TC 4
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD DEC 15
PY 2011
VL 104
IS 4
BP 529
EP 536
DI 10.1016/j.ymgme.2011.09.023
PG 8
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 861LV
UT WOS:000298021400014
PM 21996136
DA 2024-11-01
ER

PT J
AU Hoefs, SJG
   van Spronsen, FJ
   Lenssen, EWH
   Nijtmans, LG
   Rodenburg, RJ
   Smeitink, JAM
   van den Heuvel, LP
AF Hoefs, Saskia J. G.
   van Spronsen, Francjan J.
   Lenssen, Ellen W. H.
   Nijtmans, Leo G.
   Rodenburg, Richard J.
   Smeitink, Jan A. M.
   van den Heuvel, Lambert P.
TI <i>NDUFA10</i> mutations cause complex I deficiency in a patient with Leigh disease
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE complex I deficiency; NDUFA10 gene; Leigh syndrome
ID mitochondrial complex; ubiquinone oxidoreductase; oxidative-phosphorylation; gene; nadh; identification; pathology; subunits; electrophoresis; subcomplexes
AB Mitochondrial complex I deficiency is the most common defect of the oxidative phosphorylation system. We report a patient with Leigh syndrome who showed a complex I deficiency expressed in cultured fibroblasts and muscle tissue. To find the genetic cause of the complex I deficiency, we screened the mitochondrial DNA and the nuclear-encoded subunits of complex I. We identified compound-heterozygous mutations in the NDUFA10 gene, encoding an accessory subunit of complex I. The first mutation disrupted the start codon and the second mutation resulted in an amino acid substitution. The fibroblasts of the patient displayed decreased amount and activity, and a disturbed assembly of complex I. These results indicate that NDUFA10 is a novel candidate gene to screen for disease-causing mutations in patients with complex I deficiency. European Journal of Human Genetics (2011) 19, 270-274; doi:10.1038/ejhg.2010.204; published online 8 December 2010
C1 [Hoefs, Saskia J. G.; Lenssen, Ellen W. H.; Nijtmans, Leo G.; Rodenburg, Richard J.; Smeitink, Jan A. M.; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Paediat, NL-6500 HB Nijmegen, Netherlands.
   [van Spronsen, Francjan J.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, Groningen, Netherlands.
   [van den Heuvel, Lambert P.] Catholic Univ Louvain, Dept Pediat, B-3000 Louvain, Belgium.
C3 Radboud University Nijmegen; University of Groningen; Universite Catholique Louvain
RP van den Heuvel, LP (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Paediat, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM B.vandenHeuvel@cukz.umcn.nl
FU European Community [LSHM-CT-2004-005260]
CR Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332
   Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Calvaruso MA, 2008, METHODS, V46, P281, DOI 10.1016/j.ymeth.2008.09.023
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   CHEN S, 1984, J BIOL CHEM, V259, P5124
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066
   Fernandez-Moreira D, 2007, ANN NEUROL, V61, P73, DOI 10.1002/ana.21036
   FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022
   Hoefs SJG, 2008, AM J HUM GENET, V82, P1306, DOI 10.1016/j.ajhg.2008.05.007
   Hoefs SJG, 2010, MOL GENET METAB, V100, P251, DOI 10.1016/j.ymgme.2010.03.015
   Hoefs SJG, 2009, HUM MUTAT, V30, PE728, DOI 10.1002/humu.21037
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Lazarou M, 2007, MOL CELL BIOL, V27, P4228, DOI 10.1128/MCB.00074-07
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Nouws J, 2010, CELL METAB, V12, P283, DOI 10.1016/j.cmet.2010.08.002
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t
   Schilling B, 2005, FEBS LETT, V579, P2485, DOI 10.1016/j.febslet.2005.03.061
   Schulenberg B, 2003, J BIOL CHEM, V278, P27251, DOI 10.1074/jbc.C300189200
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Sugiana C, 2008, AM J HUM GENET, V83, P468, DOI 10.1016/j.ajhg.2008.09.009
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Vogel RO, 2007, J BIOL CHEM, V282, P7582, DOI 10.1074/jbc.M609410200
   Yamaguchi M, 2000, EUR J BIOCHEM, V267, P329, DOI 10.1046/j.1432-1327.2000.00999.x
NR 34
TC 63
Z9 71
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD MAR 15
PY 2011
VL 19
IS 3
BP 270
EP 274
DI 10.1038/ejhg.2010.204
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 722PA
UT WOS:000287445600010
PM 21150889
DA 2024-11-01
ER

PT J
AU Sleigh, K
   Ball, S
   Hilton, DA
AF Sleigh, Kerry
   Ball, Susan
   Hilton, David A.
TI QUANTIFICATION OF CHANGES IN MUSCLE FROM INDIVIDUALS WITH AND WITHOUT MITOCHONDRIAL DISEASE
SO MUSCLE & NERVE
LA English
DT Article
DE aging; cytochrome c oxidase deficiency; mitochondria; muscle; "ragged-red" fibers
ID dna mutations; fibers; encephalomyopathy; diagnosis; pathology
AB Introduction: Muscle biopsy is used in the diagnosis of mitochondrial disorders. There are limited data on the normal ranges, so interpretation of findings can be difficult. Methods: We evaluated the percentage of fibers showing mitochondrial abnormalities using Gomori trichrome staining, succinate dehydrogenase, and cytochrome oxidase histochemistry in autopsy samples taken from 45 individuals without evidence of muscle disease and biopsies from 17 patients with mitochondrial disorders. Results: In controls, mitochondrial abnormalities were rare before the fifth decade, and most had <0.1% abnormal fibers. The proportion of abnormal fibers increased with age and was higher in deltoid than quadriceps. Most patients with mitochondrial disorders had >0.5% abnormal fibers. Conclusions: Although some patients with mitochondrial disease have very few muscle fibers that show mitochondrial abnormalities, a rate of abnormality of >0.5% fibers, in the absence of a primary muscle disease this should raise the possibility of a mitochondrial disorder. Muscle Nerve 43: 795-800, 2011
C1 [Sleigh, Kerry; Hilton, David A.] Derriford Hosp, Dept Cellular & Anat Pathol, Plymouth PL6 8DH, Devon, England.
   [Ball, Susan] Univ Plymouth, Ctr Hlth & Environm Stat, Plymouth PL4 8AA, Devon, England.
C3 Derriford Hospital; University of Plymouth
RP Hilton, DA (corresponding author), Derriford Hosp, Dept Cellular & Anat Pathol, Plymouth PL6 8DH, Devon, England.
EM david.hilton@phnt.swest.nhs.uk
CR Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   BYRNE E, 1992, MUTAT RES, V275, P125, DOI 10.1016/0921-8734(92)90017-J
   Chaturvedi S, 2005, MED SCI MONITOR, V11, P0
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   Cottrell DA, 2000, ANN NY ACAD SCI, V908, P199
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Hilton DA, 2001, CURR TOPICS PATHOL, V95, P207
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kyriakides T, 2003, ACTA MYOL, V22, P48
   McFarland R, 2009, J INTERN MED, V265, P210, DOI 10.1111/j.1365-2796.2008.02066.x
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   YAMAMOTO M, 1989, J NEUROL SCI, V91, P207, DOI 10.1016/0022-510X(89)90088-9
NR 22
TC 10
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUN 15
PY 2011
VL 43
IS 6
BP 795
EP 800
DI 10.1002/mus.21962
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 772DY
UT WOS:000291214200003
PM 21607963
DA 2024-11-01
ER

PT J
AU Giordano, C
   d'Amati, G
AF Giordano, Carla
   d'Amati, Giulia
TI Evaluation of Gastrointestinal mtDNA Depletion in Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
SO LASER CAPTURE MICRODISSECTION: METHODS AND PROTOCOLS, SECOND EDITION
LA English
DT Article; Book Chapter
DE Mitochondrial disease; mtDNA depletion; mtDNA deletion; CPEO
AB Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare disease characterized by severe gastro-intestinal (GI) dysmotility caused by mutations in the thymidine phosphorylase gene. Thymidine phosphorylase (TP) is involved in the control of the pyrimidine nucleoside pool of the cell. Reduced TP activity induces nucleotide pool imbalances that in turn affect both the rate and fidelity of mtDNA replication, leading to multiple deletions and depletion of mtDNA. By using laser capture microdissection and quantitative real-time-polymerase chain reaction technique, we showed that depletion of mitochondrial DNA (mtDNA) is the most prominent molecular defect in the gut wall of MNGIE patients. Depletion affects severely the smooth muscle cells of muscularis propria and the skeletal muscle component of the upper esophagus, while ganglion cells of the myenteric plexus show only a milder mtDNA reduction.
C1 [Giordano, Carla; d'Amati, Giulia] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy.
C3 Sapienza University Rome
RP Giordano, C (corresponding author), Univ Roma La Sapienza, Dept Expt Med, Rome, Italy.
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Gilbert MTP, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000537
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Nishino I, 2000, ANN NEUROL, V47, P792
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
NR 9
TC 10
Z9 10
U1 0
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
EI 1940-6029
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PD JUN 15
PY 2011
VL 755
IS 
BP 223
EP 232
DI 10.1007/978-1-61779-163-5_18
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Pathology
SC Biochemistry & Molecular Biology; Pathology
GA BWE67
UT WOS:000293771800018
PM 21761307
DA 2024-11-01
ER

PT J
AU Müller-Höcker, J
   Horvath, R
   Schäfer, S
   Hessel, H
   Müller-Felber, W
   Kühr, J
   Copeland, WC
   Seibel, P
AF Mueller-Hoecker, J.
   Horvath, R.
   Schaefer, S.
   Hessel, H.
   Mueller-Felber, W.
   Kuehr, J.
   Copeland, W. C.
   Seibel, P.
TI Mitochondrial DNA depletion and fatal infantile hepatic failure due to mutations in the mitochondrial polymerase γ (POLG) gene: a combined morphological/enzyme histochemical and immunocytochemical/biochemical and molecular genetic study
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE depletion of mtDNA; polymerase gamma; mitochondrial single stranded binding protein(mtSSB); mitochondrial transcription factor A (mtTFA); liver failure; in situ hybridization
ID deoxyguanosine kinase gene; mtdna depletion; respiratory-chain; transcription factor; insitu hybridization; copy number; liver; expression; replication; deficiency
AB Combined morphological, immunocytochemical, biochemical and molecular genetic studies were performed on skeletal muscle, heart muscle and liver tissue of a 16-months boy with fatal liver failure. The pathological characterization of the tissues revealed a severe depletion of mtDNA (mitochondrial DNA) that was most pronounced in liver, followed by a less severe, but still significant depletion in skeletal muscle and the heart. The primary cause of the disease was linked to compound heterozygous mutations in the polymerase gamma (POLG) gene (DNA polymerase gamma; A467T, K1191N). We present evidence, that compound heterozygous POLG mutations lead to tissue selective impairment of mtDNA replication and thus to a mosaic defect pattern even in the severely affected liver. A variable defect pattern was found in liver, muscle and heart tissue as revealed by biochemical, cytochemical, immunocytochemical and in situ hybridization analysis. Functionally, a severe deficiency of cytochrome-c-oxidase (cox) activity was seen in the liver. Although mtDNA depletion was detected in heart and skeletal muscle, there was no cox deficiency in these tissues. Depletion of mtDNA and microdissection of cox-positive or negative areas correlated with the histological pattern in the liver. Interestingly, the mosaic pattern detected for cox-activity and mtDNA copy number fully aligned with the immunohistologically revealed defect pattern using Pol gamma, mtSSB-and mtTFA-antibodies, thus substantiating the hypothesis that nuclear encoded proteins located within mitochondria become unstable and are degraded when they are not actively bound to mtDNA. Their disappearance could also aggravate the mtDNA depletion and contribute to the non-homogenous defect pattern.
C1 [Mueller-Hoecker, J.; Schaefer, S.; Hessel, H.] Univ Munich, Inst Pathol, D-80337 Munich, Germany.
   [Horvath, R.] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-80337 Munich, Germany.
   [Horvath, R.] Newcastle Univ, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Mueller-Felber, W.] Univ Munich, Neurol Klin & Poliklin, Friedrich Baur Inst, D-80337 Munich, Germany.
   [Kuehr, J.] Municipal Hosp Karlsruhe, Clin Pediat & Adolescent Med, Karlsruhe, Germany.
   [Copeland, W. C.] NIEHS, Res Triangle Pk, NC 27709 USA.
   [Seibel, P.] Univ Leipzig, Biotechnol Biomed Zentrum, Leipzig, Germany.
C3 University of Munich; University of Munich; Newcastle University - UK; University of Munich; Municipal Hospital Karlsruhe; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Leipzig University
RP Müller-Höcker, J (corresponding author), Univ Munich, Inst Pathol, Thalkirchnerstr 36, D-80337 Munich, Germany.
EM josef.mueller-hoecker@med.uni-muenchen.de
FU National Institutes of Health, NIEHS; Sachsische Ministerium fur Wissenschaft und Kunst; Deutsche Forschungsgemeinschaft [HO 2505/2-1]
CR Bakker HD, 1996, J PEDIATR-US, V128, P683, DOI 10.1016/S0022-3476(96)80135-1
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   BLACKSCHAEFER CL, 1991, BIOCHEM J, V274, P199, DOI 10.1042/bj2740199
   Bonod-Bidaud C, 2001, MITOCHONDRION, V1, P217, DOI 10.1016/S1567-7249(01)00017-4
   Campbell KM, 2007, J PEDIATR GASTR NUTR, V44, P99, DOI 10.1097/01.mpg.0000243434.54958.21
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Ducluzeau PH, 2002, J HEPATOL, V36, P698, DOI 10.1016/S0168-8278(02)00021-1
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   FISHER RP, 1992, J BIOL CHEM, V267, P3358
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   MaaswinkelMooij PD, 1996, J PEDIATR-US, V128, P679, DOI 10.1016/S0022-3476(96)80134-X
   Mandel H, 2001, HEPATOLOGY, V34, P776, DOI 10.1053/jhep.2001.27664
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X
   Müller-Höcker J, 1998, VIRCHOWS ARCH, V433, P529, DOI 10.1007/s004280050285
   Müller-Höcker J, 1998, VIRCHOWS ARCH, V432, P349, DOI 10.1007/s004280050177
   Müller-Höcker J, 2002, HUM PATHOL, V33, P247, DOI 10.1053/hupa.2002.31477
   Müller-Höcker J, 2001, APPL IMMUNOHISTO M M, V9, P276, DOI 10.1097/00022744-200109000-00013
   MUller-Hocker J, 1996, METHODS ENZYMOLOGY M, V0, P540
   MullerHocker J, 1997, HEPATOLOGY, V26, P709
   MULLERHOCKER J, 1992, HUM PATHOL, V23, P1431, DOI 10.1016/0046-8177(92)90065-B
   MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127
   MULLERHOCKER J, 1989, HUM PATHOL, V20, P666, DOI 10.1016/0046-8177(89)90154-8
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   Reichenbach J, 2006, PEDIATR RES, V60, P321, DOI 10.1203/01.pdr.0000233252.60457.cf
   Roels F, 2009, BMC CLIN PATHOL, V9, P0, DOI 10.1186/1472-6890-9-4
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Santorelli FM, 2002, NEUROMUSCULAR DISORD, V12, P56, DOI 10.1016/S0960-8966(01)00248-6
   Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447
   SEIBEL P, 1991, METHODS IN MOLECULAR AND CELLULAR BIOLOGY, V2, P147
   Setzer B, 2005, J INFECT DIS, V191, P848, DOI 10.1086/427655
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tanji K, 2003, LIVER INT, V23, P397, DOI 10.1034/j.1478-3231.2003.00864.x
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 63
TC 12
Z9 15
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD FEB 15
PY 2011
VL 15
IS 2
BP 445
EP 456
DI 10.1111/j.1582-4934.2009.00819.x
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 726TL
UT WOS:000287749000023
PM 19538466
DA 2024-11-01
ER

PT J
AU Okamoto, Y
   Higuchi, I
   Sakiyama, Y
   Tokunaga, S
   Watanabe, O
   Arimura, K
   Nakagawa, M
   Takashima, H
AF Okamoto, Yuji
   Higuchi, Itsuro
   Sakiyama, Yusuke
   Tokunaga, Shoko
   Watanabe, Osamu
   Arimura, Kimiyoshi
   Nakagawa, Masanori
   Takashima, Hiroshi
TI A New Mitochondria-Related Disease Showing Myopathy with Episodic Hyper-creatine Kinase-emia
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID hereditary optic neuropathy; dna; mutation; microarray; gene
AB Objective: To elucidate the relationship between mitochondrial DNA (mtDNA) alterations and a mitochondrial disease with a distinct combination of characteristic symptoms, namely episodic hyper-creatine kinase (CK)-emia and mild myopathy. Methods: We selected 9 patients with mtDNA np8291 alteration from 586 patients suspected to have a mitochondrial disease, and assessed them clinically, pathologically, and genetically. These 9 patients had undiagnosed mitochondrial myopathy with episodic hyper-CK-emia, all showing similar symptoms and progression. Results: Patients had mild muscle weakness and episodic hyper-CK-emia triggered by infections or drugs. Five of 9 patients were initially diagnosed with other conditions, such as myasthenia gravis, polymyositis, viral myositis, and drug-induced myopathy, because these conditions were acute or subacute, and 9 patients showed the same 16 mtDNA alterations, which have been reported to be nonpathological polymorphisms. Muscle biopsy revealed ragged-red fibers, highly expressed succinate dehydrogenase staining fibers, and cytochrome c oxidase-deficient fibers. Because their mitochondrial sequence data was almost the same, and 9 patients live in widely separated cities in Japan, the alterations may have arisen from a single source. Interpretation: These findings suggest that mild myopathy with episodic hyper-CK-emia associated with some of the 16 mtDNA alterations or at least with their mitochondria, could be a novel mitochondrial disease. Therefore, we propose that this disease be named as "mitochondrial myopathy with episodic hyper-CK-emia (MIMECK).'' These alterations could work concomitantly and probably modify the impact of medications or other environmental factors. We believe these findings provide an insight into a novel aspect of mitochondrial disease pathogenesis. ANN NEUROL 2011;70:486-492
C1 [Okamoto, Yuji; Higuchi, Itsuro; Sakiyama, Yusuke; Tokunaga, Shoko; Watanabe, Osamu; Takashima, Hiroshi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, Kagoshima 8908520, Japan.
   [Arimura, Kimiyoshi] Okatsu Neurol & Rehabil Hosp, Kagoshima, Japan.
   [Nakagawa, Masanori] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Neurol, Kyoto, Japan.
C3 Kagoshima University; Kyoto Prefectural University of Medicine
RP Takashima, H (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM thiroshi@m3.kufm.kagoshima-u.ac.jp
FU Nervous and Mental Disorders and Research Committee for Ataxic Disease of the Japanese Ministry of Health, Welfare and Labor [19A-1]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [21591095, 21591094]; Nervous and Mental Disorders from the Ministry of Health, Labor, and Welfare [20B-13]; Eisai; Pfizer; Sanofi-Aventis; Teijin Pharma; Novartis; Tanabe-Mitsubishi Dainippon-Sumitomo; Astellas; GlaxoSmithkline; Benesis; Grants-in-Aid for Scientific Research [21591095, 22590939, 21591094] Funding Source: KAKEN
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Baker SK, 2001, CLIN INVEST MED, V24, P258
   Boerkoel CF, 2001, AM J HUM GENET, V68, P325, DOI 10.1086/318208
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   Chariot Patrick, 1995, CURRENT OPINION IN RHEUMATOLOGY, V7, P497, DOI 10.1097/00002281-199511000-00006
   Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201
   Dalakas MC, 2001, J PERIPHER NERV SYST, V6, P14, DOI 10.1046/j.1529-8027.2001.006001014.x
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Dugué A, 2004, EUR J CLIN PHARMACOL, V60, P285, DOI 10.1007/s00228-004-0760-1
   Evans M, 2002, DRUG SAFETY, V25, P649, DOI 10.2165/00002018-200225090-00004
   HAYS AP, 1994, MYOLOGY, V2, P1399
   Hirata K, 1999, J HUM GENET, V44, P210, DOI 10.1007/s100380050145
   JOY JL, 1989, MUSCLE NERVE, V12, P206, DOI 10.1002/mus.880120308
   Kallianpur AR, 2009, PHARMACOGENOMICS, V10, P623, DOI 10.2217/pgs.09.14
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Kong QP, 2006, HUM MOL GENET, V15, P2076, DOI 10.1093/hmg/ddl130
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Masanés F, 1998, J NEUROL SCI, V159, P226, DOI 10.1016/S0022-510X(98)00151-8
   Melberg A, 1998, NEUROLOGY, V50, P299, DOI 10.1212/WNL.50.1.299
   Mimaki M, 2003, J HUM GENET, V48, P47, DOI 10.1007/s100380300005
   Mimaki M, 2009, MITOCHONDRION, V9, P115, DOI 10.1016/j.mito.2009.01.005
   MUNSAT TL, 1973, JAMA-J AM MED ASSOC, V226, P1536, DOI 10.1001/jama.226.13.1536
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   RIODANEVA P, 1995, BRAIN, V118, P319
   Rowland LP, 1980, MUSCULAR DYSTROPHY R, V0, P3
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681
   Zhou SY, 2006, J MOL DIAGN, V8, P476, DOI 10.2353/jmoldx.2006.060008
NR 30
TC 4
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD SEP 15
PY 2011
VL 70
IS 3
BP 486
EP 492
DI 10.1002/ana.22498
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 819HU
UT WOS:000294816800022
PM 21905081
DA 2024-11-01
ER

PT J
AU Shikata, C
   Nemoto, M
   Ebisawa, T
   Nishiyama, A
   Takeda, N
AF Shikata, Chihiro
   Nemoto, Masami
   Ebisawa, Takanori
   Nishiyama, Akihiro
   Takeda, Nobuakira
TI Mitochondrial DNA and Heart Disease
SO GENES AND CARDIOVASCULAR FUNCTION
LA English
DT Article; Book Chapter
DE Arrhythmia; Cardiomyopathy; Heart failure; Kearns-Sayre syndrome; MELAS; MERRF; Mitochondrial DNA; Mitochondrial encephalomyopathy
ID kearns-sayre syndrome; progressive external ophthalmoplegia; maternally inherited myopathy; parkinson-white-syndrome; cardiac involvement; lactic-acidosis; leigh-syndrome; dilated cardiomyopathy; point mutations; melas subgroup
AB The relationship between abnormalities of myocardial mitochondrial DNA and heart disease is reviewed. Myocardial mitochondrial DNA abnormalities can induce both hypertrophic and dilated cardiomyopathies. In mitochondrial encephalomyopathy, abnormalities of myocardial mitochondrial DNA can also induce cardiac involvement, for example, heart failure and arrhythmia. The influence of acquired mitochondrial DNA mutations is also discussed.
C1 [Shikata, Chihiro] Jikei Univ, Dept Internal Med, Aoto Hosp, Sch Med, Tokyo, Japan.
C3 Jikei University
RP Takeda, N (corresponding author), Jikei Univ, Dept Internal Med, Aoto Hosp, Sch Med, Tokyo, Japan.
EM ntakeda@jikei.ac.jp
CR ADACHI K, 1993, BIOCHEM BIOPH RES CO, V195, P945, DOI 10.1006/bbrc.1993.2135
   Akita Y, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU15>3.0.CO;2-B
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Azevedo O, 2010, CARDIOLOGY, V115, P71, DOI 10.1159/000252811
   BAUMER A, 1994, AM J HUM GENET, V54, P618
   BORDARIER C, 1990, NEUROPEDIATRICS, V21, P106, DOI 10.1055/s-2008-1071473
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   ELLES CN, 1987, BIOCHEM J, V245, P309
   Fosslien E, 2003, ANN CLIN LAB SCI, V33, P371
   FOURET RJ, 1994, FORENSIC SCI, V39, P693
   GERBITZ KD, 1990, J NEUROL, V237, P5, DOI 10.1007/BF00319660
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HATTORI K, 1991, AM HEART J, V122, P866, DOI 10.1016/0002-8703(91)90542-P
   HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I
   HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   HAYASHI JI, 1994, J BIOL CHEM, V269, P19060
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   HOLT IJ, 1988, LANCET, V1, P1462
   KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899
   KENNY D, 1990, AM HEART J, V120, P440, DOI 10.1016/0002-8703(90)90097-H
   Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6
   Komaki H, 2010, BBA-GEN SUBJECTS, V1800, P313, DOI 10.1016/j.bbagen.2009.07.008
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   Li YY, 2001, CIRCULATION, V104, P2492, DOI 10.1161/hc4501.098944
   Limongelli G, 2010, EUR J HEART FAIL, V12, P114, DOI 10.1093/eurjhf/hfp186
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   MELACINI P, 1990, JPN HEART J, V31, P115
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   OBERMAIERKUSSER B, 1990, BIOCHEM BIOPH RES CO, V169, P1007, DOI 10.1016/0006-291X(90)91994-4
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W
   OZAWA T, 1991, JPN CIRC J, V55, P1158, DOI 10.1253/jcj.55.1158
   Ozawa T, 1995, EUR HEART J, V16, P10, DOI 10.1093/eurheartj/16.suppl_O.10
   OZAWA T, 1995, BIOCHEM BIOPH RES CO, V207, P613, DOI 10.1006/bbrc.1995.1232
   OZAWA T, 1988, BIOCHEM BIOPH RES CO, V154, P1240, DOI 10.1016/0006-291X(88)90272-0
   OZAWA T, 1995, LANCET, V345, P189, DOI 10.1016/S0140-6736(95)90191-4
   OZAWA T, 1994, HERZ, V19, P105
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PONZETTO C, 1990, J NEUROL SCI, V96, P207, DOI 10.1016/0022-510X(90)90133-8
   Ruiter EM, 2007, EUR J HUM GENET, V15, P155, DOI 10.1038/sj.ejhg.5201735
   Salles JE, 2006, DIABETES RES CLIN PR, V72, P100, DOI 10.1016/j.diabres.2005.09.005
   SATO W, 1993, AM HEART J, V125, P550, DOI 10.1016/0002-8703(93)90046-C
   SATO W, 1994, AM HEART J, V128, P733, DOI 10.1016/0002-8703(94)90272-0
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Sproule DM, 2007, ARCH NEUROL-CHICAGO, V64, P1625, DOI 10.1001/archneur.64.11.1625
   SUGIYAMA S, 1991, BIOCHEM BIOPH RES CO, V180, P894, DOI 10.1016/S0006-291X(05)81149-0
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950
   TAKEDA N, 1993, MOL CELL BIOCHEM, V119, P105, DOI 10.1007/BF00926860
   TAKEDA N, 1995, HEART HYPERTROPHY FA, V0, P59
   TAKEI YI, 1995, MUSCLE NERVE, V18, P1321, DOI 10.1002/mus.880181115
   TANAKA M, 1989, BIOCHEM BIOPH RES CO, V164, P156, DOI 10.1016/0006-291X(89)91696-3
   TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z
   TANAKA M, 1995, MUSCLE NERVE, V0, PS165
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   TRANCHANT C, 1993, NEUROMUSCULAR DISORD, V3, P561, DOI 10.1016/0960-8966(93)90116-2
   Turner LF, 1998, EUR HEART J, V19, P1725, DOI 10.1053/euhj.1998.1125
   ULICNY KS, 1994, PACE, V17, P991, DOI 10.1111/j.1540-8159.1994.tb01445.x
   Vydt TCG, 2007, AM J CARDIOL, V99, P264, DOI 10.1016/j.amjcard.2006.07.089
   Wahbi K, 2010, NEUROLOGY, V74, P674, DOI 10.1212/WNL.0b013e3181d0ccf4
   Wang Shi-Bing, 2008, PEDIATRICS AND NEONATOLOGY, V49, P145, DOI 10.1016/S1875-9572(08)60030-3
   Wortmann SB, 2007, ACTA PAEDIATR, V96, P450, DOI 10.1111/j.1651-2227.2006.00158.x
   YOON KL, 1993, PEDIATR RES, V33, P433, DOI 10.1203/00006450-199305000-00002
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   ZEVIANI M, 1995, MUSCLE NERVE, V0, PS170
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
NR 82
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
SN 
EI 
J9 
PD JUN 15
PY 2011
VL 0
IS 
BP 79
EP 84
DI 10.1007/978-1-4419-7207-1_8
PG 6
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA BWM92
UT WOS:000294269500008
DA 2024-11-01
ER

PT J
AU Stumpf, JD
   Copeland, WC
AF Stumpf, Jeffrey D.
   Copeland, William C.
TI Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Mitochondria; mtDNA replication; DNA polymerase gamma; POLG; DNA repair
ID progressive external ophthalmoplegia; base excision-repair; p55 accessory subunit; encoding mip1 gene; saccharomyces-cerevisiae; mtdna mutations; polg mutations; mutator mice; hearing-loss; autosomal-dominant
AB DNA polymerase gamma (pol gamma), encoded by POLG, is responsible for replicating human mitochondrial DNA. About 150 mutations in the human POLG have been identified in patients with mitochondrial diseases such as Alpers syndrome, progressive external ophthalmoplegia, and ataxia-neuropathy syndromes. Because many of the mutations are described in single citations with no genotypic family history, it is important to ascertain which mutations cause or contribute to mitochondrial disease. The vast majority of data about POLG mutations has been generated from biochemical characterizations of recombinant pol gamma. However, recently, the study of mitochondrial dysfunction in Saccharomyces cerevisiae and mouse models provides important in vivo evidence for the role of POLG mutations in disease. Also, the published 3D-structure of the human pol gamma assists in explaining some of the biochemical and genetic properties of the mutants. This review summarizes the current evidence that identifies and explains disease-causing POLG mutations.
C1 [Stumpf, Jeffrey D.; Copeland, William C.] NIEHS, NIH, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, NIH, Mol Genet Lab, 111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU NIH, National Institute of Environmental Health Sciences [ES 065078]
CR Akbari M, 2008, DNA REPAIR, V7, P605, DOI 10.1016/j.dnarep.2008.01.002
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2010, METHODS, V51, P426, DOI 10.1016/j.ymeth.2010.02.023
   Baruffini E, 2010, MITOCHONDRION, V10, P183, DOI 10.1016/j.mito.2009.10.002
   Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137
   Bensch KG, 2007, DIABETES OBES METAB, V9, P74, DOI 10.1111/j.1463-1326.2007.00776.x
   Bensch KG, 2009, AM J PHYSIOL-ENDOC M, V296, PE672, DOI 10.1152/ajpendo.90839.2008
   Bienstock RJ, 2004, MITOCHONDRION, V4, P203, DOI 10.1016/j.mito.2004.05.018
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P404, DOI 10.1016/S0968-0004(03)00165-8
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   Brown TA, 2008, J BIOL CHEM, V283, P36743, DOI 10.1074/jbc.M806174200
   Chabes A, 2007, P NATL ACAD SCI USA, V104, P1183, DOI 10.1073/pnas.0610585104
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Copeland WC, 2008, MOL CELL, V32, P457, DOI 10.1016/j.molcel.2008.11.007
   Dai DF, 2010, AGING CELL, V9, P536, DOI 10.1111/j.1474-9726.2010.00581.x
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   de Moura MB, 2010, ENVIRON MOL MUTAGEN, V51, P391, DOI 10.1002/em.20575
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Dubec SJ, 2008, REJUV RES, V11, P611, DOI 10.1089/rej.2007.0617
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Fernández-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   FOURY F, 1989, J BIOL CHEM, V264, P20552
   Fusté JM, 2010, MOL CELL, V37, P67, DOI 10.1016/j.molcel.2009.12.021
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   GENGA A, 1986, J BIOL CHEM, V261, P9328
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Greaves LC, 2009, AGING CELL, V8, P566, DOI 10.1111/j.1474-9726.2009.00505.x
   Guo XH, 2010, BBA-BIOENERGETICS, V1797, P1159, DOI 10.1016/j.bbabio.2010.04.005
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R
   Kalifa L, 2007, DNA REPAIR, V6, P1732, DOI 10.1016/j.dnarep.2007.06.005
   Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Lee DY, 1996, J BIOL CHEM, V271, P24262, DOI 10.1074/jbc.271.39.24262
   Lee YS, 2010, J BIOL CHEM, V285, P28105, DOI 10.1074/jbc.M110.122283
   Lee YS, 2010, J BIOL CHEM, V285, P1490, DOI 10.1074/jbc.M109.062752
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Martínez-Azorín F, 2008, J NEUROCHEM, V105, P165, DOI 10.1111/j.1471-4159.2007.05122.x
   Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Mookerjee SA, 2006, MUTAT RES-FUND MOL M, V595, P91, DOI 10.1016/j.mrfmmm.2005.10.006
   Mott JL, 2004, BIOCHEM BIOPH RES CO, V319, P1210, DOI 10.1016/j.bbrc.2004.05.104
   Mott JL, 2006, BBA-BIOENERGETICS, V1757, P596, DOI 10.1016/j.bbabio.2006.04.014
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Niu X, 2007, EXP CELL RES, V313, P3924, DOI 10.1016/j.yexcr.2007.05.029
   Phadnis N, 2005, GENETICS, V171, P1549, DOI 10.1534/genetics.105.047092
   Pogorzala L, 2009, GENETICS, V182, P699, DOI 10.1534/genetics.109.103796
   Pohjoismäki JLO, 2010, J MOL BIOL, V397, P1144, DOI 10.1016/j.jmb.2010.02.029
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   ROBBERSODL, 1972, P NATL ACAD SCI USA, V69, P3810, DOI 10.1073/pnas.69.12.3810
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Someya S, 2008, NEUROBIOL AGING, V29, P1080, DOI 10.1016/j.neurobiolaging.2007.01.014
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
   Strand Micheline K, 2002, METHODS MOL BIOL, V197, P151, DOI 10.1385/1-59259-284-8:151
   Strand MK, 2003, EUKARYOT CELL, V2, P809, DOI 10.1128/EC.2.4.809-820.2003
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Sweasy JB, 2006, RADIAT RES, V166, P693, DOI 10.1667/RR0706.1
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Szczesny B, 2008, J BIOL CHEM, V283, P26349, DOI 10.1074/jbc.M803491200
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   TAPPER DP, 1981, J BIOL CHEM, V256, P5109
   Tarnopolsky MA, 2009, APPL PHYSIOL NUTR ME, V34, P348, DOI 10.1139/H09-022
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vermulst M, 2009, CELL METAB, V10, P437, DOI 10.1016/j.cmet.2009.11.001
   Vermulst M, 2008, METHODS, V46, P263, DOI 10.1016/j.ymeth.2008.10.008
   Wiltshire E, 2008, ARCH NEUROL-CHICAGO, V65, P121, DOI 10.1001/archneurol.2007.14
   WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0
   Xu BJ, 1996, EMBO J, V15, P3135, DOI 10.1002/j.1460-2075.1996.tb00676.x
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yamasoba T, 2007, HEARING RES, V226, P185, DOI 10.1016/j.heares.2006.06.004
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
   Zhang DX, 2005, AM J PHYSIOL-HEART C, V288, PH302, DOI 10.1152/ajpheart.00661.2004
   Zhang HS, 2006, GENETICS, V172, P2683, DOI 10.1534/genetics.105.051029
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
NR 122
TC 81
Z9 100
U1 0
U2 26
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JAN 15
PY 2011
VL 68
IS 2
BP 219
EP 233
DI 10.1007/s00018-010-0530-4
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 703IA
UT WOS:000285970400005
PM 20927567
DA 2024-11-01
ER

PT J
AU Emmanuele, V
   Sotiriou, E
   Shirazi, M
   Tanji, K
   Haller, RG
   Heinicke, K
   Bosch, PE
   Hirano, M
   Di Mauro, S
AF Emmanuele, Valentina
   Sotiriou, Evangelia
   Shirazi, Maryam
   Tanji, Kurenai
   Haller, Ronald G.
   Heinicke, Katja
   Bosch, Peter E.
   Hirano, Michio
   Di Mauro, Salvatore
TI Recurrent myoglobinuria in a sporadic patient with a novel mitochondrial DNA tRNA<SUP>Ile</SUP> mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial myopathy; Myoglobinuria; Mitochondrial DNA; tRNA(Ile); Myalgia; Elevated serum CK
ID progressive external ophthalmoplegia; cytochrome-b gene; point mutation; transfer-rna; hypertrophic cardiomyopathy; exercise intolerance; nonsense mutation; leigh-syndrome; rhabdomyolysis; deficiency
AB The differential diagnosis of myoglobinuria includes multiple etiologies, such as infection, inflammation, trauma, endocrinopathies, drugs toxicity, and primary metabolic disorders. Metabolic myopathies can be due to inherited disorders of glycogen metabolism or to defects of fatty acid oxidation. Primary respiratory chain dysfunction is a rare cause of myoglobinuria, but it has been described in sporadic cases with mutations in genes encoding cytochrome b or cytochrome c oxidase (COX) subunits and in four cases with tRNA mutations. We describe a 39-year-old woman with myalgia and exercise-related recurrent myoglobinuria, who harbored a novel mitochondrial DNA mutation at nucleotide 4281 (m.4281A > G) in the tRNA-isoleucine gene. Her muscle biopsy revealed ragged-red and COX-deficient fibers. No deletions or duplication were detected by Southern blot analysis. The m.4281A > G mutation was present in the patient's muscle with a mutation load of 46% and was detected in trace amounts in urine and cheek mucosa. Single-fiber analysis revealed significantly higher levels of the mutation in COX-deficient (65%) than in normal fibers (45%). This novel mutation has to be added to the molecular causes of recurrent myoglobinuria. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Emmanuele, Valentina; Sotiriou, Evangelia; Shirazi, Maryam; Tanji, Kurenai; Hirano, Michio; Di Mauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA.
   [Tanji, Kurenai] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA.
   [Haller, Ronald G.; Heinicke, Katja] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   [Haller, Ronald G.; Heinicke, Katja] VA Med Ctr, Dept Neurol, Inst Exercise & Environm Med, Dallas, TX USA.
   [Bosch, Peter E.] Mayo Clin Arizona, Dept Neurol, Scottsdale, AZ USA.
C3 Columbia University; Columbia University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; Mayo Clinic Phoenix
RP Di Mauro, S (corresponding author), Coll Phys & Surg, 4-424 B,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NIH [HD32062]; Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF)
CR Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Berardo A, 2010, CURR NEUROL NEUROSCI, V10, P118, DOI 10.1007/s11910-010-0096-4
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   Bosch X, 2009, NEW ENGL J MED, V361, P62, DOI 10.1056/NEJMra0801327
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Crimi M, 2004, MITOCHONDRION, V3, P279, DOI 10.1016/j.mito.2004.02.004
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Finnila Saara, 2001, MUTATION RESEARCH, V458, P31, DOI 10.1016/S1383-5726(01)00012-7
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   Giannoglou GD, 2007, EUR J INTERN MED, V18, P90, DOI 10.1016/j.ejim.2006.09.020
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612
   Kwon JH, 2003, EUR NEUROL, V50, P123, DOI 10.1159/000072517
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   SANTORELLI FM, 1995, BIOCHEM BIOPH RES CO, V216, P835, DOI 10.1006/bbrc.1995.2697
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   Smits BW, 2007, J NEUROL, V254, P1614, DOI 10.1007/s00415-007-0608-6
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   WROGEMANN K, 1976, LANCET, V1, P672
NR 39
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2011
VL 303
IS 1-2
BP 39
EP 42
DI 10.1016/j.jns.2011.01.018
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 747SO
UT WOS:000289339900006
PM 21324494
DA 2024-11-01
ER

PT J
AU Moran, MM
   Allen, NM
   Treacy, EP
   King, MD
AF Moran, Margaret M.
   Allen, Nicholas M.
   Treacy, Eileen P.
   King, Mary D.
TI "Stiff Neonate" With Mitochondrial DNA Depletion and Secondary Neurotransmitter Defects
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID mutations; diseases; gene
AB Mitochondrial disorders comprise a heterogenous group. A neonate who presented with episodes of severe truncal hypertonia and apnea progressed to a hypokinetic rigid syndrome characterized by hypokinesia, tremulousness, profound head lag, absent suck and gag reflexes, brisk deep tendon reflexes, ankle and jaw clonus, and evidence of autonomic dysfunction. Analysis of cerebrospinal fluid neurotransmitters from age 7 weeks demonstrated low levels of amine metabolites (homovanillic acid and 5-hydroxyindoleacetic acid), tetrahydrobiopterin, and pyridoxal phosphate. Mitochondrial DNA quantitative studies on muscle homogenate demonstrated a mitochondrial DNA depletion disorder. Respiratory chain enzymology demonstrated decreased complex IV activity. Screening for mitochondrial DNA rearrangement disorders and sequencing relevant mitochondrial genes produced negative results. No clinical or biochemical response to treatment with pyridoxal phosphate, tetrahydrobiopterin, or L-dopa occurred. The clinical course was progressive, and the patient died at age 19 months. Mitochondrial disorders causing secondary neurotransmitter diseases are usually severe, but are rarely reported. This diagnosis should be considered in neonates or infants who present with hypertonia, hypokinesia rigidity, and progressive neurodegeneration. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Moran, Margaret M.; Allen, Nicholas M.; King, Mary D.] Childrens Univ Hosp, Dept Paediat Neurol & Clin Neurophysiol, Dublin 1, Ireland.
   [Treacy, Eileen P.] Childrens Univ Hosp, Natl Ctr Inherited Metab Disorders, Dublin 1, Ireland.
C3 Childrens University Hospital - Temple Street; Childrens University Hospital - Temple Street
RP Allen, NM (corresponding author), Childrens Univ Hosp, Dept Paediat Neurol & Clin Neurophysiol, Temple St, Dublin 1, Ireland.
EM nicholasallen@physicians.ie
CR Assmann B, 2003, ANN NEUROL, V54, PS18, DOI 10.1002/ana.10628
   Footitt EJ, 2011, J INHERIT METAB DIS, V34, P529, DOI 10.1007/s10545-011-9279-7
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   García-Cazorla A, 2007, DEV MED CHILD NEUROL, V49, P740, DOI 10.1111/j.1469-8749.2007.00740.x
   Garcia-Cazorla A, 2008, MITOCHONDRION, V8, P273, DOI 10.1016/j.mito.2008.05.001
   Herlenius E, 2004, EXP NEUROL, V190, PS8, DOI 10.1016/j.expneurol.2004.03.027
   Herlenius E, 2001, EARLY HUM DEV, V65, P21, DOI 10.1016/S0378-3782(01)00189-X
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pons R, 2009, J INHERIT METAB DIS, V32, P321, DOI 10.1007/s10545-008-1007-6
   Spinazzola A, 2011, SEMIN FETAL NEONAT M, V16, P190, DOI 10.1016/j.siny.2011.04.011
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
NR 13
TC 8
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0887-8994
EI 
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD DEC 15
PY 2011
VL 45
IS 6
BP 403
EP 405
DI 10.1016/j.pediatrneurol.2011.08.009
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 859OL
UT WOS:000297885600010
PM 22115005
DA 2024-11-01
ER

PT J
AU Galmiche, L
   Jaubert, F
   Sauvat, F
   Sarnacki, S
   Goulet, O
   Assouline, Z
   Vedrenne, V
   Lebre, AS
   Boddaert, N
   Brousse, N
   Chrétien, D
   Munnich, A
   Rötig, A
AF Galmiche, L.
   Jaubert, F.
   Sauvat, F.
   Sarnacki, S.
   Goulet, O.
   Assouline, Z.
   Vedrenne, V.
   Lebre, A-S.
   Boddaert, N.
   Brousse, N.
   Chretien, D.
   Munnich, A.
   Roetig, A.
TI Normal oxidative phosphorylation in intestinal smooth muscle of childhood chronic intestinal pseudo-obstruction
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article
DE childhood; chronic intestinal pseudo-obstruction; mitochondria; smooth muscle
ID of-the-literature; hypoperistalsis syndrome; children; manifestations; diagnosis; myopathy; infants; disease; mngie
AB Background Chronic intestinal pseudo-obstruction (CIPO) is a severe disease of the digestive tract motility. In pediatric population, CIPO remains of unknown origin for most patients. Chronic intestinal pseudo-obstruction is also a common feature in the course of mitochondrial oxidative phosphorylation disorders related for some patients to mutations in TYMP, POLG1, mtDNA tRNAleu(UUR) or tRNAlys genes. We hypothesized that CIPOs could be the presenting symptom of respiratory chain enzyme deficiency and thus we investigated oxidative phosphorylation in small bowel and/or colon smooth muscle of primary CIPO children. Methods We studied eight children with CIPO and 12 pediatric controls. We collected clinical, radiological and pathological data and measured respiratory chain enzymatic activity in isolated smooth muscle of the small bowel and/or the colon. We also sequenced TYMP, POLG, mtDNA tRNAleu(UUR) and tRNAlys genes. Key Results Neither pathological nor radiological data were in favor of a mitochondrial dysfunction. No respiratory chain enzyme deficiency was detected in CIPO children. In myogenic CIPO, respiratory enzymes and citrate synthase activities were increased in small bowel and/or colon whereas no abnormality was noted in neurogenic and unclassified CIPO. Levels of enzyme activities were higher in control small bowel than in control colon muscle. Sequencing of TYMP, POLG, mtDNA tRNAleu(UUR) and tRNAlys genes and POLG gene did not reveal mutation for any of the patients. Conclusions & Inferences The normal enzymatic activities as the lack of radiological and genetic abnormalities indicate that, at variance with adult patients, oxidative phosphorylation deficiency is not a common cause of childhood CIPO.
C1 [Galmiche, L.] Univ Paris 05, Hop Necker Enfants Malad, Fac Med, INSERM,U781,Dept Pathol & Tumorotheque, F-75015 Paris, France.
   [Galmiche, L.; Jaubert, F.; Sauvat, F.; Sarnacki, S.; Goulet, O.; Assouline, Z.; Vedrenne, V.; Lebre, A-S.; Boddaert, N.; Brousse, N.; Chretien, D.; Munnich, A.; Roetig, A.] Univ Paris 05, AP HP, F-75015 Paris, France.
   [Galmiche, L.; Assouline, Z.; Vedrenne, V.; Lebre, A-S.; Chretien, D.; Munnich, A.; Roetig, A.] Univ Paris 05, Hop Necker Enfants Malad, Fac Med, Dept Genet, F-75015 Paris, France.
   [Sauvat, F.; Sarnacki, S.] Univ Paris 05, Hop Necker Enfants Malad, Fac Med, Dept Paediat Surg, F-75015 Paris, France.
   [Goulet, O.] Univ Paris 05, Hop Necker Enfants Malad, Fac Med, Dept Paediat Gastroenterol, F-75015 Paris, France.
   [Boddaert, N.] Univ Paris 05, Hop Necker Enfants Malad, Fac Med, Dept Paediat Radiol, F-75015 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP
RP Galmiche, L (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, Fac Med, INSERM,U781,Dept Pathol & Tumorotheque, 149 Rue Sevres, F-75015 Paris, France.
EM louise.galmiche@inserm.fr
CR Amiot A, 2009, GASTROENTEROLOGY, V137, P101, DOI 10.1053/j.gastro.2009.03.054
   Blondon H, 2005, GASTROEN CLIN BIOL, V29, P773, DOI 10.1016/S0399-8320(05)86346-8
   Ciftci AO, 1996, J PEDIATR SURG, V31, P1706, DOI 10.1016/S0022-3468(96)90058-5
   De Giorgio R, 2004, GUT, V53, P1549, DOI 10.1136/gut.2004.043968
   Di Lorenzo C, 1999, GASTROENTEROLOGY, V116, P980
   Faure C, 1999, DIGEST DIS SCI, V44, P953, DOI 10.1023/A:1026656513463
   Feldstein AE, 2003, J PEDIATR GASTR NUTR, V36, P492, DOI 10.1097/00005176-200304000-00016
   García-Velasco A, 2003, J INTERN MED, V253, P381, DOI 10.1046/j.1365-2796.2003.01095.x
   Gillis LA, 2003, GASTROENTEROL CLIN N, V32, P789, DOI 10.1016/S0889-8553(03)00052-9
   Goulet O, 1999, EUR J PEDIATR SURG, V9, P83, DOI 10.1055/s-2008-1072218
   HYMAN PE, 1995, SCAND J GASTROENTERO, V30, P39
   KERN IB, 1990, J PEDIATR GASTR NUTR, V11, P411, DOI 10.1097/00005176-199010000-00023
   Köhler M, 2004, EUR J PEDIATR SURG, V14, P362, DOI 10.1055/s-2004-821208
   KRISHNAMURTHY S, 1993, GASTROENTEROLOGY, V104, P1398, DOI 10.1016/0016-5085(93)90348-G
   Lapointe SP, 2002, J UROLOGY, V168, P1768, DOI 10.1016/S0022-5347(05)64410-2
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   NONAKA M, 1989, PEDIATRIC PATHOLOGY, V9, P409
   Rudolph CD, 1997, J PEDIATR GASTR NUTR, V24, P102, DOI 10.1097/00005176-199701000-00021
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SCHUFFLER MD, 1988, GASTROENTEROLOGY, V94, P892, DOI 10.1016/0016-5085(88)90544-6
NR 21
TC 2
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
EI 1365-2982
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD JAN 15
PY 2011
VL 23
IS 1
BP 24
EP E1
DI 10.1111/j.1365-2982.2010.01595.x
PG 7
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 691WH
UT WOS:000285111000005
PM 20879992
DA 2024-11-01
ER

PT J
AU Isohanni, P
   Hakonen, AH
   Euro, L
   Paetau, I
   Linnankivi, T
   Liukkonen, E
   Wallden, T
   Luostarinen, L
   Valanne, L
   Paetau, A
   Uusimaa, J
   Lönnqvist, T
   Suomalainen, A
   Pihko, H
AF Isohanni, P.
   Hakonen, A. H.
   Euro, L.
   Paetau, I.
   Linnankivi, T.
   Liukkonen, E.
   Wallden, T.
   Luostarinen, L.
   Valanne, L.
   Paetau, A.
   Uusimaa, J.
   Lonnqvist, T.
   Suomalainen, A.
   Pihko, H.
TI <i>POLG1</i> manifestations in childhood
SO NEUROLOGY
LA English
DT Article
ID mutations; disorders; depletion; ataxia
AB Objective: Mitochondrial DNA polymerase gamma (POLG1) mutations in children often manifest as Alpers syndrome, whereas in adults, a common manifestation is mitochondrial recessive ataxia syndrome (MIRAS) with severe epilepsy. Because some patients with MIRAS have presented with ataxia or epilepsy already in childhood, we searched for POLG1 mutations in neurologic manifestations in childhood. Methods: We investigated POLG1 in 136 children, all clinically suspected to have mitochondrial disease, with one or more of the following: ataxia, axonal neuropathy, severe epilepsy without known epilepsy syndrome, epileptic encephalopathy, encephalohepatopathy, or neuropathologically verified Alpers syndrome. Results: Seven patients had POLG1 mutations, and all of them had severe encephalopathy with intractable epilepsy. Four patients had died after exposure to sodium valproate. Brain MRI showed parieto-occipital or thalamic hyperintense lesions, white matter abnormality, and atrophy. Muscle histology and mitochondrial biochemistry results were normal in all. Conclusions: POLG1 analysis should belong to the first-line DNA diagnostic tests for children with an encephalitis-like presentation evolving into epileptic encephalopathy with liver involvement (Alpers syndrome), even if brain MRI and morphology, respiratory chain activities, and the amount of mitochondrial DNA in the skeletal muscle are normal. POLG1 analysis should precede valproate therapy in pediatric patients with a typical phenotype. However, POLG1 is not a common cause of isolated epilepsy or ataxia in childhood. Neurology (R) 2011;76:811-815
C1 [Isohanni, P.; Hakonen, A. H.; Euro, L.; Paetau, I.; Suomalainen, A.] Univ Helsinki, Res Program Mol Neurol, Helsinki 00290, Finland.
   [Valanne, L.] Univ Helsinki, Helsinki Med Imaging Ctr, Helsinki 00290, Finland.
   [Paetau, A.] Univ Helsinki, Dept Pathol, Helsinki 00290, Finland.
   [Isohanni, P.; Linnankivi, T.; Liukkonen, E.; Lonnqvist, T.; Pihko, H.] Univ Helsinki, Div Child Neurol, Cent Hosp, Helsinki 00290, Finland.
   [Wallden, T.] Cent Hosp Kymenlaakso, Dept Pediat, Kotka, Finland.
   [Luostarinen, L.] Cent Hosp Paijat Hame, Dept Neurol, Lahti, Finland.
   [Uusimaa, J.] Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Oulu; University of Oulu
RP Isohanni, P (corresponding author), Univ Helsinki, Res Program Mol Neurol, C518b,Haartmaninkatu 8, Helsinki 00290, Finland.
EM pirjo.isohanni@helsinki.fi
FU Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation; Academy of Finland; University of Helsinki; Helsinki University Central Hospital; Biomedicum Helsinki Foundation; Nutricia; Arvo and Lea Ylppo Foundation; Janssen
CR de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
NR 10
TC 41
Z9 44
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD MAR 1
PY 2011
VL 76
IS 9
BP 811
EP 815
DI 10.1212/WNL.0b013e31820e7b25
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 728JE
UT WOS:000287869600011
PM 21357833
DA 2024-11-01
ER

PT J
AU Gianotti, TF
   Castaño, G
   Gemma, C
   Burgueño, AL
   Rosselli, MS
   Pirola, CJ
   Sookoian, S
AF Fernandez Gianotti, Tomas
   Castano, Gustavo
   Gemma, Carolina
   Burgueno, Adriana L.
   Soledad Rosselli, Maria
   Pirola, Carlos J.
   Sookoian, Silvia
TI Mitochondrial DNA copy number is modulated by genetic variation in the signal transducer and activator of transcription 3 (<i>STAT3</i>)
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID genome-wide association; insulin sensitivity; skeletal-muscle; disease; variants; cancer; cells; pcr; biogenesis; expression
AB The regulation of mitochondrial DNA (mtDNA) copy number not only is critical for the maintenance of the normal mitochondrial function but has a strong clinical significance. A recent report revealed that the signal transducer and activator of transcription 3 (STAT3) is involved in the regulation of the mitochondrial function and is required for the optimal function of the electron transport chain. In this study, we explored whether gene variants in the STAT3 influence the leukocyte mtDNA copy number. Clinical data and blood samples were collected from 179 subjects (aged 52.8 +/- 0.9 years). Mitochondrial DNA quantification using nuclear DNA (nDNA) as a reference was carried out by a real-time quantitative polymerase chain reaction method; results are presented as the mtDNA/nDNA ratio. We selected 3 tag single nucleotide polymorphisms showing a minor allele frequency greater than 10% (rs2293152 C/G, rs6503695 C/T, and rs9891119 A/C), representing 24 polymorphic sites of the STAT3 (r(2) > 0.8). We observed a significant association between mtDNA/nDNA ratio and both rs6503695 and rs9891119, adjusted by age and homeostasis model assessment index. The proportion of the total variance of the mtDNA/nDNA ratio accounted for by the rs6503695 and rs9891119 genotypes was 4.7% and 6.53%, respectively. Common variation in the STAT3 may influence mtDNA copy number. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Castano, Gustavo; Sookoian, Silvia] Govt City Buenos Aires, Res Council Hlth, Buenos Aires, DF, Argentina.
   [Castano, Gustavo; Sookoian, Silvia] Hosp Abel Zubizarreta, Dept Med & Surg, Buenos Aires, DF, Argentina.
   [Soledad Rosselli, Maria] Univ Buenos Aires, Dept Clin & Mol Hepatol, Inst Med Res A Lanari IDIM, CONICET, Buenos Aires, DF, Argentina.
   [Fernandez Gianotti, Tomas; Gemma, Carolina; Burgueno, Adriana L.; Pirola, Carlos J.] Univ Buenos Aires, Dept Mol Genet & Biol Complex Dis, Inst Med Res A Lanari IDIM, CONICET, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires
RP Sookoian, S (corresponding author), Inst Invest Med A Lanari, RA-1427 Buenos Aires, DF, Argentina.
EM ssookoian@lanari.fmed.uba.ar
FU UBACyT, Universidad de Buenos Aires [M055]; Agencia Nacional de Promocion Cientifica y Tecnologica [PICT 2006-124, PICT 2008-1521]; Consejo de Investigacion en Salud, Gobierno de la Ciudad de Buenos Aires
CR Alvarez V, 2008, J ALZHEIMERS DIS, V13, P275
   Alvarez V, 2008, NEUROSCI LETT, V432, P79, DOI 10.1016/j.neulet.2007.12.010
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   Curran JE, 2010, HUM GENET, V127, P183, DOI 10.1007/s00439-009-0756-0
   Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099
   Elam MB, 2010, METABOLISM, V59, P587, DOI 10.1016/j.metabol.2009.09.001
   Gemma C, 2006, OBESITY, V14, P2193, DOI 10.1038/oby.2006.257
   Gianotti TF, 2008, OBESITY, V16, P1591, DOI 10.1038/oby.2008.253
   Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721
   Günther C, 2004, NEUROSCI LETT, V369, P219, DOI 10.1016/j.neulet.2004.07.070
   Higuchi M, 2007, MITOCHONDRION, V7, P53, DOI 10.1016/j.mito.2006.12.001
   Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687
   Inghirami G, 2005, CELL CYCLE, V4, P1131, DOI 10.4161/cc.4.9.1985
   Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100
   Jakkula E, 2010, AM J HUM GENET, V86, P285, DOI 10.1016/j.ajhg.2010.01.017
   Kawasaki E-S, 1990, PCR PROTOCOLS GUIDE, V0, P0
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650
   Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001
   Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7
   Myakishev MV, 2001, GENOME RES, V11, P163, DOI 10.1101/gr.157901
   Pagani F, 2004, NAT REV GENET, V5, P389, DOI 10.1038/nrg1327
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316
   Rutledge RG, 2004, NUCLEIC ACIDS RES, V32, P0, DOI 10.1093/nar/gnh177
   Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004
   Song J, 2001, DIABETES CARE, V24, P865, DOI 10.2337/diacare.24.5.865
   Sookoian S, 2008, CYTOKINE, V44, P201, DOI 10.1016/j.cyto.2008.08.001
   Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Vassilev AO, 2002, LEUKEMIA LYMPHOMA, V43, P1461, DOI 10.1080/1042819022386716
   VELTRI KL, 1990, J CELL PHYSIOL, V143, P160, DOI 10.1002/jcp.1041430122
   Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551
   Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003
   Xu ZL, 2009, NUCLEIC ACIDS RES, V37, PW600, DOI 10.1093/nar/gkp290
   Yang Y, 2005, CANCER SCI, V96, P425, DOI 10.1111/j.1349-7006.2005.00063.x
NR 41
TC 12
Z9 14
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 
J9 METABOLISM
JI Metab.-Clin. Exp.
PD AUG 15
PY 2011
VL 60
IS 8
BP 1142
EP 1149
DI 10.1016/j.metabol.2010.12.008
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 799AW
UT WOS:000293256900013
PM 21310444
DA 2024-11-01
ER

PT J
AU Lodi, R
   Tonon, C
   Valentino, ML
   Manners, D
   Testa, C
   Malucelli, E
   La Morgia, C
   Barboni, P
   Carbonelli, M
   Schimpf, S
   Wissinger, B
   Zeviani, M
   Baruzzi, A
   Liguori, R
   Barbiroli, B
   Carelli, V
AF Lodi, Raffaele
   Tonon, Caterina
   Valentino, Maria Lucia
   Manners, David
   Testa, Claudia
   Malucelli, Emil
   La Morgia, Chiara
   Barboni, Piero
   Carbonelli, Michele
   Schimpf, Simone
   Wissinger, Bernd
   Zeviani, Massimo
   Baruzzi, Agostino
   Liguori, Rocco
   Barbiroli, Bruno
   Carelli, Valerio
TI Defective Mitochondrial Adenosine Triphosphate Production in Skeletal Muscle From Patients With Dominant Optic Atrophy Due to <i>OPA1</i> Mutations
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID magnetic-resonance-spectroscopy; external ophthalmoplegia; complex-i; neuropathy; disease; gene; dysfunction; metabolism; deletion; carriers
AB Objective: To assess whether impaired energy metabolism in skeletal muscle is a hallmark feature of patients with dominant optic atrophy due to several different mutations in the OPA1 gene. Design: We used phosphorus 31 magnetic resonance spectroscopy to assess calf muscle oxidative metabolism in subjects with molecularly defined dominant optic atrophy carrying different mutations in the OPA1 gene. In a subset of patients, we also evaluated serum lactate levels after exercise and muscle biopsy results for histology and mitochondrial DNA analysis. Setting: University neuromuscular and neurogenetics and magnetic resonance imaging units. Patients: Eighteen patients with dominant optic atrophy were enrolled from 8 unrelated families, 7 of which carried an OPA1 mutation predicted to induce haplo-insufficiency and 1 with a missense mutation in exon 27. Fifteen patients had documented optic atrophy. Main Outcome Measures: Presence of skeletal muscle mitochondrial oxidative phosphorylation dysfunction as assessed by phosphorus 31 magnetic resonance spectroscopy, serum lactate levels, and histological and mitochondrial DNA analysis. Results: Phosphorus 31 magnetic resonance spectroscopy showed reduced phosphorylation potential in the calf muscle at rest in patients with an OPA1 mutation (-24% from normal mean; P=.003) as well as a reduced maximum rate of mitochondrial adenosine triphosphate synthesis (-36%; P<.001; ranging from -28% to -49% in association with different mutations). In 4 of 10 patients (40%), the serum lactate level after exercise was elevated. Only 2 of 5 muscle biopsies, from the 2 patients with a missense mutation, showed slight myopathic changes. Low levels of mitochondrial DNA multiple deletions were found in all muscle biopsies. Conclusions: Defective oxidative phosphorylation in skeletal muscle is a subclinical feature of patients with OPA1-related dominant optic atrophy, indicating a systemic expression of the OPA1 defect, similar to that previously reported for Leber hereditary optic neuropathy due to complex I dysfunction. This defect of oxidative phosphorylation does not appear to depend on the low amounts of mitochondrial DNA multiple deletions detected in muscle biopsies.
C1 [Lodi, Raffaele; Tonon, Caterina; Manners, David; Testa, Claudia; Malucelli, Emil; Barbiroli, Bruno] Univ Bologna, MR Spect Unit, Dept Internal Med Aging & Nephrol, I-40138 Bologna, Italy.
   [Valentino, Maria Lucia; La Morgia, Chiara; Barboni, Piero; Carbonelli, Michele; Baruzzi, Agostino; Liguori, Rocco; Carelli, Valerio] Univ Bologna, Dept Neurol Sci, I-40138 Bologna, Italy.
   [Carbonelli, Michele] Studio Oculist dAzeglio, Bologna, Italy.
   [Zeviani, Massimo] Natl Neurol Inst, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Milan, Italy.
   [Schimpf, Simone; Wissinger, Bernd] Univ Augenklin, Mol Genet Lab, Tubingen, Germany.
C3 University of Bologna; University of Bologna; Fondazione IRCCS Istituto Neurologico Carlo Besta; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital
RP Lodi, R (corresponding author), Univ Bologna, MR Spect Unit, Dept Internal Med Aging & Nephrol, Via Massarenti 9, I-40138 Bologna, Italy.
EM raffaele.lodi@unibo.it
FU Telethon-Italy [GGP06233]
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   BARBIROLI B, 1995, NEUROLOGY, V45, P1364, DOI 10.1212/WNL.45.7.1364
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 1998, J NEUROL SCI, V160, P183, DOI 10.1016/S0022-510X(98)00239-1
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Chevrollier A, 2008, ANN NEUROL, V63, P794, DOI 10.1002/ana.21385
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   KJER P, 1959, ACTA OPHTHALMOL S, V54, P1
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511
   Lodi R, 2000, BRAIN, V123, P1896, DOI 10.1093/brain/123.9.1896
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Lodi R, 1997, ANN NEUROL, V42, P573, DOI 10.1002/ana.410420407
   Martinuzzi A, 2008, MUSCLE NERVE, V37, P350, DOI 10.1002/mus.20937
   Mayorov Vladimir I, 2008, BMC BIOCHEMISTRY, V9, P9, DOI 10.1186/1471-2091-9-22
   MONTAGNA P, 1995, J NEUROL NEUROSUR PS, V58, P640, DOI 10.1136/jnnp.58.5.640
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2006, BBA-MOL CELL RES, V1763, P500, DOI 10.1016/j.bbamcr.2006.04.003
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Schimpf S, 2006, HUM GENET, V118, P767, DOI 10.1007/s00439-005-0096-7
   Spinazzi M, 2008, HUM MOL GENET, V17, P3291, DOI 10.1093/hmg/ddn225
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270
   Yu-Wai-Man P, 2009, INVEST OPHTH VIS SCI, V50, P4561, DOI 10.1167/iovs.09-3634
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
NR 35
TC 33
Z9 37
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JAN 15
PY 2011
VL 68
IS 1
BP 67
EP 73
DI 10.1001/archneurol.2010.228
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 704MO
UT WOS:000286057300009
PM 20837821
DA 2024-11-01
ER

PT J
AU Chaudhary, KR
   El-Sikhry, H
   Seubert, JM
AF Chaudhary, Ketul R.
   El-Sikhry, Haitham
   Seubert, John M.
TI Mitochondria and the aging heart
SO JOURNAL OF GERIATRIC CARDIOLOGY
LA English
DT Review
DE aging; heart; mitochondria; heart diseases; reactive oxygen species
ID preserved ejection fraction; diastolic dysfunction; rate-variability; skeletal-muscle; life-span; myocardial injury; oxidative damage; dna mutations; nuclear-dna; age
AB The average human life span has markedly increased in modern society largely attributed to advances in medical and therapeutic sciences that have successfully reduced important health risks. However, advanced age results in numerous alterations to cellular and subcellular components that can impact the overall health and function of an individual. Not surprisingly, advanced age is a major risk factor for the development of heart disease in which elderly populations observe increased morbidity and mortality. Even healthy individuals that appear to have normal heart function under resting conditions, actually have an increased susceptibility and vulnerability to stress. This is confounded by the impact that stress and disease can have over time to both the heart and vessels. Although, there is a rapidly growing body of literature investigating the effects of aging on the heart and how age-related alterations affect cardiac function, the biology of aging and underlying mechanisms remain unclear. In this review, we summarize effects of aging on the heart and discuss potential theories of cellular aging with special emphasis on mitochondrial dysfunction.
C1 [Chaudhary, Ketul R.; El-Sikhry, Haitham; Seubert, John M.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
C3 University of Alberta
RP Seubert, JM (corresponding author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
EM jseubert@pharmacy.ualberta.ca
FU Alberta Innovates Health Solutions; Heart and Stroke Foundation of Canada; Alberta Heritage Foundation for Medical Research (AHFMR)
CR Abete P, 1999, J MOL CELL CARDIOL, V31, P227, DOI 10.1006/jmcc.1998.0862
   Ahmed A, 2011, MED CLIN N AM, V95, P439, DOI 10.1016/j.mcna.2011.02.001
   Ahmet I, 2011, J MOL CELL CARDIOL, V51, P263, DOI 10.1016/j.yjmcc.2011.04.015
   Alexeyev MF, 2004, CLIN SCI, V107, P355, DOI 10.1042/CS20040148
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680
   Bhatia RS, 2006, NEW ENGL J MED, V355, P260, DOI 10.1056/NEJMoa051530
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Boyle AJ, 2011, EXP GERONTOL, V46, P549, DOI 10.1016/j.exger.2011.02.010
   Brady NR, 2006, ANTIOXID REDOX SIGN, V8, P1651, DOI 10.1089/ars.2006.8.1651
   Bratic I, 2010, BBA-BIOENERGETICS, V1797, P961, DOI 10.1016/j.bbabio.2010.01.004
   Bujak M, 2008, J AM COLL CARDIOL, V51, P1384, DOI 10.1016/j.jacc.2008.01.011
   Burlew Brad S, 2000, CARDIOLOGY CLINICS, V18, P435, DOI 10.1016/S0733-8651(05)70154-5
   Carter JB, 2003, MED SCI SPORT EXER, V35, P1333, DOI 10.1249/01.MSS.0000079046.01763.8F
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chen L, 2009, CARDIOVASC RES, V84, P91, DOI 10.1093/cvr/cvp181
   Cheng S, 2009, CIRC-CARDIOVASC IMAG, V2, P191, DOI 10.1161/CIRCIMAGING.108.819938
   Cuervo AM, 1998, FRONT BIOSCI, V3, P0
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   DEMEERSMAN RE, 1993, AM HEART J, V125, P726, DOI 10.1016/0002-8703(93)90164-5
   Desler C, 2011, J AGING RES, V0, P0
   Desler C, 2007, MUTAT RES-FUND MOL M, V625, P112, DOI 10.1016/j.mrfmmm.2007.06.002
   Desler C, 2010, J NUCLEIC ACIDS, V2010, P0, DOI 10.4061/2010/701518
   Di Lisa F, 2005, CARDIOVASC RES, V66, P222, DOI 10.1016/j.cardiores.2005.02.009
   Fares E, 2010, CLIN EXP PHARMACOL P, V37, P1, DOI 10.1111/j.1440-1681.2009.05276.x
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   FLEG JL, 1995, J APPL PHYSIOL, V78, P890, DOI 10.1152/jappl.1995.78.3.890
   FRENZEL H, 1984, MECH AGEING DEV, V27, P29, DOI 10.1016/0047-6374(84)90080-0
   Gottlieb RA, 2011, BBA-MOL CELL RES, V1813, P1295, DOI 10.1016/j.bbamcr.2010.11.017
   Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, PC203, DOI 10.1152/ajpcell.00097.2010
   Grivennikova VG, 2010, BBA-BIOENERGETICS, V1797, P939, DOI 10.1016/j.bbabio.2010.02.013
   Hafner AV, 2010, AGING-US, V2, P914, DOI 10.18632/aging.100252
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hees PS, 2002, AM J CARDIOL, V90, P1231, DOI 10.1016/S0002-9149(02)02840-0
   Hom J, 2009, J MOL CELL CARDIOL, V46, P811, DOI 10.1016/j.yjmcc.2009.02.023
   Jansen-Duerr Pidder, 2002, EMBO REPORTS, V3, P1127, DOI 10.1093/embo-reports/kvf247
   Jovanovic S, 2004, AGEING RES REV, V3, P199, DOI 10.1016/j.arr.2003.10.001
   Jugdutt BI, 2010, HEART FAIL REV, V15, P401, DOI 10.1007/s10741-010-9164-8
   Kajstura J, 2010, CIRC RES, V107, P305, DOI 10.1161/CIRCRESAHA.110.223024
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782
   Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0
   LESNEFSKY EJ, 1994, J LAB CLIN MED, V124, P843
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   LINZBACH AJ, 1973, KLIN WOCHENSCHR, V51, P156, DOI 10.1007/BF01468338
   LIU M, 2011, AGE DORDR IN PRESS, V0, P0
   MARGULIS I, 1970, J THEOR BIOL, V26, P337, DOI 10.1016/S0022-5193(70)80023-6
   Margulis L, 1975, SYMP SOC EXP BIOL, V0, P21
   Mariani J, 2000, J THORAC CARDIOV SUR, V120, P660, DOI 10.1067/mtc.2000.106528
   MELISSARI M, 1991, GIORNALE ITALIANO DI CARDIOLOGIA, V21, P119
   Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311
   MING Z, 2011, J APPL PHYS IN PRESS, V0, P0
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   MISARE BD, 1992, J THORAC CARDIOV SUR, V103, P60
   Olivetti G, 1996, J MOL CELL CARDIOL, V28, P1463, DOI 10.1006/jmcc.1996.0137
   OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560
   Onose Y, 1999, J AM SOC ECHOCARDIOG, V12, P921, DOI 10.1016/S0894-7317(99)70144-6
   Raffaello A, 2011, BBA-MOL CELL RES, V1813, P260, DOI 10.1016/j.bbamcr.2010.10.007
   Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8
   Raveaud S, 2009, BIOGERONTOLOGY, V10, P537, DOI 10.1007/s10522-008-9196-9
   Reddy AK, 2007, J GERONTOL A-BIOL, V62, P1319, DOI 10.1093/gerona/62.12.1319
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Roger VL, 2011, CIRCULATION, V123, PE18, DOI 10.1161/CIR.0b013e3182009701
   Romanowicz M, 2011, ALCOHOL CLIN EXP RES, V35, P1092, DOI 10.1111/j.1530-0277.2011.01442.x
   Rosenfeldt FL, 1999, BIOFACTORS, V9, P291, DOI 10.1002/biof.5520090226
   SAGAN L, 1967, J THEOR BIOL, V14, P225, DOI 10.1016/0022-5193(67)90079-3
   Sanders David, 2009, ANESTHESIOL CLIN, V27, P497, DOI 10.1016/j.anclin.2009.07.008
   Sangaralingham SJ, 2011, HYPERTENSION, V57, P201, DOI 10.1161/HYPERTENSIONAHA.110.160796
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SHANNON RP, 1991, AM J CARDIOL, V67, P1110, DOI 10.1016/0002-9149(91)90874-K
   Shibata S, 2011, J APPL PHYSIOL, V110, P964, DOI 10.1152/japplphysiol.00826.2010
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Shinmura K, 2011, J MOL CELL CARDIOL, V50, P117, DOI 10.1016/j.yjmcc.2010.10.018
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269
   Slotwiner DJ, 1998, AM J CARDIOL, V82, P621, DOI 10.1016/S0002-9149(98)00390-7
   Starnes JW, 1997, AGING-CLIN EXP RES, V9, P268, DOI 10.1007/BF03341829
   Statistics Canada, 2007, MORT SUMM LIST CAUS, V0, P0
   Sun JT, 2002, GENETICS, V161, P661
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Ussher JR, 2008, CARDIOVASC RES, V79, P259, DOI 10.1093/cvr/cvn130
   Vendelbo MH, 2011, BBA-MOL CELL RES, V1813, P634, DOI 10.1016/j.bbamcr.2011.01.029
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wierzbowska-Drabik K, 2008, ECHOCARDIOGR-J CARD, V25, P149, DOI 10.1111/j.1540-8175.2007.00569.x
   Wood P, 2011, CAN J CARDIOL, V27, P302, DOI 10.1016/j.cjca.2011.02.008
   XIAO RP, 1994, J CLIN INVEST, V94, P2051, DOI 10.1172/JCI117559
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yang XP, 2006, FASEB J, V20, P1024, DOI 10.1096/fj.05-5288fje
   Yang XP, 2005, ENDOCRINE, V26, P127, DOI 10.1385/ENDO:26:2:127
   Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289
NR 105
TC 46
Z9 53
U1 1
U2 25
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1671-5411
EI 
J9 J GERIATR CARDIOL
JI J. Geriatr. Cardiol.
PD JUN 15
PY 2011
VL 8
IS 3
BP 159
EP 167
DI 10.3724/SP.J.1263.2011.00159
PG 9
WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology
SC Cardiovascular System & Cardiology; Geriatrics & Gerontology
GA 838WV
UT WOS:000296325400005
PM 22783302
DA 2024-11-01
ER

PT J
AU Orsucci, D
   Ienco, EC
   Mancuso, M
   Siciliano, G
AF Orsucci, Daniele
   Ienco, Elena Caldarazzo
   Mancuso, Michelangelo
   Siciliano, Gabriele
TI POLG1-Related and other "Mitochondrial Parkinsonisms": an Overview
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Haplogroups; Mitochondria; Mitochondrial diseases; mtDNA; Parkinson's disease; POLG
ID dna-polymerase-gamma; progressive external ophthalmoplegia; familial parkinsonism; polg1 mutations; w748s mutation; a8344g merrf; common-cause; disease; risk; polymorphisms
AB Mitochondrial dysfunction has been implicated in the pathogenesis of sporadic, idiopathic Parkinson disease. In some cases, mitochondrial DNA primary genetic abnormalities, or more commonly, secondary rearrangements due to polymerase gamma (POLG1) gene mutation, can directly cause parkinsonism. The case of a Parkinson disease patient with some signs or symptoms suggestive of mitochondrial disease (i.e., ptosis, myopathy, neuropathy) is a relatively common event in the neurological practice. Mitochondrial parkinsonisms do not have distinctive features allowing an immediate diagnosis, and a negative family history does not rule out a possible diagnosis of mitochondrial disorder. In this article, we do not revise the mitochondrial hypothesis of sporadic, idiopathic Parkinson disease, extensively discussed elsewhere, but we review POLG1-related parkinsonism and other well-defined forms of "mitochondrial parkinsonisms", with mtDNA mutations or rearrangements. Lastly, we try to introduce a possible diagnostic approach for patients with parkinsonism and suspected mitochondrial disorder.
C1 [Orsucci, Daniele; Ienco, Elena Caldarazzo; Mancuso, Michelangelo; Siciliano, Gabriele] Univ Pisa, Dept Neurosci, Neurol Clin, I-56126 Pisa, Italy.
C3 University of Pisa
RP Orsucci, D (corresponding author), Univ Pisa, Dept Neurosci, Neurol Clin, Via Roma 67, I-56126 Pisa, Italy.
EM d.orsucci@sssup.it
FU Telethon [GUP09004]
CR Anvret A, 2010, NEUROSCI LETT, V485, P117, DOI 10.1016/j.neulet.2010.08.082
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Batabyal D, 2010, J BIOL CHEM, V285, P34191, DOI 10.1074/jbc.M110.156182
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Büeler H, 2009, EXP NEUROL, V218, P235, DOI 10.1016/j.expneurol.2009.03.006
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Copeland WC, 2010, SUBCELL BIOCHEM, V50, P211, DOI 10.1007/978-90-481-3471-7_11
   Craig K, 2007, BRAIN, V130, P0, DOI 10.1093/brain/awm009
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Eerola J, 2010, NEUROSCI LETT, V477, P1, DOI 10.1016/j.neulet.2010.04.021
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fukae J, 2007, MITOCHONDRION, V7, P58, DOI 10.1016/j.mito.2006.12.002
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Latsoudis H, 2008, J HUM GENET, V53, P349, DOI 10.1007/s10038-008-0259-1
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2009, CURR MOL MED, V9, P1095, DOI 10.2174/156652409789839099
   Mancuso M, 2008, MOVEMENT DISORD, V23, P2098, DOI 10.1002/mds.22050
   Mancuso M, 2008, PARKINSONISM RELAT D, V14, P381, DOI 10.1016/j.parkreldis.2007.10.001
   Mancuso Michelangelo, 2008, HUMAN GENOMICS, V3, P71
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   Nishioka K, 2010, PARKINSONISM RELAT D, V16, P686, DOI 10.1016/j.parkreldis.2010.09.007
   Orsucci D, 2009, NUTR REV, V67, P427, DOI 10.1111/j.1753-4887.2009.00221.x
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schicks J, 2010, MOVEMENT DISORD, V25, P2678, DOI 10.1002/mds.23286
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Simon DK, 2010, BMC MED GENET, V11, P0, DOI 10.1186/1471-2350-11-53
   Simon DK, 2003, NEUROGENETICS, V4, P199, DOI 10.1007/s10048-003-0150-3
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Solano A, 2003, ANN NEUROL, V54, P527, DOI 10.1002/ana.10682
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   Synofzik M, 2010, MOVEMENT DISORD, V25, P243, DOI 10.1002/mds.22865
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wang K, 2009, NEUROGENETICS, V10, P337, DOI 10.1007/s10048-009-0194-0
   Wilcox RA, 2007, MOVEMENT DISORD, V22, P1020, DOI 10.1002/mds.21416
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 67
TC 42
Z9 46
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD MAY 15
PY 2011
VL 44
IS 1
BP 17
EP 24
DI 10.1007/s12031-010-9488-9
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 750FL
UT WOS:000289530900004
PM 21221844
DA 2024-11-01
ER

PT J
AU Salsano, E
   Giovagnoli, AR
   Morandi, L
   Maccagnano, C
   Lamantea, E
   Marchesi, C
   Zeviani, M
   Pareyson, D
AF Salsano, Ettore
   Giovagnoli, Anna Rita
   Morandi, Lucia
   Maccagnano, Carmelo
   Lamantea, Eleonora
   Marchesi, Chiara
   Zeviani, Massimo
   Pareyson, Davide
TI Mitochondrial dementia: A sporadic case of progressive cognitive and behavioral decline with hearing loss due to the rare m.3291T&gt;C MELAS mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial disorders; Dementia; Hearing loss; MELAS syndrome; Olanzapine; Wolff-Parkinson-White syndrome
ID point mutation; dichloroacetate; patient; disease; gene; dna
AB We report the case of a 23-year-old Italian female harboring the rare m.3291T>C mutation in the MT-TL1 gene, that encodes the mitochondria! transfer RNA for leucine 1 (UUA/G). MT-TL1 mutations usually cause the MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) syndrome. Our patient, however, suffered from a non-syndromic mitochondrial disorder (MID), clinically characterized by progressive cognitive and behavioral decline, and hearing loss; brain MRI disclosed diffuse supratentorial and infratentorial atrophy; EKG revealed a Wolff-Parkinson-White syndrome; combined neuroleptic and antidepressant treatment markedly improved her behavioral symptoms. This case expands the clinical spectrum of non-syndromic MIDs, and further confirms that no obvious genotype-phenotype correlation exists for the m.3291T>C DNA mutation; indeed, this mutation has been previously reported in a Japanese child, who suffered from MELAS, and in an Italian child, who presented an apparently isolated mild myopathy. Moreover, it supports the hypothesis that at least in MT-TL1-related MIDs, dementia may be caused by a progressive neurodegenerative process, rather than by injury accumulation due to stroke-like episodes. Finally, our case suggests that common neuroleptic and antidepressant drugs may be clinically efficacious in the management of psychiatric symptoms associated with MIDs. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Salsano, Ettore] C Besta Neurol Inst, IRCCS Fdn, Dept Clin Neurosci, Clin Cent & Peripheral Degenerat Neuropathies, I-20133 Milan, Italy.
RP Salsano, E (corresponding author), C Besta Neurol Inst, IRCCS Fdn, Dept Clin Neurosci, Clin Cent & Peripheral Degenerat Neuropathies, Via Celoria 11, I-20133 Milan, Italy.
EM ettore.salsano@istituto-besta.it
CR Finsterer J, 2009, J NEUROL SCI, V283, P143, DOI 10.1016/j.jns.2009.02.347
   Giovagnoli AR, 2008, NEUROPSYCHOLOGIA, V46, P1495, DOI 10.1016/j.neuropsychologia.2007.12.023
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Majamaa-Voltti KAM, 2006, NEUROLOGY, V66, P1470, DOI 10.1212/01.wnl.0000216136.61640.79
   Manes F, 2009, J NEUROL SCI, V283, P95, DOI 10.1016/j.jns.2009.02.316
   NEARY D, 1988, J NEUROL NEUROSUR PS, V51, P353, DOI 10.1136/jnnp.51.3.353
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   Sudo A, 2004, NEUROLOGY, V62, P338, DOI 10.1212/01.WNL.0000103443.61141.76
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 15
TC 23
Z9 27
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2011
VL 300
IS 1-2
BP 165
EP 168
DI 10.1016/j.jns.2010.09.022
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 714ZT
UT WOS:000286850900033
PM 20943236
DA 2024-11-01
ER

PT J
AU Schaller, A
   Hahn, D
   Jackson, CB
   Kern, I
   Chardot, C
   Belli, DC
   Gallati, S
   Nuoffer, JM
AF Schaller, Andre
   Hahn, Dagmar
   Jackson, Christopher B.
   Kern, Ilse
   Chardot, Christophe
   Belli, Dominique C.
   Gallati, Sabina
   Nuoffer, Jean-Marc
TI Molecular and biochemical characterisation of a novel mutation in <i>POLG</i> associated with Alpers syndrome
SO BMC NEUROLOGY
LA English
DT Article
ID mitochondrial-dna polymerase; ataxic neuropathy; quantification; hepatotoxicity; phenotypes; depletion; spectrum
AB Background: DNA polymerase g (POLG) is the only known mitochondrial DNA (mtDNA) polymerase. It mediates mtDNA replication and base excision repair. Mutations in the POLG gene lead to reduction of functional mtDNA (mtDNA depletion and/or deletions) and are therefore predicted to result in defective oxidative phosphorylation (OXPHOS). Many mutations map to the polymerase and exonuclease domains of the enzyme and produce a broad clinical spectrum. The most frequent mutation p.A467T is localised in the linker region between these domains. In compound heterozygote patients the p.A467T mutation has been described to be associated amongst others with fatal childhood encephalopathy. These patients have a poorer survival rate compared to homozygotes. Methods: mtDNA content in various tissues (fibroblasts, muscle and liver) was quantified using quantitative PCR (qPCR). OXPHOS activities in the same tissues were assessed using spectrophotometric methods and catalytic stain of BN-PAGE. Results: We characterise a novel splice site mutation in POLG found in trans with the p.A467T mutation in a 3.5 years old boy with valproic acid induced acute liver failure (Alpers-Huttenlocher syndrome). These mutations result in a tissue specific depletion of the mtDNA which correlates with the OXPHOS-activities. Conclusions: mtDNA depletion can be expressed in a high tissue-specific manner and confirms the need to analyse primary tissue. Furthermore, POLG analysis optimises clinical management in the early stages of disease and reinforces the need for its evaluation before starting valproic acid treatment.
C1 [Schaller, Andre; Jackson, Christopher B.; Gallati, Sabina] Univ Hosp Bern, Div Human Genet, CH-3010 Bern, Switzerland.
   [Hahn, Dagmar; Nuoffer, Jean-Marc] Univ Hosp Bern, Inst Clin Chem, CH-3010 Bern, Switzerland.
   [Kern, Ilse; Belli, Dominique C.] Univ Geneva, Childrens Hosp, Dept Paediat, Geneva, Switzerland.
   [Chardot, Christophe] Univ Geneva, Childrens Hosp, Paediat Surg Unit, Geneva, Switzerland.
   [Chardot, Christophe] Hop Necker Enfants Malad, Paediat Surg Unit, Paris, France.
C3 University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Geneva; University of Geneva; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP
RP Schaller, A (corresponding author), Univ Hosp Bern, Div Human Genet, CH-3010 Bern, Switzerland.
EM andre.schaller@insel.ch
FU Novartis Research Foundation; Novartis
CR Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Delarue A, 2000, PEDIATR TRANSPLANT, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   KONIG SA, 1994, EPILEPSIA, V35, P1005
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338
   McFarland R, 2008, ARCH DIS CHILD, V93, P151, DOI 10.1136/adc.2007.122911
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Schägger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3
   SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597
   Silva MFB, 2008, J INHERIT METAB DIS, V31, P205, DOI 10.1007/s10545-008-0841-x
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Sweasy JB, 2006, RADIAT RES, V166, P693, DOI 10.1667/RR0706.1
   Thomson M, 1998, J PEDIATR GASTR NUTR, V26, P478, DOI 10.1097/00005176-199804000-00024
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131
NR 33
TC 30
Z9 34
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD JAN 14
PY 2011
VL 11
IS 
BP 
EP 
DI 10.1186/1471-2377-11-4
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 714LQ
UT WOS:000286811500001
PM 21235791
DA 2024-11-01
ER

PT J
AU Davis, RL
   Sue, CM
AF Davis, Ryan L.
   Sue, Carolyn M.
TI The Genetics of Mitochondrial Disease
SO SEMINARS IN NEUROLOGY
LA English
DT Article
DE Mitochondrial disease; mitochondria; mitochondrial DNA; nuclear DNA-encoded mitochondrial disease
ID hereditary optic neuropathy; ragged-red fibers; progressive external ophthalmoplegia; coenzyme q(10) deficiency; a3243g point mutation; dna deletions; ubiquinone deficiency; abnormal mitochondria; myoclonic epilepsy; cerebellar-ataxia
AB The discovery that defects in mitochondria and mitochondrial DNA could cause human disease has led to the development of a rapidly expanding group of disorders known as mitochondrial disease. Mitochondrial disease is so named because of the common feature of impaired mitochondrial function. The main function of the mitochondrion is to produce energy for the cell in the form of ATP. ATP is generated by the respiratory chain, a series of complex proteins that are located in the mitochondrial membrane, and are encoded for by both the mitochondrial and nuclear genomes. Consequently, mitochondrial disease can be caused by mutations in either mitochondrial or nuclear DNA. Given the distribution of mitochondria throughout the body, the specific properties of mitochondrial DNA, and the mitochondrion's dependence on nuclear genes for its normal function, the clinical presentation of mitochondrial disease can be highly variable. Thus, familiarity with typical clinical presentations and knowledge of the genes that contribute to mitochondrial function will aid the clinician in the recognition, diagnosis, and management of patients with this group of diverse disorders.
C1 [Davis, Ryan L.; Sue, Carolyn M.] Royal N Shore Hosp, Kolling Inst Med Res, Neurogenet Res Grp, Sydney, NSW, Australia.
   [Davis, Ryan L.; Sue, Carolyn M.] Univ Sydney, Sydney, NSW 2006, Australia.
   [Sue, Carolyn M.] Royal N Shore Hosp, Dept Neurol, Sydney, NSW, Australia.
C3 University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital; University of Sydney; University of Sydney; Royal North Shore Hospital
RP Sue, CM (corresponding author), Royal N Shore Hosp, Kolling Inst Med Res, Dept Neurogenet, Bldg 6,Reserve Rd, St Leonards, NSW 2065, Australia.
EM carolyn.sue@sydney.edu.au
FU Royal North Shore Hospital; NHMRC
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CRIMMINS D, 1993, J NEUROL NEUROSUR PS, V56, P900, DOI 10.1136/jnnp.56.8.900
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DiMauro S, 1993, MOL GENETIC BASIS NE, V0, P665
   DiMauro S, 2006, MITOCHONDRIAL MEDICINE, V0, P261
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Fichera M, 2004, NEUROLOGY, V63, P1108, DOI 10.1212/01.WNL.0000138731.60693.D2
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, V0, PS107
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   JOHNS DR, 1993, NEUROLOGY, V43, P2471, DOI 10.1212/WNL.43.12.2471
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Koene S, 2009, J INTERN MED, V265, P193, DOI 10.1111/j.1365-2796.2008.02058.x
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lawson VH, 2005, NEUROLOGY, V65, P197, DOI 10.1212/01.wnl.0000168898.76071.70
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   POULTON J, 1989, LANCET, V1, P236
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Rocher C, 2002, MOL GENET METAB, V76, P123, DOI 10.1016/S1096-7192(02)00024-0
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHY GM, 1966, BRAIN, V89, P133, DOI 10.1093/brain/89.1.133
   SHY GM, 1964, SCIENCE, V145, P493, DOI 10.1126/science.145.3631.493
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Sue CM, 2010, MED J AUSTRALIA, V193, P195, DOI 10.5694/j.1326-5377.2010.tb03864.x
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tengan CH, 1996, BIOCHEM MOL MED, V58, P130, DOI 10.1006/bmme.1996.0040
   Vandebona H, 2009, NEW ENGL J MED, V360, P642, DOI 10.1056/NEJMc0806397
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wong LJC, 2010, DEV DISABIL RES REV, V16, P154, DOI 10.1002/ddrr.104
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 71
TC 24
Z9 29
U1 2
U2 43
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0271-8235
EI 1098-9021
J9 SEMIN NEUROL
JI Semin. Neurol.
PD DEC 15
PY 2011
VL 31
IS 5
BP 519
EP 530
DI 10.1055/s-0031-1299790
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA 883SK
UT WOS:000299655000011
PM 22266889
DA 2024-11-01
ER

PT J
AU Kato, M
   Nakamura, M
   Ichiba, M
   Tomiyasu, A
   Shimo, H
   Higuchi, I
   Ueno, S
   Sano, A
AF Kato, Maiko
   Nakamura, Masayuki
   Ichiba, Mio
   Tomiyasu, Akiyuki
   Shimo, Hirochika
   Higuchi, Itsuro
   Ueno, Shu-ichi
   Sano, Akira
TI Mitochondrial DNA deletion mutations in patients with neuropsychiatric symptoms
SO NEUROSCIENCE RESEARCH
LA English
DT Article
DE Mitochondrial DNA; Deletion mutations; Psychiatric symptoms; Schizophrenia; Depression; Dementia
ID progressive external ophthalmoplegia; multiple deletions; pearson marrow; disorder; protein; muscle; expression; opa1
AB It has been suggested that mitochondrial dysfunction is important in the pathogenesis of psychiatric disorders such as depression, schizophrenia and dementia. We report herein three adult patients exhibiting such psychiatric symptoms as the core manifestation, accompanied by various degrees of myopathic symptoms. Pathological findings in biopsied skeletal muscle were compatible with mitochondrial myopathy in all cases. Maternal inheritance was not apparent in all three cases; however, two patients were born to consanguineous parents. Mutation analysis on the mitochondria! DNA (mtDNA) and seven nuclear genes, in which pathogenic mutations are known to cause mtDNA deletions, was performed. MtDNA deletion mutations were identified in skeletal muscles of all patients. Nether pathogenic mutations nor copy number variation was identified among the nuclear genes. Although further studies are needed, the molecular pathways inducing mitochondrial abnormalities may be implicated in a variety of psychiatric conditions. (c) 2010 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
C1 [Kato, Maiko; Nakamura, Masayuki; Ichiba, Mio; Tomiyasu, Akiyuki; Shimo, Hirochika; Sano, Akira] Kagoshima Univ, Dept Psychiat, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   [Higuchi, Itsuro] Kagoshima Univ, Dept Neurol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   [Higuchi, Itsuro] Kagoshima Univ, Dept Geriatr, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   [Ueno, Shu-ichi] Ehime Univ, Dept Psychiat, Grad Sch Med, Toon, Ehime 7910295, Japan.
C3 Kagoshima University; Kagoshima University; Kagoshima University; Ehime University
RP Sano, A (corresponding author), Kagoshima Univ, Dept Psychiat, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM sano@m3.kufm.kagoshima-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [23390291, 23659568] Funding Source: KAKEN
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   [Anonymous], 2000, DIAGN STAT MAN MENT, V0, P0
   Ben-Shachar D, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0003676
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DEVRIES DD, 1992, NEUROMUSCULAR DISORD, V2, P185, DOI 10.1016/0960-8966(92)90005-Q
   Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116
   Gardner A, 2003, J AFFECT DISORDERS, V76, P55, DOI 10.1016/S0165-0327(02)00067-8
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Hirata K, 1999, J HUM GENET, V44, P210, DOI 10.1007/s100380050145
   Houshmand M, 2004, NEUROMUSCULAR DISORD, V14, P195, DOI 10.1016/j.nmd.2003.12.002
   Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441
   Karry R, 2004, BIOL PSYCHIAT, V55, P676, DOI 10.1016/j.biopsych.2003.12.012
   Kato T, 2001, MOL PSYCHIATR, V6, P625, DOI 10.1038/sj.mp.4000926
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mancuso M, 2008, J AFFECT DISORDERS, V106, P173, DOI 10.1016/j.jad.2007.05.016
   Maurer I, 2001, SCHIZOPHR RES, V48, P125, DOI 10.1016/S0920-9964(00)00075-X
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2006, ACTA NEUROL BELG, V106, P66
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 28
TC 21
Z9 22
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0168-0102
EI 1872-8111
J9 NEUROSCI RES
JI Neurosci. Res.
PD APR 15
PY 2011
VL 69
IS 4
BP 331
EP 336
DI 10.1016/j.neures.2010.12.013
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 741DR
UT WOS:000288843800009
PM 21185889
DA 2024-11-01
ER

PT J
AU Zhong, Y
   Hu, YJ
   Yang, Y
   Peng, W
   Sun, Y
   Chen, B
   Huang, X
   Kong, WJ
AF Zhong, Yi
   Hu, Yu-Juan
   Yang, Yang
   Peng, Wei
   Sun, Yu
   Chen, Bei
   Huang, Xiang
   Kong, Wei-Jia
TI Contribution of common deletion to total deletion burden in mitochondrial DNA from inner ear of D-galactose-induced aging rats
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Aging; Mitochondrial DNA; Common deletion; Cytochrome c oxidase subunit III; Mitochondrial dysfunction; Inner ear
ID 4977 bp deletion; human skeletal-muscle; copy number; oxidative damage; mtdna deletions; temporal bone; hearing-loss; blood-cells; mutations; disease
AB Mitochondrial DNA (mtDNA) mutations, especially deletions, have been suggested to play an important role in aging and degenerative diseases. In particular, the common deletion in humans and rats (4977 bp and 4834 bp deletion, respectively) has been shown to accumulate with age in post-mitotic tissues with high energetic demands. Among numerous deletions, the common deletion has been proposed to serve as a molecular marker for aging and play a critical role in presbyacusis. However, so far no previous publication has quantified the contribution of common deletion to the total burden of mtDNA deletions in tissues during aging process. In the present study, we established a rat model with various degrees of aging in inner ear induced by three different doses of n-galactose (D-gal) administration. Firstly, multiple mtDNA deletions in inner ear were detected by nested PCR and long range PCR. In addition to the common deletion, three novel mtDNA deletions were identified. All four deletions, located in the major arc of mtDNA, are flanked by direct repeats and involve the cytochrome c oxidase (COX) subunit III gene, encoded by mtDNA. Additionally, absolute quantitative real-time PCR assay was used to detect the level of common deletion and total deletion burden of mtDNA. The quantitative data show that the common deletion is the most frequent type of mtDNA deletions, exceeding 67.86% of the total deletion burden. Finally, increased mtDNA copy number, reduced COX activity and mosaic ultrastructural impairments in inner ear were identified in D-gal-induced aging rats. The increase of mtDNA replication may contribute to the accelerated accumulation of mtDNA deletions, which may result in impairment of mitochondrial function in inner ear. Taken together, these findings suggest that the common deletion may serve as an ideal molecular marker to assess the mtDNA damage in inner ear during aging. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Zhong, Yi; Hu, Yu-Juan; Yang, Yang; Peng, Wei; Sun, Yu; Chen, Bei; Kong, Wei-Jia] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Otorhinolaryngol, Wuhan 430022, Peoples R China.
   [Chen, Bei] Zhengzhou Univ, Affiliated Hosp 1, Dept Otorhinolaryngol, Zhengzhou 450002, Peoples R China.
   [Huang, Xiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Otorhinolaryngol, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology; Zhengzhou University; Huazhong University of Science & Technology
RP Kong, WJ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Otorhinolaryngol, 1277 Jiefang Ave, Wuhan 430022, Peoples R China.
EM entwjkong@yahoo.com.cn
FU National Nature Science Foundation of China [30730094, 81000409]; National Science and Technology Pillar Program [2007BAI18B13]; Major State Basic Research Development Program of China (973 Program) [2011CB504504]
CR Arai T, 2003, AGING CLIN EXP RES, V15, P1
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai U, 1997, AM J OTOL, V18, P449
   Bai UM, 2001, HEARING RES, V154, P73, DOI 10.1016/S0378-5955(01)00221-0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0
   Botto N, 2005, MUTAT RES-FUND MOL M, V570, P81, DOI 10.1016/j.mrfmmm.2004.10.003
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chen B, 2010, BRAIN RES, V1344, P43, DOI 10.1016/j.brainres.2010.04.082
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Cui X, 2004, BIOGERONTOLOGY, V5, P317, DOI 10.1007/s10522-004-2570-3
   Cui X, 2006, J NEUROSCI RES, V83, P1584, DOI 10.1002/jnr.20845
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   EDRIS W, 1994, MUTAT RES-DNAGING G, V316, P69, DOI 10.1016/0921-8734(94)90009-4
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   FRIEDMANN I, 1984, ULTRASTRUCTURAL ATAL, V0, P99
   Futyma K, 2008, ONCOL REP, V20, P683, DOI 10.3892/or_00000060
   GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H
   HARMAN D, 1972, AM J CLIN NUTR, V25, P839
   Hiona A, 2008, EXP GERONTOL, V43, P24, DOI 10.1016/j.exger.2007.10.001
   Ho SC, 2003, BIOGERONTOLOGY, V4, P15, DOI 10.1023/A:1022417102206
   IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616
   Kong WJ, 2006, EXP GERONTOL, V41, P628, DOI 10.1016/j.exger.2006.04.008
   Kong WJ, 2006, BIOCHEM BIOPH RES CO, V344, P425, DOI 10.1016/j.bbrc.2006.03.060
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Lezza AMS, 1999, FASEB J, V13, P1083, DOI 10.1096/fasebj.13.9.1083
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu Cheng, 2006, ZHONGHUA ER BI YAN HOU TOU JING WAI KE ZA ZHI, V41, P661
   Liu CY, 2007, MITOCHONDRION, V7, P89, DOI 10.1016/j.mito.2006.11.020
   Lu J, 2007, BIOCHEM PHARMACOL, V74, P1078, DOI 10.1016/j.bcp.2007.07.007
   Markaryan A, 2008, MUTAT RES-FUND MOL M, V640, P38, DOI 10.1016/j.mrfmmm.2007.12.007
   Markaryan A, 2009, LARYNGOSCOPE, V119, P1184, DOI 10.1002/lary.20218
   Masuyama M, 2005, BBA-GEN SUBJECTS, V1723, P302, DOI 10.1016/j.bbagen.2005.03.001
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Mohamed SA, 2006, EXP GERONTOL, V41, P508, DOI 10.1016/j.exger.2006.03.014
   Mohamed SA, 2004, EXP GERONTOL, V39, P181, DOI 10.1016/j.exger.2003.10.011
   Nicklas JA, 2004, ENVIRON MOL MUTAGEN, V44, P313, DOI 10.1002/em.20050
   Pang LJ, 2008, CANCER BIOL THER, V7, P198, DOI 10.4161/cbt.7.2.5256
   Pavicic WH, 2009, MUTAT RES-FUND MOL M, V670, P99, DOI 10.1016/j.mrfmmm.2009.07.009
   Prithivirajsingh S, 2004, FEBS LETT, V571, P227, DOI 10.1016/j.febslet.2004.06.078
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Song X, 1999, MECH AGEING DEV, V108, P239, DOI 10.1016/S0047-6374(99)00022-6
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Yamasoba T, 2007, HEARING RES, V226, P185, DOI 10.1016/j.heares.2006.06.004
   Yin S, 2007, NEUROBIOL DIS, V27, P370, DOI 10.1016/j.nbd.2007.06.006
NR 49
TC 34
Z9 38
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD JUL 1
PY 2011
VL 712
IS 1-2
BP 11
EP 19
DI 10.1016/j.mrfmmm.2011.03.013
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 786YF
UT WOS:000292343100002
PM 21473872
DA 2024-11-01
ER

PT J
AU Martin, FM
   Xu, XL
   von Löhneysen, K
   Gilmartin, TJ
   Friedman, JS
AF Martin, Florent M.
   Xu, Xiuling
   von Loehneysen, Katharina
   Gilmartin, Timothy J.
   Friedman, Jeffrey S.
TI SOD2 Deficient Erythroid Cells Up-Regulate Transferrin Receptor and Down-Regulate Mitochondrial Biogenesis and Metabolism
SO PLOS ONE
LA English
DT Article
ID linked sideroblastic anemia; missense mutation; dna mutations; gene-ontology; protein cia1; expression; myopathy; patient; rna; erythropoiesis
AB Background: Mice irradiated and reconstituted with hematopoietic cells lacking manganese superoxide dismutase (SOD2) show a persistent hemolytic anemia similar to human sideroblastic anemia (SA), including characteristic intra-mitochondrial iron deposition. SA is primarily an acquired, clonal marrow disorder occurring in individuals over 60 years of age with uncertain etiology. Methodology/Principal Findings: To define early events in the pathogenesis of this murine model of SA, we compared erythroid differentiation of Sod2(-/-) and normal bone marrow cells using flow cytometry and gene expression profiling of erythroblasts. The predominant transcriptional differences observed include widespread down-regulation of mitochondrial metabolic pathways and mitochondrial biogenesis. Multiple nuclear encoded subunits of complexes I-IV of the electron transport chain, ATP synthase (complex V), TCA cycle and mitochondrial ribosomal proteins were coordinately downregulated in Sod2(-/-) erythroblasts. Despite iron accumulation within mitochondria, we found increased expression of transferrin receptor, Tfrc, at both the transcript and protein level in SOD2 deficient cells, suggesting deregulation of iron delivery. Interestingly, there was decreased expression of ABCb7, the gene responsible for X-linked hereditary SA with ataxia, a component required for iron-sulfur cluster biogenesis. Conclusions/Significance: These results indicate that in erythroblasts, mitochondrial oxidative stress reduces expression of multiple nuclear genes encoding components of the respiratory chain, TCA cycle and mitochondrial protein synthesis. An additional target of particular relevance for SA is iron: sulfur cluster biosynthesis. By decreasing transcription of components of cluster synthesis machinery, both iron utilization and regulation of iron uptake are impacted, contributing to the sideroblastic phenotype.
C1 [Martin, Florent M.; Xu, Xiuling; von Loehneysen, Katharina; Friedman, Jeffrey S.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
   [Gilmartin, Timothy J.] Scripps Res Inst, DNA Array Core Facil, La Jolla, CA 92037 USA.
C3 Scripps Research Institute; Scripps Research Institute
RP Martin, FM (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM friedman@scripps.edu
FU NIH, NIDDK [R21DK075063, R01DK062473]
CR Alcindor T, 2002, BRIT J HAEMATOL, V116, P733, DOI 10.1046/j.0007-1048.2002.03378.x
   Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743
   Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Balk J, 2005, MOL CELL BIOL, V25, P10833, DOI 10.1128/MCB.25.24.10833-10841.2005
   BECK EA, 1967, ACTA HAEMATOL-BASEL, V38, P1
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BERGMANN AK, 2009, PEDIAT BLOOD CANC, V0, P0
   Bottomley Sylvia S, 2006, CURR HEMATOL REP, V5, P41
   Boultwood J, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0001970
   Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Bykhovskaya Y, 2007, MOL GENET METAB, V91, P148, DOI 10.1016/j.ymgme.2007.02.006
   Camaschella C, 2007, BLOOD, V110, P1353, DOI 10.1182/blood-2007-02-072520
   COTTER PD, 1994, BLOOD, V84, P3915, DOI 10.1182/blood.V84.11.3915.bloodjournal84113915
   Doniger SW, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-1-r7
   Fleming MD, 2002, SEMIN HEMATOL, V39, P270, DOI 10.1053/shem.2002.35637
   Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858
   Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925
   Gattermann N, 2000, LEUKEMIA RES, V24, P141, DOI 10.1016/S0145-2126(99)00160-5
   Gattermann N, 2004, BLOOD, V103, P1499, DOI 10.1182/blood-2003-07-2446
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Guernsey DL, 2009, NAT GENET, V41, P651, DOI 10.1038/ng.359
   HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675
   Martin FM, 2006, ANTIOXID REDOX SIGN, V8, P1217, DOI 10.1089/ars.2006.8.1217
   Martin FM, 2005, EXP HEMATOL, V33, P1493, DOI 10.1016/j.exphem.2005.08.009
   MARTIN FM, 2008, BRIT J HAEM IN PRESS, V0, P0
   MAY A, 1994, BAILLIERE CLIN HAEM, V7, P851, DOI 10.1016/S0950-3536(05)80128-3
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807
   Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   SHARP RA, 1990, BRIT J CLIN PRACT, V44, P706
   Shin MG, 2003, BLOOD, V101, P3118, DOI 10.1182/blood-2002-06-1825
   Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261
   Spiegelman BM, 2007, NOVARTIS FOUND SYMP, V287, P60, DOI 10.1002/9780470725207.ch5
   Spiegelman Bruce M, 2007, NOVARTIS FOUND SYMP, V287, P60
   Srinivasan V, 2007, STRUCTURE, V15, P1246, DOI 10.1016/j.str.2007.08.009
   Wallace D C, 2001, NOVARTIS FOUND SYMP, V235, P247
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang YL, 1999, AM J HEMATOL, V60, P83, DOI 10.1002/(SICI)1096-8652(199901)60:1<83::AID-AJH19>3.0.CO;2-N
   YUNIS AA, 1980, CLIN HAEMATOL, V9, P607
   Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479
NR 52
TC 15
Z9 15
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD FEB 4
PY 2011
VL 6
IS 2
BP 
EP 
DI 10.1371/journal.pone.0016894
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 717IN
UT WOS:000287037000030
PM 21326867
DA 2024-11-01
ER

PT J
AU Kawamata, H
   Tiranti, V
   Magrané, J
   Chinopoulos, C
   Manfredi, G
AF Kawamata, Hibiki
   Tiranti, Valeria
   Magrane, Jordi
   Chinopoulos, Christos
   Manfredi, Giovanni
TI adPEO mutations in ANT1 impair ADP-ATP translocation in muscle mitochondria
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID adenine-nucleotide translocase; progressive external ophthalmoplegia; permeability transition pore; neurogastrointestinal encephalomyopathy; nuclear genes; dna; deletions; carrier; model; stability
AB Mutations in the heart and muscle isoform of adenine nucleotide translocator 1 (ANT1) are associated with autosomal-dominant progressive external opthalmoplegia (adPEO) clinically characterized by exercise intolerance, ptosis and muscle weakness. The pathogenic mechanisms underlying the mitochondrial myopathy caused by ANT1 mutations remain largely unknown. In yeast, expression of ANT1 carrying mutations corresponding to the human adPEO ones causes a wide range of mitochondrial abnormalities. However, functional studies of ANT1 mutations in mammalian cells are lacking, because they have been hindered by the fact that ANT1 expression leads to apoptotic cell death in commonly utilized replicating cell lines. Here, we successfully express functional ANT1 in differentiated mouse myotubes, which naturally contain high levels of ANT1, without causing cell death. We demonstrate, for the first time in these disease-relevant mammalian cells, that mutant human ANT1 causes dominant mitochondrial defects characterized by decreased ADP-ATP exchange function and abnormal translocator reversal potential. These abnormalities are not due to ANT1 loss of function, because knocking down Ant1 in myotubes causes functional changes different from ANT1 mutants. Under certain physiological conditions, mitochondria consume ATP to maintain membrane potential by reversing the ADP-ATP transport. The modified properties of mutant ANT1 can be responsible for disease pathogenesis in adPEO, because exchange reversal occurring at higher than normal membrane potential can cause excessive energy depletion and nucleotide imbalance in ANT1 mutant muscle cells.
C1 [Kawamata, Hibiki; Magrane, Jordi; Manfredi, Giovanni] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.
   [Tiranti, Valeria] IRCCS Fdn Neurol Inst C Besta, Milan, Italy.
   [Chinopoulos, Christos] Semmelweis Univ, Dept Med Biochem, H-1094 Budapest, Hungary.
C3 Cornell University; Weill Cornell Medicine; Semmelweis University
RP Manfredi, G (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,A-505, New York, NY 10065 USA.
EM gim2004@med.cornell.edu
FU NIH/NINDS [F31NS054554]; NIH [R01 GM088999]; Orszagos Tudomanyos Kutatasi Alapprogram (OTKA)-Nemzeti Kutatasi es Technologiai Hivatal (NKTH) [NF68294]; OTKA [NNF78905, NNF2 85658]; Egeszsegugyi Tudomanyos Tanacs (ETT) [55160]
CR Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8
   Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200
   Brand MD, 2005, BIOCHEM J, V392, P353, DOI 10.1042/BJ20050890
   BUCHANAN BB, 1976, P NATL ACAD SCI USA, V73, P2280, DOI 10.1073/pnas.73.7.2280
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Chinopoulos C, 2010, FASEB J, V24, P2405, DOI 10.1096/fj.09-149898
   Chinopoulos C, 2009, BIOPHYS J, V96, P2490, DOI 10.1016/j.bpj.2008.12.3915
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975
   Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAWAMATA H, 1900, V407, V0, P52
   Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Limongelli A, 2002, MITOCHONDRION, V2, P39, DOI 10.1016/S1567-7249(02)00043-0
   Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   OCarroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03
   Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.9.e45
   PFANNER N, 1987, J BIOL CHEM, V262, P14851
   Pohjoismäki JLO, 2010, J MOL BIOL, V397, P1144, DOI 10.1016/j.jmb.2010.02.029
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Pouvreau S, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0013035
   Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758
   Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vijayvergiya C, 2005, J NEUROSCI, V25, P2463, DOI 10.1523/JNEUROSCI.4385-04.2005
   Wang XW, 2008, HUM MOL GENET, V17, P4036, DOI 10.1093/hmg/ddn306
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 49
TC 33
Z9 34
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2011
VL 20
IS 15
BP 2964
EP 2974
DI 10.1093/hmg/ddr200
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 790AD
UT WOS:000292560000006
PM 21586654
DA 2024-11-01
ER

PT J
AU Schrier, SA
   Falk, MJ
AF Schrier, Samantha A.
   Falk, Marni J.
TI Mitochondrial disorders and the eye
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE antioxidant; apoptosis; diabetic retinopathy; mitochondria; ocular neoplasm; oxidative stress
ID hereditary optic neuropathy; opa1 mutations; mouse model; cell-death; disease; glaucoma; atrophy; dna; gene; retinoblastoma
AB Purpose of review Mitochondrial disease is a heterogeneous group of energy metabolism disorders that present across all ages with a wide range of ocular or multisystemic manifestations. This review focuses on recent progress made toward understanding the various ophthalmologic manifestations of primary mitochondrial diseases and discusses the implications of mitochondrial dysfunction, placing particular emphasis on recent investigations into the pathogenesis and emerging therapies for mitochondrial-based ophthalmologic disorders. Recent findings Novel pathogenic mitochondrial DNA mutations continue to be detected in diverse ethnic populations for primary mitochondrial ophthalmologic disorders that commonly affect the optic nerve, retina, and extraocular muscles. Promising antioxidant and gene therapy approaches are being actively investigated to treat these ophthalmologic manifestations, as in Leber's hereditary optic neuropathy. Mitochondrial dysfunction is also increasingly implicated in common ophthalmologic disorders of aging, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Several proteins recently recognized to play a role in the mitochondrial oxidative stress response within retinal cells, such as prohibitin and MMP2, may serve as novel biomarkers and therapeutic targets for common ophthalmologic disorders. Therapies that inhibit mitochondrial function and induce apoptosis within tumor cells, such as EDL-155 and curcumin, may offer novel therapeutic agents for ocular neoplasms such as retinoblastoma and uveal melanoma. Summary Primary mitochondrial genetic disease manifestations can involve almost all aspects of the eye. Mitochondrial dysfunction is increasingly recognized as playing a causative role in the common ophthalmologic disorders in aging. This understanding has unleashed a range of emerging therapeutic approaches for mitochondrial-based ophthalmologic disorders directed at optimizing mitochondrial function.
C1 Childrens Hosp Philadelphia, Dept Pediat, Div Human Genet & Child Dev, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Dept Pediat, Div Rehabil, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Dept Pediat, Div Metab Dis, Philadelphia, PA 19104 USA.
   Univ Pennsylvania Perelman Sch Med, Philadelphia, PA USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania
RP Falk, MJ (corresponding author), ARC 1002C,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM falkm@email.chop.edu
FU NIH [T32GM008638]
CR Abu-Amero KK, 2010, BRIT J OPHTHALMOL, V94, P256, DOI 10.1136/bjo.2009.165571
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Almousa R, 2009, OPHTHAL PLAST RECONS, V25, P366, DOI 10.1097/IOP.0b013e3181b2fd06
   Amati-Bonneau P, 2009, INT J BIOCHEM CELL B, V41, P1855, DOI 10.1016/j.biocel.2009.04.012
   Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651
   Broaddus E, 2009, BRIT J OPHTHALMOL, V93, P24, DOI 10.1136/bjo.2008.143842
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   CHINNERY PEA, 2010, 135 ANN M AM NEUR AS, V0, P0
   DiMauro S, 2010, DEV DISABIL RES REV, V16, P106, DOI 10.1002/ddrr.102
   Falk MJ, 2010, J DEV BEHAV PEDIATR, V31, P610, DOI 10.1097/DBP.0b013e3181ef42c1
   Ferré M, 2009, HUM MUTAT, V30, PE692, DOI 10.1002/humu.21025
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   Grönlund MA, 2010, BRIT J OPHTHALMOL, V94, P121, DOI 10.1136/bjo.2008.154187
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Huizing M, 2010, MOL GENET METAB, V100, P149, DOI 10.1016/j.ymgme.2010.03.005
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Ju WK, 2010, MOL VIS, V16, P1331
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Lam BL, 2010, ARCH OPHTHALMOL-CHIC, V128, P1129, DOI 10.1001/archophthalmol.2010.201
   Lee H, 2010, INT J BIOL MACROMOL, V47, P685, DOI 10.1016/j.ijbiomac.2010.08.018
   Lee S, 2010, EXP EYE RES, V0, P0
   LI J, 2010, BIOCHEM BIOPH RES CO, V404, P349
   Liu XL, 2011, OPHTHALMOLOGY, V118, P978, DOI 10.1016/j.ophtha.2010.09.003
   Lu CW, 2010, CURR EYE RES, V35, P352, DOI 10.3109/02713680903521944
   Madsen-Bouterse SA, 2010, FREE RADICAL RES, V44, P313, DOI 10.3109/10715760903494168
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Milea D, 2010, CURR OPIN NEUROL, V23, P24, DOI 10.1097/WCO.0b013e3283347b27
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Mohammad G, 2011, INVEST OPHTH VIS SCI, V52, P3832, DOI 10.1167/iovs.10-6368
   Mohammad G, 2010, LAB INVEST, V90, P1365, DOI 10.1038/labinvest.2010.89
   Nassr M, 2010, INVEST OPHTH VIS SCI, V51, P3813, DOI 10.1167/iovs.09-5042
   Osborne NN, 2010, NEUROCHEM RES, V35, P2027, DOI 10.1007/s11064-010-0273-5
   Osborne NN, 2010, EXP EYE RES, V90, P750, DOI 10.1016/j.exer.2010.03.008
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Reynier P, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.016576
   Sadun AA, 2011, CURR TREAT OPTION NE, V13, P109, DOI 10.1007/s11940-010-0100-y
   Tanwar M, 2010, MOL VIS, V16, P518
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Williams PA, 2010, BRAIN, V133, P2942, DOI 10.1093/brain/awq218
   Wolf C, 2009, BMC MED GENET, V10, P0, DOI 10.1186/1471-2350-10-91
   Yu-Wai-Man P, 2010, OPHTHALMOLOGY, V117, P1538, DOI 10.1016/j.ophtha.2009.12.038
   Yu-Wai-Man P, 2011, OPHTHALMOLOGY, V118, P558, DOI 10.1016/j.ophtha.2010.07.029
   Yu-Wai-Man P, 2010, HUM MOL GENET, V19, P3043, DOI 10.1093/hmg/ddq209
   Zhang JJ, 2010, BIOCHEM BIOPH RES CO, V399, P647, DOI 10.1016/j.bbrc.2010.07.135
NR 46
TC 77
Z9 85
U1 2
U2 33
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD SEP 15
PY 2011
VL 22
IS 5
BP 325
EP 331
DI 10.1097/ICU.0b013e328349419d
PG 7
WC Ophthalmology
SC Ophthalmology
GA 806BM
UT WOS:000293776700003
PM 21730846
DA 2024-11-01
ER

PT J
AU Patki, G
   Lau, YS
AF Patki, Gaurav
   Lau, Yuen-Sum
TI Impact of exercise on mitochondrial transcription factor expression and damage in the striatum of a chronic mouse model of Parkinson's disease
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Chronic MPTP model; Cytochrome c; Mitochondrial DNA defect; Neurodegeneration; p53; Parkinson's disease; PGC-1 alpha; TFAM; Treadmill exercise
ID substantia-nigra neurons; skeletal-muscle; severe neurodegeneration; endurance exercise; dopamine neurons; dna deletions; p53; apoptosis; gene; respiration
AB The etiology of neurodegenerative disorders like Parkinson's disease remains unknown, although many genetic and environmental factors are suggested as likely causes. Neuronal oxidative stress and mitochondrial dysfunction have been implicated as possible triggers for the onset and progression of Parkinson's neurodegeneration. We have recently shown that long-term treadmill exercise prevented neurological, mitochondrial and locomotor deficits in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid-induced mouse model of Parkinson's disease that was originally established in our laboratory. In the present study, we further demonstrated that long-term exercise attenuated both cytochrome c release and elevated levels of p53, which are known to be associated with mitochondrial dysfunction in the striatum of this chronic model. On the other hand, the expressions of mitochondrial transcription factor A and peroxisome proliferator-activated receptor gamma coactivator 1 alpha were unexpectedly upregulated in the striatum of this chronic model, but long-term exercise training brought their levels down closer to normal. Our findings suggest that maintaining normal mitochondrial function is essential for preventing the process of Parkinson's disease-like neurodegeneration, whereas stimulating the mitochondrial transcription factors for biogenesis is not obligatory. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Patki, Gaurav; Lau, Yuen-Sum] Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA.
C3 University of Houston System; University of Houston
RP Lau, YS (corresponding author), Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA.
EM ylau2@uh.edu
FU US National Institute of Neurological Disorders and Stroke [NS 47920]
CR Al-Jarrah M, 2007, NEUROSCIENCE, V149, P28, DOI 10.1016/j.neuroscience.2007.07.038
   Beal MF, 2009, PARKINSONISM RELAT D, V15, PS189, DOI 10.1016/S1353-8020(09)70812-0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149
   Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Gorman AM, 2000, DEV NEUROSCI-BASEL, V22, P348, DOI 10.1159/000017460
   Hood DA, 2009, APPL PHYSIOL NUTR ME, V34, P465, DOI 10.1139/H09-045
   Keeney PM, 2009, EXP NEUROL, V220, P374, DOI 10.1016/j.expneurol.2009.09.025
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U
   LAU YS, 1990, GEN PHARMACOL-VASC S, V21, P181, DOI 10.1016/0306-3623(90)90898-V
   LAU YS, 2005, PARKINSONS DIS, V0, P109
   Lau YS, 2011, EUR J NEUROSCI, V33, P1264, DOI 10.1111/j.1460-9568.2011.07626.x
   Leick L, 2008, AM J PHYSIOL-ENDOC M, V294, PE463, DOI 10.1152/ajpendo.00666.2007
   Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Miyai I, 2000, ARCH PHYS MED REHAB, V81, P849, DOI 10.1053/apmr.2000.4439
   Nair VD, 2006, APOPTOSIS, V11, P955, DOI 10.1007/s10495-006-6316-3
   Novikova L, 2006, NEUROSCIENCE, V140, P67, DOI 10.1016/j.neuroscience.2006.02.007
   Patki G, 2011, PHARMACOL BIOCHEM BE, V99, P704, DOI 10.1016/j.pbb.2011.06.026
   Patki G, 2009, FRONT AGING NEUROSCI, V1, P0, DOI 10.3389/neuro.24.003.2009
   Petroske E, 2001, NEUROSCIENCE, V106, P589, DOI 10.1016/S0306-4522(01)00295-0
   Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850
   Pothakos K, 2009, BMC NEUROSCI, V10, P0, DOI 10.1186/1471-2202-10-6
   Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Smith AD, 2003, EXP NEUROL, V184, P31, DOI 10.1016/j.expneurol.2003.08.017
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
NR 30
TC 20
Z9 22
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0304-3940
EI 
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD NOV 21
PY 2011
VL 505
IS 3
BP 268
EP 272
DI 10.1016/j.neulet.2011.10.036
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 867PE
UT WOS:000298465500011
PM 22040668
DA 2024-11-01
ER

PT J
AU Schara, U
   von Kleist-Retzow, JC
   Lainka, E
   Gerner, P
   Pyle, A
   Smith, PM
   Lochmüller, H
   Czermin, B
   Abicht, A
   Holinski-Feder, E
   Horvath, R
AF Schara, Ulrike
   von Kleist-Retzow, Juergen-Christoph
   Lainka, Elke
   Gerner, Patrick
   Pyle, Angela
   Smith, Paul M.
   Lochmueller, Hanns
   Czermin, Birgit
   Abicht, Angela
   Holinski-Feder, Elke
   Horvath, Rita
TI Acute liver failure with subsequent cirrhosis as the primary manifestation of <i>TRMU</i> mutations
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID mitochondrial-dna depletion; sideroblastic anemia-mlasa; ribosomal-rna mutations; phenotypic-expression; molecular-basis; coenzyme q(10); human-disease; translation; deficiency; myopathy
AB Combined respiratory chain deficiency accounts for about 30% of mitochondrial respiratory chain deficiencies and is frequently associated with mtDNA depletion, deletions or point mutations. However combined respiratory chain deficiency may also be caused by mutations in nuclear genes affecting mitochondrial translation. Here we describe a 2-year-old girl, who developed an acute, isolated, severe liver failure with mitochondrial pathology and decreased respiratory chain enzyme activities both in liver and skeletal muscle at 4 months of age. Her liver function improved significantly within a month, liver function tests returned to normal. Liver cirrhosis remained without any further complications so far. Pathogenic compound heterozygous mutations were identified in the TRMU gene. This condition is one of the few mitochondrial disorders with a life-threatening onset showing recovery later in life, therefore a prompt diagnosis and treatment of these patients has great importance in clinical practice. We suggest that TRMU deficiency should be considered in infants with acute liver disease.
C1 [Pyle, Angela; Lochmueller, Hanns; Horvath, Rita] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Pyle, Angela; Smith, Paul M.; Horvath, Rita] Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Czermin, Birgit; Abicht, Angela; Holinski-Feder, Elke; Horvath, Rita] Ctr Med Genet, Munich, Germany.
   [Schara, Ulrike; Lainka, Elke; Gerner, Patrick] Univ Essen Gesamthsch, Essen, Germany.
   [von Kleist-Retzow, Juergen-Christoph] Univ Cologne, Ctr Mol Med CMMC, Cologne, Germany.
   [von Kleist-Retzow, Juergen-Christoph] Univ Cologne, Dept Pediat, Cologne, Germany.
C3 Newcastle University - UK; Newcastle University - UK; University of Duisburg Essen; University of Cologne; University of Cologne
RP Horvath, R (corresponding author), Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM Rita.Horvath@ncl.ac.uk
FU Newcastle upon Tyne Hospitals NHS Charity [RES0211/7262]; Academy of Medical Sciences (UK) [BH090164]; MRC (UK); German ministry of education and research (BMBF, Bonn, Germany)
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Montero R, 2009, CLIN BIOCHEM, V42, P742, DOI 10.1016/j.clinbiochem.2008.10.027
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Smits P, 2010, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2010/737385
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Yan QF, 2006, BIOCHEM BIOPH RES CO, V342, P1130, DOI 10.1016/j.bbrc.2006.02.078
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 22
TC 54
Z9 56
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD FEB 15
PY 2011
VL 34
IS 1
BP 197
EP 201
DI 10.1007/s10545-010-9250-z
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 711QR
UT WOS:000286607000023
PM 21153446
DA 2024-11-01
ER

PT J
AU Young, MJ
   Longley, MJ
   Li, FY
   Kasiviswanathan, R
   Wong, LJ
   Copeland, WC
AF Young, Matthew J.
   Longley, Matthew J.
   Li, Fang-Yuan
   Kasiviswanathan, Rajesh
   Wong, Lee-Jun
   Copeland, William C.
TI Biochemical analysis of human <i>POLG2</i> variants associated with mitochondrial disease
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID dna-polymerase-gamma; transfer-rna synthetases; progressive external ophthalmoplegia; comparative genomic hybridization; accessory subunit; processivity factor; crystal-structure; escherichia-coli; catalytic subunit; mutations
AB Defects in mitochondrial DNA (mtDNA) maintenance comprise an expanding repertoire of polymorphic diseases caused, in part, by mutations in the genes encoding the p140 mtDNA polymerase (POLG), its p55 accessory subunit (POLG2) or the mtDNA helicase (C10orf2). In an exploration of nuclear genes for mtDNA maintenance linked to mitochondrial disease, eight heterozygous mutations (six novel) in POLG2 were identified in one control and eight patients with POLG-related mitochondrial disease that lacked POLG mutations. Of these eight mutations, we biochemically characterized seven variants [c.307G>A (G103S); c.457C>G (L153V); c.614C>G (P205R); c.1105A>G (R369G); c.1158T>G (D386E); c.1268C>A (S423Y); c.1423_1424delTT (L475DfsX2)] that were previously uncharacterized along with the wild-type protein and the G451E pathogenic variant. These seven mutations encode amino acid substitutions that map throughout the protein, including the p55 dimer interface and the C-terminal domain that interacts with the catalytic subunit. Recombinant proteins harboring these alterations were assessed for stimulation of processive DNA synthesis, binding to the p140 catalytic subunit, binding to dsDNA and self-dimerization. Whereas the G103S, L153V, D386E and S423Y proteins displayed wild-type behavior, the P205R and R369G p55 variants had reduced stimulation of processivity and decreased affinity for the catalytic subunit. Additionally, the L475DfsX2 variant, which possesses a C-terminal truncation, was unable to bind the p140 catalytic subunit, unable to bind dsDNA and formed aberrant oligomeric complexes. Our biochemical analysis helps explain the pathogenesis of POLG2 mutations in mitochondrial disease and emphasizes the need to quantitatively characterize the biochemical consequences of newly discovered mutations before classifying them as pathogenic.
C1 [Li, Fang-Yuan; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Mitochondrial Diagnost Lab, Houston, TX 77030 USA.
   [Young, Matthew J.; Longley, Matthew J.; Kasiviswanathan, Rajesh; Copeland, William C.] NIEHS, Mol Genet Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
C3 Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Wong, LJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Mitochondrial Diagnost Lab, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu; copelan1@niehs.nih.gov
FU NIH, National Institute of Environmental Health Sciences [ES 065078]
CR Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018
   Baneyx F, 2004, NAT BIOTECHNOL, V22, P1399, DOI 10.1038/nbt1029
   Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909
   Chen HC, 2009, HUM MOL GENET, V18, PR169, DOI 10.1093/hmg/ddp326
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Cohen BH, 2010, POLG RELATED DISORDE, V0, P0
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Di Re M, 2009, NUCLEIC ACIDS RES, V37, P5701, DOI 10.1093/nar/gkp614
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102
   HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744
   Iyengar B, 2002, P NATL ACAD SCI USA, V99, P4483, DOI 10.1073/pnas.072664899
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Kasiviswanathan R, 2010, METHODS, V51, P379, DOI 10.1016/j.ymeth.2010.02.015
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I
   KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee YS, 2010, J BIOL CHEM, V285, P28105, DOI 10.1074/jbc.M110.122283
   Lee YS, 2010, J BIOL CHEM, V285, P1490, DOI 10.1074/jbc.M109.062752
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Masuyama M, 2005, BBA-GEN SUBJECTS, V1723, P302, DOI 10.1016/j.bbagen.2005.03.001
   Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511
   Shoubridge EA, 2007, CURR TOP DEV BIOL, V77, P87, DOI 10.1016/S0070-2153(06)77004-1
   Twig G, 2008, BBA-BIOENERGETICS, V1777, P1092, DOI 10.1016/j.bbabio.2008.05.001
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yakubovskaya E, 2007, EMBO J, V26, P4283, DOI 10.1038/sj.emboj.7601843
   Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0
NR 46
TC 51
Z9 53
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2011
VL 20
IS 15
BP 3052
EP 3066
DI 10.1093/hmg/ddr209
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 790AD
UT WOS:000292560000014
PM 21555342
DA 2024-11-01
ER

PT J
AU Uusimaa, J
   Jungbluth, H
   Fratter, C
   Crisponi, G
   Feng, L
   Zeviani, M
   Hughes, I
   Treacy, EP
   Birks, J
   Brown, GK
   Sewry, CA
   McDermott, M
   Muntoni, F
   Poulton, J
AF Uusimaa, J.
   Jungbluth, H.
   Fratter, C.
   Crisponi, G.
   Feng, L.
   Zeviani, M.
   Hughes, I.
   Treacy, E. P.
   Birks, J.
   Brown, G. K.
   Sewry, C. A.
   McDermott, M.
   Muntoni, F.
   Poulton, J.
TI Reversible infantile respiratory chain deficiency is a unique, genetically heterogenous mitochondrial disease
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID c-oxidase deficiency; phenotypic-expression; mutation; myopathy; trna(glu); mtdna; encephalomyopathy; involvement; secondary; a3243g
AB Objectives Homoplasmic maternally inherited, m. 14674T>C or m. 14674T>G mt-tRNA(Glu) mutations have recently been identified in reversible infantile cytochrome c oxidase deficiency (or 'benign COX deficiency'). This study sought other genetic defects that may give rise to similar presentations. Patients Eight patients from seven families with clinicopathological features of infantile reversible cytochrome c oxidase deficiency were investigated. Methods The study reviewed the diagnostic features and performed molecular genetic analyses of mitochondrial DNA and nuclear encoded candidate genes. Results Patients presented with subacute onset of profound hypotonia, feeding difficulties and lactic acidosis within the first months of life. Although recovery was remarkable, a mild myopathy persisted into adulthood. Histopathological findings in muscle included increased lipid and/or glycogen content, ragged-red and COX negative fibres. Biochemical studies suggested more generalised abnormalities than pure COX deficiency. Clinical improvement was reflected by normalisation of lactic acidosis and histopathological abnormalities. The m. 14674T>C mt-tRNA(Glu) mutation was identified in four families, but none had the m. 14674T>G mutation. Furthermore, in two families pathogenic mutations were also found in the nuclear TRMU gene which has not previously been associated with this phenotype. In one family, the genetic aetiology still remains unknown. Conclusions Benign COX deficiency is better described as 'reversible infantile respiratory chain deficiency'. It is genetically heterogeneous,and patients not carring the m. 14674T>C or T>G mt-tRNA(Glu) mutations may have mutations in the TRMU gene. Diagnosing this disorder at the molecular level is a significant advance for paediatric neurologists and intensive care paediatricians, enabling them to select children with an excellent prognosis for continuing respiratory support from those with severe mitochondrial presentation in infancy.
C1 [Uusimaa, J.; Poulton, J.] John Radcliffe Hosp, Womens Ctr, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
   [Jungbluth, H.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England.
   [Jungbluth, H.] St Thomas Hosp, Evelina Childrens Hosp, Dept Paediat Neurol, Neuromuscular Serv, London, England.
   [Fratter, C.] Churchill Hosp, Oxford Med Genet Lab, Oxford OX3 7LJ, England.
   [Crisponi, G.] Univ Cagliari, Serv Puericultura, Cagliari, Italy.
   [Feng, L.; Sewry, C. A.; Muntoni, F.] UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, Oxford, England.
   [Zeviani, M.] IRCCS Fdn, C Besta Neurol Inst, Unit Mol Neurogenet, Milan, Italy.
   [Hughes, I.] Manchester Childrens Hosp, Dept Paediat Neurol, Manchester, Lancs, England.
   [Treacy, E. P.] Childrens Univ Hosp, Natl Ctr Inherited Metab Dis, Dublin, Ireland.
   [Birks, J.] Univ Oxford, Ctr Stat Med, Oxford, England.
   [Brown, G. K.] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.
   [McDermott, M.] Our Ladys Hosp Sick Children, Dublin, Ireland.
C3 University of Oxford; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Oxford; University of Cagliari; University of London; University College London; Royal Manchester Children's Hospital; Childrens University Hospital - Temple Street; University of Oxford; University of Oxford; Our Ladys Children Hospital Crumlin
RP Poulton, J (corresponding author), John Radcliffe Hosp, Womens Ctr, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
EM joanna.poulton@obs-gyn.ox.ac.uk
FU Arvo and Lea Ylppo Foundation; Foundation for Paediatric Research; Sigrid Juselius Foundation; MRC; Wellcome Trust; Angus Memorial Mitochondrial Fund; MRC [G0601943, G0500695] Funding Source: UKRI
CR Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   CORDA S, 2001, PROSPETTIVE PEDIAT, V31, P235
   CormierDaire V, 1996, AM J MED GENET, V66, P457, DOI 10.1002/(SICI)1096-8628(19961230)66:4<457::AID-AJMG15>3.0.CO;2-T
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DIMAURO S, 1981, T AM NEUROL ASSOC, V106, P205
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Hargreaves IP, 2007, MITOCHONDRION, V7, P284, DOI 10.1016/j.mito.2007.02.001
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Low E, 2008, PEDIATR NEUROL, V39, P368, DOI 10.1016/j.pediatrneurol.2008.07.023
   Mayr JA, 2006, NEUROMUSCULAR DISORD, V16, P874, DOI 10.1016/j.nmd.2006.08.010
   Meulemans A, 2007, EUR J PAEDIATR NEURO, V11, P17, DOI 10.1016/j.ejpn.2006.10.004
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   Nogueira C, 2007, MITOCHONDRION, V7, P396, DOI 10.1016/j.mito.2007.08.002
   NONAKA I, 1988, ACTA NEUROPATHOL, V77, P152
   Pancrudo J, 2007, J CHILD NEUROL, V22, P858, DOI 10.1177/0883073807304199
   Pereira C, 2007, BIOCHEM BIOPH RES CO, V354, P937, DOI 10.1016/j.bbrc.2007.01.068
   PERUCCALOSTANLED, 2002, BIOCHIM BIOPHYS ACTA, V588, P210
   Pihlajaniemi TL, 2010, CLEFT PALATE-CRAN J, V47, P234, DOI 10.1597/08-131.1
   ROODHOOFT AM, 1986, NEUROPEDIATRICS, V17, P221, DOI 10.1055/s-2008-1052534
   SALO MK, 1992, ARCH DIS CHILD, V67, P1033, DOI 10.1136/adc.67.8.1033
   Sawano T, 1996, BIOCHEM MOL BIOL INT, V38, P693
   Schara U, 2011, J INHERIT METAB DIS, V34, P197, DOI 10.1007/s10545-010-9250-z
   SUZUKI M, 1989, NO TO HATTATSU, V21, P543
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   TRITSCHLER HJ, 1991, NEUROLOGY, V41, P300, DOI 10.1212/WNL.41.2_Part_1.300
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   Wada H, 1996, BRAIN DEV-JPN, V18, P263, DOI 10.1016/0387-7604(96)00017-4
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
   ZEVIANI M, 1987, NEUROLOGY, V37, P64, DOI 10.1212/WNL.37.1.64
NR 34
TC 49
Z9 51
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD OCT 15
PY 2011
VL 48
IS 10
BP 660
EP 668
DI 10.1136/jmg.2011.089995
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 822FZ
UT WOS:000295030700003
PM 21931168
DA 2024-11-01
ER

PT J
AU Song, Z
   Cao, Y
   Samuels, DC
AF Song, Zhuo
   Cao, Yang
   Samuels, David C.
TI Replication Pauses of the Wild-Type and Mutant Mitochondrial DNA Polymerase Gamma: A Simulation Study
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID polg mutations; nucleotide incorporation; accessory subunit; alpers-syndrome; reconstitution; efficiency; deletions; fidelity; spectrum; muscle
AB The activity of polymerase gamma is complicated, involving both correct and incorrect DNA polymerization events, exonuclease activity, and the disassociation of the polymerase: DNA complex. Pausing of pol-gamma might increase the chance of deletion and depletion of mitochondrial DNA. We have developed a stochastic simulation of pol-gamma that models its activities on the level of individual nucleotides for the replication of mtDNA. This method gives us insights into the pausing of two pol-gamma variants: the A467T substitution that causes PEO and Alpers syndrome, and the exonuclease deficient pol-gamma (exo(-)) in premature aging mouse models. To measure the pausing, we analyzed simulation results for the longest time for the polymerase to move forward one nucleotide along the DNA strand. Our model of the exo(-) polymerase had extremely long pauses, with a 30 to 300-fold increase in the time required for the longest single forward step compared to the wild-type, while the naturally occurring A467T variant showed at most a doubling in the length of the pauses compared to the wild-type. We identified the cause of these differences in the polymerase pausing time to be the number of disassociations occurring in each forward step of the polymerase.
C1 [Song, Zhuo; Samuels, David C.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37235 USA.
   [Cao, Yang] Virginia Tech, Dept Comp Sci, Blacksburg, VA USA.
C3 Vanderbilt University; Virginia Polytechnic Institute & State University
RP Song, Z (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37235 USA.
EM david.samuels@chgr.mc.vanderbilt.edu
FU NIH/NIGMS [GM073744]
CR Ameur A, 2011, PLOS GENET, V7, P0, DOI 10.1371/journal.pgen.1002028
   Atanassova N, 2011, HUM MOL GENET, V20, P1212, DOI 10.1093/hmg/ddq565
   Bailey LJ, 2009, NUCLEIC ACIDS RES, V37, P2327, DOI 10.1093/nar/gkp091
   Bertram JG, 2010, BIOCHEMISTRY-US, V49, P20, DOI 10.1021/bi901653g
   Boes M, 2009, SEIZURE-EUR J EPILEP, V18, P232, DOI 10.1016/j.seizure.2008.08.003
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Estep PA, 2011, BIOCHEMISTRY-US, V50, P6376, DOI 10.1021/bi200280r
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3
   GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2004, STRUCTURE FUNCTION D, V0, P64
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Johnson AA, 2001, J BIOL CHEM, V276, P38097
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   McHugh JC, 2010, MUSCLE NERVE, V41, P265, DOI 10.1002/mus.21494
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   POLLAK JK, 1970, BIOCHEM J, V117, P913, DOI 10.1042/bj1170913
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Song Z, 2010, METHODS, V51, P385, DOI 10.1016/j.ymeth.2010.02.019
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Utzig N, 2007, ACTA NEUROPATHOL, V114, P329
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2009, CELL METAB, V10, P437, DOI 10.1016/j.cmet.2009.11.001
   Wendelsdorf KV, 2009, PLOS COMPUT BIOL, V5, P0, DOI 10.1371/journal.pcbi.1000261
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Young MJ, 2009, MITOCHONDRION, V10, P96
NR 49
TC 4
Z9 4
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD NOV 15
PY 2011
VL 7
IS 11
BP 
EP 
DI 10.1371/journal.pcbi.1002287
PG 9
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 851JG
UT WOS:000297263700030
PM 22125488
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Parkinson's Syndrome and Parkinson's Disease in Mitochondrial Disorders
SO MOVEMENT DISORDERS
LA English
DT Review
DE mitochondrial myopathy; metabolic disease; neurodegenerative disorder; extrapyramidal disease; mitochondrial DNA; genetics
ID progressive external ophthalmoplegia; dna deletions; familial parkinsonism; oxidative-stress; polg1 mutations; point mutations; leigh-syndrome; nigra neurons; cybrid cells; a8344g merrf
AB In the majority of cases, mitochondrial disorders are multisystem conditions that most frequently affect the skeletal muscle, followed by the central nervous system. One of the clinical manifestations of central nervous system involvement is Parkinson's syndrome (PS). Evidence for an association of mitochondrial defects with PS comes from mitochondrial disorder patients who have developed Parkinson's syndrome and from Parkinson's syndrome patients who have developed a mitochondrial disorder. In addition, there are a number of patients with Parkinson's syndrome or Parkinson's disease (PD) who later develop subclinical immunohistological or biochemical indications of mitochondrial defects or accumulates mitochondrial DNA mutations within various cerebral regions. There are also Parkinson's syndrome patients who present with elevated cerebrospinal-fluid lactate by magnetic resonance spectroscopy. Furthermore, it has been shown that mutations in genes causing PD, such as PINK1, parkin, DJ1, alpha-synuclein, and LRRK2, also cause mitochondrial dysfunction, which is one of the reasons why they are called mitochondrial nigropathies. Parkinson's syndrome in patients with a mitochondrial disorder may also result from oxidative stress or exogenous toxins. Treatment of mitochondrial Parkinson's syndrome is not at variance with the treatment of Parkinson's syndrome due to other causes, but because of the multisystem nature of mitochondrial disorders, mitochondrial Parkinson's syndrome requires additional therapeutic support. (C) 2011 Movement Disorder Society
C1 [Finsterer, Josef] Danube Univ, Krems, Austria.
   [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Danube University Krems; Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bayir H, 2009, J BIOL CHEM, V284, P15951, DOI 10.1074/jbc.M900418200
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   Bisaglia M, 2010, BBA-MOL BASIS DIS, V1802, P699, DOI 10.1016/j.bbadis.2010.06.006
   Borland MK, 2009, BBA-MOL BASIS DIS, V1792, P68, DOI 10.1016/j.bbadis.2008.09.014
   Cavelier L, 2001, HEREDITAS, V135, P65, DOI 10.1111/j.1601-5223.2001.00065.x
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Chu CT, 2010, HUM MOL GENET, V19, PR28, DOI 10.1093/hmg/ddq143
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   de Moura MB, 2010, ENVIRON MOL MUTAGEN, V51, P391, DOI 10.1002/em.20575
   Dermaut B, 2010, J NEUROL NEUROSUR PS, V81, P90, DOI 10.1136/jnnp.2008.157354
   Eerola J, 2010, NEUROSCI LETT, V477, P1, DOI 10.1016/j.neulet.2010.04.021
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   Finsterer J, 2002, ACTA NEUROL SCAND, V105, P384, DOI 10.1034/j.1600-0404.2002.01221.x
   Finsterer J, 2001, NEURORADIOLOGY, V43, P997, DOI 10.1007/s002340100618
   Finsterer J, 2008, INT J CARDIOL, V123, PE45, DOI 10.1016/j.ijcard.2006.11.120
   Finsterer J, 2009, CAN J NEUROL SCI, V36, P143, DOI 10.1017/S0317167100006508
   Foti R, 2010, J BIOL CHEM, V285, P18565, DOI 10.1074/jbc.M109.088294
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   García-Cazorla A, 2006, ANN NEUROL, V59, P121, DOI 10.1002/ana.20709
   Garcia-Cazorla A, 2008, MITOCHONDRION, V8, P273, DOI 10.1016/j.mito.2008.05.001
   Gdynia HJ, 2009, PARKINSONISM RELAT D, V15, P633, DOI 10.1016/j.parkreldis.2009.06.003
   Gispert S, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005777
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Grünewald A, 2009, EXP NEUROL, V219, P266, DOI 10.1016/j.expneurol.2009.05.027
   Hara K, 1994, RINSHO SHINKEIGAKU, V34, P361
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Huang JY, 2010, FREE RADICAL BIO MED, V49, P1099, DOI 10.1016/j.freeradbiomed.2010.06.026
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Iaccarino C, 2007, HUM MOL GENET, V16, P1319, DOI 10.1093/hmg/ddm080
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Irrcher I, 2010, HUM MOL GENET, V19, P3734, DOI 10.1093/hmg/ddq288
   Keeney PM, 2009, EXP NEUROL, V220, P374, DOI 10.1016/j.expneurol.2009.09.025
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   Kösel S, 2000, NEUROGENETICS, V2, P227
   Lin Tsu-Kung, 2009, CHANG GUNG MED J, V32, P589
   Liu WC, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0004597
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   MACAYA A, 1993, NEUROPEDIATRICS, V24, P60, DOI 10.1055/s-2008-1071515
   Mancuso M, 2008, PARKINSONISM RELAT D, V14, P381, DOI 10.1016/j.parkreldis.2007.10.001
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   McFarland MA, 2008, MOL CELL PROTEOMICS, V7, P2123, DOI 10.1074/mcp.M800116-MCP200
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   MILONE M, 2010, ACTA MYOL, V29, P235
   Misiak M, 2010, BBA-BIOENERGETICS, V1797, P1178, DOI 10.1016/j.bbabio.2010.04.009
   MIZUNO Y, 1987, BIOCHEM BIOPH RES CO, V143, P971, DOI 10.1016/0006-291X(87)90346-9
   Narendra DP, 2010, PLOS BIOL, V8, P0, DOI 10.1371/journal.pbio.1000298
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   Nuytemans K, 2010, HUM MUTAT, V31, P763, DOI 10.1002/humu.21277
   Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x
   Pienaar IS, 2010, EXPERT REV PROTEOMIC, V7, P205, DOI 10.1586/epr.10.8
   PRZEDBORSKI S, 1993, ANN NEUROL, V34, P715, DOI 10.1002/ana.410340515
   Rakovic A, 2010, HUM MOL GENET, V19, P3124, DOI 10.1093/hmg/ddq215
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202
   Schnopp NM, 1996, CLIN NEUROPATHOL, V15, P348
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Simon DK, 2010, BMC MED GENET, V11, P0, DOI 10.1186/1471-2350-11-53
   Snow BJ, 2010, MOVEMENT DISORD, V25, P1670, DOI 10.1002/mds.23148
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Tan EK, 2010, EXP NEUROL, V221, P10, DOI 10.1016/j.expneurol.2009.10.018
   Tanaka M, 1996, ANN NY ACAD SCI, V786, P102, DOI 10.1111/j.1749-6632.1996.tb39055.x
   Thobois S, 1997, REV NEUROL, V153, P595
   Thomas B, 2009, ANTIOXID REDOX SIGN, V11, P2077, DOI 10.1089/ars.2009.2697
   Trimmer PA, 2009, EXP NEUROL, V218, P320, DOI 10.1016/j.expneurol.2009.03.016
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   VANERVEN PMM, 1989, DEV MED CHILD NEUROL, V31, P81
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Wilcox RA, 2007, MOVEMENT DISORD, V22, P1020, DOI 10.1002/mds.21416
   Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013
   Yamamoto M, 1997, J NEUROL NEUROSUR PS, V62, P290, DOI 10.1136/jnnp.62.3.290
   Zhou C, 2008, ANN NY ACAD SCI, V1147, P93, DOI 10.1196/annals.1427.023
   ZIVIANI E, 2010, AUTOPHAGY, V0, P6
NR 77
TC 22
Z9 26
U1 1
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
EI 
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR 15
PY 2011
VL 26
IS 5
BP 784
EP 791
DI 10.1002/mds.23651
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 762AT
UT WOS:000290445400030
PM 21384429
DA 2024-11-01
ER

PT J
AU Martin-Negrier, ML
   Sole, G
   Jardel, C
   Vital, C
   Ferrer, X
   Vital, A
AF Martin-Negrier, M. -L.
   Sole, G.
   Jardel, C.
   Vital, C.
   Ferrer, X.
   Vital, A.
TI <i>TWINKLE</i> gene mutation: report of a French family with an autosomal dominant progressive external ophthalmoplegia and literature review
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Review
DE mitochondria; myopathy; neuropathy; ophthalmoplegia; Twinkle gene
ID sensory ataxic neuropathy; mitochondrial-dna; multiple deletions; disease; helicase; ant1; parkinsonism; myopathy; disorders; phenotype
AB Background: Multiple mitochondrial DNA (mtDNA) deletions usually have a mendelian inheritance secondary to mutation in nuclear genes. One of these is the Twinkle gene whose mutation is responsible for autosomal dominant progressive external ophthalmoplegia (PEO). The number of reported cases with mainly myopathic symptoms and possible nervous system involvement related to Twinkle gene mutation is limited. We present a new French family of whom two members displayed myopathy and neuropathy associated with PEO, and we perform a clinical review in light of other observations reported in the literature. Methods: The proband, one son and the daughter have been investigated. Southern blot analysis and long-range PCR assay have been performed from muscle biopsy specimens. Coding exons and flanking intron regions of polymerase gamma (POLG) and DNA helicase (Twinkle) genes were sequenced. Results: Multiple mitochondrial DNA deletions have been found and sequencing of the Twinkle gene showed the change p. R374Q. Conclusion: Two other families from the literature also had the R374Q mutation. Symptoms reported in association with this mutation were myopathy, peripheral neuropathy, dysarthria and/or dysphagia, respiratory insufficiency and parkinsonism. Respiratory insufficiency caused by chest wall weakness was reported in other families with different Twinkle gene mutations, and one might provide exercise intolerance, dysarthria and/or dysphagia as symptoms in favor of the diagnosis. Occurrence of impressive emaciation was a peculiarity in our family.
C1 [Martin-Negrier, M. -L.; Vital, C.; Vital, A.] Bordeaux Inst Neurosci, CNRS, UMR 5227, Bordeaux, France.
   [Sole, G.; Ferrer, X.] Bordeaux Univ Hosp, Dept Neurol, Bordeaux, France.
   [Jardel, C.] Grp Hosp Pitie Salpetriere, INSERM, UMRS 975, F-75634 Paris, France.
C3 Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CHU Bordeaux; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Vital, A (corresponding author), Univ Victor Segalen, BP42,146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM anne.vital@chu-bordeaux.fr
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bohlega S, 2009, NEUROMUSCULAR DISORD, V19, P845, DOI 10.1016/j.nmd.2009.10.002
   Bouillot S, 2002, J PERIPHER NERV SYST, V7, P213, DOI 10.1046/j.1529-8027.2002.02027.x
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Echaniz-Laguna A, 2010, NEUROGENETICS, V11, P21, DOI 10.1007/s10048-009-0202-4
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   HANNA MG, 2005, PERIPHERAL NEUROPATH, V0, P1937
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hong DJ, 2010, MUSCLE NERVE, V41, P92, DOI 10.1002/mus.21439
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   LAMPERTI C, 2009, ACTA MYOL, V23, P2
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Negro R, 2009, NEUROMUSCULAR DISORD, V19, P423, DOI 10.1016/j.nmd.2009.04.008
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
NR 33
TC 18
Z9 20
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAR 15
PY 2011
VL 18
IS 3
BP 436
EP 441
DI 10.1111/j.1468-1331.2010.03171.x
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 722RB
UT WOS:000287450900013
PM 20880070
DA 2024-11-01
ER

PT J
AU Sakiyama, Y
   Okamoto, Y
   Higuchi, I
   Inamori, Y
   Sangatsuda, Y
   Michizono, K
   Watanabe, O
   Hatakeyama, H
   Goto, Y
   Arimura, K
   Takashima, H
AF Sakiyama, Yusuke
   Okamoto, Yuji
   Higuchi, Itsuro
   Inamori, Yukie
   Sangatsuda, Yoko
   Michizono, Kumiko
   Watanabe, Osamu
   Hatakeyama, Hideyuki
   Goto, Yu-ichi
   Arimura, Kimiyoshi
   Takashima, Hiroshi
TI A new phenotype of mitochondrial disease characterized by familial late-onset predominant axial myopathy and encephalopathy
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE Mitochondrial disease; Predominant axial myopathy; Encephalopathy; Late-onset; Familial case
ID hereditary optic neuropathy; bent spine syndrome; muscular-dystrophy; trna(phe) gene; dna mutation; camptocormia; identification; thyroiditis; defects; patient
AB Axial myopathy is a rare neuromuscular disease that is characterized by paraspinal muscle atrophy and abnormal posture, most notably camptocormia (also known as bent spine). The genetic cause of familial axial myopathy is unknown. Described here are the clinical features and cause of late-onset predominant axial myopathy and encephalopathy. A 73-year-old woman presented with a 10-year history of severe paraspinal muscle atrophy and cerebellar ataxia. Her 84-year-old sister also developed late-onset paraspinal muscle atrophy and generalized seizures with encephalopathy. Computed tomography showed severe atrophy and fatty degeneration of their paraspinal muscles. Their mother and maternal aunt also developed bent spines. The existence of many ragged-red fibers and cytochrome c oxidase-negative fibers in the biceps brachii muscle of the proband indicated a mitochondrial abnormality. No significant abnormalities were observed in the respiratory chain enzyme activities; however, the activities of complexes I and IV were relatively low compared with the activities of other complexes. Sequence analysis of the mitochondrial DNA from the muscle revealed a novel heteroplasmic mutation (m.602C > T) in the mitochondrial tRNA(Phe) gene. This familial case of late-onset predominant axial myopathy and encephalopathy may represent a new clinical phenotype of a mitochondrial disease.
C1 [Sakiyama, Yusuke; Okamoto, Yuji; Higuchi, Itsuro; Inamori, Yukie; Michizono, Kumiko; Watanabe, Osamu; Takashima, Hiroshi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, Kagoshima 8908520, Japan.
   [Sangatsuda, Yoko] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychiat, Kagoshima 8908520, Japan.
   [Hatakeyama, Hideyuki; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
   [Arimura, Kimiyoshi] Okatsu Hosp, Div Neurol, Kagoshima, Japan.
C3 Kagoshima University; Kagoshima University; National Center for Neurology & Psychiatry - Japan
RP Takashima, H (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM thiroshi@m3.kufm.kagoshima-u.ac.jp
FU Nervous and Mental Disorders and Research Committee for Ataxic Disease of the Japanese Ministry of Health, Welfare and Labor [19A-1]; Ministry of Education, Culture, Sports, Science and Technology of Japan [21591095, 21591094]; Grants-in-Aid for Scientific Research [22590939, 21591095, 21591094] Funding Source: KAKEN
CR Azher SN, 2005, NEUROLOGY, V65, P355, DOI 10.1212/01.wnl.0000171857.09079.9f
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Berio A, 2002, PANMINERVA MED, V44, P265
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Boerkoel CF, 2001, AM J HUM GENET, V68, P325, DOI 10.1086/318208
   DAurelio M, 2006, HUM MOL GENET, V15, P2157, DOI 10.1093/hmg/ddl141
   Darin N, 2006, NEUROMUSCULAR DISORD, V16, P504, DOI 10.1016/j.nmd.2006.05.010
   Delcey V, 2002, REV MED INTERNE, V23, P144, DOI 10.1016/S0248-8663(01)00530-6
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   Genasetti A, 2007, J MOL DIAGN, V9, P538, DOI 10.2353/jmoldx.2007.060183
   Gómez-Puerta JA, 2007, CLIN RHEUMATOL, V26, P1017, DOI 10.1007/s10067-006-0259-5
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   Higuchi I, 1999, ACTA NEUROPATHOL, V98, P313, DOI 10.1007/s004010051086
   Iizuka T, 2009, J NEUROL SCI, V278, P35, DOI 10.1016/j.jns.2008.11.016
   Jungbluth H, 2009, NEUROMUSCULAR DISORD, V19, P344, DOI 10.1016/j.nmd.2009.02.005
   Karbowski K, 1999, SPINE, V24, P1494, DOI 10.1097/00007632-199907150-00017
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Konings A, 2008, MITOCHONDRION, V8, P377, DOI 10.1016/j.mito.2008.08.001
   Kottlors M, 2010, MUSCLE NERVE, V42, P273, DOI 10.1002/mus.21722
   Kovács GG, 2005, BRAIN, V128, P35, DOI 10.1093/brain/awh310
   Mahjneh I, 2002, J NEUROL, V249, P730, DOI 10.1007/s00415-002-0701-9
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Mithani SK, 2007, CLIN CANCER RES, V13, P7335, DOI 10.1158/1078-0432.CCR-07-0220
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   Müller-Höcker J, 1998, ULTRASTRUCT PATHOL, V22, P91
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   POULLIN P, 1993, REV RHUM, V60, P159
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Schäbitz WR, 2003, MOVEMENT DISORD, V18, P408, DOI 10.1002/mds.10385
   Serratrice G, 1996, J NEUROL NEUROSUR PS, V60, P51, DOI 10.1136/jnnp.60.1.51
   Serratrice G, 2007, ACTA MYOL, V26, P11
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
   Zhou SY, 2006, J MOL DIAGN, V8, P476, DOI 10.2353/jmoldx.2006.060008
NR 37
TC 17
Z9 17
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
EI 
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD JUN 15
PY 2011
VL 121
IS 6
BP 775
EP 783
DI 10.1007/s00401-011-0818-y
PG 9
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766OX
UT WOS:000290796000008
PM 21424749
DA 2024-11-01
ER

PT J
AU Jash, S
   Adhya, S
AF Jash, Sukanta
   Adhya, Samit
TI Suppression of reactive oxygen species in cells with multiple mitochondrial DNA deletions by exogenous protein-coding RNAs
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA; Multiple deletions; RNA delivery; Respiration; ROS suppression
ID mutant mitochondria; human brain; muscle; import; sufficient; mutations; age
AB Many human diseases are associated with mutations and deletions in mitochondrial DNA (mtDNA). We have generated a cell line, EB delta1, with multiple mtDNA deletions, that is respiration-defective and generates high levels of superoxide, a reactive oxygen species. Treatment of EB delta1 with tagged polycistronic (pc) RNAs, encoding parts of the mitochondrial proteome, bound to a multi-subunit carrier complex, resulted in cellular uptake and transfer of the RNA to mitochondria, restoration of respiration, and suppression of superoxide levels. These findings have implications for correction of mitochondrial defects in age-related disorders due to mtDNA mutations. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Jash, Sukanta; Adhya, Samit] CSIR, Indian Inst Chem Biol, Genet Engn Lab, Kolkata 700032, W Bengal, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)
RP Adhya, S (corresponding author), CSIR, Indian Inst Chem Biol, Genet Engn Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.
EM sadhya@iicb.res.in
FU Council of Scientific and Industrial Research (CSIR) [SIP0007]
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Berliner LJ, 2009, APPL MAGN RESON, V36, P157, DOI 10.1007/s00723-009-0034-2
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Dean OM, 2009, CURR MED CHEM, V16, P2965, DOI 10.2174/092986709788803060
   Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478
   Han YH, 2008, ONCOL REP, V20, P689, DOI 10.3892/or_00000061
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037
   Mahata B, 2005, J BIOL CHEM, V280, P5141, DOI 10.1074/jbc.C400572200
   Mahata B, 2006, SCIENCE, V314, P471, DOI 10.1126/science.1129754
   Mahato B, 2011, MITOCHONDRION, V11, P564, DOI 10.1016/j.mito.2011.03.006
   Mukherjee S, 2007, EMBO REP, V8, P589, DOI 10.1038/sj.embor.7400979
   Robinson KM, 2008, NAT PROTOC, V3, P941, DOI 10.1038/nprot.2008.56
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337
   SOONG NW, 1992, NAT GENET, V2, P318
   Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI 10.1089/ars.2008.2331
NR 26
TC 7
Z9 8
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JUL 15
PY 2011
VL 11
IS 4
BP 607
EP 614
DI 10.1016/j.mito.2011.03.124
PG 8
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 779GD
UT WOS:000291765200009
PM 21496501
DA 2024-11-01
ER

PT J
AU Qi, ZT
   He, J
   Zhang, YA
   Shao, Y
   Ding, SZ
AF Qi, Zhengtang
   He, Jie
   Zhang, Yuan
   Shao, Yue
   Ding, Shuzhe
TI Exercise training attenuates oxidative stress and decreases p53 protein content in skeletal muscle of type 2 diabetic Goto-Kakizaki rats
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE p53; Oxidative stress; Cytochrome oxidase deficient homolog 2; TP53-induced glycolysis and apoptosis regulator; Insulin resistance; Exercise training; Free radicals
ID induced insulin-resistance; n-acetylcysteine; in-vivo; pathways; pathogenesis; respiration; metabolism; mutation; mouse; tigar
AB Oxidative stress can impair mitochondrial function and fuel utilization and is closely linked with the development of insulin resistance in skeletal muscle in diabetes mellitus as well as fatty liver disease. In vitro data indicate that cellular levels of reactive oxygen species depend on the expression and activity of p53, which plays a key role in energy metabolism and as a crucial transcription factor for SCO cytochrome oxidase deficient homolog 2 (SCO2) and tumor p53-induced glycolysis and apoptosis regulator (TIGAR), which regulate mitochondrial respiration and glycolysis in cells. The aims of this study were: (1) to investigate whether exercise training could attenuate the development of oxidative stress in skeletal muscle in rats with diabetes mellitus (DM) and (2) to evaluate the potential role of p53 and its transcriptional targets in exercise-induced mitochondrial adaptation in skeletal muscle in rats with DM. Goto-Kakizaki (GK) rats, which develop type 2 DM (T2DM) early in life, were randomly divided into two groups: (1) subjected to regular exercise on a treadmill at 20 m/min for 30-60 min, 6 days per week for 8 weeks (GK exercising, n = 7), and (2) rested controls (GK control, n = 7). Exercise training increased serum adiponectin and decreased serum insulin and levels of glycosylated hemoglobin (P < 0.05). Skeletal muscle GSH content and GSH:GSSG ratio increased in GK exercising rats vs GK controls (P < 0.05). Skeletal muscle COX activity (P < 0.05), mtDNA markers (P < 0.01), and COXII protein levels (P < 0.05) increased in response to exercise training. Exercise training decreased p53 protein levels and TIGAR expression in skeletal muscle (P < 0.05), but SCO2 expression was unchanged. These data indicate that exercise training can attenuate oxidative stress and increase mitochondrial DNA content in skeletal muscle in rats with T2DM and that exercise-induced suppression of p53 and TIGAR expression may play a role in preventing oxidative stress in insulin resistance. Crown Copyright (C) 2010 Published by Elsevier Inc. All rights reserved.
C1 [Qi, Zhengtang; He, Jie; Zhang, Yuan; Shao, Yue; Ding, Shuzhe] E China Normal Univ, Coll Phys Educ & Hlth, Shanghai 200241, Peoples R China.
   [Qi, Zhengtang] E China Normal Univ, Inst Biomed Sci, Shanghai 200241, Peoples R China.
C3 East China Normal University; East China Normal University
RP Ding, SZ (corresponding author), E China Normal Univ, Coll Phys Educ & Hlth, Shanghai 200241, Peoples R China.
EM szding@tyxx.ecnu.edu.cn
FU National Natural Science Foundation of China [30871212]; Program for New Century Excellent Talents in University [790013P8]
CR Abbasi F, 2004, DIABETES, V53, P585, DOI 10.2337/diabetes.53.3.585
   Agardh CD, 1997, J DIABETES COMPLICAT, V11, P158, DOI 10.1016/S1056-8727(96)00049-9
   Assaily W, 2006, CANCER CELL, V10, P4, DOI 10.1016/j.ccr.2006.06.014
   Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Booth FW, 2009, J PHYSIOL-LONDON, V587, P5527, DOI 10.1113/jphysiol.2009.179507
   Corcoran CA, 2006, CANCER BIOL THER, V5, P1610, DOI 10.4161/cbt.5.12.3617
   Dhar SK, 2009, J BIOL CHEM, V284, P16409, DOI 10.1074/jbc.M109.005736
   Dokken BB, 2008, AM J PHYSIOL-ENDOC M, V294, PE615, DOI 10.1152/ajpendo.00578.2007
   Dudley RWR, 2006, AM J PHYSIOL-REG I, V291, PR704, DOI 10.1152/ajpregu.00031.2006
   Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032
   Haber CA, 2003, AM J PHYSIOL-ENDOC M, V285, PE744, DOI 10.1152/ajpendo.00355.2002
   Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, PE1039, DOI 10.1152/ajpendo.2000.279.5.E1039
   Knuf M, 2007, ACTA PAEDIATR, V96, P130, DOI 10.1111/j.1651-2227.2007.00008.x
   Koopman R, 2006, AM J PHYSIOL-ENDOC M, V290, PE1245, DOI 10.1152/ajpendo.00530.2005
   Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013
   Kruse JP, 2006, CELL METAB, V4, P1, DOI 10.1016/j.cmet.2006.06.004
   Lam T, 2003, DIABETES, V52, P0
   Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343
   Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   McGuinness OP, 2009, AM J PHYSIOL-ENDOC M, V297, PE849, DOI 10.1152/ajpendo.90996.2008
   Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014
   Ogihara T, 2004, DIABETOLOGIA, V47, P794, DOI 10.1007/s00125-004-1391-x
   Ogihara T, 2003, DIABETES, V52, P0
   Olovnikov IA, 2009, SEMIN CANCER BIOL, V19, P32, DOI 10.1016/j.semcancer.2008.11.005
   Pang CY, 2001, DIABETES RES CLIN PR, V54, PS45, DOI 10.1016/S0168-8227(01)00335-7
   Park JY, 2009, CIRC RES, V105, P705, DOI 10.1161/CIRCRESAHA.109.205310
   Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x
   Saleem A, 2009, PHYSIOL GENOMICS, V37, P58, DOI 10.1152/physiolgenomics.90346.2008
   Schrauwen P, 2004, DIABETES, V53, P1412, DOI 10.2337/diabetes.53.6.1412
   Steinberg GR, 2004, AM J PHYSIOL-ENDOC M, V286, PE57, DOI 10.1152/ajpendo.00302.2003
   Sun LJ, 2010, LIFE SCI, V86, P39, DOI 10.1016/j.lfs.2009.11.003
   Virkamäki A, 2001, DIABETES, V50, P2337, DOI 10.2337/diabetes.50.10.2337
   Wang Y, 2009, DIABETES-METAB RES, V25, P13, DOI 10.1002/dmrr.928
   Wei W, 2009, HEMOGLOBIN, V33, P370, DOI 10.3109/03630260903212175
   Yahagi N, 2004, J BIOL CHEM, V279, P20571, DOI 10.1074/jbc.M400884200
   Yokota T, 2009, AM J PHYSIOL-HEART C, V297, PH1069, DOI 10.1152/ajpheart.00267.2009
NR 40
TC 39
Z9 46
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD APR 1
PY 2011
VL 50
IS 7
BP 794
EP 800
DI 10.1016/j.freeradbiomed.2010.12.022
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 733UL
UT WOS:000288288700003
PM 21185935
DA 2024-11-01
ER

PT J
AU Villarroya, J
   Dorado, B
   Vilà, MR
   Garcia-Arumí, E
   Domingo, P
   Giralt, M
   Hirano, M
   Villarroya, F
AF Villarroya, Joan
   Dorado, Beatriz
   Vila, Maya R.
   Garcia-Arumi, Elena
   Domingo, Pere
   Giralt, Marta
   Hirano, Michio
   Villarroya, Francesc
TI Thymidine Kinase 2 Deficiency-Induced Mitochondrial DNA Depletion Causes Abnormal Development of Adipose Tissues and Adipokine Levels in Mice
SO PLOS ONE
LA English
DT Article
ID gene-expression; biogenesis; transcription; adipocyte; activation; mutations; transport; myopathy; depots; lipoma
AB Mammal adipose tissues require mitochondrial activity for proper development and differentiation. The components of the mitochondrial respiratory chain/oxidative phosphorylation system (OXPHOS) are encoded by both mitochondrial and nuclear genomes. The maintenance of mitochondrial DNA (mtDNA) is a key element for a functional mitochondrial oxidative activity in mammalian cells. To ascertain the role of mtDNA levels in adipose tissue, we have analyzed the alterations in white (WAT) and brown (BAT) adipose tissues in thymidine kinase 2 (Tk2) H126N knockin mice, a model of TK2 deficiency-induced mtDNA depletion. We observed respectively severe and moderate mtDNA depletion in TK2-deficient BAT and WAT, showing both tissues moderate hypotrophy and reduced fat accumulation. Electron microscopy revealed altered mitochondrial morphology in brown but not in white adipocytes from TK2-deficient mice. Although significant reduction in mtDNA-encoded transcripts was observed both in WAT and BAT, protein levels from distinct OXPHOS complexes were significantly reduced only in TK2-deficient BAT. Accordingly, the activity of cytochrome c oxidase was significantly lowered only in BAT from TK2-deficient mice. The analysis of transcripts encoding up to fourteen components of specific adipose tissue functions revealed that, in both TK2-deficient WAT and BAT, there was a consistent reduction of thermogenesis related gene expression and a severe reduction in leptin mRNA. Reduced levels of resistin mRNA were found in BAT from TK2-deficient mice. Analysis of serum indicated a dramatic reduction in circulating levels of leptin and resistin. In summary, our present study establishes that mtDNA depletion leads to a moderate impairment in mitochondrial respiratory function, especially in BAT, causes substantial alterations in WAT and BAT development, and has a profound impact in the endocrine properties of adipose tissues.
C1 [Villarroya, Joan; Giralt, Marta; Villarroya, Francesc] Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain.
   [Villarroya, Joan; Giralt, Marta; Villarroya, Francesc] Univ Barcelona, Inst Biomed IBUB, Barcelona, Spain.
   [Villarroya, Joan; Domingo, Pere] Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona, Spain.
   [Villarroya, Joan; Giralt, Marta; Villarroya, Francesc] ISCIII, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Santiago De Compostela, Spain.
   [Dorado, Beatriz; Hirano, Michio] Columbia Univ Med Ctr, Dept Neurol, New York, NY USA.
   [Vila, Maya R.; Garcia-Arumi, Elena] Hosp Univ Vall dHebron, Inst Recerca, Barcelona, Spain.
   [Garcia-Arumi, Elena] ISCIII, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Valencia, Spain.
C3 University of Barcelona; University of Barcelona; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Columbia University; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER
RP Villarroya, J (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain.
EM joanvillarroya@gmail.com
FU Ministerio de Ciencia e Innovacion [SAF2008-01896]; Instituto de Salud Carlos III; Red de Investigacion en SIDA [PI081715]; Fundacion para la Investigacion y la Prevencion del Sida en Espana (FIPSE) [36610/06]
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251
   BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x
   Bogacka I, 2005, J CLIN ENDOCR METAB, V90, P6650, DOI 10.1210/jc.2005-1024
   Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003
   Carmona MC, 2002, J BIOL CHEM, V277, P21489, DOI 10.1074/jbc.M201710200
   Chevillotte E, 2007, DIABETES, V56, P1042, DOI 10.2337/db06-1300
   Cote HC, 2005, ANTIVIR THER, V0, P10
   Dessolin S, 1997, FASEB J, V11, P382, DOI 10.1096/fasebj.11.5.9141506
   DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   GREENWOOD MR, 1974, J LIPID RES, V15, P474
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5
   HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887
   HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689
   Kim MJ, 2008, ANTIMICROB AGENTS CH, V52, P1670, DOI 10.1128/AAC.01449-07
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   LIN PY, 1977, J NUTR, V107, P1715, DOI 10.1093/jn/107.9.1715
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Nagy GS, 2003, CLIN INFECT DIS, V36, P795, DOI 10.1086/367859
   Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, PE444, DOI 10.1152/ajpendo.00691.2006
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Oliver P, 2003, MOL CELL BIOCHEM, V252, P397, DOI 10.1023/A:1025500605884
   Oliver P, 2001, PFLUG ARCH EUR J PHY, V442, P383, DOI 10.1007/s004240100540
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pace CS, 2003, ANTIVIR THER, V8, P323
   Ravussin E, 2009, OBES REV, V10, P265, DOI 10.1111/j.1467-789X.2008.00559.x
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Shi XR, 2008, J BIOL CHEM, V283, P30658, DOI 10.1074/jbc.M800510200
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Suzuki S, 2003, DIABETES RES CLIN PR, V59, P207, DOI 10.1016/S0168-8227(02)00246-2
   Suzuki Y, 2004, DIABETES RES CLIN PR, V63, P225, DOI 10.1016/j.diabres.2003.10.024
   Suzuki Y, 2002, DIABETES CARE, V25, P407, DOI 10.2337/diacare.25.2.407
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Villarroya F, 2005, TRENDS PHARMACOL SCI, V26, P88, DOI 10.1016/j.tips.2004.12.005
   Villarroya J, 2010, ANTIVIR THER, V15, P1021, DOI 10.3851/IMP1669
   Villarroya J, 2009, OBESITY, V17, P1814, DOI 10.1038/oby.2009.152
   Villena JA, 2002, CELL MOL LIFE SCI, V59, P1934, DOI 10.1007/PL00012516
   Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752
   Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 47
TC 17
Z9 19
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2011
VL 6
IS 12
BP 
EP 
DI 10.1371/journal.pone.0029691
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 897SB
UT WOS:000300674900054
PM 22216345
DA 2024-11-01
ER

PT J
AU Chennupati, SK
   Levi, J
   Loftus, P
   Jornlin, C
   Morlet, T
   O'Reilly, RC
AF Chennupati, Sri Kiran
   Levi, Jessica
   Loftus, Patricia
   Jornlin, Carly
   Morlet, Thierry
   O'Reilly, Robert C.
TI Hearing loss in children with mitochondrial disorders
SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
LA English
DT Article
DE Hearing loss; Mitochondrial disorder
ID kearns-sayre-syndrome; ragged-red fibers; auditory neuropathy; melas syndrome; deafness; impairment; mutations; diagnosis; epilepsy; gene
AB Objective: At least 1-5 children per 1000 suffer from congenital hearing loss, and 50% of these cases can be attributed to genetic causes. It has been estimated that 1% of pre-lingual hearing loss is due to mutations in mitochondrial DNA. Previous literature reports audiometric data for few patients, usually less than 20 per study. The goal of this study was to characterize the hearing loss associated with mitochondrial mutations and determine whether previously characterized patterns of hearing loss in these patients (progressive, sensorineural, high frequency losses) are found in our population as well. Methods: An IRB-approved retrospective chart review of the electronic medical records in the Nemours/Alfred I. dupont Hospital for Children system from January 2004 to October 2009 (a five-year period) was undertaken using ICD-9 codes 277.87 (mitochondrial disorder) and 359.89BA (mitochondrial myopathy). These 149 records were then evaluated for audiologic data, resulting in 26 charts with both a mitochondrial disorder and hearing evaluation. Results: Of 26 patients with known mitochondrial disorders and audiometric documentation, 15 (58%) had hearing loss, and 11 patients had normal hearing (42%). Ten patients had sensorineural hearing loss (38%), two patients had conductive hearing loss (7.7%), one patient had a mixed hearing loss (3.8%), and two patients had an as yet undefined hearing loss (ABR had not yet been performed at the time of this study) (7.7%). Conclusion: In comparison with previous studies, generally including less than 20 patients, this is one of the largest collections of audiometric data on children with mitochondrial disorders. Unlike prior studies describing a progressive, sensorineural loss across all frequencies or mainly affecting high frequencies, the hearing loss in our patients was more variable including low frequency losses, mid-frequency losses, and conductive losses and was often not progressive or even improved. Our overall 38% rate of sensorineural hearing loss correlates well with previous case series: this study clearly justifies the use of routine audiometric screening in children with mitochondrial disorders, including use of A,BR and OAEs as ASND can be seen in this population, as well as repeat testing over time to evaluate for progression. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Levi, Jessica; Jornlin, Carly; Morlet, Thierry; O'Reilly, Robert C.] Alfred I duPont Hosp Children, Div Pediat Otolaryngol, Wilmington, DE 19899 USA.
   [Chennupati, Sri Kiran] St Christophers Hosp Children, Div Otolaryngol, Philadelphia, PA 19134 USA.
   [Loftus, Patricia] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA.
C3 Nemours Alfred I. duPont Hospital for Children; Jefferson University
RP O'Reilly, RC (corresponding author), Alfred I duPont Hosp Children, Div Pediat Otolaryngol, POB 269, Wilmington, DE 19899 USA.
EM roreilly@nemours.org
CR Ballana E, 2006, BIOCHEM BIOPH RES CO, V341, P950, DOI 10.1016/j.bbrc.2006.01.049
   Berlin CI, 2010, INT J AUDIOL, V49, P30, DOI 10.3109/14992020903160892
   Ceranic B, 2004, J NEUROL NEUROSUR PS, V75, P626, DOI 10.1136/jnnp.2003.017673
   Clark J G, 1981, ASHA, V23, P493
   Corley V M, 1999, J AM ACAD AUDIOL, V10, P484
   Forli F, 2006, J LARYNGOL OTOL, V120, P888, DOI 10.1017/S0022215106001472
   Jacobs HT, 2005, EUR J HUM GENET, V13, P26, DOI 10.1038/sj.ejhg.5201250
   Karkos PD, 2004, CLIN OTOLARYNGOL, V29, P1, DOI 10.1111/j.1365-2273.2004.00769.x
   Kokotas H, 2007, CLIN GENET, V71, P379, DOI 10.1111/j.1399-0004.2007.00800.x
   Kornblum C, 2005, J NEUROL, V252, P1101, DOI 10.1007/s00415-005-0827-7
   MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504
   OLDFORS A, 1995, ACTA NEUROPATHOL, V90, P328
   Scaglia F, 2006, GENET MED, V8, P641, DOI 10.1097/01.gim.0000237781.10594.d1
   SEIBEL P, 1991, J NEUROL SCI, V105, P217, DOI 10.1016/0022-510X(91)90148-Z
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Tsutsumi T, 2001, J LARYNGOL OTOL, V115, P777
   Warrick PD, 1997, J LARYNGOL OTOL, V111, P279, DOI 10.1017/S0022215100137089
   Wong LJC, 2004, ANN NY ACAD SCI, V1011, P246, DOI 10.1196/annals.1293.024
   Yamasoba T, 1996, LARYNGOSCOPE, V106, P49, DOI 10.1097/00005537-199601000-00010
   Young TJ, 2005, PACE, V28, P454, DOI 10.1111/j.1540-8159.2005.40049.x
   Zwirner P, 2001, LARYNGOSCOPE, V111, P515, DOI 10.1097/00005537-200103000-00024
NR 21
TC 13
Z9 14
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0165-5876
EI 
J9 INT J PEDIATR OTORHI
JI Int. J. Pediatr. Otorhinolaryngol.
PD DEC 15
PY 2011
VL 75
IS 12
BP 1519
EP 1524
DI 10.1016/j.ijporl.2011.08.019
PG 6
WC Otorhinolaryngology; Pediatrics
SC Otorhinolaryngology; Pediatrics
GA 854JQ
UT WOS:000297491200008
PM 21982076
DA 2024-11-01
ER

PT J
AU Viader, A
   Golden, JP
   Baloh, RH
   Schmidt, RE
   Hunter, DA
   Milbrandt, J
AF Viader, Andreu
   Golden, Judith P.
   Baloh, Robert H.
   Schmidt, Robert E.
   Hunter, Daniel A.
   Milbrandt, Jeffrey
TI Schwann Cell Mitochondrial Metabolism Supports Long-Term Axonal Survival and Peripheral Nerve Function
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID transcription factor; neuropathy; mice; gene; inactivation; progression; disruption; mutations; mechanism; proteins
AB Mitochondrial dysfunction is a common cause of peripheral neuropathies. While the role of neuron and axonal mitochondria in peripheral nerve disease is well appreciated, whether Schwann cell (SC) mitochondrial deficits contribute to peripheral neuropathies is unclear. Here, we examine how SC mitochondrial dysfunction affects axonal survival and contributes to the decline of peripheral nerve function by generating mice with SC-specific mitochondrial deficits. These mice (Tfam-SCKOs) were produced through the tissue-specific deletion of the mitochondrial transcription factor A gene (Tfam), which is essential for mitochondrial DNA (mtDNA) transcription and maintenance. Tfam-SCKOs were viable, but as they aged, they developed a progressive peripheral neuropathy characterized by nerve conduction abnormalities as well as extensive muscle denervation. Morphological examination of Tfam-SCKO nerves revealed early preferential loss of small unmyelinated fibers followed by prominent demyelination and degeneration of larger-caliber axons. Tfam-SCKOs displayed sensory and motor deficits consistent with this pathology. Remarkably, the severe mtDNA depletion and respiratory chain abnormalities in Tfam-SCKO mice did not affect SC proliferation or survival. Mitochondrial function in SCs is therefore essential for maintenance of axonal survival and normal peripheral nerve function, suggesting that SC mitochondrial dysfunction contributes to human peripheral neuropathies.
C1 [Viader, Andreu; Milbrandt, Jeffrey] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
   [Golden, Judith P.] Washington Univ, Sch Med, Pain Ctr, St Louis, MO 63110 USA.
   [Golden, Judith P.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.
   [Baloh, Robert H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
   [Schmidt, Robert E.] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
   [Baloh, Robert H.; Schmidt, Robert E.; Milbrandt, Jeffrey] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA.
   [Hunter, Daniel A.] Washington Univ, Sch Med, Div Plast & Reconstruct Surg, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)
RP Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Genet, 660 S Euclid Ave,Box 8232, St Louis, MO 63110 USA.
EM jmilbrandt@wustl.edu
FU NIH Neuroscience Blueprint Center [P30 NS057105]; Hope Center for Neurological Disorders; NIH [NS040745, AG13730, NS055980, DK19645, R21NS059566]; Muscular Dystrophy Association [10040, 135428]
CR Arezzo JC, 2002, INT REV NEUROBIOL, V50, P229
   Baloh RH, 2008, NEUROSCIENTIST, V14, P12, DOI 10.1177/1073858407307354
   Baloh RH, 2009, J NEUROSCI, V29, P2312, DOI 10.1523/JNEUROSCI.2168-08.2009
   Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511
   Chen SZ, 2003, NAT NEUROSCI, V6, P1186, DOI 10.1038/nn1139
   Dalakas MC, 2001, LAB INVEST, V81, P1537, DOI 10.1038/labinvest.3780367
   Ebenezer GJ, 2007, J NEUROPATH EXP NEUR, V66, P1059, DOI 10.1097/nen.0b013e31815c8989
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Feltri ML, 2002, J CELL BIOL, V156, P199, DOI 10.1083/jcb.200109021
   Feltri ML, 1999, ANN NY ACAD SCI, V883, P116, DOI 10.1111/j.1749-6632.1999.tb08574.x
   Fernyhough P, 2003, J PERIPHER NERV SYST, V8, P227, DOI 10.1111/j.1085-9489.2003.03028.x
   Geuna S, 2009, INT REV NEUROBIOL, V87, P27, DOI 10.1016/S0074-7742(09)87003-7
   Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013
   Golden JP, 2010, J NEUROSCI, V30, P3983, DOI 10.1523/JNEUROSCI.5930-09.2010
   Grinspan JB, 1996, J NEUROSCI, V16, P6107
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   Hughes RAC, 2002, BRIT MED J, V324, P466, DOI 10.1136/bmj.324.7335.466
   Hunter DA, 2007, J NEUROSCI METH, V166, P116, DOI 10.1016/j.jneumeth.2007.06.018
   Ilieva H, 2009, J CELL BIOL, V187, P761, DOI 10.1083/jcb.200908164
   Kalichman MW, 1998, ACTA NEUROPATHOL, V95, P47, DOI 10.1007/s004010050764
   Kennedy WR, 1996, NEUROLOGY, V47, P1042, DOI 10.1212/WNL.47.4.1042
   KENNEDY WR, 1993, J NEUROL SCI, V115, P184, DOI 10.1016/0022-510X(93)90223-L
   KING RHM, 2005, PERIPHERAL NEUROPATH, V0, P35
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Le N, 2005, NAT NEUROSCI, V8, P932, DOI 10.1038/nn1490
   Mancuso DJ, 2010, J BIOL CHEM, V285, P36495, DOI 10.1074/jbc.M110.115766
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4
   Horste GMZ, 2007, ANN NEUROL, V61, P61, DOI 10.1002/ana.21026
   Montana MC, 2009, J PHARMACOL EXP THER, V330, P834, DOI 10.1124/jpet.109.154138
   Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3
   Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309
   Niemann A, 2006, NEUROMOL MED, V8, P217, DOI 10.1385/NMM:8:1:217
   Pellerin L, 2003, J PHYSIOL-LONDON, V546, P325, DOI 10.1113/jphysiol.2002.035105
   Reddy LV, 2003, NEURON, V40, P563, DOI 10.1016/S0896-6273(03)00682-2
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Ryu EJ, 2007, J NEUROSCI, V27, P11552, DOI 10.1523/JNEUROSCI.5497-06.2007
   Sadun Alfredo A, 2002, SEMIN OPHTHALMOL, V17, P29, DOI 10.1076/soph.17.1.29.10290
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Véga C, 2003, J PHYSIOL-LONDON, V546, P551, DOI 10.1113/jphysiol.2002.029751
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wang LJ, 2009, NEUROBIOL DIS, V35, P234, DOI 10.1016/j.nbd.2009.05.002
   Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Yamanaka K, 2008, NAT NEUROSCI, V11, P251, DOI 10.1038/nn2047
   Yazawa I, 2005, NEURON, V45, P847, DOI 10.1016/j.neuron.2005.01.032
NR 49
TC 131
Z9 151
U1 0
U2 20
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
EI 
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 13
PY 2011
VL 31
IS 28
BP 10128
EP 10140
DI 10.1523/JNEUROSCI.0884-11.2011
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 791WP
UT WOS:000292699600003
PM 21752989
DA 2024-11-01
ER

PT J
AU Viikov, K
   Väljamäe, P
   Sedman, J
AF Viikov, Katrin
   Vaeljamaee, Priit
   Sedman, Juhan
TI Yeast mitochondrial DNA polymerase is a highly processive single-subunit enzyme
SO MITOCHONDRION
LA English
DT Article
DE DNA polymerase gamma; Mip1; Yeast mtDNA replication; Processivity; Strand displacement DNA synthesis
ID progressive external ophthalmoplegia; saccharomyces-cerevisiae; accessory subunit; in-vitro; catalytic subunit; gamma; replication; identification; mutations; helicase
AB Polymerase gamma is solely responsible for fast and faithful replication of the mitochondrial genome. High processivity of the polymerase gamma is often achieved by association of the catalytic subunit with accessory factors that enhance its catalytic activity and/or DNA binding. Here we characterize the intrinsic catalytic activity and processivity of the recombinant catalytic subunit of yeast polymerase gamma, the Mip1 protein. We demonstrate that Mip1 can efficiently synthesize DNA stretches of up to several thousand nucleotides without dissociation from the template. Furthermore, we show that Mip1 can perform DNA synthesis on double-stranded templates utilizing a strand displacement mechanism. Our observations confirm that in contrast to its homologues in other organisms, Mip1 can function as a single-subunit replicative polymerase. (C) 2010 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Viikov, Katrin; Vaeljamaee, Priit; Sedman, Juhan] Univ Tartu, Dept Biochem, Inst Mol & Cell Biol, EE-51014 Tartu, Estonia.
C3 University of Tartu
RP Sedman, J (corresponding author), Univ Tartu, Dept Biochem, Inst Mol & Cell Biol, Vanemuise 46, EE-51014 Tartu, Estonia.
EM jsedman@ebc.ee
FU Estonian Science Foundation [7013]
CR Andraos N, 2004, J BIOL CHEM, V279, P50609, DOI 10.1074/jbc.M408428200
   Bambara RA, 1995, METHOD ENZYMOL, V262, P270
   Baruffini E, 2007, GENETICS, V177, P1227, DOI 10.1534/genetics.107.079293
   BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0
   BISWAS TK, 1995, ACTA BIOCHIM POL, V42, P317
   BLANCO L, 1991, NUCLEIC ACIDS RES, V19, P955, DOI 10.1093/nar/19.4.955
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   DAS SK, 1979, J BIOL CHEM, V254, P1227
   DAUM G, 1982, J BIOL CHEM, V257, P3028
   Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903
   ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929
   Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x
   FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345
   FUJIMURA RK, 1976, J BIOL CHEM, V251, P2168
   GENGA A, 1986, J BIOL CHEM, V261, P9328
   Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u
   GRAY H, 1992, J BIOL CHEM, V267, P5835
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200
   HUBER HE, 1987, J BIOL CHEM, V262, P16224
   INSDORF NF, 1989, J BIOL CHEM, V264, P21491
   ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   JONES EW, 1991, METHOD ENZYMOL, V194, P428
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kuusk S, 2005, J BIOL CHEM, V280, P24322, DOI 10.1074/jbc.M500354200
   LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lee JB, 2006, NATURE, V439, P621, DOI 10.1038/nature04317
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   LESTIENNE P, 1987, BIOCHEM BIOPH RES CO, V146, P1146, DOI 10.1016/0006-291X(87)90767-4
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Lucas P, 2004, MITOCHONDRION, V4, P13, DOI 10.1016/j.mito.2004.04.001
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   MALESZKA R, 1991, EMBO J, V10, P3923, DOI 10.1002/j.1460-2075.1991.tb04962.x
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   ORourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002
   OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932
   Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257
   Sedman T, 2000, MOL CELL BIOL, V20, P1816, DOI 10.1128/MCB.20.5.1816-1824.2000
   Sedman T, 2005, CURR GENET, V47, P213, DOI 10.1007/s00294-005-0566-4
   TABOR S, 1987, J BIOL CHEM, V262, P16212
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   WERNETTE CM, 1986, J BIOL CHEM, V261, P4764
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Young MJ, 2006, YEAST, V23, P101, DOI 10.1002/yea.1344
NR 55
TC 23
Z9 28
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN 15
PY 2011
VL 11
IS 1
BP 119
EP 126
DI 10.1016/j.mito.2010.08.007
PG 8
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 709OP
UT WOS:000286450300017
PM 20807588
DA 2024-11-01
ER

PT J
AU Nakada, K
   Hayashi, JI
AF Nakada, Kazuto
   Hayashi, Jun-Ichi
TI Transmitochondrial Mice as Models for Mitochondrial DNA-Based Diseases
SO EXPERIMENTAL ANIMALS
LA English
DT Review
DE mitochondria; mitochondrial diseases; mitochondrial DNA mutation; mitochondrial respiration defects; model mice
ID lactic-acidosis; oxidative-phosphorylation; dilated cardiomyopathy; respiration defects; missense mutation; protein-synthesis; mutant mtdna; mito-mice; cells; generation
AB Mitochondrial genome (mtDNA) mutations and the resultant mitochondrial respiratory abnormalities are associated with a wide variety of disorders, such as mitochondrial diseases, neurodegenerative diseases, diabetes, and cancer, as well as aging. Generation of model animals carrying mutant nntDNAs is important for understanding the pathophysiological mechanisms of the mtDNA-based diseases. We have succeeded in generating three kinds of mice with pathogenic mutant mtDNAs, named "mito-mice," by the introduction of mitochondria carrying pathogenic mutant mtDNAs into mouse zygotes and mouse embryonic stem (ES) cells. In the case of mito-mice possessing the heteroplasmic state of wild-type mtDNA and pathogenic mtDNA with a large-scale deletion (Delta mtDNA, mito-miceA), a high load of Delta mtDNA induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, male infertility, long-term memory defects, and renal failure. In this review, we summarize generation and clinical phenotypes of three types of mito-mice and we introduce several treatment trials for mitochondrial diseases using mito-mice Delta.
C1 [Nakada, Kazuto; Hayashi, Jun-Ichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
C3 University of Tsukuba
RP Hayashi, JI (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
CR Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701
   Grad LI, 2005, P NATL ACAD SCI USA, V102, P18367, DOI 10.1073/pnas.0506939102
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue SI, 2007, FEBS LETT, V581, P1910, DOI 10.1016/j.febslet.2007.03.092
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jackson DC, 2004, RESP PHYSIOL NEUROBI, V144, P173, DOI 10.1016/j.resp.2004.06.020
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Minczuk M, 2008, NUCLEIC ACIDS RES, V36, P3926, DOI 10.1093/nar/gkn313
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, BIOCHEM BIOPH RES CO, V288, P901, DOI 10.1006/bbrc.2001.5873
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103
   NAKAI A, 1994, LANCET, V343, P1397, DOI 10.1016/S0140-6736(94)92527-5
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Ogasawara E, 2010, HUM MOL GENET, V19, P3179, DOI 10.1093/hmg/ddq228
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Sato A, 2007, GENETICS, V177, P2031, DOI 10.1534/genetics.107.081026
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   SKUDER P, 1995, INTELLIGENCE, V21, P1, DOI 10.1016/0160-2896(95)90035-7
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Tanaka D, 2008, MOL BRAIN, V1, P0, DOI 10.1186/1756-6606-1-21
   Tysoe C, 1996, J MED GENET, V33, P1002, DOI 10.1136/jmg.33.12.1002
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Yokota M, 2010, FEBS LETT, V584, P3943, DOI 10.1016/j.febslet.2010.07.048
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 49
TC 20
Z9 22
U1 0
U2 9
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD OCT 15
PY 2011
VL 60
IS 5
BP 421
EP 431
DI 
PG 11
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 837EW
UT WOS:000296174900001
PM 22041279
DA 2024-11-01
ER

PT J
AU Lopez-Gallardo, E
   Iceta, R
   Iglesias, E
   Montoya, J
   Ruiz-Pesini, E
AF Lopez-Gallardo, Ester
   Iceta, Ruth
   Iglesias, Eldris
   Montoya, Julio
   Ruiz-Pesini, Eduardo
TI OXPHOS toxicogenomics and Parkinson's disease
SO MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
LA English
DT Review
DE Mitochondrial DNA; Oxidative phosphorylation; Xenobiotics; Parkinson's disease; Toxicogenomics
ID mitochondrial complex-i; magnetic-resonance-spectroscopy; cyanide-induced parkinsonism; alpha-synuclein; respiratory-chain; substantia-nigra; skeletal-muscle; oxidative-phosphorylation; dna deletions; familial parkinsonism
AB Activities and quantities of several oxidative phosphorylation (OXPHOS) system complexes are decreased in many Parkinson's disease (PD) patients. Mutations in PD-associated nuclear genes affect OXPHOS function. Moreover, the inactivation of other nuclear genes related to mitochondrial DNA (mtDNA) replication and expression also leads to Parkinsonism. MtDNA only encodes OXPHOS subunits and the RNAs required for their expression. Mutations in mtDNA genes have also been associated with PD. Furthermore, many xenobiotics that inhibit different OXPHOS complexes provoke Parkinsonism. The binding sites for these venoms are usually mtDNA-encoded subunits. However, and despite the existence of mutations or toxicants that can cause Parkinsonism, PD only rarely results from isolated genetic or environmental factors. Combinations of nuclear and mitochondrial genetic and environmental factors have additive effects and increase the risk of PD. It is also possible that population polymorphisms in mtDNA genes, affecting interactions with different xenobiotics, may behave as susceptibility factors for developing PD only in the presence of that particular xenobiotic. Therefore, a deeper analysis of the OXPHOS function in PD is required if we want to unravel the complexities of this disorder. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Lopez-Gallardo, Ester; Iceta, Ruth; Iglesias, Eldris; Montoya, Julio; Ruiz-Pesini, Eduardo] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, CIBERER, Inst Aragones Ciencias Salud I CS, E-50013 Zaragoza, Spain.
   [Ruiz-Pesini, Eduardo] Univ Zaragoza, Fdn ARAID, E-50013 Zaragoza, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Zaragoza; University of Zaragoza
RP Ruiz-Pesini, E (corresponding author), Univ Zaragoza, Dept Bioquim Biol Mol & Celular, CIBERER, Inst Aragones Ciencias Salud I CS, C Miguel Servet 177, E-50013 Zaragoza, Spain.
EM eduruiz@unizar.es
FU Institut de Salud Carlos III-FIS [PI08-0264, PI10-00662]; Diputacion General de Aragon (Fundacion ARAID) [Grupos Consolidados B33, PIPAMER 09-01]
CR Abahuni N, 2007, NEUROSCI LETT, V414, P126, DOI 10.1016/j.neulet.2006.12.053
   Abeliovich A, 2010, NATURE, V463, P744, DOI 10.1038/463744a
   ALI SF, 1986, ACTA PHARMACOL TOX, V59, P179
   Amo T, 2011, NEUROBIOL DIS, V41, P111, DOI 10.1016/j.nbd.2010.08.027
   Amouyel P, 2002, CR BIOL, V325, P741, DOI 10.1016/S1631-0691(02)01481-6
   Andreassen OA, 2001, EXP NEUROL, V167, P189, DOI 10.1006/exnr.2000.7525
   Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
   Arthur CR, 2009, MOL NEURODEGENER, V4, P0, DOI 10.1186/1750-1326-4-37
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Banerjee R, 2009, BBA-MOL BASIS DIS, V1792, P651, DOI 10.1016/j.bbadis.2008.11.007
   Barbiroli B, 1999, MOVEMENT DISORD, V14, P430, DOI 10.1002/1531-8257(199905)14:3<430::AID-MDS1007>3.0.CO;2-S
   Barton MD, 2000, NUTR RES REV, V13, P279, DOI 10.1079/095442200108729106
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BENECKE R, 1993, BRAIN, V116, P1451, DOI 10.1093/brain/116.6.1451
   BERGEN WG, 1971, P SOC EXP BIOL MED, V136, P732, DOI 10.3181/00379727-136-35352
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Bove Jordi, 2005, NEURORX, V2, P484, DOI 10.1602/neurorx.2.3.484
   BOWEN BC, 1995, AM J NEURORADIOL, V16, P61
   Brown TP, 2006, ENVIRON HEALTH PERSP, V114, P156, DOI 10.1289/ehp.8095
   Büeler H, 2009, EXP NEUROL, V218, P235, DOI 10.1016/j.expneurol.2009.03.006
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   CARELLA F, 1988, J NEUROL NEUROSUR PS, V51, P1345, DOI 10.1136/jnnp.51.10.1345
   Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7
   Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x
   Champy P, 2004, J NEUROCHEM, V88, P63, DOI 10.1046/j.1471-4159.2003.02138.x
   Chelvanayakam S J V, 2003, CEYLON MED J, V48, P133
   Chen JJ, 2010, AM J MANAG CARE, V16, P0
   CLEETER MWJ, 1992, J NEUROCHEM, V58, P786, DOI 10.1111/j.1471-4159.1992.tb09789.x
   Corrigan FM, 2000, J TOXICOL ENV HEAL A, V59, P229, DOI 10.1080/009841000156907
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   DEHAVEN DL, 1986, NEUROBEH TOXICOL TER, V8, P475
   DEHAVEN DL, 1984, TOXICOL APPL PHARM, V75, P182, DOI 10.1016/0041-008X(84)90200-X
   Devi L, 2008, J BIOL CHEM, V283, P9089, DOI 10.1074/jbc.M710012200
   Di Filippo M, 2008, MOVEMENT DISORD, V23, P468, DOI 10.1002/mds.21871
   Drechsel DA, 2008, FREE RADICAL BIO MED, V44, P1873, DOI 10.1016/j.freeradbiomed.2008.02.008
   Drechsel DA, 2009, TOXICOL SCI, V112, P427, DOI 10.1093/toxsci/kfp223
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Ekstrand MI, 2009, PARKINSONISM RELAT D, V15, PS185, DOI 10.1016/S1353-8020(09)70811-9
   Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2
   Esteves AR, 2010, J NEUROCHEM, V113, P674, DOI 10.1111/j.1471-4159.2010.06631.x
   Esteves AR, 2009, ANTIOXID REDOX SIGN, V11, P439, DOI 10.1089/ars.2008.2247
   Esteves ARF, 2008, MITOCHONDRION, V8, P219, DOI 10.1016/j.mito.2008.03.004
   ESTEVES AR, 2010, AGING NEUROSCI, V1, P5
   FELDMAN JM, 1990, INT J PSYCHIAT MED, V20, P173, DOI 10.2190/2XVU-MGTC-RUMJ-JY7X
   Ferrer I, 2007, NEUROSCI LETT, V415, P205, DOI 10.1016/j.neulet.2007.01.026
   FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119
   Gautier CA, 2008, P NATL ACAD SCI USA, V105, P11364, DOI 10.1073/pnas.0802076105
   Gaweda-Walerych K, 2008, J NEURAL TRANSM, V115, P1521, DOI 10.1007/s00702-008-0121-9
   Gaweda-Walerych K, 2010, NEUROSCI LETT, V469, P24, DOI 10.1016/j.neulet.2009.11.037
   Gegg ME, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0004756
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   GRANDAS F, 1989, MOVEMENT DISORD, V4, P188, DOI 10.1002/mds.870040211
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604
   Hanagasi HA, 2009, INT J NEUROSCI, V119, P1572, DOI 10.1080/00207450903088019
   Hatcher JM, 2007, EXP NEUROL, V204, P619, DOI 10.1016/j.expneurol.2006.12.020
   Hattingen E, 2009, BRAIN, V132, P3285, DOI 10.1093/brain/awp293
   Hattori N, 1998, GENOMICS, V49, P52, DOI 10.1006/geno.1997.5192
   HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409
   Hayashi T, 2009, BIOCHEM BIOPH RES CO, V390, P667, DOI 10.1016/j.bbrc.2009.10.025
   Henchcliffe C, 2008, ANN NY ACAD SCI, V1147, P206, DOI 10.1196/annals.1427.037
   Hoepken HH, 2007, NEUROBIOL DIS, V25, P401, DOI 10.1016/j.nbd.2006.10.007
   Hu MTM, 2000, BRAIN, V123, P340, DOI 10.1093/brain/123.2.340
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   HUNTER CG, 1969, ARCH ENVIRON HEALTH, V18, P12, DOI 10.1080/00039896.1969.10665367
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   Jenkins SM, 2004, DEV BRAIN RES, V151, P1, DOI 10.1016/j.devbrainres.2004.03.015
   Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Kitazawa M, 2001, FREE RADICAL BIO MED, V31, P1473, DOI 10.1016/S0891-5849(01)00726-2
   Klein C, 2007, NEUROLOGY, V69, P2093, DOI 10.1212/01.wnl.0000271880.27321.a7
   Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191
   KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.ne.11.030188.000501
   Koschel MJ, 2006, J EMERG NURS, V32, PS19, DOI 10.1016/j.jen.2006.05.010
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Lannuzel A, 2003, NEUROSCIENCE, V121, P287, DOI 10.1016/S0306-4522(03)00441-X
   Li CH, 2010, TOXICOL SCI, V116, P140, DOI 10.1093/toxsci/kfq085
   Liu GW, 2009, NEUROSCI LETT, V454, P187, DOI 10.1016/j.neulet.2009.02.056
   Liu WC, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0004597
   Loeb V, 2010, J BIOL CHEM, V285, P7334, DOI 10.1074/jbc.M109.061051
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902
   Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006
   MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539
   McFarland MA, 2008, MOL CELL PROTEOMICS, V7, P2123, DOI 10.1074/mcp.M800116-MCP200
   MECO G, 1994, SCAND J WORK ENV HEA, V20, P301, DOI 10.5271/sjweh.1394
   Meijer SN, 2001, ENVIRON SCI TECHNOL, V35, P1989, DOI 10.1021/es0000955
   MESSING B, 1991, J NEURAL TRANSM-GEN, V0, P141
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   Moisoi N, 2009, CELL DEATH DIFFER, V16, P449, DOI 10.1038/cdd.2008.166
   Montoya J, 2009, BBA-BIOENERGETICS, V1787, P476, DOI 10.1016/j.bbabio.2008.09.003
   Morais VA, 2009, EMBO MOL MED, V1, P99, DOI 10.1002/emmm.200900006
   Mortiboys H, 2008, ANN NEUROL, V64, P555, DOI 10.1002/ana.21492
   Müftüoglu M, 2004, MOVEMENT DISORD, V19, P544, DOI 10.1002/mds.10695
   Nagashima R, 2008, NEUROSCI LETT, V440, P232, DOI 10.1016/j.neulet.2008.05.100
   NAKAGAWAHATTORI Y, 1992, J NEUROL SCI, V107, P29, DOI 10.1016/0022-510X(92)90205-Y
   Navarro A, 2009, FREE RADICAL BIO MED, V46, P1574, DOI 10.1016/j.freeradbiomed.2009.03.007
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   Onyango IG, 2005, MOL CELL NEUROSCI, V28, P452, DOI 10.1016/j.mcn.2004.10.006
   Onyango IG, 2005, NEUROBIOL DIS, V20, P141, DOI 10.1016/j.nbd.2005.02.009
   Ossowska K, 2005, EUR J NEUROSCI, V22, P1294, DOI 10.1111/j.1460-9568.2005.04301.x
   Otaegui D, 2004, NEUROSCI LETT, V370, P171, DOI 10.1016/j.neulet.2004.08.012
   Pacheu-Grau D, 2010, DRUG DISCOV TODAY, V15, P33, DOI 10.1016/j.drudis.2009.10.008
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Papa S, 2009, J BIOENERG BIOMEMBR, V41, P509, DOI 10.1007/s10863-009-9252-4
   Parker WD, 2008, BRAIN RES, V1189, P215, DOI 10.1016/j.brainres.2007.10.061
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   PENN AMW, 1995, NEUROLOGY, V45, P2097, DOI 10.1212/WNL.45.11.2097
   Pentore R, 1996, ITAL J NEUROL SCI, V17, P233, DOI 10.1007/BF01995689
   Prigione A, 2007, AUTOPHAGY, V3, P377, DOI 10.4161/auto.4239
   Rachinger J, 2002, AM J NEURORADIOL, V23, P1398
   Ramalho TC, 2010, J BIOMOL STRUCT DYN, V28, P227, DOI 10.1080/07391102.2010.10507355
   RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1
   Rango M, 2006, J CEREBR BLOOD F MET, V26, P283, DOI 10.1038/sj.jcbfm.9600192
   Richardson JR, 2006, FASEB J, V20, P1695, DOI 10.1096/fj.06-5864fje
   Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X
   ROSENBERG NL, 1989, NEUROLOGY, V39, P142, DOI 10.1212/WNL.39.1.142
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Rothfuss O, 2009, HUM MOL GENET, V18, P3832, DOI 10.1093/hmg/ddp327
   Ruiz-Pesini E, 2010, PHARMACOGENOMICS, V11, P1185, DOI 10.2217/pgs.10.115
   Sarikaya I, 2006, CLIN NUCL MED, V31, P363, DOI 10.1097/01.rlu.0000219168.92370.77
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7
   Sheehan JP, 1997, J NEUROCHEM, V68, P1221
   Shinde S, 2006, NEUROL INDIA, V54, P390, DOI 10.4103/0028-3886.28112
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Swerdlow RH, 2001, PARKINSONISM RELAT D, V7, P129, DOI 10.1016/S1353-8020(00)00029-8
   Talpade DJ, 2000, J NEUROCHEM, V75, P2611, DOI 10.1046/j.1471-4159.2000.0752611.x
   Tang BS, 2006, HUM MOL GENET, V15, P1816, DOI 10.1093/hmg/ddl104
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   Trimmer PA, 2009, EXP NEUROL, V218, P320, DOI 10.1016/j.expneurol.2009.03.016
   UITTI RJ, 1985, NEUROLOGY, V35, P921, DOI 10.1212/WNL.35.6.921
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   VanItallie TB, 2008, METABOLISM, V57, PS50, DOI 10.1016/j.metabol.2008.07.015
   Varghese M, 2009, J NEUROL SCI, V279, P39, DOI 10.1016/j.jns.2008.12.021
   Veech GA, 2000, J NEUROSCI RES, V61, P693
   von Ballmoos C, 2004, P NATL ACAD SCI USA, V101, P11239, DOI 10.1073/pnas.0402869101
   von Campenhausen S, 2005, EUR NEUROPSYCHOPHARM, V15, P473, DOI 10.1016/j.euroneuro.2005.04.007
   Wild P, 2010, NAT CELL BIOL, V12, P104, DOI 10.1038/ncb0210-104
   Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013
   Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
   Yuan XL, 2010, BRAIN RES, V1351, P229, DOI 10.1016/j.brainres.2010.06.005
   Zhang J, 2003, J NEUROCHEM, V84, P336, DOI 10.1046/j.1471-4159.2003.01525.x
NR 165
TC 16
Z9 17
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1383-5742
EI 1388-2139
J9 MUTAT RES-REV MUTAT
JI Mutat. Res.-Rev. Mutat. Res.
PD NOV-DEC 15
PY 2011
VL 728
IS 3
BP 98
EP 106
DI 10.1016/j.mrrev.2011.06.004
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 846WH
UT WOS:000296933400003
PM 21763451
DA 2024-11-01
ER

PT J
AU Leshinsky-Silver, E
   Shuvalov, R
   Inbar, S
   Cohen, S
   Lev, D
   Lerman-Sagie, T
AF Leshinsky-Silver, Esther
   Shuvalov, Ruslan
   Inbar, Shani
   Cohen, Sarit
   Lev, Dorit
   Lerman-Sagie, Tally
TI Juvenile Leigh Syndrome, Optic Atrophy, Ataxia, Dystonia, and Epilepsy due to T14487C Mutation in the mtDNA-ND6 Gene: A Mitochondrial Syndrome Presenting From Birth to Adolescence
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE Leigh syndrome; ND6; dystonia; optic atrophy; ataxia
ID complex-i deficiency; dna g13513a mutation; nd3 gene; missense mutation; trna(trp) gene; disease; encephalopathy; secondary; insertion; children
AB An increasing number of reports describe mutations in mitochondrial DNA coding regions, especially in mitochondrial DNA-encoded nicotinamide adenine dinucleotide dehydrogenase subunit genes of the respiratory chain complex I, as causing early-onset Leigh syndrome. The authors report the molecular findings in a 24-year-old patient with juvenile-onset Leigh syndrome presenting with optic atrophy, ataxia dystonia, and epilepsy. A brain magnetic resonance imaging revealed bilateral basal ganglia and thalamic hypointensities, and a magnetic resonance spectroscopy revealed an increased lactate peak. The authors identified a T14487C change causing M63V substitution in the mitochondrial ND6 gene. The mutation was heteroplasmic in muscle and blood samples, with different mutation loads, and was absent in the patient's mother's urine and blood samples. They suggest that the T14487C mtDNA mutation should be analyzed in Leigh syndrome, presenting with optic atrophy, ataxia, dystonia, and epilepsy, regardless of age.
C1 [Leshinsky-Silver, Esther; Inbar, Shani; Cohen, Sarit] Wolfson Med Ctr, Mol Genet Lab, IL-58100 Holon, Israel.
   [Leshinsky-Silver, Esther; Shuvalov, Ruslan; Lev, Dorit] Wolfson Med Ctr, Mitochondrial Dis Ctr, IL-58100 Holon, Israel.
   [Leshinsky-Silver, Esther; Lev, Dorit; Lerman-Sagie, Tally] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Shuvalov, Ruslan; Lerman-Sagie, Tally] Wolfson Med Ctr, Pediat Neurol Unit, IL-58100 Holon, Israel.
   [Lev, Dorit] Wolfson Med Ctr, Inst Med Genet, IL-58100 Holon, Israel.
C3 Tel Aviv University
RP Leshinsky-Silver, E (corresponding author), Wolfson Med Ctr, Mol Genet Lab, IL-58100 Holon, Israel.
EM leshinsky@wolfson.health.gov.il
CR Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P4211, DOI 10.1167/iovs.06-0295
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   Dermaut B, 2010, J NEUROL NEUROSUR PS, V81, P90, DOI 10.1136/jnnp.2008.157354
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   Howell N, 1996, NEUROLOGY, V46, P219, DOI 10.1212/WNL.46.1.219
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Komaki H, 2003, MITOCHONDRION, V2, P293, DOI 10.1016/S1567-7249(03)00003-5
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Naess K, 2009, BBA-BIOENERGETICS, V1787, P484, DOI 10.1016/j.bbabio.2008.11.014
   Raspall-Chaure M, 2004, REV NEUROLOGIA, V39, P1129, DOI 10.33588/rn.3912.2004296
   Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Schapira AHV, 2010, EXP NEUROL, V224, P331, DOI 10.1016/j.expneurol.2010.03.028
   Solano A, 2003, ANN NEUROL, V54, P527, DOI 10.1002/ana.10682
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Tsao CY, 2003, J CHILD NEUROL, V18, P62, DOI 10.1177/08830738030180011401
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   Wang J, 2009, MOL GENET METAB, V96, P59, DOI 10.1016/j.ymgme.2008.10.006
NR 30
TC 14
Z9 15
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 
J9 J CHILD NEUROL
JI J. Child Neurol.
PD APR 15
PY 2011
VL 26
IS 4
BP 476
EP 481
DI 10.1177/0883073810384615
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 751OO
UT WOS:000289627600010
PM 21196529
DA 2024-11-01
ER

PT J
AU Bai, P
   Cantó, C
   Oudart, H
   Brunyánszki, A
   Cen, YN
   Thomas, C
   Yamamoto, H
   Huber, A
   Kiss, B
   Houtkooper, RH
   Schoonjans, K
   Schreiber, V
   Sauve, AA
   Menissier-de Murcia, J
   Auwerx, J
AF Bai, Peter
   Canto, Caries
   Oudart, Hugues
   Brunyanszki, Attila
   Cen, Yana
   Thomas, Charles
   Yamamoto, Hiroyasu
   Huber, Aline
   Kiss, Borbala
   Houtkooper, Riekelt H.
   Schoonjans, Kristina
   Schreiber, Valerie
   Sauve, Anthony A.
   Menissier-de Murcia, Josiane
   Auwerx, Johan
TI PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
SO CELL METABOLISM
LA English
DT Article
ID small-molecule activators; poly(adp-ribose) polymerase; dna-damage; excision-repair; enzyme cd38; cell-death; nicotinamide; deacetylase; nad; depletion
AB SIRT1 regulates energy homeostasis by controlling the acetylation status and activity of a number of enzymes and transcriptional regulators. The fact that NAD(+) levels control SIRT1 activity confers a hypothetical basis for the design of new strategies to activate SIRT1 by increasing NAD(+) availability. Here we show that the deletion of the poly(ADPribose) polymerase-1 (PARP-1) gene, encoding a major NAD(+)-consuming enzyme, increases NAD(+) content and SIRT1 activity in brown adipose tissue and muscle. PARP-1(-/-) mice phenocopied many aspects of SIRT1 activation, such as a higher mitochondrial content, increased energy expenditure, and protection against metabolic disease. Also, the pharmacologic inhibition of PARP in vitro and in vivo increased NAD(+) content and SIRT1 activity and enhanced oxidative metabolism. These data show how PARP-1 inhibition has strong metabolic implications through the modulation of SIRT1 activity, a property that could be useful in the management not only of metabolic diseases, but also of cancer.
C1 [Canto, Caries; Thomas, Charles; Yamamoto, Hiroyasu; Houtkooper, Riekelt H.; Schoonjans, Kristina; Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, CH-1015 Lausanne, Switzerland.
   [Bai, Peter; Huber, Aline; Kiss, Borbala; Schreiber, Valerie; Menissier-de Murcia, Josiane] Univ Strasbourg, ESBS, CNRS, UMR7242, Illkirch Graffenstaden, France.
   [Bai, Peter; Brunyanszki, Attila] Univ Debrecen, Dept Med Chem, Debrecen, Hungary.
   [Oudart, Hugues] CNRS, UPR9010, CEPE, Strasbourg, France.
   [Cen, Yana; Sauve, Anthony A.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY 10021 USA.
C3 Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Debrecen; Centre National de la Recherche Scientifique (CNRS); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cornell University; Weill Cornell Medicine
RP Auwerx, J (corresponding author), Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, CH-1015 Lausanne, Switzerland.
EM admin.auwerx@epfl.ch
FU Bolyai; SNSF; EMBO; FEBS; NWO; NKTH; OTKA [NFF78498, IN80481]; Mecenatura [DE OEC Mec-1/2008]; NIH [DK59820, DK73466]; ERC [2008-AdG-23118]; CNRS; ANR EGIDE [22873YC]; Ellison Medical Foundation
CR ADAMIETZ P, 1987, EUR J BIOCHEM, V169, P365, DOI 10.1111/j.1432-1033.1987.tb13621.x
   Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105
   Aksoy P, 2006, BIOCHEM BIOPH RES CO, V349, P353, DOI 10.1016/j.bbrc.2006.08.066
   Allinson SL, 2003, ACTA BIOCHIM POL, V50, P169
   Asher G, 2010, CELL, V142, P943, DOI 10.1016/j.cell.2010.08.016
   Barbosa MTP, 2007, FASEB J, V21, P3629, DOI 10.1096/fj.07-8290com
   Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200
   Cantó C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303
   Devalaraja-Narashimha K, 2010, J ENDOCRINOL, V205, P242, DOI 10.1677/JOE-09-0402
   DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Knight MI, 2001, PROTEIN EXPRES PURIF, V23, P453, DOI 10.1006/prep.2001.1513
   Kolthur-Seetharam U, 2006, CELL CYCLE, V5, P873, DOI 10.4161/cc.5.8.2690
   Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682
   Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200
   Sauve AA, 2005, MOL CELL, V17, P595, DOI 10.1016/j.molcel.2004.12.032
   SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436
   SIMS JL, 1981, J SUPRAMOL STR CELL, V16, P281, DOI 10.1002/jsscb.1981.380160308
   Smith BC, 2009, ANAL BIOCHEM, V394, P101, DOI 10.1016/j.ab.2009.07.019
   Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241
   Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035
NR 27
TC 637
Z9 699
U1 1
U2 68
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 6
PY 2011
VL 13
IS 4
BP 461
EP 468
DI 10.1016/j.cmet.2011.03.004
PG 8
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 748HM
UT WOS:000289381300016
PM 21459330
DA 2024-11-01
ER

PT J
AU Zhao, D
   Hong, DJ
   Zhang, W
   Yao, S
   Qi, XK
   Lv, H
   Zheng, RL
   Feng, LQ
   Huang, YN
   Yuan, Y
   Wang, ZX
AF Zhao, Danhua
   Hong, Daojun
   Zhang, Wei
   Yao, Sheng
   Qi, Xiaokun
   Lv, He
   Zheng, Riliang
   Feng, Liqun
   Huang, Yining
   Yuan, Yun
   Wang, Zhaoxia
TI Mutations in mitochondrially encoded complex I enzyme as the second common cause in a cohort of Chinese patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE MELAS; mitochondrial DNA; mitochondrially encoded complex I; MTND; mutation
ID melas-syndrome; dna mutations; nd5 gene; overlap syndrome; mtdna mutation; frequent cause; disease; deficiency; subunit; identification
AB The mutation pattern of mitochondrial DNA (mtDNA) in mainland Chinese patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) has been rarely reported, though previous data suggested that the mutation pattern of MELAS could be different among geographically localized populations. We presented the results of comprehensive mtDNA mutation analysis in 92 unrelated Chinese patients with MELAS (85 with classic MELAS and 7 with MELAS/Leigh syndrome (LS) overlap syndrome). The mtDNA A3243G mutation was the most common causal genotype in this patient group (79/92 and 85.9%). The second common gene mutation was G13513A (7/92 and 7.6%). Additionally, we identified T10191C (p.S45P) in ND3, A11470C (p. K237N) in ND4, T13046C (p.M237T) in ND5 and a large-scale deletion (13025-13033: 14417-14425) involving partial ND5 and ND6 subunits of complex I in one patient each. Among them, A11470C, T13046C and the single deletion were novel mutations. In summary, patients with mutations affecting mitochondrially encoded complex I (MTND) reached 12.0% (11/92) in this group. It is noteworthy that all seven patients with MELAS/LS overlap syndrome were associated with MTND mutations. Our data emphasize the important role of MTND mutations in the pathogenicity of MELAS, especially MELAS/LS overlap syndrome. Journal of Human Genetics (2011) 56, 759-764; doi: 10.1038/jhg.2011.96; published online 18 August 2011
C1 [Zhao, Danhua; Hong, Daojun; Zhang, Wei; Lv, He; Zheng, Riliang; Huang, Yining; Yuan, Yun; Wang, Zhaoxia] Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
   [Yao, Sheng; Qi, Xiaokun] Navy Gen Hosp, Dept Neurol, Beijing, Peoples R China.
   [Feng, Liqun] Anzhen Hosp, Dept Neurol, Beijing, Peoples R China.
C3 Peking University; Sixth Medical Center of Chinese PLA General Hospital
RP Wang, ZX (corresponding author), Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
EM drwangzx@yahoo.com.cn
FU National Nature Science Foundation of China [30870864]
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Blok MJ, 2007, J MED GENET, V44, P0, DOI 10.1136/jmg.2006.045716
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   Cao YY, 2010, MITOCHONDRION, V10, P330, DOI 10.1016/j.mito.2010.01.008
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   Chou HF, 2008, PEDIATR NEUROL, V38, P143, DOI 10.1016/j.pediatrneurol.2007.09.015
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Jaksch M, 2001, J MED GENET, V38, P665, DOI 10.1136/jmg.38.10.665
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Ma YN, 2009, MITOCHONDRION, V9, P139, DOI 10.1016/j.mito.2009.01.004
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   MITOMAP, 2011, HUM MIT GEN DAT, V0, P0
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Ringelstein EB, 2010, J NEUROL SCI, V299, P81, DOI 10.1016/j.jns.2010.08.037
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   UJIKE H, 1993, JPN J PSYCHIAT NEUR, V47, P637
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Wang ZX, 2010, NEUROPATHOLOGY, V30, P606, DOI 10.1111/j.1440-1789.2010.01115.x
   Yu Q, 2007, MITOCHONDRION, V7, P147, DOI 10.1016/j.mito.2006.11.019
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 42
TC 27
Z9 33
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD NOV 15
PY 2011
VL 56
IS 11
BP 759
EP 764
DI 10.1038/jhg.2011.96
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 861XN
UT WOS:000298053900002
PM 21850008
DA 2024-11-01
ER

PT J
AU Ferreira, M
   Evangelista, T
   Almeida, LS
   Martins, J
   Macario, MC
   Martins, E
   Moleirinho, A
   Azevedo, L
   Vilarinho, L
   Santorelli, FM
AF Ferreira, Mariana
   Evangelista, Teresinha
   Almeida, Ligia S.
   Martins, Joao
   Macario, Maria Carmo
   Martins, Esmeralda
   Moleirinho, Ana
   Azevedo, Luisa
   Vilarinho, Laura
   Santorelli, Filippo M.
TI Relative frequency of known causes of multiple mtDNA deletions: Two novel <i>POLG</i> mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Multiple deletions; POLG; Mitochondrial disorders; Cancer; mtDNA; Oxidative metabolism
ID mitochondrial-dna deletions; disorders; disease; phenotypes; spectrum; criteria; adults; common
AB Diseases affecting mtDNA stability, termed nuclear mitochondrial intergenomic communication disorders, are caused by a primary nuclear gene defect resulting in multiple mtDNA deletions. The aim of this study was to estimate the frequency of known etiologies and the spectrum of mutations in a cohort of 21 patients harboring multiple mtDNA deletions in skeletal muscle. We showed that 10 cases (48%) display mutations in POLG, including eight previously reported variants and two novel mutations (namely, p.Trp585X and p.Arg1081Gln). The novel mutations affect evolutionary conserved residues and were absent in a large set of control chromosomes. These findings expand the array of mutations associated with multiple rearranged mtDNA attributed to mutations in POLG. The relatively high diagnostic yield (about one in two cases) supports the notion that it is recommended to test POLG routinely in diagnostic laboratories whenever multiple mtDNA deletions are present, regardless of the age of onset of patients and their clinical phenotype. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ferreira, Mariana; Almeida, Ligia S.; Vilarinho, Laura] INSA, Ctr Genet Med Jacinto de Magalhaes, P-4099028 Oporto, Portugal.
   [Evangelista, Teresinha] Hosp Santa Maria, Serv Neurol, Lisbon, Portugal.
   [Martins, Joao] Hosp Egas Moniz, Serv Neurol, Lisbon, Portugal.
   [Macario, Maria Carmo] Hosp Univ Coimbra, Serv Neurol, Coimbra, Portugal.
   [Martins, Esmeralda] Ctr Hosp Porto, Unidade Doencas Metab, Oporto, Portugal.
   [Moleirinho, Ana; Azevedo, Luisa] Univ Porto, Inst Patol & Imunol, Oporto, Portugal.
   [Santorelli, Filippo M.] IRCCS Fdn Stella Maris, Pisa, Italy.
C3 Universidade de Lisboa; Hospital Santa Maria; Egas Moniz Hospital; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade do Porto; IRCCS Fondazione Stella Maris
RP Vilarinho, L (corresponding author), INSA, Ctr Genet Med Jacinto de Magalhaes, Praca Pedro Nunes 88, P-4099028 Oporto, Portugal.
EM laura.vilarinho@insa.min-saude.pt; filippo3364@gmail.com
FU Portuguese Ministry of Health [PTDC/CVT/64154/2006]; Portuguese Foundation for Science and Technology [FCT-SFRH/BD/28197/2006]; FCT [C2008/INSA/P4, C2007/IPATIMUP/AA1]; European Social Fund; Italian Ministry of Health; Fundação para a Ciência e a Tecnologia [PTDC/CVT/64154/2006] Funding Source: FCT
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Chinnery Patrick F, 2008, NEUROMUSCUL DISORD, V18, P259, DOI 10.1016/j.nmd.2007.11.005
   Copeland WC, 2002, CANCER INVEST, V20, P557, DOI 10.1081/CNV-120002155
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Lamperti C, 2009, ACTA MYOL, V28, P2
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54
   Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601
   Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802
   Palin EJH, 2010, BBA-MOL BASIS DIS, V1802, P545, DOI 10.1016/j.bbadis.2010.02.003
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Singh KK, 2009, J HUM GENET, V54, P516, DOI 10.1038/jhg.2009.71
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 24
TC 15
Z9 17
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL 15
PY 2011
VL 21
IS 7
BP 483
EP 488
DI 10.1016/j.nmd.2011.03.011
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 805IF
UT WOS:000293719400005
PM 21550804
DA 2024-11-01
ER

PT J
AU Clark, J
   Dai, Y
   Simon, DK
AF Clark, Joanne
   Dai, Ying
   Simon, David K.
TI Do Somatic Mitochondrial DNA Mutations Contribute to Parkinson's Disease?
SO PARKINSONS DISEASE
LA English
DT Review
ID mtdna point mutations; complex-i; polymerase-gamma; substantia-nigra; clonal expansion; pathogenic mtdna; muscle-fibers; deletions; risk; polymorphisms
AB A great deal of evidence supports a role for mitochondrial dysfunction in the pathogenesis of Parkinson's disease (PD), although the origin of the mitochondrial dysfunction in PD remains unclear. Expression of mitochondrial DNA (mtDNA) from PD patients in "cybrid" cell lines recapitulates the mitochondrial defect, implicating a role for mtDNA mutations, but the specific mutations responsible for the mitochondrial dysfunction in PD have been difficult to identify. Somatic mtDNA point mutations and deletions accumulate with age and reach high levels in substantia nigra (SN) neurons. Mutations in mitochondrial DNA polymerase gamma (POLG) that lead to the accumulation of mtDNA mutations are associated with a premature aging phenotype in "mutator" mice, although overt parkinsonism has not been reported in these mice, and with parkinsonism in humans. Together these data support, but do not yet prove, the hypothesis that the accumulation of somatic mtDNA mutations in SN neurons contribute to the pathogenesis of PD.
C1 [Clark, Joanne; Dai, Ying; Simon, David K.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center
RP Simon, DK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave,E CLS 628, Boston, MA 02215 USA.
EM dsimon1@bidmc.harvard.edu
FU NINDS [1R01NS058988, 1R03AG035223]; Michael J. Fox Foundation
CR ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082
   Bashkatova V, 2004, EXP NEUROL, V186, P235, DOI 10.1016/j.expneurol.2003.12.005
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   BURNS RS, 1985, NEW ENGL J MED, V312, P1418, DOI 10.1056/NEJM198505303122203
   Cantuti-Castelvetria I, 2005, NEUROBIOL AGING, V26, P1343, DOI 10.1016/j.neurobiolaging.2004.11.008
   Capaldi RA, 2002, BBA-BIOENERGETICS, V1555, P192, DOI 10.1016/S0005-2728(02)00277-3
   Carbon M, 2007, NEUROIMAGE, V34, P361, DOI 10.1016/j.neuroimage.2006.08.019
   Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Chen HC, 2009, HUM MOL GENET, V18, PR169, DOI 10.1093/hmg/ddp326
   CHENG KC, 1992, J BIOL CHEM, V267, P166
   Coller HA, 2002, ANN NY ACAD SCI, V959, P434, DOI 10.1111/j.1749-6632.2002.tb02113.x
   Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Edgar D, 2009, AGING-US, V1, P1028, DOI 10.18632/aging.100109
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   FRIDLENDER B, 1972, P NATL ACAD SCI USA, V69, P452, DOI 10.1073/pnas.69.2.452
   Fukuda M, 2001, PARKINSONISM RELAT D, V8, P91, DOI 10.1016/S1353-8020(01)00022-0
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   Gilkerson RW, 2008, J CELL BIOL, V181, P1117, DOI 10.1083/jcb.200712101
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x
   HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Huerta C, 2007, NEUROSCI LETT, V413, P202, DOI 10.1016/j.neulet.2006.11.044
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Imam SZ, 2006, NEUROBIOL AGING, V27, P1129, DOI 10.1016/j.neurobiolaging.2005.06.002
   Jenner P, 1996, NEUROLOGY, V47, PS161, DOI 10.1212/WNL.47.6_Suppl_3.161S
   Johnson AA, 2001, J BIOL CHEM, V276, P38097
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Khrapko K, 2006, AGING CELL, V5, P279, DOI 10.1111/j.1474-9726.2006.00209.x
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mayr-Wohlfart U, 1997, EUR J MED RES, V2, P111
   Mecocci P, 1997, MOL CHEM NEUROPATHOL, V31, P53, DOI 10.1007/BF02815160
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MIZUNO Y, 1987, BIOCHEM BIOPH RES CO, V143, P971, DOI 10.1016/0006-291X(87)90346-9
   MULLERHOCKER J, 1993, ARCH PATHOL LAB MED, V117, P202
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nicholas A, 2009, EXP NEUROL, V218, P316, DOI 10.1016/j.expneurol.2009.04.029
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Rajasimha HK, 2008, AM J HUM GENET, V82, P333, DOI 10.1016/j.ajhg.2007.10.007
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCHAPIRA AHV, 1990, MOVEMENT DISORD, V5, P294, DOI 10.1002/mds.870050406
   Schon EA, 2010, TRENDS MOL MED, V16, P268, DOI 10.1016/j.molmed.2010.04.007
   Schon EA, 2010, BBA-GEN SUBJECTS, V1800, P245, DOI 10.1016/j.bbagen.2009.07.007
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Sherer TB, 2007, J NEUROCHEM, V100, P1469, DOI 10.1111/j.1471-4159.2006.04333.x
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Stuart JA, 2006, BBA-BIOENERGETICS, V1757, P79, DOI 10.1016/j.bbabio.2006.01.003
   Swerdlow RH, 2001, EXP NEUROL, V169, P479, DOI 10.1006/exnr.2001.7674
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vielhaber S, 2000, BIOCHEM SOC T, V28, P159, DOI 10.1042/bst0280159
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Wang YS, 2006, J BIOL CHEM, V281, P25791, DOI 10.1074/jbc.M604501200
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   Zheng B, 2010, SCI TRANSL MED, V2, P0, DOI 10.1126/scitranslmed.3001059
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 100
TC 13
Z9 13
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-8083
EI 2042-0080
J9 PARKINSONS DIS-US
JI Parkinsons Dis.
PD JUN 15
PY 2011
VL 2011
IS 
BP 
EP 
DI 10.4061/2011/659694
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA V29RN
UT WOS:000208765600057
PM 21603185
DA 2024-11-01
ER

PT J
AU Cardoso, SM
AF Cardoso, Sandra M.
TI The Mitochondrial Cascade Hypothesis for Parkinson's Disease
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Mitochondria; mitochondrial DNA; mitochondrial biogenesis; protein oligomerization; intracellular traffic; autophagy; oxidative stress; lysosomal function
ID alpha-synuclein; complex-i; respiratory-chain; axonal-transport; oxidative stress; s-nitrosylation; skeletal-muscle; dna deletions; neurons; localization
AB During the past decades, we have witnessed significant advances in our understanding of the molecular etiology of Parkinson's disease (PD). The unearthing of the causative genes for hereditary PD accelerated not only the studies of the molecular mechanisms underlying this pathology, but also set mitochondria at the center of PD pathology. In this review we revisit mitochondrial key role and propose a hypothesis for PD, that allows the unification of both sporadic and familial PD forms. In light of this we also discuss new promising disease-modified therapies.
C1 [Cardoso, Sandra M.] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.
   [Cardoso, Sandra M.] Univ Coimbra, Fac Med, P-3004517 Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra
RP Cardoso, SM (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.
EM smacardoso@yahoo.com
FU Foundation for Science and Technology (FCT-MCTES, Portugal) [PTDC/SAU-NEU/102710/2008]; Fundação para a Ciência e a Tecnologia [PTDC/SAU-NEU/102710/2008] Funding Source: FCT
CR AHLQVIST G, 1975, LAB INVEST, V32, P673
   Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105
   Alegre-Abarrategui J, 2009, HUM MOL GENET, V18, P4022, DOI 10.1093/hmg/ddp346
   Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
   Arduíno DM, 2010, CNS NEUROL DISORD-DR, V9, P105, DOI 10.2174/187152710790966687
   Arduíno DM, 2011, PARKINSONS DIS-US, V2011, P0, DOI 10.4061/2011/767230
   Armstrong JS, 2008, ANTIOXID REDOX SIGN, V10, P575, DOI 10.1089/ars.2007.1929
   Baricault L, 2007, EXP CELL RES, V313, P3800, DOI 10.1016/j.yexcr.2007.08.008
   BARROSO N, 1993, CLIN CHEM, V39, P667
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bender A, 2008, J NEUROL, V255, P1231, DOI 10.1007/s00415-008-0892-9
   BINDOFF LA, 1989, LANCET, V2, P49, DOI 10.1016/S0140-6736(89)90291-2
   Bogaerts V, 2008, HUM MUTAT, V29, P832, DOI 10.1002/humu.20713
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Borland MK, 2008, MOL NEURODEGENER, V29, P3
   Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9
   Braak H, 2003, J NEURAL TRANSM, V110, P517, DOI 10.1007/s00702-002-0808-2
   Branco DM, 2010, FRONT AGING NEUROSCI, V2, P0, DOI 10.3389/fnagi.2010.00017
   Bras J, 2009, NEUROBIOL AGING, V30, P1515, DOI 10.1016/j.neurobiolaging.2007.11.016
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Büeler H, 2009, EXP NEUROL, V218, P235, DOI 10.1016/j.expneurol.2009.03.006
   Cappelletti G, 2005, FEBS LETT, V579, P4781, DOI 10.1016/j.febslet.2005.07.058
   Cardoso SM, 2005, CNS NEUROL DISORD-DR, V4, P405, DOI 10.2174/1568007054546072
   Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891
   Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034
   De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711
   Devi L, 2008, J BIOL CHEM, V283, P9089, DOI 10.1074/jbc.M710012200
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Elkon H, 2002, J MOL NEUROSCI, V18, P229, DOI 10.1385/JMN:18:3:229
   Esteves AR, 2011, PARKINSONS DIS-US, V2011, P0, DOI 10.4061/2011/693761
   Esteves AR, 2010, FRONT AGING NEUROSCI, V1, P0, DOI 10.3389/neuro.24.005.2009
   Esteves AR, 2010, J NEUROCHEM, V113, P674, DOI 10.1111/j.1471-4159.2010.06631.x
   Esteves AR, 2010, NEUROBIOL DIS, V37, P723, DOI 10.1016/j.nbd.2009.12.011
   Esteves AR, 2009, ANTIOXID REDOX SIGN, V11, P439, DOI 10.1089/ars.2008.2247
   Esteves ARF, 2008, MITOCHONDRION, V8, P219, DOI 10.1016/j.mito.2008.03.004
   Esteves AR, 2010, ALZHEIMERS PARKINSON, V0, P0
   Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009
   Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Ghosh S, 2010, BBA-GENE REGUL MECH, V1799, P681, DOI 10.1016/j.bbagrm.2010.08.002
   Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985
   Gray Douglas A, 2005, SCI AGING KNOWLEDGE ENVIRON, V2005, Pre1, DOI 10.1126/sageke.2005.5.re1
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Hayashi T, 2009, BIOCHEM BIOPH RES CO, V390, P667, DOI 10.1016/j.bbrc.2009.10.025
   Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.02745
   Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155
   Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052
   Junn E, 2009, J NEUROSCI RES, V87, P123, DOI 10.1002/jnr.21831
   Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440
   Kim-Han JS, 2011, J NEUROSCI, V31, P7212, DOI 10.1523/JNEUROSCI.0711-11.2011
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Leong SL, 2009, FREE RADICAL BIO MED, V46, P1328, DOI 10.1016/j.freeradbiomed.2009.02.009
   Li WW, 2007, NEUROREPORT, V18, P1543, DOI 10.1097/WNR.0b013e3282f03db4
   Liang CL, 2007, EXP NEUROL, V203, P370, DOI 10.1016/j.expneurol.2006.08.015
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Magni G, 2008, FRONT BIOSCI-LANDMRK, V13, P6135, DOI 10.2741/3143
   Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006
   Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004
   Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2010, PLOS BIOL, V8, P0, DOI 10.1371/journal.pbio.1000298
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   Parihar MS, 2008, CELL MOL LIFE SCI, V65, P1272, DOI 10.1007/s00018-008-7589-1
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   Pham NA, 2004, MICROSC MICROANAL, V10, P247, DOI 10.1017/S143192760404005X
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Ren Y, 2007, J NEUROCHEM, V103, P303, DOI 10.1111/j.1471-4159.2007.04741.x
   Ron I, 2010, HUM MOL GENET, V19, P3771, DOI 10.1093/hmg/ddq292
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Seo BB, 2006, J BIOL CHEM, V281, P14250, DOI 10.1074/jbc.M600922200
   Shavali S, 2008, NEUROSCI LETT, V439, P125, DOI 10.1016/j.neulet.2008.05.005
   Sheehan JP, 1997, J NEUROCHEM, V68, P1221
   Sidransky E, 2009, NEUROLOGY, V73, P1424, DOI 10.1212/WNL.0b013e3181b28601
   SOONG NW, 1992, NAT GENET, V2, P318
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Swerdlow RH, 2001, PARKINSONISM RELAT D, V7, P129, DOI 10.1016/S1353-8020(00)00029-8
   Swerdlow RH, 2010, J ALZHEIMERS DIS, V20, PS265, DOI 10.3233/JAD-2010-100339
   Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200
   Winkler-Stuck K, 2005, J NEURAL TRANSM, V112, P499, DOI 10.1007/s00702-004-0195-y
   Yao DD, 2004, P NATL ACAD SCI USA, V101, P10810, DOI 10.1073/pnas.0404161101
   Yoon Y, 2001, CURR BIOL, V11, PR67, DOI 10.1016/S0960-9822(01)00011-2
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
   Zhang L, 2005, HUM MOL GENET, V14, P2063, DOI 10.1093/hmg/ddi211
NR 93
TC 30
Z9 30
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD OCT 15
PY 2011
VL 17
IS 31
BP 3390
EP 3397
DI 
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 883LW
UT WOS:000299636600004
PM 21902669
DA 2024-11-01
ER

PT J
AU Mkaouar-Rebai, E
   Ellouze, E
   Chamkha, I
   Kammoun, F
   Triki, C
   Fakhfakh, F
AF Mkaouar-Rebai, Emna
   Ellouze, Emna
   Chamkha, Imen
   Kammoun, Fatma
   Triki, Chahnez
   Fakhfakh, Faiza
TI Molecular-Clinical Correlation in a Family With a Novel Heteroplasmic Leigh Syndrome Missense Mutation in the Mitochondrial Cytochrome c Oxidase III Gene
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE mitochondrial mutation; COXIII; Leigh syndrome; m.9478T > C
ID nonsense mutation; subunit-ii; cox deficiency; dna mutations; mtdna; disease; myopathy; surf1; segregation; deletion
AB Cytochrome c oxidase is an essential component of the mitochondrial respiratory chain that catalyzes the reduction of molecular oxygen by reduced cytochrome c. In this study, the authors report the second mutation associated with Leigh syndrome in the blood and buccal mucosa of 2 affected members of a Tunisian family. It was a novel heteroplasmic missense mitochondrial mutation at nucleotide 9478 in the gene specifying subunit III of cytochrome c oxidase substituting the valine at position 91 to alanine in a highly conserved amino acid. It was found with a high mutant load in tissues derived from endoderm (buccal mucosa) and mesoderm (blood). However, it was nearly absent in tissue derived from ectoderm (hair follicles). It was absent in 120 healthy controls, and PolyPhen analysis showed that the hydropathy index changed from +1.276 to +0.242, and the number of structures of the 3D protein decreased from 39 to 32.
C1 [Mkaouar-Rebai, Emna; Chamkha, Imen; Fakhfakh, Faiza] Fac Med Sfax, Lab Genet Mol Humaine, Sfax 3029, Tunisia.
   [Ellouze, Emna; Kammoun, Fatma; Triki, Chahnez] CHU Hedi Chaker Sfax, Serv Neurol Infantile, Sfax, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Hedi Chaker
RP Mkaouar-Rebai, E (corresponding author), Fac Med Sfax, Lab Genet Mol Humaine, Ave Magida Boulila, Sfax 3029, Tunisia.
EM emna_mkaouar@mai12world.com
FU Ministry of Higher Education and Scientific Research in Tunisia
CR Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P4211, DOI 10.1167/iovs.06-0295
   Abu-Amero Khaled K, 2005, OPHTHALMIC GENET, V26, P31, DOI 10.1080/13816810590918235
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   BRUNORI M, 1987, EUR J BIOCHEM, V169, P1, DOI 10.1111/j.1432-1033.1987.tb13572.x
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Choi BO, 2008, EXP MOL MED, V40, P354, DOI 10.3858/emm.2008.40.3.354
   DiMauro S, 2003, NEW ENGL J MED, V349, P1294
   HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x
   Hamblet NS, 2006, ELECTROPHORESIS, V27, P398, DOI 10.1002/elps.200500420
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hoffbuhr KC, 2000, J BIOL CHEM, V275, P13994, DOI 10.1074/jbc.275.18.13994
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horváth R, 2002, J MED GENET, V39, P812, DOI 10.1136/jmg.39.11.812
   JOHNS DR, 1994, J NEURO-OPHTHALMOL, V14, P135
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kivisild T, 2004, AM J HUM GENET, V75, P752, DOI 10.1086/425161
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   LERTRIT P, 1992, HUM GENET, V90, P251
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   Matsumoto M, 1999, OPHTHALMIC GENET, V20, P153, DOI 10.1076/opge.20.3.153.2281
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Péquignot MO, 2001, J BIOL CHEM, V276, P15326, DOI 10.1074/jbc.M100388200
   Poulton J, 2002, REPRODUCTION, V123, P751, DOI 10.1530/rep.0.1230751
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   SAVONTAUS ML, 1995, BBA-MOL BASIS DIS, V1271, P261, DOI 10.1016/0925-4439(95)00037-5
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 42
TC 20
Z9 20
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JAN 15
PY 2011
VL 26
IS 1
BP 12
EP 20
DI 10.1177/0883073810371227
PG 9
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 703VE
UT WOS:000286008600003
PM 20525945
DA 2024-11-01
ER

PT J
AU Lorenzoni, PJ
   Scola, RH
   Kay, CSK
   Arndt, RC
   Silvado, CE
   Werneck, LC
AF Lorenzoni, Paulo Jose
   Scola, Rosana H.
   Kay, Claudia S. Kamoi
   Arndt, Raquel C.
   Silvado, Carlos E.
   Werneck, Lineu C.
TI MERRF: Clinical features, muscle biopsy and molecular genetics in Brazilian patients
SO MITOCHONDRION
LA English
DT Article
DE MERRF; Mitochondrial DNA; Mitochondrial myopathy; Muscle biopsy; Genetics
ID ragged-red fibers; mitochondrial disorders; myoclonic epilepsy
AB Myoclonic epilepsy with ragged red fibers (MERRF) is a mitochondrial disease that is characterized by myoclonic epilepsy with ragged red fibers (RRF) in muscle biopsies. The aim of this study was to analyze Brazilian patients with MERRF. Six patients with MERRF were studied and correlations between clinical findings, laboratory data, electrophysiology, histology and molecular features were examined. We found that blood lactate was increased in four patients. Electroencephalogram studies revealed generalized epileptiform discharges in five patients and generalized photoparoxysmal responses during intermittent photic stimulation in two patients. Muscle biopsies showed RRF in all patients using modified Gomori-trichrome and succinate dehydrogenase stains. Cytochrome c oxidase (COX) stain analysis indicated deficient activity in five patients and subsarcolemmal accumulation in one patient. Molecular analysis of the tRNA(Lys) gene with PCR/RFLP and direct sequencing showed the A8344G mutation of mtDNA in five patients. The presence of RRFs and COX deficiencies in muscle biopsies often confirmed the MERRF diagnosis. We conclude that molecular analysis of the tRNA(Lys) gene is an important criterion to help confirm the MERRF diagnosis. Furthermore, based on the findings of this study, we suggest a revision of the main characteristics of this disease. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Lorenzoni, Paulo Jose; Scola, Rosana H.; Kay, Claudia S. Kamoi; Arndt, Raquel C.; Silvado, Carlos E.; Werneck, Lineu C.] Univ Fed Parana, Dept Internal Med, Div Neurol, BR-80060900 Curitiba, Parana, Brazil.
C3 Universidade Federal do Parana
RP Scola, RH (corresponding author), Univ Fed Parana, Hosp Clin, Serv Neurol, Rua Gen Carneiro 181, BR-80060900 Curitiba, Parana, Brazil.
EM scola@hc.ufpr.br
FU Fundacao Araucaria; CAPES; CNPq
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arruda W O, 1990, ARQ NEUROPSIQUIATR, V48, P32
   Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   Da Cunha FMB, 2006, MUSCLE NERVE, V33, P409, DOI 10.1002/mus.20465
   DiMauro S, 2002, ADV NEUROL, V89, P217
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   FUKUHARA N, 1995, MUSCLE NERVE, V0, PS90
   Haas R, 2004, MITOCHONDRION, V4, P471, DOI 10.1016/j.mito.2004.07.008
   LARSSON NG, 1995, MUSCLE NERVE, V0, PS102
   Lorenzoni PJ, 2009, ARQ NEURO-PSIQUIAT, V67, P668, DOI 10.1590/S0004-282X2009000400018
   OZAWA M, 1995, NEUROMUSCULAR DISORD, V5, P483, DOI 10.1016/0960-8966(95)00009-C
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Shahwan A, 2005, LANCET NEUROL, V4, P239, DOI 10.1016/S1474-4422(05)70043-0
   SHOFFNER JM, 1992, AM J HUM GENET, V51, P1179
   Sinha S, 2007, J NEUROL SCI, V252, P16, DOI 10.1016/j.jns.2006.09.021
   Werneck LC, 1981, REV BRAS CLIN TERAP, V0, P2
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 17
TC 30
Z9 31
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAY 15
PY 2011
VL 11
IS 3
BP 528
EP 532
DI 10.1016/j.mito.2011.01.003
PG 5
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 753HS
UT WOS:000289763500020
PM 21303704
DA 2024-11-01
ER

PT J
AU Schröder, JM
   Klossok, T
   Weis, J
AF Schroeder, J. M.
   Klossok, T.
   Weis, J.
TI Oculopharyngeal muscle dystrophy: fine structure and mRNA expression levels of <i>PABPN1</i>
SO CLINICAL NEUROPATHOLOGY
LA English
DT Article
DE oculopharyngeal muscular dystrophy (PMD); PABPN1 gene; GCG and GCA repeats; genotype; fine structural phenotype
ID poly(a)-binding protein ii; inclusion-body myositis; unequal crossing-over; muscular-dystrophy; mitochondrial abnormality; neurogenic involvement; nuclear inclusions; cell-death; myopathy; family
AB Objective: The underlying molecular mechanism leading to the OPMD causing mutation in the PABPN1 gene has not been elucidated so far. Two models are under consideration: the first model is the polymerase slippage mechanism. The second model is unequal crossing over. The aim of the present study is to correlate clinical, fine structural, and molecular genetic data. Material and methods: In 6 cases of OPMD, confirmed by electron microscopy, we analyzed mutations in exon 1 of the polyadenine binding protein nuclear1 (PABPN1) gene on chromosome 14q11.1 using DNA isolated from biopsied muscle tissue. Furthermore, the corresponding mRNA from frozen biopsies was analyzed. Results: In addition to the usual expansion of the (GCG)(6) sequence to the well known (GCG)(8-13) trinucleotide repeats in 5 of the patients, we detected a novel (GCA)(2)(GCG) insertion in one patient. This mutation favors a pathomechanism of "unequal crossing over" instead of a "polymerase slippage" model. Tubulofilamentous (8.5 nm) nuclear inclusions were especially prominent in an isolated nucleus of a nuclear clump in a severely atrophic muscle fiber. However, no correlation was found between muscle weakness, the frequency of repeats, and the frequency and size of nuclear inclusions. Conclusions: Muscle weakness was not obviously correlated to the number of repeats, but it is suggested that it might be linked to an increase of the transcription rate representing the ratio between mutated versus normal RT-PCR products.
C1 [Schroeder, J. M.; Klossok, T.; Weis, J.] Rhein Westfal TH Aachen, Dept Neuropathol, Univ Hosp, D-52074 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital
RP Schröder, JM (corresponding author), Rhein Westfal TH Aachen, Dept Neuropathol, Univ Hosp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM jmschroder@ukaachen.de
CR ARENAS J, 1992, MUSCLE NERVE, V15, P1055, DOI 10.1002/mus.880150911
   ASKANAS V, 1991, NEUROSCI LETT, V130, P73, DOI 10.1016/0304-3940(91)90230-Q
   Blumen SC, 2009, NEUROLOGY, V73, P596, DOI 10.1212/WNL.0b013e3181b388a3
   Blumen SC, 2000, NEUROLOGY, V55, P1267, DOI 10.1212/WNL.55.9.1267
   Boukriche Y, 2002, MUSCLE NERVE, V25, P98, DOI 10.1002/mus.1213
   BRAIS B, 1995, HUM MOL GENET, V4, P429, DOI 10.1093/hmg/4.3.429
   Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164
   Brais B, 2003, CYTOGENET GENOME RES, V100, P252, DOI 10.1159/000072861
   Brais B, 2009, CURR NEUROL NEUROSCI, V9, P76, DOI 10.1007/s11910-009-0012-y
   Brunet G, 1997, NEUROMUSCULAR DISORD, V7, PS34, DOI 10.1016/S0960-8966(97)00079-5
   Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908
   Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273
   Davies JE, 2008, HUM MOL GENET, V17, P1097, DOI 10.1093/hmg/ddm382
   Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341
   GOAS JY, 1991, REV NEUROL, V147, P536
   HARDIMAN O, 1993, ARCH NEUROL-CHICAGO, V50, P481, DOI 10.1001/archneur.1993.00540050033011
   Hill ME, 2001, BRAIN, V124, P522, DOI 10.1093/brain/124.3.522
   JULIEN J, 1974, J NEUROL SCI, V21, P165, DOI 10.1016/0022-510X(74)90067-7
   Kühn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008
   KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1
   Lampe JB, 2001, NERVENARZT, V72, P652, DOI 10.1007/s001150170068
   LECLERC A, 1993, NEUROMUSCULAR DISORD, V3, P283, DOI 10.1016/0960-8966(93)90021-B
   Marsh EA, 2008, CLIN NEUROL NEUROSUR, V110, P525, DOI 10.1016/j.clineuro.2008.02.007
   Meyer S, 2002, BIOCHEMISTRY-US, V41, P6082, DOI 10.1021/bi0160866
   Mihaylova V, 2008, J NEUROL, V255, P609, DOI 10.1007/s00415-008-0769-y
   Minami N, 2001, NEUROMUSCULAR DISORD, V11, P699, DOI 10.1016/S0960-8966(01)00227-9
   Müller T, 2006, J NEUROL, V253, P892, DOI 10.1007/s00415-006-0126-y
   Myers RH, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, V0, P301
   Nakamoto M, 2002, ARCH NEUROL-CHICAGO, V59, P474, DOI 10.1001/archneur.59.3.474
   Ohshima K, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, V0, P717
   PAUZNER R, 1991, MUSCLE NERVE, V14, P947, DOI 10.1002/mus.880141004
   Porschke H, 1997, NEUROMUSCULAR DISORD, V7, PS57, DOI 10.1016/S0960-8966(97)00084-9
   PRATT MF, 1986, LARYNGOSCOPE, V96, P368
   PROBST A, 1982, ACTA NEUROPATHOL, V57, P209, DOI 10.1007/BF00685391
   Rankin J, 2000, BIOCHEM J, V348, P15, DOI 10.1042/0264-6021:3480015
   Rivera D, 2008, BRIT J OPHTHALMOL, V92, P998, DOI 10.1136/bjo.2007.131482
   Robinson DO, 2005, HUM GENET, V116, P267, DOI 10.1007/s00439-004-1235-2
   Robinson I, 2006, J MED GENET, V43, P0
   SATOYOSHI E, 1977, ARCH NEUROL-CHICAGO, V34, P89, DOI 10.1001/archneur.1977.00500140043007
   Scacheri PC, 1999, AM J MED GENET, V86, P477, DOI 10.1002/(SICI)1096-8628(19991029)86:5<477::AID-AJMG14>3.0.CO;2-A
   SCHMITT HP, 1981, MUSCLE NERVE, V4, P296, DOI 10.1002/mus.880040406
   Schober R, 2001, NEUROPATHOLOGY, V21, P45, DOI 10.1046/j.1440-1789.2001.00374.x
   SCHRODER JM, 1995, NEUROPATH APPL NEURO, V21, P68, DOI 10.1111/j.1365-2990.1995.tb01030.x
   SCHRODER JM, 1982, PATHOLOGIC MUSKULATU, V0, P0
   Taylor EW, 1915, J NERV MENT DIS, V42, P129, DOI 10.1097/00005053-191503000-00001
   Tome FMS, 1997, NEUROMUSCULAR DISORD, V7, PS63, DOI 10.1016/S0960-8966(97)00085-0
   TOME FMS, 1980, ACTA NEUROPATHOL, V49, P85, DOI 10.1007/BF00692226
   Uyama E, 1998, NEUROMUSCULAR DISORD, V8, P119, DOI 10.1016/S0960-8966(98)00002-9
   van der Sluijs BM, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9138
   van der Sluijs BM, 2003, J NEUROL, V250, P1307, DOI 10.1007/s00415-003-0201-6
   VICTOR M, 1962, NEW ENGL J MED, V267, P1267, DOI 10.1056/NEJM196212202672501
   Warren ST, 1997, SCIENCE, V275, P408, DOI 10.1126/science.275.5298.408
   Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875
NR 53
TC 7
Z9 8
U1 0
U2 5
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0722-5091
EI 
J9 CLIN NEUROPATHOL
JI Clin. Neuropathol.
PD MAY-JUN 15
PY 2011
VL 30
IS 3
BP 94
EP 103
DI 10.5414/NPP30094
PG 10
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 767SW
UT WOS:000290877400002
PM 21545772
DA 2024-11-01
ER

PT J
AU Tellis, CM
   Rosen, C
   Close, JM
   Horton, M
   Yaruss, JS
   Verdolini-Abbott, K
   Sciote, JJ
AF Tellis, Cari M.
   Rosen, Clark
   Close, John M.
   Horton, Michael
   Yaruss, J. Scott
   Verdolini-Abbott, Katherine
   Sciote, James J.
TI Cytochrome c Oxidase Deficiency in Human Posterior Cricoarytenoid Muscle
SO JOURNAL OF VOICE
LA English
DT Article
DE Laryngeal muscles; Cytochrome c oxidase; Aging; Posterior cricoarytenoid muscle
ID human thyroarytenoid muscle; age-related-changes; laser-scanning microscopy; dna deletion mutations; skeletal-muscle; motor units; mitochondrial myopathy; laryngeal synkinesis; respiratory-chain; satellite cells
AB Background. Mitochondrial alterations occur in skeletal muscle fibers throughout the normal aging process, resulting from increased accumulation of reactive oxide species (ROS). These result in respiratory chain abnormalities, which decrease the oxidative capacity of muscle fibers, leading to decreased contractile force, sarcopenia, or fiber necrosis. Intrinsic laryngeal muscles are a cranial muscle group that possesses some distinctive genotypic, phenotypic, and physiologic properties. Their susceptibility to mitochondrial alterations resulting from biological processes that increase levels of oxidative stress may be one of these distinctive characteristics. Objectives. The incidence of cytochrome c oxidase (COX) deficiency (COX-) was determined in human posterior cricoarytenoid (PCA) muscle when compared with the human thyrohyoid (TH) muscle, an extrinsic laryngeal muscle that served as "control" muscle. Ten PCA and 10TH muscles were harvested postlaryngectomy from 10 subjects ranging in age from 55 to 86 years. Differences in COX- were compared within and between muscle types using tissue section staining and standard morphometric analysis. Results and Conclusions. COX- fibers were identified in both the PCA and TH muscles. The PCA muscle had 10 times as may affected fibers as the TH muscle, with significant differences in COX- found between muscle type and fiber type (P = 0.003). Almost all of this effect was the result of elevated levels of COX- in type 1 fibers from the PCA muscle (P = 0.002) that showed a strong positive correlation with increased age. These results suggest that increased mitochondrial alterations may occur in the PCA muscle during normal aging.
C1 [Tellis, Cari M.] Misericordia Univ, Speech Language Pathol Dept, Dallas, PA 18612 USA.
   [Rosen, Clark] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
   [Close, John M.] Univ Pittsburgh, Sch Dent Med, Dept Publ Hlth, Pittsburgh, PA USA.
   [Horton, Michael; Sciote, James J.] Temple Univ, Kornberg Sch Dent, Dept Orthodont, Philadelphia, PA 19122 USA.
   [Yaruss, J. Scott; Verdolini-Abbott, Katherine] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA.
C3 Misericordia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh
RP Tellis, CM (corresponding author), Misericordia Univ, Speech Language Pathol Dept, Dallas, PA 18612 USA.
EM ctellis@misericordia.edu
FU NIDCD NIH HHS [R01 DC005058] Funding Source: Medline
CR Andrade FH, 2000, MICROSC RES TECHNIQ, V48, P192, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J
   ANSVED T, 1989, J NEUROL SCI, V93, P105, DOI 10.1016/0022-510X(89)90165-2
   Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Borisov AB, 2000, ANAT RECORD, V258, P305
   Brandon CA, 2003, J VOICE, V17, P63, DOI 10.1016/S0892-1997(03)00027-4
   BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313
   BROWN WF, 1972, J NEUROL NEUROSUR PS, V35, P845, DOI 10.1136/jnnp.35.6.845
   BROWN WM, 1971, P NATL ACAD SCI USA, V76, P1969
   BYRNE E, 1992, MUTAT RES, V275, P125, DOI 10.1016/0921-8734(92)90017-J
   CAMPBELL MJ, 1973, J NEUROL NEUROSUR PS, V36, P174, DOI 10.1136/jnnp.36.2.174
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CARLSON BM, 1995, J GERONTOL A-BIOL, V50, P96
   Chargé SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Connor NP, 2002, ANN OTO RHINOL LARYN, V111, P579, DOI 10.1177/000348940211100703
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526
   Crumley RL, 2000, ANN OTO RHINOL LARYN, V109, P365, DOI 10.1177/000348940010900405
   Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Goding GS, 2005, ANN OTO RHINOL LARYN, V114, P552, DOI 10.1177/000348940511400711
   Hammond TH, 2000, ANN OTO RHINOL LARYN, V109, P913, DOI 10.1177/000348940010901004
   Kadhiresan VA, 1996, J PHYSIOL-LONDON, V493, P543, DOI 10.1113/jphysiol.1996.sp021402
   Kahane JC, 1983, VOCAL FOLD PHYSIOLOGY: CONTEMPORARY RESEARCH AND CLINICAL ISSUES, V0, P44
   KALRA J, 1991, INT J EXP PATHOL, V72, P1
   Kersing W, 2004, EUR ARCH OTO-RHINO-L, V261, P386, DOI 10.1007/s00405-003-0702-z
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3
   Linville SE, 2001, J VOICE, V15, P323, DOI 10.1016/S0892-1997(01)00034-0
   Malmgren LT, 1999, OTOLARYNG HEAD NECK, V121, P441, DOI 10.1016/S0194-5998(99)70235-4
   Malmgren LT, 2001, OTOLARYNG HEAD NECK, V125, P34, DOI 10.1067/mhn.2001.116449
   Malmgren LT, 2000, ARCH OTOLARYNGOL, V126, P851, DOI 10.1001/archotol.126.7.851
   Maronian NC, 2004, ANN OTO RHINOL LARYN, V113, P877, DOI 10.1177/000348940411301106
   MCCOMAS AJ, 1971, J NEUROL NEUROSUR PS, V34, P121, DOI 10.1136/jnnp.34.2.121
   MCCULLY KK, 1985, J APPL PHYSIOL, V59, P119, DOI 10.1152/jappl.1985.59.1.119
   MCLOON KL, 2003, INVEST OPHTH VIS SCI, V44, P1927
   McLoon LK, 2004, MUSCLE NERVE, V29, P707, DOI 10.1002/mus.20012
   McMullen CA, 2006, J APPL PHYSIOL, V100, P602, DOI 10.1152/japplphysiol.01066.2005
   MullerHocker J, 1996, MECH AGEING DEV, V86, P197, DOI 10.1016/0047-6374(95)01692-9
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P12
   NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420, DOI 10.1177/5.4.420
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Rader EP, 2006, J APPL PHYSIOL, V101, P887, DOI 10.1152/japplphysiol.00380.2006
   RODENO MT, 1993, ACTA OTO-LARYNGOL, V113, P445, DOI 10.3109/00016489309135842
   RODRIGUES AD, 1995, ANAT RECORD, V243, P430
   ROSENBERG IH, 1989, AM J CLIN NUTR, V50, P1231, DOI 10.1093/ajcn/50.5.1231
   ROUBENOFF R, 2000, J GERONTOL A-BIOL, V55, P0
   Sastre J, 2000, FREE RADICAL RES, V32, P189, DOI 10.1080/10715760000300201
   Sataloff RT, 1997, J VOICE, V11, P156, DOI 10.1016/S0892-1997(97)80072-0
   SKOWRONEK P, 1992, BIOCHEM BIOPH RES CO, V187, P991, DOI 10.1016/0006-291X(92)91295-2
   Suzuki T, 2002, ANN OTO RHINOL LARYN, V111, P962, DOI 10.1177/000348940211101102
   TUCKER HM, 1978, LARYNGOSCOPE, V88, P598
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   WARD PH, 1989, OTOLARYNG HEAD NECK, V100, P283, DOI 10.1177/019459988910000405
   Welle S, 2002, CAN J APPL PHYSIOL, V27, P19, DOI 10.1139/h02-002
   WILDER C, 1979, 7 S CAR PROF VOIC 2, V0, P0
   YAMAMOTO M, 1988, ACTA NEUROPATHOL, V76, P558, DOI 10.1007/BF00689593
NR 59
TC 1
Z9 1
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0892-1997
EI 1873-4588
J9 J VOICE
JI J. Voice
PD JUL 15
PY 2011
VL 25
IS 4
BP 387
EP 394
DI 10.1016/j.jvoice.2010.03.002
PG 8
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 790HL
UT WOS:000292579000001
PM 20685075
DA 2024-11-01
ER

PT J
AU Thomas, A
   Rey, M
   Aubry, L
   Pelosi, L
AF Thomas, Amandine
   Rey, Martial
   Aubry, Laurence
   Pelosi, Ludovic
TI A hybrid model to study pathological mutations of the human ADP/ATP carriers
SO BIOCHIMIE
LA English
DT Article
DE ADP/ATP carrier; Mitochondrial diseases; Saccharomyces cerevisiae; Dictyostelium discoideum
ID adenine-nucleotide translocator; progressive external ophthalmoplegia; yeast saccharomyces-cerevisiae; ant1 gene; functional-characterization; dictyostelium-discoideum; molecular-mechanisms; mitochondrial-dna; protein; purification
AB The adenine nucleotide carrier (Ancp) plays an essential role in the metabolism of cellular energy by catalyzing the transport of ADP and ATP across the inner mitochondria! membrane. Previous reports have indicated that mutations in the HANC1 gene, encoding the muscle isoform of human Ancp (HAnc1p), are directly involved in several diseases, including autosomal dominant progressive external ophthalmoplegia and cardiomyopathies. In this work, we studied three pathogenic HANC1 mutations at the biochemical level. To do so, we expressed the DdANCA gene, encoding the unique Ancp carrier of Dictyostelium discoideum (DdAncAp), in a yeast strain lacking all endogenous ANC genes. Our results indicate that DdAncAp is a good model for the human protein. It allows the carrier to be studied in yeast, and provides information on how the HANC1 mutations impair ADP/ATP transport in humans. A94D, A126D and V291M mutations, corresponding to A90D, A123D and V289M in HAnc1p, respectively, did not affect levels of DdAncAp in yeast mitochondria. However, while the wild-type DdAncAp fully restored growth of the ANC-null yeast strain on a non-fermentable carbon source, the carriers encompassing either the A94D or the A126D mutation failed to complement the null strain. The effect of the V291M mutation was not as pronounced, but led to impairment mainly of the nucleotide translocation process per se. These findings provide new insights into the mechanisms responsible for the diseases induced by HAnc1p mutations. (C) 2011 Elsevier Masson SAS. All rights reserved.
C1 [Pelosi, Ludovic] Univ Grenoble 1, CNRS, CEA,UMR 5092, BBSI,iRTSV,DSV,Lab Biochim & Biophys Syst Integre, F-38054 Grenoble, France.
   [Thomas, Amandine; Rey, Martial; Aubry, Laurence; Pelosi, Ludovic] CNRS, UMR5092, LBBSI, F-38054 Grenoble, France.
C3 CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)
RP Pelosi, L (corresponding author), Univ Grenoble 1, CNRS, CEA,UMR 5092, BBSI,iRTSV,DSV,Lab Biochim & Biophys Syst Integre, F-38054 Grenoble, France.
EM ludovic.pelosi@cea.fr
FU Universite Joseph Fourier (UJF); French Centre National de la Recherche Scientifique (CNRS); Commissariat a l'Energie Atomique (CEA)
CR Bach S, 2003, NAT BIOTECHNOL, V21, P1075, DOI 10.1038/nbt855
   Bof M, 1999, EUR J BIOCHEM, V259, P795, DOI 10.1046/j.1432-1327.1999.00088.x
   BRANDOLIN G, 1974, FEBS LETT, V46, P149, DOI 10.1016/0014-5793(74)80356-X
   BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025
   BRANDOLIN G, 1993, BIOCHEM BIOPH RES CO, V192, P143, DOI 10.1006/bbrc.1993.1393
   BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Clémencon B, 2008, J BIOL CHEM, V283, P11218, DOI 10.1074/jbc.M709565200
   Dahout-Gonzalez C, 2006, PHYSIOLOGY, V21, P242, DOI 10.1152/physiol.00005.2006
   Dahout-Gonzalez C, 2005, BIOCHEMISTRY-US, V44, P16310, DOI 10.1021/bi0514820
   Dassa EP, 2005, PROTEIN EXPRES PURIF, V40, P358, DOI 10.1016/j.pep.2004.12.019
   DAUM G, 1982, J BIOL CHEM, V257, P3028
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DRGON T, 1991, FEBS LETT, V289, P159, DOI 10.1016/0014-5793(91)81059-H
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kucharczyk R, 2009, BBA-MOL CELL RES, V1793, P186, DOI 10.1016/j.bbamcr.2008.06.012
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   LeSaux A, 1996, BIOCHEMISTRY-US, V35, P16116, DOI 10.1021/bi961714i
   LI K, 1989, J BIOL CHEM, V264, P13998
   Lodi T, 2006, BIOCHEM BIOPH RES CO, V341, P810, DOI 10.1016/j.bbrc.2006.01.034
   Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Rey M, 2010, J BIOL CHEM, V285, P34981, DOI 10.1074/jbc.M110.146209
   Satre M, 2007, BIOCHIMIE, V89, P1058, DOI 10.1016/j.biochi.2007.03.004
   Schwimmer Christine, 2006, BIOTECHNOLOGY JOURNAL, V1, P270, DOI 10.1002/biot.200500053
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Trézéguet V, 2008, J BIOENERG BIOMEMBR, V40, P435, DOI 10.1007/s10863-008-9178-2
   WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171
NR 34
TC 2
Z9 2
U1 0
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
EI 
J9 BIOCHIMIE
JI Biochimie
PD SEP 15
PY 2011
VL 93
IS 9
BP 1415
EP 1423
DI 10.1016/j.biochi.2011.04.015
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 811TA
UT WOS:000294237800006
PM 21549803
DA 2024-11-01
ER

PT J
AU Mehta, AR
   Fox, SH
   Tarnopolsky, M
   Yoon, G
AF Mehta, Arpan R.
   Fox, Susan H.
   Tarnopolsky, Mark
   Yoon, Grace
TI Mitochondrial Mimicry of Multiple System Atrophy of the Cerebellar Subtype
SO MOVEMENT DISORDERS
LA English
DT Article
DE mitochondrial disease; multiple system atrophy; polymerase gamma gene; parkinsonism; ataxia
ID dna-polymerase-gamma; progressive external ophthalmoplegia; polg1 mutations; parkinsonism; gene; perspective; disorders; children; disease; ataxia
AB Background: We describe a patient with clinical and radiological findings suggestive of multiple system atrophy of the cerebellar subtype (MSA-C). Methods/Results: Sequencing of the polymerase-gamma 1 (POLG1) gene revealed the patient had compound heterozygous mutations of the POLG1 gene. Muscle biopsy revealed the presence of multiple mitochondrial DNA deletions and depletion, confirming the pathogenic nature of the POLG1 mutations. Discussion: This case expands the spectrum of phenotypes associated with POLG1 mutations to include multiple system atrophy and prompts further consideration regarding whether routine screening for POLG1 mutations is indicated in this patient population. (C) 2011 Movement Disorder Society
C1 [Yoon, Grace] Univ Toronto, Hosp Sick Children, Div Clin Metab Genet, Toronto, ON M5G 1X8, Canada.
   [Yoon, Grace] Univ Toronto, Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada.
   [Mehta, Arpan R.; Fox, Susan H.] Univ Toronto, Toronto Western Hosp, Movement Disorder Clin, Toronto, ON M5G 1X8, Canada.
   [Tarnopolsky, Mark] McMaster Univ, Med Ctr, Div Neuromuscular & Neurometab Dis, Hamilton, ON, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; University Health Network Toronto; McMaster University
RP Yoon, G (corresponding author), Univ Toronto, Hosp Sick Children, Div Clin Metab Genet, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM grace.yoon@utoronto.ca
CR Corral J, 2005, ANN NEUROL, V57, P549, DOI 10.1002/ana.20421
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Gilman S, 2008, NEUROLOGY, V71, P670, DOI 10.1212/01.wnl.0000324625.00404.15
   Hadjivassiliou M, 2003, BRAIN, V126, P685, DOI 10.1093/brain/awg050
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2009, MOVEMENT DISORD, V24, P1092, DOI 10.1002/mds.22310
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   TRUONG DD, 1990, MOVEMENT DISORD, V5, P109, DOI 10.1002/mds.870050204
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Venna N, 2004, NEUROL INDIA, V52, P305
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 21
TC 17
Z9 17
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
EI 
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAR 15
PY 2011
VL 26
IS 4
BP 753
EP 755
DI 10.1002/mds.23510
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 762AO
UT WOS:000290444800034
PM 21259344
DA 2024-11-01
ER

PT J
AU Sunami, Y
   Sugaya, K
   Chihara, N
   Goto, Y
   Matsubara, S
AF Sunami, Yoko
   Sugaya, Keizo
   Chihara, Norio
   Goto, Yu-ichi
   Matsubara, Shiro
TI Variable phenotypes in a family with mitochondrial encephalomyopathy harboring a 3291T &gt; C mutation in mitochondrial DNA
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial encephalomyopathy; Family case; 3291T > C; mtDNA mutation
ID melas
AB We present a Japanese family suffering from mitochondrial encephalomyopathy associated with a T-to-C transition at mitochondrial DNA (mtDNA) nucleotide position 3291. Clinical manifestations of the patients include cerebellar ataxia with myopathy, recurrent headache, and myoclonus and epilepsy. The phenotypic variation among the affected members of a single family and the mutational analysis showing maternal inheritance in a heteroplasmic fashion are consistent with well-recognized phenomena associated with many pathogenic point mutations of mtDNA tRNA genes. The 3291 mutation is a rare mtDNA mutation whose clinical presentation had only been reported in three sporadic cases. This is the first report of a family segregating the 3291 mutation with multigenerational matrilinear recurrence of mitochondrial encephalopathy. Our findings provide conclusive evidence for the pathogenicity of the 3291T > C mutation in mtDNA and its characteristic clinical heterogeneity.
C1 [Sunami, Yoko; Sugaya, Keizo; Matsubara, Shiro] Tokyo Metropolitan Neurol Hosp, Dept Neurol, Fuchu, Tokyo 1830042, Japan.
   [Chihara, Norio] Natl Ctr Hosp Neurol & Psychiat, Dept Neurol, Tokyo, Japan.
   [Goto, Yu-ichi] NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
C3 Tokyo Metropolitan Institute for Neuroscience; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan
RP Sunami, Y (corresponding author), Tokyo Metropolitan Neurol Hosp, Dept Neurol, 2-6-1 Musashidai, Fuchu, Tokyo 1830042, Japan.
EM youko_sunami@tmhp.jp
CR GOTO Y, 1995, MUSCLE NERVE S, V3, P107
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Salsano E, 2011, J NEUROL SCI, V300, P165, DOI 10.1016/j.jns.2010.09.022
   Thajeb Peterus, 2006, TAIWAN J OBSTET GYNECOL, V45, P201
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wallace DC, 2008, GENETICS, V179, P727, DOI 10.1534/genetics.104.91769
NR 8
TC 9
Z9 9
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1590-1874
EI 
J9 NEUROL SCI
JI Neurol. Sci.
PD OCT 15
PY 2011
VL 32
IS 5
BP 861
EP 864
DI 10.1007/s10072-011-0719-9
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 855EK
UT WOS:000297546400013
PM 21863273
DA 2024-11-01
ER

PT J
AU Wang, WY
   Shen, PD
   Thiyagarajan, S
   Lin, SR
   Palm, C
   Horvath, R
   Klopstock, T
   Cutler, D
   Pique, L
   Schrijver, I
   Davis, RW
   Mindrinos, M
   Speed, TP
   Scharfe, C
AF Wang, Wenyi
   Shen, Peidong
   Thiyagarajan, Sreedevi
   Lin, Shengrong
   Palm, Curtis
   Horvath, Rita
   Klopstock, Thomas
   Cutler, David
   Pique, Lynn
   Schrijver, Iris
   Davis, Ronald W.
   Mindrinos, Michael
   Speed, Terence P.
   Scharfe, Curt
TI Identification of rare DNA variants in mitochondrial disorders with improved array-based sequencing
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID progressive external ophthalmoplegia; high-throughput; microarrays; mutations; genes; deletions; algorithm; genome; model; polymorphisms
AB A common goal in the discovery of rare functional DNA variants via medical resequencing is to incur a relatively lower proportion of false positive base-calls. We developed a novel statistical method for resequencing arrays (SRMA, sequence robust multi-array analysis) to increase the accuracy of detecting rare variants and reduce the costs in subsequent sequence verifications required in medical applications. SRMA includes single and multi-array analysis and accounts for technical variables as well as the possibility of both low- and high-frequency genomic variation. The confidence of each base-call was ranked using two quality measures. In comparison to Sanger capillary sequencing, we achieved a false discovery rate of 2% (false positive rate 1.2 x 10(-5), false negative rate 5%), which is similar to automated second-generation sequencing technologies. Applied to the analysis of 39 nuclear candidate genes in disorders of mitochondrial DNA (mtDNA) maintenance, we confirmed mutations in the DNA polymerase gamma POLG in positive control cases, and identified novel rare variants in previously undiagnosed cases in the mitochondrial topoisomerase TOP1MT, the mismatch repair enzyme MUTYH, and the apurinic-apyrimidinic endonuclease APEX2. Some patients carried rare heterozygous variants in several functionally interacting genes, which could indicate synergistic genetic effects in these clinically similar disorders.
C1 [Wang, Wenyi; Shen, Peidong; Thiyagarajan, Sreedevi; Lin, Shengrong; Palm, Curtis; Davis, Ronald W.; Mindrinos, Michael; Scharfe, Curt] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.
   [Wang, Wenyi; Speed, Terence P.] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.
   [Horvath, Rita] Newcastle Univ, Inst Hlth & Aging, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Klopstock, Thomas] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-80336 Munich, Germany.
   [Cutler, David] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA.
   [Pique, Lynn; Schrijver, Iris] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.
   [Schrijver, Iris] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
C3 Stanford University; University of California System; University of California Berkeley; Newcastle University - UK; University of Munich; Emory University; Stanford University; Stanford University
RP Scharfe, C (corresponding author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.
EM wenyiw@stanford.edu; curts@stanford.edu
FU National Eye Institute [R01EY016240]; German Ministry of Education and Research (BMBF); National Institutes of Health
CR Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828
   Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430
   Bacman SR, 2009, NUCLEIC ACIDS RES, V37, P4218, DOI 10.1093/nar/gkp348
   BANFIELD JD, 1993, BIOMETRICS, V49, P803, DOI 10.2307/2532201
   Bengtsson H, 2009, BIOINFORMATICS, V25, P861, DOI 10.1093/bioinformatics/btp074
   Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136
   Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090
   Carvalho B, 2007, BIOSTATISTICS, V8, P485, DOI 10.1093/biostatistics/kxl042
   Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610
   Cole SA, 2010, AM J CLIN NUTR, V91, P191, DOI 10.3945/ajcn.2009.28514
   Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871
   Di XJ, 2005, P ANN INT IEEE EMBS, V0, P2809
   Ferlin T, 1997, MOL CELL BIOCHEM, V174, P221, DOI 10.1023/A:1006860508606
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131
   Franke L, 2006, AM J HUM GENET, V78, P1011, DOI 10.1086/504300
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Gresham D, 2010, P NATL ACAD SCI USA, V107, P1482, DOI 10.1073/pnas.0913883107
   Hacia JC, 1998, GENOME RES, V8, P1245, DOI 10.1101/gr.8.12.1245
   Harismendy O, 2009, GENOME BIOL, V10, P0, DOI 10.1186/gb-2009-10-3-r32
   Ji WZ, 2008, NAT GENET, V40, P592, DOI 10.1038/ng.118
   Krishnakumar S, 2008, P NATL ACAD SCI USA, V105, P9296, DOI 10.1073/pnas.0803240105
   Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004
   Lebet T, 2008, GENET MED, V10, P575, DOI 10.1097/GIM.0b013e31818063bc
   Liu WM, 2003, BIOINFORMATICS, V19, P2397, DOI 10.1093/bioinformatics/btg332
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandal MNA, 2005, INVEST OPHTH VIS SCI, V46, P3355, DOI 10.1167/iovs.05-0007
   Pandya GA, 2007, NUCLEIC ACIDS RES, V35, P0, DOI 10.1093/nar/gkm918
   Pinheiro JC, 2000, MIXED-EFFECTS MODELS IN S AND S-PLUS, V0, P0
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   PURDUE PE, 1991, P NATL ACAD SCI USA, V88, P10900, DOI 10.1073/pnas.88.23.10900
   Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7
   Scharfe C, 2009, PLOS COMPUT BIOL, V5, P0, DOI 10.1371/journal.pcbi.1000374
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Shen YF, 2010, GENOME RES, V20, P273, DOI 10.1101/gr.096388.109
   Shendure J, 2008, NAT METHODS, V5, P585, DOI 10.1038/nmeth0708-585
   Shendure Jay A, 2008, CURR PROTOC MOL BIOL, VChapter 7, P0, DOI 10.1002/0471142727.mb0701s81
   Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
   Stephens M, 2006, NAT GENET, V38, P375, DOI 10.1038/ng1746
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Szoke D, 2009, INT J MOL MED, V23, P217, DOI 10.3892/ijmm_00000120
   Tarpey PS, 2009, NAT GENET, V41, P535, DOI 10.1038/ng.367
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Waldmüller S, 2008, CLIN CHEM, V54, P682, DOI 10.1373/clinchem.2007.099119
   Wang AL, 2008, MOL VIS, V14, P644
   Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077
   Wang WY, 2008, J COMPUT BIOL, V15, P857, DOI 10.1089/cmb.2007.0148
   Warrington JA, 2002, HUM MUTAT, V19, P402, DOI 10.1002/humu.10075
   Xiao YY, 2007, BIOINFORMATICS, V23, P1459, DOI 10.1093/bioinformatics/btm131
   Zheng JB, 2009, P NATL ACAD SCI USA, V106, P6712, DOI 10.1073/pnas.0901902106
NR 55
TC 16
Z9 28
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN 15
PY 2011
VL 39
IS 1
BP 44
EP 58
DI 10.1093/nar/gkq750
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 703VD
UT WOS:000286008500009
PM 20843780
DA 2024-11-01
ER

PT J
AU Xie, HBM
   Perin, JC
   Schurr, TG
   Dulik, MC
   Zhadanov, SI
   Baur, JA
   King, MP
   Place, E
   Clarke, C
   Grauer, M
   Schug, J
   Santani, A
   Albano, A
   Kim, C
   Procaccio, V
   Hakonarson, H
   Gai, XW
   Falk, MJ
AF Xie, Hongbo M.
   Perin, Juan C.
   Schurr, Theodore G.
   Dulik, Matthew C.
   Zhadanov, Sergey I.
   Baur, Joseph A.
   King, Michael P.
   Place, Emily
   Clarke, Colleen
   Grauer, Michael
   Schug, Jonathan
   Santani, Avni
   Albano, Anthony
   Kim, Cecilia
   Procaccio, Vincent
   Hakonarson, Hakon
   Gai, Xiaowu
   Falk, Marni J.
TI Mitochondrial genome sequence analysis: A custom bioinformatics pipeline substantially improves Affymetrix MitoChip v2.0 call rate and accuracy
SO BMC BIOINFORMATICS
LA English
DT Article
ID dna; microarray; heteroplasmy
AB Background: Mitochondrial genome sequence analysis is critical to the diagnostic evaluation of mitochondrial disease. Existing methodologies differ widely in throughput, complexity, cost efficiency, and sensitivity of heteroplasmy detection. Affymetrix MitoChip v2.0, which uses a sequencing-by-genotyping technology, allows potentially accurate and high-throughput sequencing of the entire human mitochondrial genome to be completed in a cost-effective fashion. However, the relatively low call rate achieved using existing software tools has limited the wide adoption of this platform for either clinical or research applications. Here, we report the design and development of a custom bioinformatics software pipeline that achieves a much improved call rate and accuracy for the Affymetrix MitoChip v2.0 platform. We used this custom pipeline to analyze MitoChip v2.0 data from 24 DNA samples representing a broad range of tissue types (18 whole blood, 3 skeletal muscle, 3 cell lines), mutations (a 5.8 kilobase pair deletion and 6 known heteroplasmic mutations), and haplogroup origins. All results were compared to those obtained by at least one other mitochondrial DNA sequence analysis method, including Sanger sequencing, denaturing HPLC-based heteroduplex analysis, and/or the Illumina Genome Analyzer II next generation sequencing platform. Results: An average call rate of 99.75% was achieved across all samples with our custom pipeline. Comparison of calls for 15 samples characterized previously by Sanger sequencing revealed a total of 29 discordant calls, which translates to an estimated 0.012% for the base call error rate. We successfully identified 4 known heteroplasmic mutations and 24 other potential heteroplasmic mutations across 20 samples that passed quality control. Conclusions: Affymetrix MitoChip v2.0 analysis using our optimized MitoChip Filtering Protocol (MFP) bioinformatics pipeline now offers the high sensitivity and accuracy needed for reliable, high-throughput and cost-efficient whole mitochondrial genome sequencing. This approach provides a viable alternative of potential utility for both clinical diagnostic and research applications to traditional Sanger and other emerging sequencing technologies for whole mitochondrial genome analysis.
C1 [Xie, Hongbo M.; Perin, Juan C.; Grauer, Michael; Gai, Xiaowu] Childrens Hosp Philadelphia, Ctr Informat Biol, Philadelphia, PA 19104 USA.
   [Schurr, Theodore G.; Dulik, Matthew C.; Zhadanov, Sergey I.] Univ Penn, Dept Anthropol, Sch Arts & Sci, Philadelphia, PA 19104 USA.
   [Baur, Joseph A.] Univ Penn, Dept Physiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [King, Michael P.] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.
   [Place, Emily; Clarke, Colleen; Falk, Marni J.] Childrens Hosp Philadelphia, Div Human Genet, Dept Pediat, Philadelphia, PA 19104 USA.
   [Schug, Jonathan] Univ Penn, Computat Biol & Informat Lab, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Santani, Avni] Childrens Hosp Philadelphia, Mol Genet Lab, Dept Pathol, Philadelphia, PA 19104 USA.
   [Albano, Anthony; Kim, Cecilia; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Dept Pediat, Philadelphia, PA 19104 USA.
   [Procaccio, Vincent] Angers Univ Hosp, Dept Biochem & Genet, Sch Med, F-49000 Angers, France.
   [Hakonarson, Hakon] Childrens Hosp Philadelphia, Div Pulm Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Gai, Xiaowu] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Stritch Sch Med, Maywood, IL 60153 USA.
   [Falk, Marni J.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Jefferson University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Loyola University Chicago; University of Pennsylvania
RP Gai, XW (corresponding author), Childrens Hosp Philadelphia, Ctr Informat Biol, Philadelphia, PA 19104 USA.
EM xigai@lumc.edu; falkm@email.chop.edu
FU Children's Hospital of Philadelphia Research Institute Mitochondria Research Affinity Group; National Institutes of Health [R03-DK082521]; University of Pennsylvania; Social Sciences and the Humanities Research Council of Canada [MCRI 412-2005-1004]
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   [Anonymous], 1993, DETECT HANDLE OUTLIE, V0, P0
   Behar DM, 2008, AM J HUM GENET, V82, P1130, DOI 10.1016/j.ajhg.2008.04.002
   Behar DM, 2007, PLOS GENET, V3, P1083, DOI 10.1371/journal.pgen.0030104
   Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201
   Hartmann A, 2009, HUM MUTAT, V30, P115, DOI 10.1002/humu.20816
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Milne I, 2010, BIOINFORMATICS, V26, P401, DOI 10.1093/bioinformatics/btp666
   Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871
   Pandya GA, 2007, NUCLEIC ACIDS RES, V35, P0, DOI 10.1093/nar/gkm918
   Tang S, 2010, BIOTECHNIQUES, V48, P287, DOI 10.2144/000113389
   Thieme M, 2009, BMC BIOINFORMATICS, V10, P0, DOI 10.1186/1471-2105-10-440
   Wang Jing, 2011, CURR PROTOC HUM GENET, VChapter 19, P0, DOI 10.1002/0471142905.hg1906s68
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Zhou SY, 2006, J MOL DIAGN, V8, P476, DOI 10.2353/jmoldx.2006.060008
NR 20
TC 19
Z9 22
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
EI 
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD OCT 19
PY 2011
VL 12
IS 
BP 
EP 
DI 10.1186/1471-2105-12-402
PG 16
WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Mathematical & Computational Biology
GA 858GT
UT WOS:000297784600001
PM 22011106
DA 2024-11-01
ER

PT J
AU Suomalainen, A
AF Suomalainen, Anu
TI Biomarkers for mitochondrial respiratory chain disorders
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID disease; mutation; ataxia; dna; involvement; deficiency; neuropathy; deletions; children; lactate
AB Mitochondrial respiratory chain deficiencies are a group of more than 100 disorders of adults and children, with highly variable phenotypes. Their diagnosis is a great challenge, in spite of the fact that knowledge on their molecular genetic background has increased considerably during the last 20 years. Muscle biopsy is the key diagnostic procedure, including histological and biochemical analysis of mitochondria. Less invasive, specific and sensitive diagnostic tools based on serum biomarkers are still lacking. Recent technological developments, especially in mass spectrometry, enable novel tools for identification of local and global molecular consequences of mitochondrial respiratory chain dysfunction in patient samples. Furthermore, emerging disease models, especially genetically modified mice, offer unique materials to tackle pathophysiology with modern transcriptomic, proteomic, and metabolomic approaches. Identified molecular signals or metabolic fingerprints have the potential to be highly useful biomarkers for future diagnosis of mitochondrial respiratory chain disorders.
C1 [Suomalainen, Anu] Univ Helsinki, Biomedicum Helsinki, Res Program Mol Neurol, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Finnish Inst Mol Med, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Biomedicum Helsinki, Res Program Mol Neurol, RC523B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
FU Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; Centre of Excellence Program of the Academy of Finland; University of Helsinki; Biocentrum Helsinki; Helsinki University Central Hospital
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   [Anonymous], 2000, GENEREVIEWS, V0, P0
   Atkuri KR, 2009, P NATL ACAD SCI USA, V106, P3941, DOI 10.1073/pnas.0813409106
   Boot RG, 2004, BLOOD, V103, P33, DOI 10.1182/blood-2003-05-1612
   Bylesjö M, 2007, PLANT J, V52, P1181, DOI 10.1111/j.1365-313X.2007.03293.x
   Chretien D, 1998, BIOCHEM J, V329, P249, DOI 10.1042/bj3290249
   Davidov E, 2004, OMICS, V8, P267, DOI 10.1089/omi.2004.8.267
   Gloerich J, 2007, J PROTEOME RES, V6, P506, DOI 10.1021/pr060487w
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   Lindroos MM, 2009, BRAIN, V132, P3274, DOI 10.1093/brain/awp259
   Linnankivi T, 2004, NEUROLOGY, V63, P688, DOI 10.1212/01.WNL.0000134658.35601.41
   Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001
   Schweitzer PJ, 2010, DRUG DISCOV TODAY, V15, P933, DOI 10.1016/j.drudis.2010.08.012
   Shaham O, 2010, P NATL ACAD SCI USA, V107, P1571, DOI 10.1073/pnas.0906039107
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   van der Knaap MS, 2003, ANN NEUROL, V53, P252, DOI 10.1002/ana.10456
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
NR 24
TC 35
Z9 37
U1 1
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD APR 15
PY 2011
VL 34
IS 2
BP 277
EP 282
DI 10.1007/s10545-010-9222-3
PG 6
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 739YI
UT WOS:000288757700005
PM 20941643
DA 2024-11-01
ER

PT J
AU Gerards, M
   van den Bosch, BJC
   Danhauser, K
   Serre, V
   van Weeghel, M
   Wanders, RJA
   Nicolaes, GAF
   Sluiter, W
   Schoonderwoerd, K
   Scholte, HR
   Prokisch, H
   Rötig, A
   de Coo, IFM
   Smeets, HJM
AF Gerards, Mike
   van den Bosch, Bianca J. C.
   Danhauser, Katharina
   Serre, Valerie
   van Weeghel, Michel
   Wanders, Ronald J. A.
   Nicolaes, Gerry A. F.
   Sluiter, Wim
   Schoonderwoerd, Kees
   Scholte, Hans R.
   Prokisch, Holger
   Roetig, Agnes
   de Coo, Irenaeus F. M.
   Smeets, Hubert J. M.
TI Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective <i>ACAD9</i>: new function for an old gene
SO BRAIN
LA English
DT Article
DE ACAD9; oxidative phosphorylation; riboflavin
ID hereditary optic neuropathy; mitochondrial-complex; leigh-syndrome; respiratory-chain; beta-oxidation; nd3 gene; mutation; disease; subunit; dna
AB Mitochondrial complex I deficiency is the most common oxidative phosphorylation defect. Mutations have been detected in mitochondrial and nuclear genes, but the genetics of many patients remain unresolved and new genes are probably involved. In a consanguineous family, patients presented easy fatigability, exercise intolerance and lactic acidosis in blood from early childhood. In muscle, subsarcolemmal mitochondrial proliferation and a severe complex I deficiency were observed. Exercise intolerance and complex I activity was improved by a supplement of riboflavin at high dosage. Homozygosity mapping revealed a candidate region on chromosome three containing six mitochondria-related genes. Four genes were screened for mutations and a homozygous substitution was identified in ACAD9 (c.1594C > T), changing the highly conserved arginine-532 into tryptophan. This mutation was absent in 188 ethnically matched controls. Protein modelling suggested a functional effect due to the loss of a stabilizing hydrogen bond in an alpha-helix and a local flexibility change. To test whether the ACAD9 mutation caused the complex I deficiency, we transduced fibroblasts of patients with wild-type and mutant ACAD9. Wild-type, but not mutant, ACAD9 restored complex I activity. An unrelated patient with the same phenotype was compound heterozygous for c.380G > A and c.1405C > T, changing arginine-127 into glutamine and arginine-469 into tryptophan, respectively. These amino acids were highly conserved and the substitutions were not present in controls, making them very probably pathogenic. Our data support a new function for ACAD9 in complex I function, making this gene an important new candidate for patients with complex I deficiency, which could be improved by riboflavin treatment.
C1 [Gerards, Mike; van den Bosch, Bianca J. C.; Smeets, Hubert J. M.] Maastricht Univ, Clin Genom Unit, Dept Genet & Cell Biol, NL-6200 MD Maastricht, Netherlands.
   [Gerards, Mike; van den Bosch, Bianca J. C.; Smeets, Hubert J. M.] Maastricht Univ, Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands.
   [Danhauser, Katharina; Prokisch, Holger] Tech Univ Munich, Inst Human Genet, Munich, Germany.
   [Danhauser, Katharina] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Human Genet, D-85764 Neuherberg, Germany.
   [Serre, Valerie; Roetig, Agnes] Univ Paris 05, Hop Necker Enfants Malad, INSERM, U781, F-75015 Paris, France.
   [Serre, Valerie; Roetig, Agnes] Univ Paris 05, Hop Necker Enfants Malad, Dept Genet, F-75015 Paris, France.
   [van Weeghel, Michel; Wanders, Ronald J. A.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem,Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands.
   [Nicolaes, Gerry A. F.] Maastricht Univ, Cardiovasc Res Inst, Dept Biochem, NL-6200 MD Maastricht, Netherlands.
   [Sluiter, Wim] Erasmus MC, Ctr Lysosomal & Metab Dis, Rotterdam, Netherlands.
   [Schoonderwoerd, Kees] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
   [Scholte, Hans R.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands.
   [de Coo, Irenaeus F. M.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Smeets, HJM (corresponding author), Maastricht Univ, Clin Genom Unit, Dept Genet & Cell Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM Bert.Smeets@maastrichtuniversity.nl
FU EU [005260]; Helmholtz Association in the framework of the Helmholtz Alliance for Mental Health in an Ageing Society [HA-215]; German Network for Mitochondrial Disorders [01GM0862, 01GM0867]; Systems Biology of Metabotypes [0315494A]
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   BAKKER HD, 1994, J INHERIT METAB DIS, V17, P196, DOI 10.1007/BF00711617
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332
   BERNSEN PLJA, 1993, J NEUROL SCI, V118, P181, DOI 10.1016/0022-510X(93)90108-B
   Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200
   de Wit LEA, 2008, CLIN CHEM, V54, P1921, DOI 10.1373/clinchem.2008.104802
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Ensenauer R, 2005, J BIOL CHEM, V280, P32309, DOI 10.1074/jbc.M504460200
   Feng DJ, 2009, J BIOL CHEM, V284, P11436, DOI 10.1074/jbc.M806991200
   Fernandez-Moreira D, 2007, ANN NEUROL, V61, P73, DOI 10.1002/ana.21036
   Gerards M, 2010, J MED GENET, V47, P507, DOI 10.1136/jmg.2009.067553
   Grad LI, 2006, BBA-BIOENERGETICS, V1757, P115, DOI 10.1016/j.bbabio.2005.11.009
   He M, 2007, AM J HUM GENET, V81, P87, DOI 10.1086/519219
   Hoefs SJG, 2008, AM J HUM GENET, V82, P1306, DOI 10.1016/j.ajhg.2008.05.007
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   NAGAO M, 1992, J BIOL CHEM, V267, P17925
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Olsen RKJ, 2007, BRAIN, V130, P2045, DOI 10.1093/brain/awm135
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   SAIJO T, 1995, J BIOL CHEM, V270, P1899, DOI 10.1074/jbc.270.4.1899
   SCHOLTE HR, 1995, BBA-MOL BASIS DIS, V1271, P75, DOI 10.1016/0925-4439(95)00013-T
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sgobbo P, 2007, BBA-BIOENERGETICS, V1767, P222, DOI 10.1016/j.bbabio.2007.01.023
   SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Sugiana C, 2008, AM J HUM GENET, V83, P468, DOI 10.1016/j.ajhg.2008.09.009
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   van den Bosch BJC, 2005, CARDIOVASC RES, V65, P411, DOI 10.1016/j.cardiores.2004.10.025
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Vockley J, 2008, J INHERIT METAB DIS, V31, P619, DOI 10.1007/s10545-008-1005-8
   Vogel RO, 2007, BBA-BIOENERGETICS, V1767, P1215, DOI 10.1016/j.bbabio.2007.07.008
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 50
TC 98
Z9 109
U1 0
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JAN 15
PY 2011
VL 134
IS 
BP 210
EP 219
DI 10.1093/brain/awq273
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 698WK
UT WOS:000285625000019
PM 20929961
DA 2024-11-01
ER

PT J
AU Kasiviswanathan, R
   Copeland, WC
AF Kasiviswanathan, Rajesh
   Copeland, William C.
TI Biochemical analysis of the G517V <i>POLG</i> variant reveals wild-type like activity
SO MITOCHONDRION
LA English
DT Article
DE POLG; DNA polymerase; Mitochondrial disease
ID dna-polymerase-gamma; progressive external ophthalmoplegia; accessory subunit; disease mutations; replication; neuropathy; depletion; defects
AB The c.1550g --> t mutation in the POW gene causing the G517V substitution has been reported by many groups to be associated with a variety of mitochondrial diseases, including autosomal dominant and recessive forms of ataxia neuropathy, myopathy and microcephaly, progressive external ophthalmoplegia, diabetes, strokes, hypotonia, and epilepsy. However, the variable disease presentation and age of onset raises suspicion of its pathogenicity. Because of the varied reported associated symptoms and request from physicians to address the consequence of this mutation, we have carried out the biochemical analysis of the purified recombinant human DNA polymerase gamma protein harboring the G517V substitution. These analyses revealed that the G517V mutant enzyme retained 80-90% of wild-type DNA polymerase activity, in addition to its functional interaction with the p55 accessory subunit. DNA binding by the mutant was also only slightly lower than the wild-type enzyme. Our data suggest that the G517V mutation by itself in pol gamma most likely does not have a role in mitochondrial disorders. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Kasiviswanathan, Rajesh; Copeland, William C.] Natl Inst Environm Hlth Sci, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, NIH, 111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU NIH, National Institute of Environmental Health Sciences [ES 065078, ES 065080]
CR Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Bolszak M, 2009, EPILEPSY RES, V85, P300, DOI 10.1016/j.eplepsyres.2009.03.004
   Burusnukul P, 2009, J CHILD NEUROL, V24, P482, DOI 10.1177/0883073808324539
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hopkins SE, 2010, J CHILD NEUROL, V25, P752, DOI 10.1177/0883073809343313
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kasiviswanathan R, 2010, METHODS, V51, P379, DOI 10.1016/j.ymeth.2010.02.015
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Lucas P, 2004, MITOCHONDRION, V4, P13, DOI 10.1016/j.mito.2004.04.001
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Schulte C, 2009, NEUROLOGY, V73, P898, DOI 10.1212/WNL.0b013e3181b78488
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wong LJC, 2008, HUM MUTAT, V29, PE150, DOI 10.1002/humu.20824
NR 29
TC 21
Z9 21
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD NOV 15
PY 2011
VL 11
IS 6
BP 929
EP 934
DI 10.1016/j.mito.2011.08.003
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 846ZI
UT WOS:000296941300014
PM 21856450
DA 2024-11-01
ER

PT J
AU Pinós, T
   Marotta, M
   Gallardo, E
   Illa, I
   Díaz-Manera, J
   Gonzalez-Vioque, E
   García-Arumí, E
   Andreu, AL
   Martí, R
AF Pinos, Tomas
   Marotta, Mario
   Gallardo, Eduard
   Illa, Isabel
   Diaz-Manera, Jorge
   Gonzalez-Vioque, Emiliano
   Garcia-Arumi, Elena
   Andreu, Antoni L.
   Marti, Ramon
TI A novel mutation in the mitochondrial tRNA<SUP>Ala</SUP> gene (m.5636T&gt;C) in a patient with progressive external ophthalmoplegia
SO MITOCHONDRION
LA English
DT Article
DE Mitochondria; PEO; mt-tRNA(Ala); Laser capture microdissection
ID dna deletions
AB We report a heteroplasmic novel mutation m.5636T>C in the mt-tRNA(Ala) in a patient with bilateral ptosis and ophthalmoparesis in whom a muscle biopsy showed cytochrome c oxdidase (COX) negative and ragged red fibers. Using laser capture microdissection we have isolated COX negative fibers and COX positive fibers from the muscle of the patient and determined that the mutation load was clearly increased in COX negative muscle fibers. Additionally, the mutated m.5636T nucleotide is conserved in all the mammal and non-mammal species analyzed and might be structurally relevant as it is located in a position involved in the formation of tertiary structure of canonical mitochondrial tRNAs. (C) 2010 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Pinos, Tomas; Gonzalez-Vioque, Emiliano; Garcia-Arumi, Elena; Andreu, Antoni L.; Marti, Ramon] Univ Autonoma Barcelona, Unitat Patol Mitocondrial & Neuromuscular, Inst Recerca Hosp Univ Vall dHebron, E-08193 Barcelona, Spain.
   [Marotta, Mario] Univ Autonoma Barcelona, Lab Neurol Infantil, Inst Recerca Hosp Univ Vall dHebron, E-08193 Barcelona, Spain.
   [Gallardo, Eduard; Illa, Isabel; Diaz-Manera, Jorge] Hosp Santa Creu & Sant Pau, Serv Neurol, Barcelona, Spain.
   [Gallardo, Eduard; Illa, Isabel; Diaz-Manera, Jorge] CIBERNED, Barcelona, Spain.
C3 Autonomous University of Barcelona; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; CIBERNED
RP Martí, R (corresponding author), Inst Recerca Hosp Univ dHebron, Unitat Patol Mitocondrial & Neuromuscular, Pg Vall dHebron 119-129, Barcelona 08035, Spain.
EM tpinos@ir.vhebron.net; mmarotta@ir.vhebron.net; EGallardo@santpau.cat; iilla@santpau.cat; JdiazM@santpau.cat; emigonza@ir.vhebron.net; aandreu@ir.vhebron.net; rmarti@ir.vhebron.net
FU Spanish Institut de Salud Carlos III [PI07/0347, PI08/90355, PS09/01602]
CR Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Di Mauro S, 2004, MYOLOGY PHILADELPHIA, V0, P1623
   Dubowitz C, 2007, MUSCLE BIOPSY PRACTI, V3rd, P0
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, PW70, DOI 10.1093/nar/gkn188
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Marotta M, 2007, NEUROMUSCULAR DISORD, V17, P707, DOI 10.1016/j.nmd.2007.05.007
   Messmer M, 2009, NUCLEIC ACIDS RES, V37, P6881, DOI 10.1093/nar/gkp697
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, PD823, DOI 10.1093/nar/gkl927
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
NR 22
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN 15
PY 2011
VL 11
IS 1
BP 228
EP 233
DI 10.1016/j.mito.2010.08.008
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 709OP
UT WOS:000286450300031
PM 20813205
DA 2024-11-01
ER

PT J
AU Sudo, A
   Takeichi, N
   Hosoki, K
   Saitoh, S
AF Sudo, A.
   Takeichi, N.
   Hosoki, K.
   Saitoh, S.
TI Successful cochlear implantation in a patient with mitochondrial hearing loss and m.625G&gt;A transition
SO JOURNAL OF LARYNGOLOGY AND OTOLOGY
LA English
DT Article
DE Sensorineural Hearing Loss; Cochlear Implantation; Mitochondrial DNA
ID melas-syndrome; gene mutation; children; disease
AB Objective: We present a patient with mitochondrial hearing loss and a novel mitochondrial DNA transition, who underwent successful cochlear implantation. Case report: An 11-year-old girl showed epilepsy and progressive hearing loss. Despite the use of hearing aids, she gradually lost her remaining hearing ability. Laboratory data revealed elevated lactate levels, indicating mitochondrial dysfunction. Magnetic resonance imaging showed diffuse, mild brain atrophy. Cochlear implantation was performed, and the patient's hearing ability was markedly improved. Whole mitochondrial DNA genome analysis revealed a novel heteroplasmic mitochondrial 625G>A transition in the transfer RNA gene for phenylalanine. This transition was not detected in blood DNA from the patient's mother and healthy controls. Mitochondrial respiratory chain activities in muscle were predominantly decreased in complex III. Conclusion: This case indicates that cochlear implantation can be a valuable therapeutic option for patients with mitochondrial syndromic hearing loss.
C1 [Sudo, A.] Sapporo City Gen Hosp, Dept Pediat, Chuo Ku, Sapporo, Hokkaido 0608604, Japan.
   [Takeichi, N.] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol, Sapporo, Hokkaido, Japan.
   [Hosoki, K.; Saitoh, S.] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido, Japan.
C3 Sapporo City General Hospital; Hokkaido University; Hokkaido University
RP Sudo, A (corresponding author), Sapporo City Gen Hosp, Dept Pediat, Chuo Ku, Kita 11,Nishi 13, Sapporo, Hokkaido 0608604, Japan.
EM akira.sudo@doc.city.sapporo.jp
FU Ministry of Education, Science and Culture of Japan; Grants-in-Aid for Scientific Research [11J04823] Funding Source: KAKEN
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Darin N, 2006, NEUROMUSCULAR DISORD, V16, P504, DOI 10.1016/j.nmd.2006.05.010
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   Karkos PD, 2005, EUR ARCH OTO-RHINO-L, V262, P322, DOI 10.1007/s00405-004-0817-x
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Konings A, 2008, MITOCHONDRION, V8, P377, DOI 10.1016/j.mito.2008.08.001
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Papsin BC, 2007, NEW ENGL J MED, V357, P2380, DOI 10.1056/NEJMct0706268
   RAHMAN S, 1996, ANN NEUROL, V39, P345
   Rosenthal EL, 1999, AM J OTOL, V20, P187
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Yamasoba T, 2006, NEUROSCI LETT, V395, P18, DOI 10.1016/j.neulet.2005.10.045
   Yamasoba T, 1999, NEUROLOGY, V52, P1705, DOI 10.1212/WNL.52.8.1705
NR 16
TC 13
Z9 14
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022-2151
EI 
J9 J LARYNGOL OTOL
JI J. Laryngol. Otol.
PD DEC 15
PY 2011
VL 125
IS 12
BP 1282
EP 1285
DI 10.1017/S0022215111002453
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 865CQ
UT WOS:000298288800016
PM 21914246
DA 2024-11-01
ER

